levoleucovorin profile

Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	135398559
CHEMBL ID	1908841
CHEBI ID	63606
SCHEMBL ID	571901
SCHEMBL ID	16946130
MeSH ID	M0544494

Synonym
n-[4-({[(6s)-2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-l-glutamic acid
C03479
5-formyltetrahydrofolate
leucovorin
(6s)-leucovorin
58-05-9
l(-)-5-formyl-5,6,7,8-tetrahydrofolic acid
5-formyl-5,6,7,8-tetrahydrofolate
l-leucovorin
5-formyltetrahydropteroylglutamate
(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
l-glutamic acid, n-(4-((((6s)-2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-
(6s)-5-formyl-5,6,7,8-tetrahydrofolic acid
unii-990s25980y
levo-folinic
levoleucovorin
990s25980y ,
l-glutamic acid, n-(4-(((2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-, (s)-
68538-85-2
(s)-leucovorin
(6s)-folinic acid
levofolinic acid
levofolene
l-folinic acid
isovorin
(6s)-5-formyltetrahydrofolic acid
CHEBI:63606 ,
n-[4-({[(6s)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-l-glutamic acid
SCHEMBL571901
(2s)-2-{[4-({[(6s)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid
bdbm286
5-cho-h4pteglu1
levoleucovorin [orange book]
levoleucovorin [vandf]
khapzory
lfp-754
levofolinic acid [who-dd]
VVIAGPKUTFNRDU-STQMWFEESA-N
n5-formyl-(6s)-tetrahydrofolic acid
CHEMBL1908841
5-formyltetrahydropteroylglutamic acid
SCHEMBL16946130
DTXSID4023204
n5-formyltetrahydrofolate
l-n-[p-[[(2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
(6r,s)-5-formyltetrahydrofolate
n5-formyl-5,6,7,8-tetrahydrofolate
n5-formyl-thf
DB11596
[6s]-5-formyl-tetrahydrofolate; 6s-folinic acid
Q192464
calcium-levofolinate
(s)-2-(4-((((s)-2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid
A923282
(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
(s)-methyl2-amino-3-n-boc-propanoate
EN300-19768275
CS-0091268
HY-127009
AKOS040752533
6s leucovorin
n-(4-((((6s)-2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-l-glutamic acid
n-(4-((((6s)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-l-glutamic acid
elvorine, isovorin, levofolene, levorin
leucovorin, (s)-isomer
s leucovorin
6s-leucovorin
acido levofolinico
levo leucovorin
cl-307,782
levo-leucovorin
l-5-formyltetrahydrofolate
6-s-leucovorin
6 s leucovorin
levofolinate
s-leucovorin

Excerpt	Reference
"Levoleucovorin has been studied in other cancers."	( Levoleucovorin as replacement for leucovorin in cancer treatment. Chuang, VT; Suno, M, 2012)

Excerpt	Reference
" Determination of 48- and 72-h methotrexate concentrations proved to be a valuable method for identifying patients at high risk for toxic side effects."	( [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)]. Bidlingmaier, F; Haas, RJ; Janka, GE; Wiesner, H, 1979)
" While 10(-5) M MTX was rescued by 10(-3) M leucovorin, rescue of the toxic effect of 10(-4) M MTX by 10(-3) M leucovorin was not observed."	( The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Bull, JM; Chabner, BA; Pinedo, HM; Zaharko, DS, 1976)
"The rationale for melanoma-specific antitumor agents containing phenolic amines is based in part on the ability of the enzyme tyrosinase to oxidize these prodrugs to toxic intermediates."	( Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol. Bloomer, WD; Prezioso, JA; Wang, N, 1992)
" None of the nonresponders responded to the addition of folinic acid, on the contrary toxicity was increased and 2 toxic deaths were reported."	( Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity. Karvounis, N; Kosmidis, P; Tsavaris, N; Tzannou, I, 1992)
" There are few reports of such toxic effects during therapy for ALL."	( Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Bowman, WP; Buchanan, GR; Jacaruso, D; Kamen, BA; Roach, ES; Rollins, N; Winick, NJ, 1992)
"This report describes these toxic effects and outlines our successful approach to the problem."	( Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Bowman, WP; Buchanan, GR; Jacaruso, D; Kamen, BA; Roach, ES; Rollins, N; Winick, NJ, 1992)
" The publication of cases of overdoses may provide useful information on the causes of the mistakes, on drug-induced toxic effects, and on salvage therapy."	( Overdose of vinblastine in a child with Langerhans' cell histiocytosis: toxicity and salvage therapy. Conter, V; Corbetta, A; D'Angelo, P; Fraschini, D; Jankovic, M; Masera, G; Pacheco, C; Rabbone, ML, )
" In the phase I part we found that the main side-effect in 27 evaluable patients (pts) was gastrointestinal toxicity, mainly in the form of nausea/vomiting (92%) and diarrhea (70%) which caused one therapy-related death."	( A phase I-II study on the toxicity and therapeutic efficacy of 5-fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma. Borsellino, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A; Rustum, Y, 1990)
" Previously reported unpredictable and severe toxic effects were probably due to an interaction between methotrexate and nitrous oxide used in anesthesia."	( On the safety of perioperative adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in breast cancer. , 1988)
" The procedure described allows the safe administration of HDMTX-CFR at the 50-g range to adults with advanced malignant solid tumors."	( The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients. Djerassi, I; Reggev, A, 1988)
" Unpredictable and severe toxic effects were significantly more common in patients aged greater than or equal to 50 who had received at least 80% of the full chemotherapy dose and in patients who had received chemotherapy within 6 h of mastectomy than in other patients."	( Toxic effects of early adjuvant chemotherapy for breast cancer. , 1983)
" We found that MTX-CF is the least toxic single agent chemotherapeutic regimen in the management of GTN."	( Methotrexate with citrovorum factor rescue: reduced chemotherapy toxicity in the management of gestational trophoblastic neoplasms. Berkowitz, RS; Bernstein, MR; Goldstein, DP; Jones, MA; Marean, AR, 1980)
" The 3 patients with mild toxicity had low drug clearance, but others with similar low MTX clearance experienced no apparent toxic effects beyond the expected transient nausea."	( High-dose methotrexate with a safe rescue program. Decker, DA; Edmonson, JH; Gilchrist, GS; Kovach, JS; Offord, JR; Taylor, WF, 1981)
" In an attempt to reduce the duration of toxic effects in our patient, leucovorin was administered 24 hours after the overdose."	( Massive vincristine overdose: failure of leucovorin to reduce toxicity. Braat, PC; Goudsmit, R; Somers, R; Thomas, LL, 1982)
" The most common adverse reactions are acute gastrointestinal effects and bone marrow suppression while neurological, ocular and dermatological toxicities are unusual."	( Dermatological toxicity from chemotherapy containing 5-fluorouracil. Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994)
" Adverse experiences were generally mild or moderate and occurred in 54 (60%) of 90 courses of l-leucovorin therapy."	( Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma. George, M; Goorin, A; Letvak, LA; Link, M; Poplack, D; Strother, D, 1995)
"We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer."	( [Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993)
"Clinical response to chemotherapy and observed toxic effects during chemotherapy."	( Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Bajorin, D; Bosl, G; Harrison, L; Louison, C; Motzer, R; Pfister, DG; Scher, H; Shah, J; Strong, E, 1994)
" Other significant toxic effects included grade 3 to 4 mucositis in eight patients and grade 3 to 4 neutropenia in 10."	( Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Bajorin, D; Bosl, G; Harrison, L; Louison, C; Motzer, R; Pfister, DG; Scher, H; Shah, J; Strong, E, 1994)
" Its use can be associated with significant toxic effects."	( Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Bajorin, D; Bosl, G; Harrison, L; Louison, C; Motzer, R; Pfister, DG; Scher, H; Shah, J; Strong, E, 1994)
" Therefore toxic potentiation of 5-FU due to simultaneous 1-LV dosing is presumed to be concerned with an increased ternary complex (FdUMP-TS-5,10-methylenetetrahydrofolate) formation and a greater extent of TS inhibition."	( Effects of levofolinate calcium on subacute intravenous toxicity of 5-fluorouracil in rats. Fujii, H; Ichimura, A; Murakami, Y; Murata, A; Takagi, H; Tauchi, K; Yamashita, N, 1998)
" Other toxic manifestations included mucositis of varying degrees, diarrhea, and neutropenic fever, but all patients recovered."	( High-dose leucovorin as sole therapy for methotrexate toxicity. Flombaum, CD; Meyers, PA, 1999)
"The aim of this study was to clarify whether preoperative chemotherapy caused adverse effects on the perioperative course of patients undergoing esophagectomy."	( Does preoperative chemotherapy cause adverse effects on the perioperative course of patients undergoing esophagectomy for carcinoma? Aikou, T; Baba, M; Fukumoto, T; Kusano, C; Nakano, S; Natsugoe, S; Shimada, M; Shirao, K, 1999)
" 5-Fu+LVLD is significantly more toxic than the other two regimens in terms of neutropenia, mucositis and diarrhea."	( Retrospective evaluation of toxicity in three different schedules of adjuvant chemotherapy for patients with resected colorectal cancer. TTD Spanish Cooperative Group. Alonso, MC; Antón, A; Aranda, E; Camps, C; Checa, T; Díaz-Rubio, E; Fonseca, E; Gallen, M; Navarro, M; Sastre, J, )
" To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU."	( Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999)
" Forty-seven patients (35%+/-8%) experienced significant toxicity and were unable to receive the second cycle as scheduled: 76% required dose reduction, 11% discontinued therapy (including two toxic deaths), 11% discontinued therapy during the first cycle, and 2% required dose delay."	( Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: prohibitive toxicity? Griffeth, S; Keith, B; Kocha, W; Sawyer, M; Stitt, L; Taylor, M; Tomiak, A; Vincent, M; Whiston, F; Winquist, E, 2000)
" Haematologic side effects could not be analyzed, since details of each haematologic side effect by patients were not provided."	( Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Moher, D; Ortiz, Z; Shea, B; Suarez Almazor, M; Tugwell, P; Wells, G, 2000)
" Some studies have been proven it to be safe for outpatient treatment and to have significant antitumor activity in colorectal and breast cancer patients."	( [Capecitabine--a review of its antitumor activity and toxicity in clinical studies]. Maeda, Y; Sasaki, T, 2000)
"Methotrexate can influence the central nervous system through several metabolic toxic pathways."	( Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. Aviner, S; Cohen, IJ; Goshen, Y; Kornreich, L; Shuper, A; Stark, B; Stein, J; Steinmetz, A; Yaniv, I, 2000)
" Treatment dosages were adjusted if toxic events above WHO grade 2 occurred."	( Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1. Beger, HG; Link, KH; Staib, L, )
"To study the effect of folates on discontinuation of methotrexate (MTX) as single-drug antirheumatic treatment due to toxicity, to determine which type of adverse events are reduced, to study the effects on the efficacy of MTX, and to compare folic with folinic acid supplementation in a 48-week, randomized, double-blind, placebo-controlled trial."	( Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Breedveld, FC; de Boo, TM; de Rooij, DJ; Dijkmans, BA; Hartman, M; Huizinga, TW; Jacobs, MJ; Krabbe, PF; Laan, RF; Romme, TC; Rood, MJ; Severens, JL; van de Laar, MA; van de Putte, LB; van Denderen, CJ; van der Wilt, GJ; van Ede, AE; Westgeest, TA, 2001)
" The primary end point was MTX withdrawal because of adverse events."	( Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Breedveld, FC; de Boo, TM; de Rooij, DJ; Dijkmans, BA; Hartman, M; Huizinga, TW; Jacobs, MJ; Krabbe, PF; Laan, RF; Romme, TC; Rood, MJ; Severens, JL; van de Laar, MA; van de Putte, LB; van Denderen, CJ; van der Wilt, GJ; van Ede, AE; Westgeest, TA, 2001)
" No between-group differences were found in the frequency of other adverse events or in the duration of adverse events."	( Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Breedveld, FC; de Boo, TM; de Rooij, DJ; Dijkmans, BA; Hartman, M; Huizinga, TW; Jacobs, MJ; Krabbe, PF; Laan, RF; Romme, TC; Rood, MJ; Severens, JL; van de Laar, MA; van de Putte, LB; van Denderen, CJ; van der Wilt, GJ; van Ede, AE; Westgeest, TA, 2001)
" Folates seem to have no effect on the incidence, severity, and duration of other adverse events, including gastrointestinal and mucosal side effects."	( Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Breedveld, FC; de Boo, TM; de Rooij, DJ; Dijkmans, BA; Hartman, M; Huizinga, TW; Jacobs, MJ; Krabbe, PF; Laan, RF; Romme, TC; Rood, MJ; Severens, JL; van de Laar, MA; van de Putte, LB; van Denderen, CJ; van der Wilt, GJ; van Ede, AE; Westgeest, TA, 2001)
" This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues."	( Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001)
" The severity of adverse events was associated with increased 5-FU/5-FDHU AUC ratio and reduced 5-FU CL, while 5-FU and 5-FDHU pharmacokinetics were not related to DPD activity."	( Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Allegrini, G; Bocci, G; Cionini, L; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Mini, E; Vannozzi, F, 2001)
" All patients in the capecitabine group received a starting dose of 1250 mg/m2 twice daily and the majority (66%) did not require dose modification for adverse events."	( First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E, 2002)
" Analysis of data from two large phase III trials demonstrates that efficacy is not compromised in patients requiring a dose reduction for adverse events."	( First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E, 2002)
"Exclusive CRT approach is not safe to treat patients with low infiltrative rectal carcinoma."	( Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? David Filho, WJ; de O Ferreira, F; Ferrigno, R; Lopes, A; Nakagawa, WT; Nishimoto, IN; Rossi, BM; Vieira, RA, 2002)
" Female patients exhibited a higher incidence of severe toxicity (18%) and toxic death (4/105) than did male patients (9% and 1/138, respectively)."	( Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Bar-Sela, G; Beny, A; Haim, N; Tsalic, M; Visel, B, 2003)
" We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma."	( Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002)
"Weekly treatment at these doses is convenient and well-tolerated for the large majority of patients, and achieves DI comparable with the 5 days a month QUASAR schedule and other more toxic standard regimens."	( Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Anthoney, DA; Crellin, AM; Messruther, J; Patel, K; Sebag-Montefiore, D; Seymour, MT, 2004)
" The safe minimum dose of folinic acid can be defined in terms of the dose of methotrexate given; the time to start of rescue is probably less important."	( Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. Cohen, IJ, 2004)
"3%), no toxic death, and only one grade 3 neutropenia (4."	( Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients. Artru, P; Atlan, D; Bouché, O; Dahan, L; Lledo, G; Mitry, E; Nguyen, T; Richard, K; Ries, P; Rougier, P; Seitz, JF, 2005)
" This study was to explore relationship of DPD to serum concentration of 5-FU in colorectal cancer patients treated with FOLFOX6 regimen, and their correlation to treatment response and adverse events."	( [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. Dong, QM; He, YJ; Li, S; Li, YY; Xia, ZJ; Zhang, L; Zhou, ZM; Zhou, ZW, 2005)
" Treatment response and adverse events in the patients were assessed."	( [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. Dong, QM; He, YJ; Li, S; Li, YY; Xia, ZJ; Zhang, L; Zhou, ZM; Zhou, ZW, 2005)
" The predictability of neurotoxicity associated with oxaliplatin-based therapy should allow patients and doctors to develop strategies to manage this side effect in view of the individual patient's clinical situation."	( Clinical management of oxaliplatin-associated neurotoxicity. Grothey, A, 2005)
" Adverse effects, including bone marrow suppression, liver damage, renal damage, and glucose tolerance, were evaluated daily during 3 courses of l-LV/5FU-modified RPMI regimen adjuvant chemotherapy for 22 patients with stage III colorectal cancer."	( Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. Arii, K; Higashiguchi, T; Hotta, T; Matsuda, K; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2005)
" These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval."	( [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]. Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T, 2005)
" There was one toxic death."	( Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study. Buccilli, A; Ciccarese, M; Ferraresi, V; Gabriele, A; Gamucci, T; Giampaolo, MA; Giannarelli, D; Mansueto, G, 2005)
" Adverse effects associated with the Saltz regimen included diarrhea and neutropenia."	( Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. Bricarello, A; Christian, BJ; Gaudreault, J; Mounho, B; Shiu, V; Zuch, CL, )
" During the whole study period, the common grade 3/4 adverse events were acne-like rash (38%) and diarrhea (29%)."	( Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T, 2006)
"Addition of cetuximab to weekly infusional 5-FU/FA plus irinotecan is safe and first data suggest a promising activity."	( Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T, 2006)
" The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81."	( Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006)
"Pharmacokinetics and non-hematological adverse events could be assessed in all patients included in the study."	( Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigation. Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Roskos, M; Wedding, U, 2006)
" Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen."	( Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ, 2006)
" End points included grade > or = 3 adverse events, response rate (in advanced disease), progression or relapse-free survival, dose-intensity, and overall survival in the studies with mature survival data."	( Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C, 2006)
" Older age was not associated with increased rates of severe neurologic adverse events, diarrhea, nausea/vomiting, infection, overall incidence of grade > or = 3 toxicity (63% v 67%; P = ."	( Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C, 2006)
" This study was to explore the relationship between activity of DPD and concentration of 5-FU, and their correlation to adverse events among advanced gastric cancer patients treated with the same regimen containing 5-FU continuous infusion."	( [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. Cao, Y; Dong, QM; Jiang, WQ; Li, H; Li, S; Peng, RJ; Shi, YX; Yuan, ZY; Zhou, ZM, 2006)
" Adverse events were assessed every cycle."	( [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. Cao, Y; Dong, QM; Jiang, WQ; Li, H; Li, S; Peng, RJ; Shi, YX; Yuan, ZY; Zhou, ZM, 2006)
" And high level of 5-FU concentration led to the increase of adverse events."	( [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. Cao, Y; Dong, QM; Jiang, WQ; Li, H; Li, S; Peng, RJ; Shi, YX; Yuan, ZY; Zhou, ZM, 2006)
"This concurrent chemoradiotherapy with PFML was safe and well tolerated."	( Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Katori, H; Taguchi, T; Tsukuda, M, 2007)
" Most treatment-related adverse events (AEs) occurred at similar rates in both treatment arms."	( Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. Cartwright, T; de Braud, F; Figer, A; Haller, DG; Hill, M; Lim, R; Maroun, J; McKendrick, J; Nowacki, MP; Park, YS; Price, T; Schmoll, HJ; Sirzén, F; Soler-Gonzalez, G; Tabernero, J; Topham, C; Van Cutsem, E, 2007)
"Neurotoxicity was recorded for all patients using standard adverse event reporting."	( Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Bearden, JD; Cecchini, RS; Cella, D; Colangelo, LH; Colman, LK; Costantino, JP; Ganz, PA; Kopec, JA; Kuebler, JP; Land, SR; Lanier, KS; Murphy, K; Needles, BM; O'Connell, MJ; Pajon, ER; Seay, TE; Smith, RE; Wieand, HS; Wolmark, N, 2007)
" The relation between adverse events on IROX to selected characteristics was analyzed."	( Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Alberts, SR; Ashley, AC; Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Grothey, A; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2007)
" Fifty-two percent of patients required dose reductions for adverse events, and 26% experienced 119 hospitalizations related to complications of treatment or their disease, with 5 treatment-related deaths."	( Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Alberts, SR; Ashley, AC; Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Grothey, A; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2007)
" We have applied goshajinkigan (TJ 107) for a case of advanced colon cancer with mFOLFOX 6, and experienced a reduction in numbness, the adverse effect of LOHP."	( [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer]. Chisato, N; Ebisawa, Y; Kono, T; Mamiya, K; Mamiya, N; Satomi, M, 2007)
"5% of the functional volume of both kidneys appears to be safe at a median follow-up of 2 years for a cumulative cisplatin dose of 200 mg/m2 administered before and after simultaneous 5-FU and radiotherapy."	( Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer. Belka, C; Bokemeyer, C; Budach, W; Hehr, T; Kollmannsberger, C; Welz, S, 2007)
"Cetuximab-based combination chemotherapy (CBCC) proved safe and effective as second-line strategy for metastatic colorectal cancer (mCRC)."	( Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. Al-Gahmi, AM; Bahadur, YA; Fawzi, EE; Ibrahim, EM; Sallam, YA; Zeeneldin, AA, )
" Administration of TroVax alongside chemotherapy was safe and well tolerated with no SAEs attributed to the vaccine and no enhancement of chemo-related toxicity."	( Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N, 2008)
"An increase of sIL-2R, CD4+CD25+ T-cells and the CD4/8 ratio in patients with symptomatic adverse reactions were found."	( Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer. Aizawa, M; Fujimoto, T; Itagaki, H; Kobayashi, R; Kuhara, K; Ogawa, K; Osawa, G; Otani, T; Yokomizo, H; Yoshimatsu, K, )
" Evaluation points included adverse events, dose intensity, response rate, progression-free survival, and overall survival."	( Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S, 2008)
" We observed adverse events, time to treatment failure, response rate, reason to discontinue treatment, and dose intensity."	( [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients]. Chin, K; Hatake, K; Ichimura, T; Kuboki, Y; Matsuda, M; Matsuzaka, S; Mizunuma, N; Ogura, M; Shinozaki, E; Suenaga, M, 2008)
"After 40 of the planned 74 patients had been randomly assigned, real-time adverse event monitoring led to early trial closure because of excess sequence-specific toxicity."	( Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. Anthoney, DA; Bradley, C; Brown, JM; Brown, S; Crawford, SM; Hennig, IM; Jackson, DP; Melcher, AM; Naik, JD; Seymour, MT; Szubert, A, 2008)
" Incidence of grade 3/4 treatment-related adverse events during the first 12 weeks of treatment were 59%, 36%, and 67% for mFOLFOX6, bFOL, and CapeOx, respectively, (TREE-1) and 59%, 51%, and 56% for the corresponding treatments plus bevacizumab (TREE-2; primary end point)."	( Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. Abubakr, Y; Childs, BH; Cohn, AL; Fehrenbacher, L; Hainsworth, JD; Hart, LL; Hedrick, E; Hochster, HS; Ramanathan, RK; Saif, MW; Schwartzberg, L; Wong, L, 2008)
" The secondary aim was to evaluate whether distal bowel clearance < or =1 cm is safe after radiation."	( Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe? Bujko, K; Chmielik, E; Nasierowska-Guttmejer, A; Nowacki, MP; Rutkowski, A; Wojnar, A, 2008)
"For advanced or metastatic colorectal cancer, FOLFOX4/mFOLFOX6 followed by FOLFIRI may be effective and comparatively safe treatments."	( Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S, 2008)
"Supplementation with folic acid is an effective measure to reduce hepatic adverse effects associated with methotrexate treatment."	( Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Paul, C; Prey, S, 2009)
" In addition, relative dose intensity (RDI), therapeutic efficacy, and adverse events in the patients who were given the regimen, we compared between the groups."	( [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer]. Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kuwabara, K; Matsuki, M; Miyazaki, T; Okada, N; Sano, M; Yokoyama, M, 2008)
" The rate of adverse events ( > or = grade 3) was not different between the groups ( 50% versus 51%)."	( [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer]. Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kuwabara, K; Matsuki, M; Miyazaki, T; Okada, N; Sano, M; Yokoyama, M, 2008)
"Similar to younger patients the mFOLFOX6 regimen is feasible, safe and effective in the selected aged patients, although the dose reduction may be needed for such patients."	( [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer]. Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kuwabara, K; Matsuki, M; Miyazaki, T; Okada, N; Sano, M; Yokoyama, M, 2008)
" Major adverse events were neutropenia, nausea, diarrhea, hand/foot syndrome, and neurotoxicity."	( Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer. Hatzopoulos, A; Heras, P; Karagiannis, S; Kritikos, K; Kritikos, N; Mitsibounas, D; Xourafas, V, )
" Serious/grade 3-5 adverse events of interest for bevacizumab included bleeding (3%), gastrointestinal perforation (2%), arterial thromboembolism (1%), hypertension (5."	( Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Berry, S; Bridgewater, J; Canon, JL; Cunningham, D; DiBartolomeo, M; Georgoulias, V; Kretzschmar, A; Mazier, MA; Michael, M; Peeters, M; Rivera, F; Van Cutsem, E, 2009)
" Follow-up for potential delayed adverse effects and efficacy is ongoing."	( Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. Allegra, CJ; Atkins, JN; Azar, CA; Chu, L; Colangelo, LH; Fehrenbacher, L; Goldberg, RM; Lopa, SH; O'Connell, MJ; O'Reilly, S; Petrelli, NJ; Seay, TE; Sharif, S; Wolmark, N; Yothers, G, 2009)
" Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event."	( The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009)
" The most frequent adverse reactions were peripheral neuropathy (82 %), neutropenia (56."	( [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. de la Rubia, A; Díaz-Carrasco, MS; Fernández-Lobato, B; Marín, M; Pareja, A; Vila, N, )
" Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases."	( The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010)
" An increase of adverse events with combination chemotherapy is predicted in elderly patients, and it remains controversial whether they should receive the same chemotherapy as younger patients."	( Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. Ikeguchi, M; Kanazawa, A; Katano, K; Kidani, A; Makino, M; Ozaki, N; Sugimoto, S; Takeda, H; Tanaka, T; Yoshimura, H, 2009)
" Adverse events and the response to treatment were compared between the elderly and non-elderly groups."	( Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. Ikeguchi, M; Kanazawa, A; Katano, K; Kidani, A; Makino, M; Ozaki, N; Sugimoto, S; Takeda, H; Tanaka, T; Yoshimura, H, 2009)
"The main adverse events were neutropenia and peripheral neuropathy, which occurred in 62."	( Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. Ikeguchi, M; Kanazawa, A; Katano, K; Kidani, A; Makino, M; Ozaki, N; Sugimoto, S; Takeda, H; Tanaka, T; Yoshimura, H, 2009)
" The primary dose of oxaliplatin (L-OHP) ranged from 60 mg/m(2) to 85 mg/m(2), and adverse reactions and serum platinum concentration were monitored."	( [The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy]. Fujita, M; Kataoka, Y; Katayama, T; Koide, T; Matsuda, H; Okuda, M; Yamagishi, Y, 2009)
"EP-UFT with lower UFT doses and without leucovorin support is a safe and effective regimen as first -line treatment of MGC."	( Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients. Alacacioglu, A; Meydan, N; Oztop, I; Somali, I; Tarhan, MO; Yilmaz, U, )
" The patient tolerated glucarpidase well without any significant adverse events."	( Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity. Al Omar, S; Tuffaha, HW, 2011)
"Glucarpidase is a safe and effective agent in the management of high-dose methotrexate-induced nephrotoxicity and delayed methotrexate elimination."	( Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity. Al Omar, S; Tuffaha, HW, 2011)
"We retrospectively investigated the frequency and severity of adverse events in 124 patients with colorectal cancer who were treated by mFOLFOX6 regimen from August, 2005 to December, 2006."	( [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen]. Boku, N; Kato, T; Kimura, H; Kudou, Y; Matsunaga, Y; Motokawa, S; Muramatsu, T; Nagata, N; Nakagaki, S; Ohashi, Y; Shino, M; Yamazaki, K; Yoshida, T, 2009)
" The primary toxicity outcome measure was toxicity-induced delay or dose reduction; the secondary outcome was Common Terminology Criteria of Adverse Events grade >or= 3 toxicity."	( Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. Adlard, JW; Allan, JM; Braun, MS; Daly, CL; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Seymour, MT; Thompson, L, 2009)
" Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy."	( Folate in depression: efficacy, safety, differences in formulations, and clinical issues. Fava, M; Mischoulon, D, 2009)
"FOLFOXIRI confers significant benefit in progression-free survival, survival, response and R0 resection rates but is more toxic compared with FOLFIRI."	( A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Chiriatti, A; Fiorentini, G; Francini, G; Montagnani, F; Turrisi, G, 2011)
" Adverse events resulting from its use include gastrointestinal perforation, wound-healing complications, hemorrhage, and arterial thromboembolism."	( Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer. Gamboa, EO; Haller, N; Rehmus, EH, 2010)
" The incidence of adverse drug reactions was not significantly different between the two groups, although the incidence rates of adverse events associated predominantly with 5-fluorouracil such as hand-and-foot syndrome, diarrhea, and oral mucositis were rather higher, though not significantly, in generic drug group than in brand drug group (16 vs."	( Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy. Fujii, H; Iihara, H; Itoh, Y; Matsuura, K; Takahashi, T; Yasuda, K; Yoshida, K, 2011)
"The addition of cetuximab to chronotherapy allowed safe and effective therapeutic control of metastases, including their complete resection, despite previous failure of several treatment regimens."	( Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R, 2011)
" 3-year disease-free survival (DFS) and adverse events as end points were compared between the two groups."	( [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. Fang, F; Li, DC; Lu, GC, 2010)
" There was no significant difference for 3-year DFS and all grades adverse events between the two groups."	( [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. Fang, F; Li, DC; Lu, GC, 2010)
" No hematologic or non-hematologic toxic effects were clearly related to UGT1A11/6 or 1/28 during the first cycle or throughout the entire course of chemotherapy."	( UGT1A11/28 and 1/6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Akiyama, Y; Ando, Y; Araki, K; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K, 2011)
" A protocol-defined prohibitive adverse event occurred in 4 patients (6%), including 2 treatment-associated deaths."	( Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Chen, HX; Christos, P; Hamilton, A; Horvath, L; Kindler, HL; Matulich, D; Ocean, AJ; Polite, B; Sparano, JA, 2010)
" The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group."	( Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Arai, T; Kobayashi, S; Koike, J; Koizumi, S; Makizumi, R; Miura, K; Miyajima, N; Nakano, H; Otsubo, T; Sakurai, J; Shimamura, T; Yamada, K, 2011)
" Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events."	( Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S, 2011)
" We investigated whether there might be a discrepancy between the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and the Neurotoxicity Criteria of Debiopharm (DEB-NTC), the commonly used oxaliplatin-specific scales, in the evaluation of peripheral neurotoxicity."	( Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Inoue, N; Ishibashi, K; Ishida, H; Kishino, T; Kumamoto, K; Okada, N; Sano, M, 2012)
" Grades 3 and 4 adverse events included diarrhea (21% in the mIFL group and 26% in the bevacizumab plus mIFL group) and neutropenia (19% in the mIFL group and 33% in the bevacizumab plus mIFL group)."	( Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY, 2011)
" The literature review describes that the use of methotrexate for abortion purpose with therapeutic-dose presents a similar adverse effects to those found in our patient, however there are no case reports that describe the use of this drug in macrodosis for the same purpose, and their cytotoxic effects."	( [Acute toxicity by methotrexate used for abortion purpose. Case report]. Belmont-Gómez, A; Carvajal-Valencia, JA; Chacón-Solís, RA; Estrada-Altamirano, A; Hernández-Pacheco, JA; Maya-Quiñones, JL; Valenzuela-Jirón, A, 2011)
" Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported."	( The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011)
" The most commonly observed adverse events by KRAS tumor status included dermatitis acneiform and pruritus."	( The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011)
"FOLFIRI-B may be an efficient and safe choice in the 2nd line treatment of patients with MCRC previously treated with oxaliplatin."	( Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment. Abali, H; Babacan, AN; Civelek, B; Dogan, U; Isik, M; Kos, T; Odabas, H; Oksuzoglu, B; Ozdemir, N; Zengin, N, )
" Most frequently reported adverse events (AE) included hematologic, gastrointestinal, and neurosensory adverse events (NSAE)."	( Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. André, T; Brienza, S; de Gramont, A; Goldberg, RM; Gomi, K; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012)
" Adverse effects ≥ grade 2 were observed in 32% of the patients and adverse effects ≥ grade 3 in 15%."	( Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM, 2012)
"In selected elderly patients, chemoradiotherapy is well-tolerated, without any significant increase in adverse events, and the results are similar to those recorded in younger patients."	( Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM, 2012)
" The aim of the study was to compare efficacy and safety, including response rate (RR), progression-free survival (PFS), overall survival, and grade ≥3 adverse events, between patients aged ≥65 years and patients aged <65 years."	( Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. Bang, HY; Cho, YH; Hong Lee, M; Kim, SY; Lee, KY; Yoo, MW; Yoon, SY, 2012)
"803E-03) with adverse drug reactions (ADRs)."	( Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Andreu, M; Baiget, M; Bessa, X; Brea-Fernández, A; Bujanda, L; Candamio, S; Carracedo, A; Castells, A; Castellví-Bel, S; Cazier, JB; Cortejoso, L; Crous-Bou, M; Durán, G; Fernandez-Rozadilla, C; Gallardo, E; García, MI; González, D; Gonzalo, V; Guinó, E; Jover, R; Lamas, MJ; Llor, X; López, R; López-Fernández, LA; Moreno, V; Páez, D; Palles, C; Paré, L; Reñé, JM; Rodrigo, L; Ruiz-Ponte, C; Tomlinson, I; Xicola, R, 2013)
" The overall incidence of adverse events (AEs) were 80% in S-1 and 74% in UFT/LV."	( Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. Boku, N; Endo, T; Ikejiri, K; Kameoka, S; Kinugasa, Y; Kotake, K; Matsubara, Y; Mochizuki, H; Mochizuki, I; Nakamoto, Y; Shinozaki, H; Sugihara, K; Takagane, A; Takahashi, K; Takahashi, Y; Takii, Y; Takiuchi, H; Tomita, N; Watanabe, M; Watanabe, T, 2012)
" The major dose-limiting toxic effect of oxaliplatin is neurotoxicity."	( Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. Ando, T; Fukuoka, J; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, Y; Ogawa, K; Sugiyama, T; Suzuki, N; Tsukioka, Y; Ueda, A; Yabushita, K, 2012)
"Sequential IRIS + bevacizumab is a safe and effective method of systemic chemotherapy against metastatic colorectal cancer and is compatible with mFOLFIRI + bevacizumab."	( Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients. Akiyama, S; Andoh, H; Gamoh, M; Ishioka, C; Kato, S; Maeda, S; Mori, T; Murakawa, Y; Ohori, H; Sasaki, Y; Shimodaira, H; Suzuki, T; Takahashi, S; Yamaguchi, T; Yoshioka, T, 2012)
"Still there is no consensus on the choice of the most efficient and the least toxic chemotherapy regimen in the treatment of advanced gastric cancer."	( [Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer]. Andrić, Z; Crevar, S; Gutović, J; Kostić, S; Kovčin, V; Murtezani, Z; Randjelović, T, )
" This rare but potentially fatal side effect has neither identified risk factors nor established treatment guideline."	( Oxaliplatin-induced lung toxicity. Case report and review of the literature. Abeni, C; Bertocchi, P; Prochilo, T; Zaniboni, A, 2012)
" Toxicity was mild; most adverse events were grade I or II and involved no severe infections or deaths."	( Efficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancer. Cai, J; Chen, RX; Meng, H; Wang, KL; Wang, Y; Wu, GC; Zhang, J; Zhang, ZT, 2012)
"These results suggest that HR + RFA after effective chemotherapy is a safe procedure with low local recurrence at the RFA site and is a potentially effective treatment option for patients with initially unresectable CRLM."	( Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Kikuchi, K; Kuroki, H; Mima, K; Miyamoto, Y; Nakagawa, S; Okabe, H; Sakamoto, Y; Watanabe, M, 2013)
" FOLFIRI regimen is safe and effective in the second-line treatment of AGC patients pre-treated with cisplatin and taxanes."	( The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. Alkis, N; Arpacı, E; Benekli, M; Berk, V; Bilici, A; Budakoglu, B; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Gumus, M; Inal, A; Isıkdogan, A; Kaya, AO; Ozkan, M; Yumuk, F, 2012)
" Grade ≥3 adverse events (AEs) that occurred during 5-FU/RT and during combined 5-FU/RT + mFOLFOX-6 were recorded."	( Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. Chen, Z; Duldulao, MP; Garcia-Aguilar, J; Ho, J; Kim, J; Le, M; Lee, W; Li, W; Nelson, RA, 2013)
" An increase in adverse events associated with systemic chemotherapy is shown in elderly patients, but it remains controversial whether they should receive the same chemotherapy used for younger patients."	( A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. Hou, MF; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, DC; Wu, IC; Yeh, YS, 2012)
" Treatment continued until disease progression or intolerable adverse events occurred."	( A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. Hou, MF; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, DC; Wu, IC; Yeh, YS, 2012)
"The mFOLFOX-4 therapy is an effective and safe first-line treatment for unresectable advanced or recurrent gastric cancer patients."	( A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. Hou, MF; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, DC; Wu, IC; Yeh, YS, 2012)
"The grades of neurosensory adverse events (NSAEs) induced by FOLFOX4 treatment were compared between Asian and Western colorectal cancer patients and correlated with cumulative oxaliplatin doses."	( Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. André, T; Brienza, S; Goldberg, RM; Gomi, K; Gramont, A; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012)
" The use of combined neoadjuvant chemotherapy is safe before hepatic resection."	( Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment. Baranyai, ZS; Besznyák, I; Bursics, A; Dede, K; Jakab, F; Landherr, L; Mersich, T; Salamon, F; Zaránd, A, 2013)
" Most treatment-related adverse events occurred at similar rates in both treatment arms."	( Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial. Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2013)
"Balancing efficacy and safety of drugs is key for successful cancer therapy, as adverse reactions can prohibit the use of efficacious treatments."	( Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Geskin, LJ; Koch, E; Story, SK, 2013)
" The most commonly reported adverse events in the FOLFOX6 cohorts included decreased appetite, neutropenia, diarrhea, peripheral neuropathy, and vomiting."	( An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS, 2013)
" The frequency of grade 3 and 4 adverse effects were comparatively assessed in each treatment arm."	( Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. Bano, N; Mateen, A; Najam, R, 2013)
" The most frequent adverse symptom of skin and subcutaneous toxicity reported in the patients treated with modified schedule of FOLFOX was pruritus (grade 1)."	( Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. Bano, N; Mateen, A; Najam, R, 2013)
" Simultaneous heterozygous UGT1A1 28 and UGT1A1 6 polymorphisms may produce higher exposure to SN-38 and a higher risk of adverse effects related to irinotecan."	( Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM, 2013)
" Grade 3/4 adverse events were: neutropenia (54."	( Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. Maruyama, S; Takii, Y, 2013)
" The bimonthly regimen of high dose leucovorin is reported to be less toxic and more effective as compared to the monthly regimen of low dose leucovorin."	( Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma. Bano, N; Mateen, A; Najam, R, 2013)
"Bevacizumab plus oxaliplatin-based treatment is safe and efficient as preoperative treatment of mCRC with primarily unresectable liver metastases."	( Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience. Cvetanovic, A; Filipovic, S; Milenkovic, D; Milenkovic, N; Pejcic, I; Vrbic, S; Zivkovic, N, )
" Recognizing this self-limiting toxic effect of oxaliplatin is important in order to avoid dose reductions that may affect clinical outcomes."	( A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria. Dasanu, CA; Joseph, R, 2014)
" The severity of OPN was assessed according to the Common Toxicity Criteria for Adverse Events at baseline, every 2 weeks until the 8th cycle, and every 4 weeks thereafter until the 26th week."	( Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. Fukunaga, M; Hata, T; Kojima, H; Kono, T; Matsui, T; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Sakamoto, J; Shimada, M; Takemoto, H, 2013)
"There were no statistically significant neuropathy differences among the study arms as measured by the primary end point or additional measures of neuropathy, including clinician-determined measurement of the time to grade 2 neuropathy by using the National Cancer Institute Common Terminology Criteria for Adverse Events scale or an oxaliplatin-specific neuropathy scale."	( Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Atherton, P; Dakhil, SR; Fehrenbacher, L; Flynn, KA; Grothey, A; Lewis, GC; Loprinzi, CL; Qamar, R; Qin, R; Seisler, D, 2014)
" The clinical efficacy and bevacizumab-related adverse reactions were observed."	( [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC]. Chen, Y; Cui, YH; Guo, X; Liu, TS; Yu, YY; Zhou, YH; Zhuang, RY, 2013)
" Severe toxic reactions to 5-FU have been associated with decreased levels of dihydropyrimidine dehydrogenase (DPD) enzyme activity."	( A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Diasio, RB; Lee, AM; McConnell, K; Offer, SM; Relias, V; Saif, MW, 2014)
"0144) adverse effects in stage II/III patients."	( Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. Beachler, C; El-Deiry, WS; Harvey, HA; Kline, CL; Mackley, HB; McKenna, K; Messaris, E; Poritz, L; Schiccitano, A; Sheikh, H; Sivik, J; Staveley-O'Carroll, K; Stewart, D; Zhu, J, 2014)
"We have planned a multicentre prospective study to examine the relative impact of the efficacy and adverse events of cetuximab plus first-line chemotherapy on the quality of life in Japanese patients with KRAS wild-type unresectable colorectal cancer."	( A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial. Ando, M; Fujii, H; Ooki, A; Sakamoto, J; Sato, A; Yamaguchi, K, 2014)
" This treatment should be considered regardless of patients' age alone, but consideration should be given to the capacity of patients to tolerate adverse events."	( Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. Bedenne, L; Bouvier, AM; Faivre, J; Hamza, S; Lepage, C; Rollot, F, 2014)
"8% and grade 3 or higher adverse events occurred in 12."	( A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study. Hasegawa, K; Ijichi, M; Kawasaki, S; Kokudo, N; Koyama, H; Makuuchi, M; Miyagawa, S; Oba, M; Saiura, A; Takayama, T; Teruya, M; Yamamoto, J; Yoshimi, F, 2014)
" The most frequent grade 3-4 adverse events included neutropenia (grade 3: 33."	( An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Asmis, TR; Ayoub, JP; Ballal, S; Cervantes, A; Garcia-Carbonero, R; Maurel, J; Moore, MJ; Nasroulah, F; Rivera, F; Schwartz, JD; Tabernero, J, 2014)
" The overall incidence of adverse events (AEs) was 75."	( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial. Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014)
"Oral UFT plus leucovorin given by either dosage schedule is a very safe regimen for adjuvant chemotherapy."	( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial. Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014)
" A series of adverse events were comparable between two arms, whereas some of the antibody therapy-associated toxicities were observed in FOLFIRI+PB arm."	( Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014)
" As psoriasis is an incurable disease, the goal of the MTX treatment is to suppress psoriasis, achieving long-term remissions with minimal treatment-related adverse events (AEs)."	( Folate supplementation reduces the side effects of methotrexate therapy for psoriasis. Baran, W; Batycka-Baran, A; Bieniek, A; Szepietowski, JC; Zychowska, M, 2014)
" The comparison revealed no significant differences in response rate, progression-free survival, overall survival, and the frequency of overall adverse events after the start of second-line chemotherapy, although the frequency of anemia(Bgrade 3, p=0."	( [The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older]. Baba, H; Chika, N; Haga, N; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Okada, N; Sano, M; Tajima, Y, 2014)
" R0 resection, survival, and adverse events were compared."	( Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. Li, Y; Sun, Z; Yang, GF; Zhu, RJ, 2014)
"The FOLFOX4 neoadjuvant chemotherapy could improve survival without increasing adverse events in patients with AGC."	( Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. Li, Y; Sun, Z; Yang, GF; Zhu, RJ, 2014)
" OBJECTIVE response rates (ORRs), progression-free survival (PFS), overall survival (OS) and adverse events were recorded, and the relationships between various clinical factors and PFS or OS were evaluated by Cox proportional hazards models."	( Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer. Chen, L; Ju, HX; Liu, BX; Liu, LY; Luo, C; Xu, Q; Yang, YS; Ying, JE; Zhao, YZ; Zhong, HJ; Zhu, LM, 2014)
" We studied whether haematological (leucopenia, neutropenia, thrombocytopenia) or non-haematological (mucositis, diarrhoea, nausea/vomiting, hand-foot syndrome or other toxicity) adverse events were associated with disease-free survival (DFS) or overall survival (OS) in a large patient material treated with 5-fluorouracil based adjuvant chemotherapy."	( Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014)
"Specific adverse events related to adjuvant fluorouracil chemotherapy are associated with improved DFS and OS in early stage CRC patients."	( Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014)
"To assess the frequency and severity of gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with four different schedules of FOLFOX."	( Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX. Bano, N; Mateen, A; Najam, R; Qazi, F, 2014)
" The severity of adverse effects (Grade 3 and 4) assessed in each treatment arm was compared."	( Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX. Bano, N; Mateen, A; Najam, R; Qazi, F, 2014)
" Radiofrequency ablation (RFA) is a safe and effective technique for treatment of isolated liver metastasis."	( Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer. Agarwal, A; Butler-Bowen, H; Daly, KP; Saif, MW, 2014)
"In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88."	( DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014)
" By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up."	( A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. Bleecker, JD; Pauwels, W; Vandamme, M, 2015)
"Peripheral sensory neurotoxicity is a frequent adverse effect of oxaliplatin therapy."	( Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Baba, H; Emi, Y; Higashijima, J; Ishida, H; Kakeji, Y; Kato, T; Kojima, H; Kon, M; Kono, T; Maehara, Y; Miyake, Y; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Shirabe, K; Takahashi, K; Tomita, N; Yamanaka, T, 2015)
" The primary endpoint was the time to grade 2 or greater neuropathy, which was determined at any point during or after oxaliplatin-based therapy using version 3 of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)."	( Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Baba, H; Emi, Y; Higashijima, J; Ishida, H; Kakeji, Y; Kato, T; Kojima, H; Kon, M; Kono, T; Maehara, Y; Miyake, Y; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Shirabe, K; Takahashi, K; Tomita, N; Yamanaka, T, 2015)
" The main side effect of pemetrexed is myelosuppression, which may be prevented by folinic acid supplementation."	( [Pemetrexed nephrotoxicity]. Izzedine, H, 2015)
"Modern anticancer chemotherapy can cause numerous adverse effects in the organism, whose functioning has already been disrupted by the neoplastic process itself."	( Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer. Filipczyk-Cisarż, E; Kowalska, T; Nartowski, K; Wiela-Hojeńska, A; Łapiński, Ł, )
"Docetaxel-cisplatin and 5-fluorouracil (TPF) chemotherapy (days 1-21) represents a standard but toxic regimen for advanced head and neck cancer (HNC)."	( Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. Breheret, R; Capitain, O; Laccourreye, L; Linot, B; Peyraga, G; Yossi, S, 2015)
"Dose-dense mTPF (days 1-14) is safe and seems to be as effective as TPF (days 1-21)."	( Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. Breheret, R; Capitain, O; Laccourreye, L; Linot, B; Peyraga, G; Yossi, S, 2015)
" The phase I dose escalation study revealed curcumin to be a safe and tolerable adjunct to FOLFOX chemotherapy in patients with CRLM (n = 12) at doses up to 2 grams daily."	( Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Berry, DP; Brown, K; Cai, H; Dennison, A; Garcea, G; Greaves, P; Griffin-Teal, N; Higgins, JA; Howells, LM; Irving, G; Iwuji, C; James, MI; Karmokar, A; Lloyd, DM; Metcalfe, M; Morgan, B; Patel, SR; Steward, WP; Thomas, A, 2015)
" Most grade ≥ 3 adverse events (AEs) were reported during the initial cycles of treatment."	( Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. Díaz de Corcuera, I; García de la Torre, M; Pérez Hoyos, MT; Salgado Fernández, M; Vidal Arbués, A, 2015)
"Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC)."	( Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. Fausti, V; Gallo, P; Imperatori, M; Picardi, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vespasiani Gentilucci, U; Vincenzi, B, 2015)
" All patients experienced at least one grade 3 or higher adverse event: neutropenia (five patients, 83%), proteinuria (two patients; 33%) and anemia, thrombocytopenia and hypertension (one patient each, 17%)."	( Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. Gao, L; Gotoh, M; Nasroulah, F; Ohtsu, A; Yamazaki, K; Yoshino, T; Yoshizuka, N, 2015)
" There was no statistically significant difference in the rates of grade 3-4 adverse events (EOX 79."	( Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. Budzynski, A; Fijorek, K; Konopka, K; Krzemieniecki, K; Lazar, A; Matlok, M; Ochenduszko, S; Pedziwiatr, M; Puskulluoglu, M; Sinczak-Kuta, A; Urbanczyk, K, 2015)
" Despite heterogeneity in response to aflibercept, no biomarkers for efficacy or adverse effects have been identified."	( Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Chiron, M; Folprecht, G; Lambrechts, D; Margherini, E; Moisse, M; Pericay, C; Peuteman, G; Sagaert, X; Thienpont, B; Thuillier, V; Van Cutsem, E; Zalcberg, J; Zilocchi, C, 2015)
" We assessed correlations of these three classes of biomarkers with progression-free survival (PFS) and adverse events (AEs)."	( Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Chiron, M; Folprecht, G; Lambrechts, D; Margherini, E; Moisse, M; Pericay, C; Peuteman, G; Sagaert, X; Thienpont, B; Thuillier, V; Van Cutsem, E; Zalcberg, J; Zilocchi, C, 2015)
"The combination of 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX) is considered the first-line chemotherapy for fit patients with advanced pancreatic ductal adenocarcinoma (PDAC) but carries an unfavourable adverse event (AE) profile."	( Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. Basu, B; Calder, J; Corrie, P; Ghorani, E; Hewitt, C; Wong, HH, 2015)
" Then the recovery time of bowel function, the incidence of adverse reactions and complications, and the pre- and post-chemotherapy routine blood tests and hepatorenal functions were compared."	( [Safety evaluation of intraoperative peritoneal chemotherapy with Lobaplatin for advanced colorectal cancers]. Feng, L; Liu, Q; Liu, Y; Wu, X; Xia, D; Xu, L, 2015)
"Peritoneal implantation of Lobaplatin as intraoperative chemotherapy for advanced colorectal cancer is safe and tolerable."	( [Safety evaluation of intraoperative peritoneal chemotherapy with Lobaplatin for advanced colorectal cancers]. Feng, L; Liu, Q; Liu, Y; Wu, X; Xia, D; Xu, L, 2015)
" The primary objective was to investigate the incidence of adverse drug reactions, particularly those of interest for bevacizumab."	( Bevacizumab safety in Japanese patients with colorectal cancer. Doi, T; Hatake, K; Ishihara, Y; Shirao, K; Takahashi, Y; Uetake, H, 2016)
"5%) were the most common adverse drug reaction."	( Bevacizumab safety in Japanese patients with colorectal cancer. Doi, T; Hatake, K; Ishihara, Y; Shirao, K; Takahashi, Y; Uetake, H, 2016)
" Toxicity over four cycles was graded according to NCI Common Toxicity Criteria V2 or V3 (Common Terminology Criteria for Adverse Events, National Cancer Institute, Bethesda, MD)."	( Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Ali, R; Assenat, E; Baracos, VE; Bianchi, L; Mollevi, C; Roberts, S; Sawyer, MB; Senesse, P, 2016)
" We evaluated the safety and tolerability of ATII-cell transplantation by assessing the emergent adverse side effects that appeared within 12 months."	( Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis. Arguis, P; Bayas, JM; Burgos, F; Closa, D; de la Bellacasa, JP; Fiblà, JJ; Gay-Jordi, G; Guillamat-Prats, R; Hernandez-Gonzalez, F; Marin, P; Martorell, J; Molins, L; Ramirez, J; Rodríguez-Villar, C; Rovira, I; Sánchez, M; Serrano-Mollar, A; Soy, D; Tetley, TD; Xaubet, A, 2016)
"No significant adverse events were associated with the ATII-cell intratracheal transplantation."	( Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis. Arguis, P; Bayas, JM; Burgos, F; Closa, D; de la Bellacasa, JP; Fiblà, JJ; Gay-Jordi, G; Guillamat-Prats, R; Hernandez-Gonzalez, F; Marin, P; Martorell, J; Molins, L; Ramirez, J; Rodríguez-Villar, C; Rovira, I; Sánchez, M; Serrano-Mollar, A; Soy, D; Tetley, TD; Xaubet, A, 2016)
"Our results support the hypothesis that ATII-cell intratracheal transplantation is safe and well tolerated in patients with IPF."	( Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis. Arguis, P; Bayas, JM; Burgos, F; Closa, D; de la Bellacasa, JP; Fiblà, JJ; Gay-Jordi, G; Guillamat-Prats, R; Hernandez-Gonzalez, F; Marin, P; Martorell, J; Molins, L; Ramirez, J; Rodríguez-Villar, C; Rovira, I; Sánchez, M; Serrano-Mollar, A; Soy, D; Tetley, TD; Xaubet, A, 2016)
" We evaluated treatment-related adverse events (AEs), progression-free survival (PFS) and overall survival (OS)."	( Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer. Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A, 2016)
" This infusion rate is safe for use in routine practice."	( Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min. Cercek, A; Kemeny, NE; Park, V; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Stadler, ZK; Varghese, A; Yaeger, R, 2016)
" All adverse events resolved with supportive management."	( Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G, 2016)
"Traditional methods of reporting adverse events in clinical trials are inadequate for modern cancer treatments with chronic administration."	( Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G, 2016)
"We developed an analytic approach and standardised, comprehensive format, the Toxicity over Time (ToxT) approach, which combines graphs and adverse event tabular displays with multiple longitudinal statistical techniques into a readily applicable method to study toxic effects."	( Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G, 2016)
"The ToxT analytical approach incorporates the dimension of time into adverse event assessment and offers a more comprehensive depiction of toxic effects than present methods."	( Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G, 2016)
"4% experienced grade 3/4 adverse events."	( Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. Becouarn, Y; Fourrier-Réglat, A; Grelaud, A; Guimbaud, R; Jové, J; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N, 2016)
"The present study adds to the literature on the safe and beneficial effect of bevacizumab in the elderly receiving FOLFIRI regimen."	( Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. Becouarn, Y; Fourrier-Réglat, A; Grelaud, A; Guimbaud, R; Jové, J; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N, 2016)
" The risk of mortality, therapeutic efficacy, and adverse effect were meta-analyzed."	( Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T, 2016)
" The most frequent grade 3/4 adverse events were nausea (18."	( Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. Bodoky, G; Harsanyi, L; Hegyi, P; Lakatos, G; Nehéz, L; Petranyi, A; Szűcs, A, 2017)
" Previous studies have suggested that apatinib is safe and effective in some solid tumors."	( Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Kong, L; Kou, P; Shao, W; Wang, H; Yu, J; Zhang, J; Zhang, Y; Zhu, H, 2017)
" The frequency and severity of these adverse events vary from patient to patient and are partially explained by genetic polymorphism into the dihydropyrimidine dehydrogenase (DPYD) gene."	( Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms. Cergnul, M; Cheli, S; Falvella, FS; Fava, S; Luoni, M, 2017)
"There is little data on the frequency of adverse events following acute methotrexate ingestions in pediatric patients."	( Evaluation of toxicity after acute accidental methotrexate ingestions in children under 6 years old: a 16-year multi-center review. Beuhler, MC; Hays, H; Mowry, JB; Ryan, ML; Spiller, HA; Spiller, NE; Webb, A; Weber, J, 2018)
" Treatment-emergent adverse events (AEs) were comparable for patients <65years and ≥65years old."	( Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. Dochy, E; Lakomy, R; Macarulla, T; Magherini, E; Moiseyenko, VM; Papamichael, D; Prausova, J; Ruff, P; Soussan-Lazard, K; Van Cutsem, E; van Hazel, GA, 2018)
" Demographics, disease presentation, initial treatment plan, treatment outcome, and treatment-related adverse events were assessed."	( Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Berkowitz, RS; de Freitas Segalla Moreira, M; Elias, KM; Goldstein, DP; Horowitz, NS; Maestá, I; Nitecki, R, 2018)
"001) and need to switch to second-line therapy due to treatment-related adverse events (5."	( Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Berkowitz, RS; de Freitas Segalla Moreira, M; Elias, KM; Goldstein, DP; Horowitz, NS; Maestá, I; Nitecki, R, 2018)
" Although treatment-related adverse events were more frequent with 8-day MTX/FA, these were all self-limited and resolved with no long-term sequelae."	( Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Berkowitz, RS; de Freitas Segalla Moreira, M; Elias, KM; Goldstein, DP; Horowitz, NS; Maestá, I; Nitecki, R, 2018)
"To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients."	( Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer. Arpaci, E; Demir, H; Eker, B; Gokmen Erdem, U; Inanc, M; Karaagac, M; Kiziltepe, M; Metin Seker, M; Ozaslan, E; Ozkan, M; Topaloglu, US, )
" The overall incidence of any Grade adverse events (AEs) were 91."	( Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. Aiba, K; Baba, H; Boku, N; Ishiguro, M; Itabashi, M; Kotake, K; Kunieda, K; Kusumoto, T; Maeda, A; Mochizuki, I; Morita, S; Okabe, M; Ota, M; Sakamoto, Y; Sugihara, K; Sunami, E; Takahashi, K; Tomita, N; Yamauchi, J; Yoshida, K, 2018)
"Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor."	( EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S, 2018)
"The primary end point was the 10-month progression-free rate (PFR); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events."	( Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V, 2018)
" Main grade 3/4 adverse events were neutropenia (occurring in 36 patients [31%]), diarrhea (in 21 patients [18%]), skin toxic effects (in 18 patients [16%]), asthenia (in 11 patients [9%]), stomatitis (in 7 patients [6%]), and febrile neutropenia (in 3 patients [3%])."	( Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V, 2018)
" We calculated the incidence of "any-grade" and "severe" toxicity for haematological and non-haematological adverse events of each group."	( A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. Baratelli, C; Brizzi, MP; Di Maio, M; Scagliotti, GV; Sonetto, C; Tampellini, M; Zichi, C, 2018)
" Secondary endpoints were the incidence of adverse events (AEs) and the completion rate of study therapy."	( Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study). Ishibashi, K; Ishida, H; Kato, H; Kato, R; Koda, K; Kosugi, C; Mori, M; Narushima, K; Oya, M; Shuto, K; Tanaka, S; Yoshimatsu, K, 2018)
" Treatment-emergent adverse events were reported in 97."	( Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018)
" It did not affect HRQL and showed similar rates of treatment-emergent adverse events as those observed in the VELOUR trial."	( Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018)
" The objective of this study was to compare outcome measures, adverse effects, and cost of FOLFOX4 and FOLFIRINOX treatments in rectal cancer patients."	( Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study. Chen, Y; Liu, J; Qi, F; Yan, Q; Zhang, G; Zheng, Z, 2018)
"FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects."	( The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Fan, Z; Liu, B; Lu, T; Tong, H, 2018)
" The most common grade 3/4 adverse events were neutropenia (13 patients, 18%), febrile neutropenia (3 patients, 4%), diarrhea (11 patients, 15%), hypertension (19 patients, 26%), proteinuria (8 patients, 11%), infections (8 patients, 11%), and mucositis (6 patients, 8%), with no toxic deaths."	( AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. Aravantinos, G; Bafaloukos, D; Efstratiou, I; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeropoulou, L; Karavasilis, V; Kentepozidis, N; Koliou, GA; Kotoula, V; Koumakis, G; Laschos, K; Pectasides, D; Pentheroudakis, G; Petraki, C; Poulios, C; Samantas, E; Sgouros, J; Souglakos, I; Tikas, I; Voutsina, A; Vrettou, E; Zarkavelis, G, 2018)
" Preliminary data hint that this regimen has cytoreductive activity in disease with adverse biology."	( AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. Aravantinos, G; Bafaloukos, D; Efstratiou, I; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeropoulou, L; Karavasilis, V; Kentepozidis, N; Koliou, GA; Kotoula, V; Koumakis, G; Laschos, K; Pectasides, D; Pentheroudakis, G; Petraki, C; Poulios, C; Samantas, E; Sgouros, J; Souglakos, I; Tikas, I; Voutsina, A; Vrettou, E; Zarkavelis, G, 2018)
" Main grade 3 or 4 adverse events in patients were neutropenia in 69 cases (22."	( [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. Cai, Y; Deng, R; Deng, Y; Hu, H; Li, J; Ling, J; Wu, Z; Yang, L; Zhang, J, 2018)
" Overall, grade 3 adverse events, such as leukopenia and neutropenia, were observed in two of three patients (66."	( Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019)
"The adverse events of mFOLFOX6-bevacizumab or CapeOX-bevacizumab in combination with ip PTX were considered similar to those described in previous studies of oxaliplatin-based treatment alone."	( Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019)
" The current study aims at evaluating the patterns and predictors of cardiac adverse events associated with various 5-FU-based systemic therapy regimens among patients with metastatic colorectal cancer."	( 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. Abdel-Rahman, O, 2019)
"Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition."	( Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. Aikawa, T; Akashi, K; Ariyama, H; Baba, E; Doi, Y; Esaki, T; Ito, M; Kobayashi, K; Kusaba, H; Makiyama, A; Mitsugi, K; Shimokawa, H; Takayoshi, K; Tsuchihashi, K; Uenomachi, M; Yoshihiro, T, 2019)
" Neurological adverse effects were assessed by CTC v2."	( Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens. Bano, N; Ikram, R, 2019)
" We included patients with rectal cancer who received 4 courses of modified FOLFOX6 (mFOLFOX6) before rectal surgery and examined the postoperative complication rate, the clinicopathological response, and the rate of chemotherapy-related adverse events (UMIN 000012559)."	( Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study. Funakoshi, T; Hattori, M; Hirose, K; Homma, S; Ichikawa, N; Iijima, H; Ishikawa, T; Ishizu, H; Kamiizumi, Y; Kawamata, F; Koike, M; Kon, H; Kuraya, D; Minagawa, N; Murata, R; Nomura, M; Ohno, Y; Omori, K; Sato, M; Takahashi, N; Takeda, K; Taketomi, A; Yokota, R; Yoshida, T, 2019)
"Surgery after four courses of mFOLFOX6 chemotherapy can be a safe and promising strategy for patients with locally advanced rectal cancer."	( Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study. Funakoshi, T; Hattori, M; Hirose, K; Homma, S; Ichikawa, N; Iijima, H; Ishikawa, T; Ishizu, H; Kamiizumi, Y; Kawamata, F; Koike, M; Kon, H; Kuraya, D; Minagawa, N; Murata, R; Nomura, M; Ohno, Y; Omori, K; Sato, M; Takahashi, N; Takeda, K; Taketomi, A; Yokota, R; Yoshida, T, 2019)
"Addition of daily oral curcumin to FOLFOX chemotherapy was safe and tolerable (primary outcome)."	( Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. Barber, S; Brown, K; Foreman, N; Gescher, A; Griffin-Teall, N; Howells, LM; Irving, GRB; Iwuji, COO; Morgan, B; Patel, SR; Sidat, Z; Singh, R; Steward, WP; Thomas, AL; Walter, H, 2019)
"Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer."	( Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. Barber, S; Brown, K; Foreman, N; Gescher, A; Griffin-Teall, N; Howells, LM; Irving, GRB; Iwuji, COO; Morgan, B; Patel, SR; Sidat, Z; Singh, R; Steward, WP; Thomas, AL; Walter, H, 2019)
"Methotrexate (MTX) increases the risk of alopecia and stomatitis, but the prevalence of these adverse events among rheumatic patients taking MTX is poorly defined."	( Low-Dose Methotrexate and Mucocutaneous Adverse Events: Results of a Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials. Lalani, R; Lyu, H; Solomon, DH; Vanni, K, 2020)
"This meta-analysis gives more precise estimates of mucocutaneous adverse events that occur in rheumatic disease patients taking MTX."	( Low-Dose Methotrexate and Mucocutaneous Adverse Events: Results of a Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials. Lalani, R; Lyu, H; Solomon, DH; Vanni, K, 2020)
" Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284)."	( Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S, 2019)
"9%) in arm B experienced grade 3/4 adverse events related to bevacizumab; the most frequent were 2 anastomotic fistulas (both in arm A) and abscesses (1 in arm A and 2 in arm B)."	( Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. Adenis, A; André, T; Azria, D; Bachet, JB; Balosso, J; Ben Abdelghani, M; Borg, C; Boudghène, F; Conroy, T; Coudert, M; François, Y; Ghiringhelli, F; Ionescu-Goga, M; Lakkis, Z; Mantion, G; Mornex, F; Quero, L; Rio, E; Roullet, B; Spaëth, D; Tanang, A; Vendrely, V, 2019)
" Until now, only a few mild adverse drug reactions (ADRs) have been published after short-term use of LDMTX, and no severe cases have been reported."	( Severe toxic effects of low-dose methotrexate treatment for placenta accreta in a patient with methylenetetrahydrofolate reductase mutations. Guo, H; Hu, K; Liu, W; Tan, Z; Zhao, R, 2020)
" The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs)."	( Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G, 2019)
"Studies of patients treated with bevacizumab and other vascular epithelial growth factor (VEGF) inhibitors have reported that hypertension adverse events (AEs) are associated with improved overall survival (OS) or progression-free survival (PFS)."	( Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. Hopkins, AM; Karapetis, CS; Lim, HH; Rowland, A; Sorich, MJ; Yuen, HY, 2019)
" The secondary endpoints were chronic cumulative neurotoxicity (EORTC QLQ-CIPN20), time to grade 2 neurotoxicity (NCI-CTCAE or the oxaliplatin-specific neuropathy scale), acute neurotoxicity (analog scale), rates of dose reduction or withdrawal due to OIPN, 3-year disease-free survival (DFS) and adverse events."	( Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. Chen, G; Deng, YH; Ding, PR; Fan, WH; Feng, F; Jin, Y; Li, YH; Liang, HL; Lu, ZH; Peng, JW; Ren, C; Shi, SM; Wang, DS; Wang, F; Wang, FH; Wang, W; Wang, ZQ; Xie, CB; Xu, RH; Zhang, JW, 2020)
" However, their use in the elderly is discouraged because of adverse events."	( The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC, 2020)
" The objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse events were compared between the groups."	( The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC, 2020)
" However, the elderly patients suffered a higher incidence of severe adverse events (50% vs."	( The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC, 2020)
" In stage two, an additional 20 patients were enrolled at a starting dose as defined in stage one, provided that in stage ≥1 objective response or ≥2 stable diseases were observed and ≤3 patients had serious adverse events (SAEs) within the first 6 weeks of treatment."	( Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. Belkouz, A; de Vos-Geelen, J; Eskens, FALM; Klümpen, HJ; Mathôt, RAA; Punt, CJA; van Gulik, TM; van Oijen, MGH; Wilmink, JW, 2020)
" One patient had a SAE during the first 6 weeks of treatment, and five patients required a dose reduction due to adverse events."	( Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. Belkouz, A; de Vos-Geelen, J; Eskens, FALM; Klümpen, HJ; Mathôt, RAA; Punt, CJA; van Gulik, TM; van Oijen, MGH; Wilmink, JW, 2020)
" However, intestinal mucositis is a common adverse effect for which no effective preventive strategies exist."	( Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. Chang, CW; Chen, MJ; Chen, YJ; Chiang Chiau, JS; Chuang, WH; Lee, HC; Li, LH; Liu, CY; Shih, SC; Tsai, TH; Wang, HY; Wang, TE, 2020)
"SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer."	( Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer. Han, JG; Wang, YB; Wang, ZJ; Wei, GH; Yi, BQ; Zeng, WG; Zhai, ZW; Zhao, BC, 2020)
" However, its efficacy is often limited by adverse effects, such as intestinal toxicity."	( Leucovorin ameliorated methotrexate induced intestinal toxicity via modulation of the gut microbiota. Chen, L; Fang, Q; Huang, X; Ouyang, D; Rao, T; Tan, Z; Zeng, X; Zhou, L, 2020)
" A modified FOLFOXIRI regimen is also widely used to reduce adverse events."	( Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience. Adachi, T; Eguchi, S; Enjoji, T; Hidaka, M; Inoue, Y; Ito, S; Kanetaka, K; Kobayashi, K; Kosaka, T; Kuba, S; Okada, S; Takatsuki, M; Tetsuo, H; Torashima, Y; Yamaguchi, S; Yamanouchi, K, 2020)
" In addition, grade 3 and 4 adverse events are found to be higher in panitumumab group than those in control group (RR = 1."	( The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. Chen, S; Chen, X; Tan, C; Wang, C, 2020)
"Panitumumab supplementation can provide some improvement in objective response for colorectal cancer patients with WT KRAS, but results in the increase in grade 3 and 4 adverse events."	( The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. Chen, S; Chen, X; Tan, C; Wang, C, 2020)
" In 15 patients (40%) 21 serious adverse events related to debulking were reported."	( Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. Bakkerus, L; Buffart, TE; de Groot, JB; Gootjes, EC; Grunhagen, DJ; Haasbeek, CJA; Hendriks, MP; Labots, M; Meijerink, MR; Nuyttens, JJME; Ten Tije, AJ; Tuynman, JB; van de Ven, PM; van der Stok, EP; van Meerten, E; Verheul, HMW; Verhoef, C; Zonderhuis, BM, 2020)
"Tumor debulking is feasible and does not prohibit administration of palliative chemotherapy in the majority of patients with multiorgan mCRC, despite the occurrence of serious adverse events related to local treatment."	( Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. Bakkerus, L; Buffart, TE; de Groot, JB; Gootjes, EC; Grunhagen, DJ; Haasbeek, CJA; Hendriks, MP; Labots, M; Meijerink, MR; Nuyttens, JJME; Ten Tije, AJ; Tuynman, JB; van de Ven, PM; van der Stok, EP; van Meerten, E; Verheul, HMW; Verhoef, C; Zonderhuis, BM, 2020)
"This first prospective randomized trial on tumor debulking in addition to chemotherapy shows that local treatment of metastases is feasible in patients with multiorgan metastatic colorectal cancer and does not prohibit administration of palliative systemic therapy, despite the occurrence of serious adverse events related to local treatment."	( Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. Bakkerus, L; Buffart, TE; de Groot, JB; Gootjes, EC; Grunhagen, DJ; Haasbeek, CJA; Hendriks, MP; Labots, M; Meijerink, MR; Nuyttens, JJME; Ten Tije, AJ; Tuynman, JB; van de Ven, PM; van der Stok, EP; van Meerten, E; Verheul, HMW; Verhoef, C; Zonderhuis, BM, 2020)
" There was no association between IVS14 + 1 G > A polymorphism and the occurrence of adverse reactions."	( Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E, 2020)
"FOLFOX and FOLFIRI were the most common regimens in CRC patients and their toxicity profile was different in some adverse reactions."	( Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E, 2020)
" No toxic death was observed."	( Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J, 2020)
" A latent class analysis defined the unobserved latent constructs that can be predicted as symptom clusters, considering the intensity of four types of adverse events (AEs)."	( Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis. Cacho Lavin, D; Calderón, C; Carmona-Bayonas, A; Gomez, D; Jimenez-Fonseca, P; Martinez Cabañez, R; Muñoz, MM, 2021)
" We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)."	( FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020)
"The strategy of monitoring MTX concentration at 54 h was safe in our cohort."	( Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India. Dhingra, H; Kalra, M; Mahajan, A, 2020)
" Whether a patient who experienced a major cardiac side effect from 5-FU can be safely rechallenged with this drug is a clinical dilemma."	( 5-Fluorouracil Rechallenge After Cardiotoxicity. Almnajam, M; Desai, A; Kim, AS; Mohammed, T; Patel, KN, 2020)
" Adverse event data collection is recorded at every visit."	( Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. Al Awabdeh, T; Al Darazi, M; Al Masri, M; Alqasem, K; Amarin, R; Charafeddine, M; Dabous, A; Daoud, F; Deeba, S; El Husseini, Z; Elkhaldi, M; Geara, F; Hushki, A; Jaber, O; Jamali, F; Kattan, J; Khalifeh, I; Kreidieh, M; Mohamad, I; Mukherji, D; Shamseddine, A; Temraz, S; Turfa, R; Zeidan, YH, 2020)
" The protocol regimen was well tolerated with no serious adverse events of grade 4 reported."	( Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. Al Awabdeh, T; Al Darazi, M; Al Masri, M; Alqasem, K; Amarin, R; Charafeddine, M; Dabous, A; Daoud, F; Deeba, S; El Husseini, Z; Elkhaldi, M; Geara, F; Hushki, A; Jaber, O; Jamali, F; Kattan, J; Khalifeh, I; Kreidieh, M; Mohamad, I; Mukherji, D; Shamseddine, A; Temraz, S; Turfa, R; Zeidan, YH, 2020)
"In patients with LARC, neoadjuvant radiation followed by mFOLFOX6 with avelumab is safe with a promising pathologic response rate."	( Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. Al Awabdeh, T; Al Darazi, M; Al Masri, M; Alqasem, K; Amarin, R; Charafeddine, M; Dabous, A; Daoud, F; Deeba, S; El Husseini, Z; Elkhaldi, M; Geara, F; Hushki, A; Jaber, O; Jamali, F; Kattan, J; Khalifeh, I; Kreidieh, M; Mohamad, I; Mukherji, D; Shamseddine, A; Temraz, S; Turfa, R; Zeidan, YH, 2020)
" We evaluated the associations between the UGT1A1 genotype linked to adverse events-caused by irinotecan-and the efficacy and safety of mXELIRI and FOLFIRI."	( Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. Ahn, JB; Bai, L; Cho, SH; Fang, WJ; Han, SW; Hong, YS; Iwasa, S; Kim, TW; Kotaka, M; Lee, KW; Matsuoka, H; Morita, S; Muro, K; Nakamura, M; Nishina, T; Park, YS; Sakamoto, J; Yamada, Y; Yuan, XL; Yuan, Y; Zhang, DS, 2021)
" And the incidence of gastrointestinal adverse reactions (OR = 1."	( The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis. Chen, D; Liu, W; Wang, X; You, J; Zhang, H; Zhang, S, 2021)
"BEV combined with the FOLFOX regimen is more effective than the FOLFOX regimen alone in the treatment of advanced colorectal cancer, but it may also increase the risk of gastrointestinal adverse reactions."	( The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis. Chen, D; Liu, W; Wang, X; You, J; Zhang, H; Zhang, S, 2021)
" Patients exhibiting EWL had worse survival and higher frequencies of adverse events."	( Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022)
" Its use may associate with adverse effects presumably originating from folate deficiency."	( Rescuing effect of folates on methotrexate cytotoxicity in human trophoblast cells. Ravaei, A; Rubini, M, 2022)
"Despite the general acceptance of administering FA to prevent adverse events of MTX therapy, our findings suggest that FA may not be optimal, and indicate FTHF or MTHF as a better choice."	( Rescuing effect of folates on methotrexate cytotoxicity in human trophoblast cells. Ravaei, A; Rubini, M, 2022)
" Grade ≥ 3 adverse events were more frequently observed in group O (90 vs."	( Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N, 2022)
"Machine learning (ML) algorithms have been used to forecast clinical outcomes or drug adverse effects by analyzing different data sets such as electronic health records, diagnostic data, and molecular data."	( Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity. Bedon, L; Buonadonna, A; Cecchin, E; Dal Bo, M; Fabbiani, E; Polano, M; Toffoli, G, 2022)
"Aflibercept in combination with FOLFIRI chemotherapy is an established safe and efficacious regimen for the treatment of mCRC as second-line chemotherapy."	( Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Chau, I; Lau, DK; Mencel, J, 2022)
" Common Terminology Criteria for Adverse Events v4."	( Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study. Alyami, M; Bakrin, N; Bardet, SM; Dumont, F; Durand Fontanier, S; Eveno, C; Gagniere, J; Glehen, O; Hübner, M; Pache, B; Pocard, M; Quenet, F; Sgarbura, O; Taibi, A; Teixeira Farinha, H; Thibaudeau, E, 2022)
" A total of 514 adverse events (AEs) occurred in 134 patients, of which 206 (49."	( Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY, 2023)
"Chemotherapy-related adverse events (AEs) can negatively impact the care of patients."	( Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022)
"In patients with mPDAC who received second-line therapy, those who received liposomal irinotecan-based regimens had the lowest rates of anemia, neutropenia, and thrombocytopenia compared to FOLFIRI, FOLFIRINOX, and FOLFOX, while requiring a similar or lower level of medication to treat and manage those adverse events."	( Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022)
" Patient characteristics were evaluated with multiple regression analyses for survival outcomes, using the Cox proportional hazard model and linear regression analyses for the worst grade of adverse events."	( Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. Amagai, K; Bando, Y; Denda, T; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Morimoto, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y, 2022)
" The study treatment was discontinued due to adverse events in 19 patients (18."	( Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. Amagai, K; Bando, Y; Denda, T; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Morimoto, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y, 2022)
"The efficacy of fluoropyrimidine plus bevacizumab was age-independent in patients with metastatic colorectal cancer aged ≥75 years, and attention should be paid to non-hematologic adverse events as age increases."	( Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. Amagai, K; Bando, Y; Denda, T; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Morimoto, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y, 2022)
" Pooled analyses for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and grade 3/4 treatment-emergent adverse events (TRAEs) were undertaken."	( Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis. Li, X; Lu, W; Tang, K; Wang, L, 2022)
" However, grade 3/4 adverse events were more frequently reported in patients administered FOLFIRINOX compared with the other three regimens."	( Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis. Li, X; Lu, W; Tang, K; Wang, L, 2022)
" The most frequent grade 3/4 adverse events were: asthenia (21."	( Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. Alonso de Castro, B; Cameselle García, S; Carmona Campos, M; Cousillas Castiñeiras, A; De la Cámara Gómez, JC; Fernández-Montes, A; Gómez-Randulfe Rodríguez, MI; González Villarroel, P; Martínez-Lago, N; Méndez Méndez, JC; Romero Reinoso, C; Salgado Fernández, M; Vidal Insua, Y, 2022)
" We followed up these patients and analyzed the relapse-free survival (RFS), overall survival (OS), and chemotherapy-induced adverse events (AEs)."	( A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma. Dai, H; Feng, W; Tang, C; Yao, L, 2022)
" The rate of adverse reactions such as hematological toxicity, neutropenia, anemia, thrombocytopenia, nonhematological toxicity, vomiting, fatigue, infection, diarrhea, intestinal obstruction, and peripheral neuropathy was lower in 10."	( Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer. Dai, S; Jiang, C; Wu, Z; Zhou, L, 2022)
"PDL1/PD-1 inhibitors in combination with FOLFIRINOX regimens have shown longer survival than treatment with FOLFIRINOX regimens for pancreatic cancer patients, with reliable clinical efficacy, tolerable adverse effects, and a high safety profile for patients."	( Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer. Dai, S; Jiang, C; Wu, Z; Zhou, L, 2022)
" Treatment regimens, body surface area, dosage, number of treatment courses, and adverse events( AEs) were evaluated."	( [Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma]. Iwai, M; Kimura, M; Usami, E; Yoshimura, T, 2022)
" The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated."	( Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S, 2022)
" Adverse events were manageable, although gastrointestinal symptoms and neutropenia were observed."	( Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S, 2022)
" The adverse events were also analyzed."	( Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022)
" The incidence of any grade of adverse events (AEs) was 96."	( Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022)
" This series highlights the importance of thorough counseling for patients regarding the course of disease for which methotrexate is prescribed and the dosing, schedule, and adverse effects that are associated with methotrexate."	( Methotrexate Toxicity: A Case Series from a Tertiary Care Center in Northern India. Bhardwaj, N; Chauhan, P; Jindal, R; Roy, S, 2022)
" The criteria for the inclusion of studies were previously defined based on the two secondary goals addressed in this review: 1) To analyze the magnitude of the differences in clinical responses and 2) To study the magnitude of the differences in adverse effects of irinotecan at high doses, as compared to the doses described in the summary of product characteristics corresponding to the FOLFIRI regimen in patients with metastatic colorectal cancer with genotypes UGT1A11/ 1 or 1/28."	( Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review. García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P, 2022)
"Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment."	( The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y, 2022)
" Most commonly, it is associated with coronary vasospasm secondary to direct toxic effects on vascular endothelium."	( Managing life-threatening 5-fluorouracil cardiotoxicity. Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022)
" However, severe adverse effects due to irinotecan have been observed even in patients who do not harbor UGT1A128 or 6."	( Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S, 2023)
"We analyzed the incidence, time to first onset, and time to resolution for adverse events that require special attention and other selected toxicities in the nal-IRI combination group (n = 46)."	( Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M, 2023)
"3%) were the most commonly reported treatment-emergent adverse events, with a median time to onset of 21."	( Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M, 2023)
" Although the treatment-emergent adverse events occurred were controllable, patients with prolonged toxicities should be closely managed."	( Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M, 2023)
" It was observed that there were fewer adverse events compared to the VELOUR trial."	( Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. Acar, R; Akbas, S; Akinci, MB; Araz, M; Arslan, C; Artac, M; Bahceci, A; Bilgetekin, I; Bilici, A; Cakir, E; Celik, E; Cilbir, E; Cincin, I; Dede, DS; Demirkiran, A; Deniz, GI; Dogan, I; Erdem, D; Erdogan, AP; Eren, OO; Erol, C; Garbioglu, DB; Gulmez, A; Hacibekiroglu, I; Hamdard, J; Hizal, M; Inal, A; Kahraman, S; Kaya, AO; Koca, S; Kubilay, P; Kucukarda, A; Kut, E; Mandel, NM; Menekse, S; Nayir, E; Oksuzoglu, B; On, S; Oyman, A; Ozyukseler, DT; Paydas, S; Sakin, A; Sen, E; Sendur Mehmet, AN; Sevinc, A; Taskaynatan, H; Tastekin, D; Turhal, S; Uncu, D; Yalcin, B; Yildirim, ME, 2022)
"Our meta-analysis shows that the aflibercept plus FOLFIRI combination shows better survival efficacies however; it is also associated with more high-grade adverse events."	( A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety. Chorawala, MR; Patel, RS; Thakur, A, 2023)
"In clinical trials, the assessment of safety is traditionally focused on the overall rate of high-grade and serious adverse events (AEs)."	( Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. Boccaccino, A; Bustreo, S; Carullo, M; Clavarezza, M; Cremolini, C; Cupini, S; Daniel, F; Libertini, M; Lonardi, S; Morano, F; Niger, M; Palermo, F; Pietrantonio, F; Procaccio, L; Raimondi, A; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A, 2023)
"We reported a patient with rheumatoid arthritis who received chronic methotrexate (MTX) therapy and experienced several adverse reactions like hemocytopenia and renal impairment."	( Calcium Folate for Reducing the Side Effects of Low-dose Methotrexate in Rheumatoid Arthritis: A Case Report. Hu, Y; Liu, R; Liu, X; Yan, Q, 2024)
"A 66-year-old man with rheumatoid arthritis received MTX and developed adverse effects of bone marrow suppression, like pancytopenia."	( Calcium Folate for Reducing the Side Effects of Low-dose Methotrexate in Rheumatoid Arthritis: A Case Report. Hu, Y; Liu, R; Liu, X; Yan, Q, 2024)
"Low-dose MTX has fewer adverse reactions but may cause bone marrow suppression- related side effects."	( Calcium Folate for Reducing the Side Effects of Low-dose Methotrexate in Rheumatoid Arthritis: A Case Report. Hu, Y; Liu, R; Liu, X; Yan, Q, 2024)
"The incidence of chemotherapy-related adverse events in colorectal cancer patients with renal insufficiency has been compared to patients with normal renal function in only a few studies."	( Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Tanaka, K; Yamagishi, H; Yoshikawa, T, 2023)
"As Grade 3 adverse events, hematological toxicities, such as neutropenia and anemia, and gastrointestinal disorders, such as diarrhea and vomiting, were significantly more frequent in the L3-4 group."	( Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Tanaka, K; Yamagishi, H; Yoshikawa, T, 2023)
" Since adverse events have the potential to shorten the duration of treatment, especially when using chemotherapy without oxaliplatin, careful management, including dose reduction, may be important in patients with renal insufficiency."	( Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Tanaka, K; Yamagishi, H; Yoshikawa, T, 2023)
" Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy."	( Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212 Alig, AHS; Caca, K; Fruehauf, S; Goekkurt, E; Graeven, U; Haas, S; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; König, AO; Kretzschmar, A; Kurreck, A; Modest, DP; Mueller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023)
" Female patients did not show the same benefit while experiencing higher rates of adverse events."	( Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212 Alig, AHS; Caca, K; Fruehauf, S; Goekkurt, E; Graeven, U; Haas, S; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; König, AO; Kretzschmar, A; Kurreck, A; Modest, DP; Mueller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023)
" Sixty-four patients (41%) treated with INCT-CRT and 57 CRT-CNCT patients (34%) experienced a grade 3+ adverse event (P = ."	( Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial. Garcia-Aguilar, J; Kim, JK; Lin, ST; Omer, DM; Qin, LX; Saltz, LB; Thompson, HM; Valdivieso, SC; Verheij, FS; Wu, AJ; Yuval, JB, 2024)
" No difference in adverse events was observed between groups."	( Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial. Garcia-Aguilar, J; Kim, JK; Lin, ST; Omer, DM; Qin, LX; Saltz, LB; Thompson, HM; Valdivieso, SC; Verheij, FS; Wu, AJ; Yuval, JB, 2024)
" Number of cycles, dose delays for any cause, and dose reductions for adverse events (AEs) were comparable between age classes."	( Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study. Anchisi, S; Bohanes, P; Derigs, HG; Geffriaud-Ricouard, C; Grünberger, B; Gueldner, M; Hofheinz, RD; Piringer, G; Scholten, F; Schwarz, L; Thaler, J; von Moos, R, 2023)

Excerpt	Reference
" The half-life of MTX in the CSF (11."	( Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Frei, E; Pitman, SW, 1977)
" Pharmacokinetic analysis shows that a biexponential function adequately describes the plasma decay for all doses."	( Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Aroesty, J; Block, JB; Isacoff, WH; Lincoln, TL; Morrison, PF; Willis, KL, 1977)
" Children excrete methotrexate at a faster rate than adults; the half-life of MTX during the first phase of plasma clearance curve is one hour shorter in children."	( Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion. Kim, PY; Lantin, E; Romsdahl, MM; Sutow, WW; van Eys, DC; Wang, YM, 1978)
"The general basis of pharmacokinetics are summarized with the clinical aims of a better utilisation of drugs by the application pharmacokinetic data."	( [Pharmacokinetics of antineoplastic agents (author's transl)]. Cano, JP; Carcassonne, Y; Meyer, G, 1979)
"The administration of calcium leucovorin, either concurrently or after high dosages of methotrexate in L1210 leukemic mice, has both pharmacokinetic and biochemical effects in tumor cells and drug-limiting proliferative normal tissue in small intestine."	( Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model. Donsbach, RC; Dorick, DM; Moccio, DM; Sirotnak, FM, 1976)
" In the present study the pharmacokinetic behavior of 5-FU was investigated in combination with interferon alfa (IFN-alpha-2b) and further after adding the second well-established biomodulating agent folinic acid (FA)."	( Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil. Czejka, MJ; Fogl, U; Jäger, W; Micksche, M; Schernthaner, G; Schüller, J, 1992)
" The present study compared the pharmacokinetic profiles of intravenous and intra-hepatic arterial infusions of folinic acid in patients with colorectal liver metastases (n = 6) who were being treated with weekly regional infusions of 5-FU."	( A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. Anderson, JH; Cooke, TG; Kerr, DJ; McArdle, CS; Setanoians, A, 1992)
" The 7-OHMTX level increased during each infusion and a Cmax of 19 mumol."	( Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. Breithaupt, H; Hartmann, R; Henze, G; Hepp, R; Wolfrom, C, 1990)
" Plasma samples were obtained during and after infusions at appropriate times for a comprehensive pharmacokinetic study of each drug."	( Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients. Evans, WE; Kavanagh, RL; Ochs, J; Rivera, GK; Rodman, JH; Sunderland, M; Yalowich, J, 1990)
" The measured MTX peak concentrations correlated closely with pharmacokinetic data such as area under the curve and total body clearance."	( [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma]. Graf, N; Jost, W; Keller, HE; Müller, J; Sitzmann, FC, )
"After the use of d,1-folinic acid (d,1-CHO-THF), pharmacokinetic measurements should take into account 1-CHO-THF and its metabolite 1-methyltetrahydrofolic acid (1-CH3-THF) as well as d-CHO-THF."	( Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. Kühl, M; Nüssler, V; Schalhorn, A; Stupp-Poutot, G, 1990)
" After administration of high doses of LV intravenously, conversion of (6S) LV to 5-CH3 THF was saturable, as indicated by the prolonged (6S) LV half-life of 58 minutes and the slow (6S) LV clearance of 119."	( Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. Ratain, MJ; Schilsky, RL, 1990)
" Along with other plasma pharmacokinetic parameters, terminal half-lives were estimated for (6S)-folinic acid (median, 45."	( Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Doroshow, JH; Newman, EM; Straw, JA, 1989)
" The bioavailability of intravenous and intramuscular doses was comparable based on area under the serum concentration-time curve, although for intramuscular administration, the peak concentration was lower and the time to peak concentration was longer."	( Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration. Gutierrez, ML; Leese, PT; McGuire, BW; Sia, LL; Stokstad, EL, 1988)
" The longer duration of MTX administration (with delayed rescue) is thought to be more beneficial from the pharmacokinetic aspect."	( Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison. Borsi, JD; Moe, PJ; Schuler, D, 1988)
"Studies are described that sought the basis for a discrepancy in values for a key kinetic parameter of methotrexate transport (influx Vmax) in L1210 cells derived alternately from biochemical or pharmacokinetic measurements."	( Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance. Barrueco, JR; Poser, RE; Sirotnak, FM, 1987)
" Methotrexate and 7-hydroxy-methotrexate concentrations were measured by specific radioimmunoassays and the data were analysed simultaneously by an integrated pharmacokinetic model."	( Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate. Bore, P; Bruno, R; Cano, JP; Favre, R; Lena, N, 1987)
" In both studies the plasma half-life (t1/2) of the active isomer, L-formyltetrahydrofolate (CHO-THF), was only 32 to 35 minutes, whereas the inactive isomer, D-CHO-THF had a plasma t 1/2 of 352 to 485 minutes."	( Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion. Doroshow, JH; Newman, EM; Straw, JA, 1987)
" The plasma half-life (beta) of the unnatural (d) isomer was 451 +/- 24 (S."	( Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Straw, JA; Szapary, D; Wynn, WT, 1984)
" The natural (l) isomer had a half-life (beta) of 47 +/- 4 (S."	( Differences in the pharmacokinetics of the diastereoisomers of citrovorum factor in dogs. Covey, JM; Straw, JA; Szapary, D, 1981)
" Pharmacokinetic models were fit to plasma ZDV concentrations using extended least squares regression."	( Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. Darnowski, J; Dudley, MN; Marchbanks, K; Posner, MR, )
" Further study of potential nonlinear pharmacokinetic behavior at doses above 20 g/m2/day is necessary."	( Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. Darnowski, J; Dudley, MN; Marchbanks, K; Posner, MR, )
" The tolerance and pharmacokinetic profile of IP 5-fluoro-2'-deoxyuridine(FUDR) alone and with (R,S)-leucovorin ((R,S)-LV) have each been evaluated in previous phase I studies."	( Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Chan, KK; Israel, VK; Jeffers, S; Jiang, C; Leichman, CG; Leichman, L; Morrow, CP; Muggia, FM; Roman, L; Tulpule, A, 1995)
"To analyze clinical and pharmacokinetic data of cisplatin (CP)/fluorouracil (FU)/l folinic acid (l FA) chemotherapy administered as first-line treatment to locally advanced head and neck cancer patients."	( Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. Dassonville, O; Demard, F; Etienne, MC; Guillot, T; Milano, G; Mobayen, H; Otto, J; Saudes, L; Schneider, M; Thyss, A, 1995)
"This study highlights the efficacy of CP/FU/l FA in head and neck carcinoma and establishes the clinical importance of coupled FU/FA pharmacokinetics to predict pharmacodynamic variability."	( Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. Dassonville, O; Demard, F; Etienne, MC; Guillot, T; Milano, G; Mobayen, H; Otto, J; Saudes, L; Schneider, M; Thyss, A, 1995)
" In contrary, the coadministration of either FA or DPM or FA/DPM to 5FU does not lead to a significant change in the pharmacokinetic profile of 5FU, but also causes higher plasma concentrations."	( Clinical pharmacokinetics of 5-fluorouracil. Influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Czejka, MJ; Fogl, U; Jäger, W; Schernthaner, G; Schüller, J; Weiss, C, 1993)
" Minimum Akaike information criterion estimation was used to determine the simplest effective pharmacokinetic model."	( Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. Joel, SP; Johnston, A; Patel, N; Seymour, MT; Slevin, ML, 1994)
"The pharmacokinetic profiles of folinic acid (FA) and its active metabolite, 5-methyltetrahydrofolic acid, were studied after oral administration of decreasing doses of calcium folinate during 37 courses of high and intermediate dose methotrexate treatment in 25 lymphoma patients."	( Pharmacokinetics of folinic acid and 5-methyltetrahydrofolic metabolite after repeated oral administration of calcium folinate following methotrexate treatment. Cano, J; Carcassonne, Y; Catalin, J; Lejeune, C; Monjanel-Mouterde, S; Payet, B; Tubiana-Mathieu, N, 1994)
" Pharmacokinetic parameters showed very wide interpatient variability."	( Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen. Creaven, PJ; Frank, C; Levine, EG; Meropol, NJ; Petrelli, NJ; Proefrock, A; Raghavan, D; Rodriguez-Bigas, M; Rustum, YM; Udvary-Nagy, S, 1994)
" The pharmacokinetic advantage of 5-FU-ip was confirmed in our study (ratio AUC peritoneum/plasma between 160 and 328)."	( [Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers]. Bugat, R; Canal, P; Chevreau, C; de Forni, M; Gualano, V; Izar-Soum, F; Martel, P; Roché, H; Soulié, P, 1993)
"LV-6S exhibits pharmacokinetic patterns similar to those obtained with LV-6R,S whatever the route used, oral or intravenous."	( Pharmacokinetics and in vitro studies of l-leucovorin. Comparison with the d and d,l-leucovorin. Zittoun, J, 1993)
" The pharmacokinetic interaction between alpha-IF and LV may play a role in the activity of this regimen."	( Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. Buter, J; de Vries, EG; Mulder, NH; Roenhorst, HW; Sinnige, HA; Sleijfer, DT; Uges, DR; Verschueren, RC; Willemse, PH, 1993)
"The pharmacokinetic values of d,l-leucovorin and l-leucovorin were compared in eight healthy volunteers following oral administration of 25 mg d,l-leucovorin and 12."	( Pharmacokinetic comparison of leucovorin and levoleucovorin. De Gialluly, E; Hancock, C; Johnson, JB; Marquet, J; Tonelli, AP; Yacobi, A; Zittoun, J, 1993)
"A phase I and pharmacokinetic trial was performed between October 1993 and June 1994 to determine the maximum-tolerated dose of hepatic arterial infusion (HAI) of fluorouracil (5-FU) and intravenous (IV) leucovorin (folinic acid; FA) in patients with hepatic metastases from colorectal cancer."	( Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. Buckels, J; Budden, J; Doughty, J; Kerr, DJ; Ledermann, JA; McArdle, CS; Neoptolemos, J; Seymour, M; Taylor, I, 1995)
" Pharmacokinetic studies were performed to determine peak and steady-state plasma concentrations (Css) of 5-FU."	( Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. Buckels, J; Budden, J; Doughty, J; Kerr, DJ; Ledermann, JA; McArdle, CS; Neoptolemos, J; Seymour, M; Taylor, I, 1995)
"The purpose of this study was to evaluate a potential pharmacokinetic (PK) interaction between fluorouracil (5-FU) and the biomodulating agent interferon alpha (IFN-alpha) in patients with metastatic colorectal carcinoma."	( Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid. b1p6uller, J; Czejka, M, 1995)
" Pharmacokinetic parameters [ftorafur, uracil, 5-fluorouracil (5-FU), 5-methyltetrahydrofolate] showed wide interpatient variations."	( A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Creaven, PJ; Frank, C; Ho, DH; Kurowski, M; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1996)
" These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU."	( A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995)
" On day 1 of treatment, CPT-11 alone was given by 90-minute infusion, and pharmacokinetic sampling was performed over 24 hours."	( Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C, 1996)
" As a consequence, the preadministration of IFN leads to a significant change in the basic pharmacokinetic parameters of both compounds: the mean area under the concentration-time curve is decreased at 27."	( Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. Bandak, S; Czejka, MJ; Meyer, B; Schüller, J; Simon, D; Weiss, C, )
" Pharmacokinetic evaluation showed that single-dose UFT results in maximum plasma levels and an area under the concentration-time curve that increased with escalating UFT doses."	( Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Pazdur, R, 1997)
" Because of laboratory data that suggests improved metabolism of AMT versus methotrexate (MTX) in lymphoblasts, we developed a phase I trial to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetic profile of AMT."	( Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. Hum, M; Kamen, BA; Marling-Cason, M; Ratliff, AF; Rose, K; Wilson, J; Winick, N, 1998)
" In a previous study with 5-FU stepwise dose escalation in a weekly regimen, and pharmacokinetic monitoring, we defined a therapeutic range for 5-FU plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 to 8 hours [AUC0-8], 16 to 24 mg x h/L)."	( Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. Alleaume, C; Boisdron-Celle, M; Burtin, P; Cailleux, PE; Danquechin-Dorval, E; Delva, R; Dumesnil, Y; Fety, R; Gamelin, E; Geslin, J; Gesta, P; Goudier, MJ; Larra, F; Lortholary, A; Maigre, M; Maillart, P; Maillet, ML; Person-Joly, MC; Picon, L; Regimbeau, C; Robert, J; Sire, M, 1998)
"Individual 5-FU dose adjustment with pharmacokinetic monitoring provided a high survival rate and percentage of responses, with good tolerance."	( Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. Alleaume, C; Boisdron-Celle, M; Burtin, P; Cailleux, PE; Danquechin-Dorval, E; Delva, R; Dumesnil, Y; Fety, R; Gamelin, E; Geslin, J; Gesta, P; Goudier, MJ; Larra, F; Lortholary, A; Maigre, M; Maillart, P; Maillet, ML; Person-Joly, MC; Picon, L; Regimbeau, C; Robert, J; Sire, M, 1998)
"The cumulative pharmacokinetic pattern of oxaliplatin, a new diamminecyclohexane platinum derivative, was studied in patients with metastatic colorectal cancer."	( Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Allain, P; Boisdron-Celle, M; Bouil, AL; Brienza, S; Cailleux, A; Cvitkovic, E; Delva, R; Gamelin, E; Krikorian, A; Larra, F; Robert, J; Turcant, A, 1997)
" Details are presented here on the methodology of NMRS data acquisition and on their pharmacokinetic analysis."	( Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. Presant, CA; Waluch, V; Wolf, W, 1998)
"Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements."	( Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999)
"SFU-dose adaptation optimal schedule using bimonthly LV5FU2 regimen was modulated by previously validated individual pharmacokinetic parameters, in 38 patients with advanced colorectal cancer."	( Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Bressolle, F; Duffour, J; Joulia, JM; Kramar, A; Pinguet, F; Topart, D; Ychou, M, )
"At the 1st cure, 5F-U pharmacokinetic parameters (particularly the area under curve (AUC) in mg."	( Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Bressolle, F; Duffour, J; Joulia, JM; Kramar, A; Pinguet, F; Topart, D; Ychou, M, )
" Pharmacokinetic and pharmacodynamic studies were conducted to look for a relationship between the ratio of UH(2) to U and 5-FU metabolic outcome and tolerance."	( Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999)
" Five patients could not tolerate the treatment even at the lowest dose of interferon and 22 patients were unavailable for the pharmacokinetic analysis because of dose reductions of 5-FU."	( A pharmacokinetic study of 5-FU/leucovorin and alpha-interferon in advanced cancer. Carlsson, G; Glimelius, B; Gustavsson, B; Jeppsson, B; Jönsson, PE; Larsson, PA; Malmberg, M; Svedberg, M, 2000)
" A single dose of IFNalpha as low as 3 MIU m(-2) can cause sustained elevation of PBL TP activity in vivo indicating that biochemical markers are important pharmacodynamic endpoints for developing optimal schedules of IFNalpha for biomodulation of 5-FU."	( Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. Braybrooke, JP; Ganesan, TS; Harris, AL; Houlbrook, S; Koukourakis, MI; Love, SD; O'Byrne, KJ; Patterson, AV; Propper, DJ; Talbot, DC; Taylor, M; Varcoe, S, 2000)
"A pharmacokinetic population approach was used to analyze the data from 21 patients with colorectal cancer."	( Dose and time dependencies of 5-fluorouracil pharmacokinetics. Boisdron-Celle, M; Bugat, R; Canal, P; Chatelut, E; Erdociain, E; Féty-Deporte, R; Gamelin, E; Guimbaud, R; Lafont, T; McLeod, HL; Terret, C, 2000)
" The relationships between the pharmacokinetic parameters and patient characteristics were tested."	( Dose and time dependencies of 5-fluorouracil pharmacokinetics. Boisdron-Celle, M; Bugat, R; Canal, P; Chatelut, E; Erdociain, E; Féty-Deporte, R; Gamelin, E; Guimbaud, R; Lafont, T; McLeod, HL; Terret, C, 2000)
"The pharmacokinetic parameters obtained in this study would be useful to predict the 5-fluorouracil plasma concentrations following other schedules of administration of 5-fluorouracil and to study the possible pharmacokinetic interactions between 5-fluorouracil and other drugs."	( Dose and time dependencies of 5-fluorouracil pharmacokinetics. Boisdron-Celle, M; Bugat, R; Canal, P; Chatelut, E; Erdociain, E; Féty-Deporte, R; Gamelin, E; Guimbaud, R; Lafont, T; McLeod, HL; Terret, C, 2000)
"Patients received a single 24-hour infusion of 5-FU (2,300 mg/m(2) on day 2) with leucovorin (15 mg orally [PO] bid on days 1 through 3) to provide reference pharmacokinetic data."	( Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. Bi, DQ; Donavan, S; Grem, JL; Grollman, F; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Quinn, MG; Shapiro, J; Takimoto, CH; Zentko, S, 2000)
" After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0."	( Clinical pharmacokinetics of capecitabine. Blesch, K; Reigner, B; Weidekamm, E, 2001)
" The mean PK parameters were: terminal half-life of ultrafiltrable platin, 17."	( Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Beckert, B; Beykirch, M; Braess, J; Goecke, E; Hiddemann, W; Kern, W; Lang, N; Schalhorn, A; Stein, J; Stemmler, J; Waggershauser, T, 2001)
" Pharmacokinetic analysis of irinotecan and its metabolites was performed after each cycle."	( Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001)
" Pharmacokinetic analysis revealed that the administration sequence significantly affected the SN-38 area under the concentration-versus-time curve (AUC), which was 40."	( Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001)
" Because no data are available for patients with severe renal failure, the pharmacokinetic parameters of 5-FU and its catabolites were determined for a patient with colorectal carcinoma and end-stage renal disease on maintenance hemodialysis therapy."	( Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Bommer, J; Göggelmann, C; Hull, WE; Rengelshausen, J; Schwenger, V; Walter-Sack, I, 2002)
" The method was proved to be applicable to the pharmacokinetic study of LV in healthy volunteers after a single oral administration (75 mg)."	( High-performance liquid chromatographic method for determination of leucovorin in plasma: validation and application to a pharmacokinetic study in healthy volunteers. Chen, J; Cheng, WB; Duan, GL; Li, D; Zheng, LX, 2002)
"A comparison of the intratumoral 5-FU pharmacokinetics indicated that there was no general effect of leucovorin on the intratumoral half-life of 5-FU."	( Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. Jacobson, J; Macdonald, JS; Presant, CA; Waluch, V; Weitz, IC; Wolf, W, 2002)
" Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co."	( [A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin]. Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002)
"Dose adaptation based on pharmacokinetic parameters has been shown to decrease toxicity of some 5-fluorouracil(5-FU)-based continuous infusion regimens."	( Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid. Brouwers, JR; Coenen, JL; De Graaf, JC; Jansman, FG; Sleijfer, DT; Tobi, H, )
"The conclusion of this study is that the application of pharmacokinetic parameters is not appropriate for identification of patients at risk for developing toxicity from treatment with 5-FU according to the Mayo-regimen."	( Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid. Brouwers, JR; Coenen, JL; De Graaf, JC; Jansman, FG; Sleijfer, DT; Tobi, H, )
" Systemic exposure based on plasma concentrations of capecitabine and its metabolites was determined using individual parameter estimates derived from a population pharmacokinetic model constructed for this purpose in NONMEM."	( Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003)
"The objective of this study was to explore correlations between a variety of covariates and oxaliplatin ultrafilterable and blood pharmacokinetic parameters."	( Population pharmacokinetics of oxaliplatin. Bugat, R; Canal, P; Chatelut, E; Delord, JP; Grégoire, N; Guimbaud, R; Lafont, T; Umlil, A, 2003)
"To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV)."	( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003)
" infusion of 5-FU 2300 mg/m(2) to provide a pharmacokinetic reference."	( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003)
" EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to >5 h, and increased the percentage of 5-FU excreted in the urine from 2% to 64-66%."	( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003)
"Either a single 20-mg dose of EU given prior to or for 3 days around the oral 5-FU dose led to comparable effects on 5-FU pharmacokinetic parameters, and inhibition of dihydropyrimidine dehydrogenase and thymidylate synthase."	( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003)
"The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine."	( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003)
"Of the 31 patients treated, 30 were available for the pharmacokinetic analysis."	( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003)
"A pharmacokinetic model for ftorafur and 5FU was developed and should be useful to further study drug interactions and establish dosing guidelines."	( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003)
" No pharmacokinetic interaction between CCI-779 and 5-FU was observed."	( Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Boni, J; Bruntsch, U; Peters, M; Punt, CJ; Thielert, C, 2003)
"Drugs pharmacokinetic control is a usual practice in case of flat continuous infusions."	( [Modeling 5-FU clearance during a chronomodulated infusion]. Chevalier, V; Chevrier, R; Chollet, P; Cure, H; Kwiatkowski, F; Richard, D, 2003)
" However, only a few pharmacokinetic data of 5-FU during chronomodulated infusion are available but up to now not for oxaliplatin."	( Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. Höffken, K; Hoffmann, A; Merkel, U; Roskos, M; Wedding, U, 2003)
" Pharmacokinetic and neurotoxicity assessments were performed at the cohort 2 MTD."	( Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ, 2003)
" Pharmacokinetic analysis revealed an AUC value of 85."	( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I, )
" He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11."	( [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004)
" Pharmacokinetic studies were performed on cycle 1 and 2 to assess the best sequence and detect any interaction between the two drugs."	( Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S, 2004)
" Blood samples for the pharmacokinetic study were obtained after the initial dose on day 1 of the first course."	( Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004)
"The efficacy and pharmacokinetic parameters of UFT and LV are comparable in Japanese and American patients; however, a difference in toxicity profile, specifically diarrhea, was noted."	( Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004)
" We assessed the feasibility and pharmacokinetic interactions of combining MMI270 with 5-fluorouracil (5-FU) and folinic acid (FA)."	( A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Blackey, R; Cassidy, J; Choi, L; Devlin, M; Eatock, M; Johnson, J; Morrison, R; Owen, S; Twelves, C, 2005)
" Pharmacokinetic analyses for both BAY 12-9566 and 5-fluorouracil were performed."	( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005)
" Pharmacokinetic analysis suggested there was no interaction between BAY 12-9566 and 5-fluorouracil."	( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005)
" Although there is some evidence of a clinical interaction, there is no apparent pharmacokinetic interaction."	( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005)
" Pharmacokinetic analysis showed that the addition of 90 mg/m2 or 100 mg/m2 of cisplatin to LV5FU2 significantly reduced the 5FU area under the curve."	( Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study. Alamanos, Y; Bamias, A; Christodoulou, C; Fountzilas, G; Karavasilis, V; Pavlidis, N; Soulti, K; Syrigos, K; Tzamakou, E, 2004)
" These results indicate that bevacizumab can be safely administered in combination with the Saltz regimen without pharmacokinetic interaction."	( Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. Bricarello, A; Christian, BJ; Gaudreault, J; Mounho, B; Shiu, V; Zuch, CL, )
"We developed a method to assess the similarity of pharmacokinetic data between ethnically different populations."	( Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations. Fukushima, A; Matsuyama, Y; Mizuno, S; Ohashi, Y; Yamaguchi, T, 2005)
" For irinotecan, SN-38, APC and NPC, similar pharmacokinetic profiles were observed from plasma and saliva data."	( Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Abderrahim, AG; Astre, C; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Ychou, M, 2006)
"8 ng/ml, indicating large inter-patient pharmacokinetic variations."	( Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006)
" Antitumor efficacy in Korean advanced colorectal cancer patients given oxaliplatin and 5-FU should be further evaluated with respect to pharmacokinetic variabilities."	( Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006)
" Pharmacokinetic parameters showed moderate interpatient variability."	( Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigation. Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Roskos, M; Wedding, U, 2006)
" This PK model could be useful in identifying predictors for PK and pharmacodynamic variability to individualize dosing."	( Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Brouwers, JR; Jansman, FG; Kho, Y; Neef, C; Prins, NH, 2006)
"To develop and a priori validate a methotrexate population pharmacokinetic model in children with acute lymphoblastic leukaemia (ALL), receiving high-dose methotrexate followed by folinic acid rescue, identifying the covariates that could explain part of the pharmacokinetic variability of methotrexate."	( Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Aumente, D; Buelga, DS; García, MJ; Gomez, P; Lukas, JC; Torres, A, 2006)
" In an index group (37 individuals; 1236 methotrexate plasma concentrations), a population pharmacokinetic model was developed using a nonlinear mixed-effects model."	( Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Aumente, D; Buelga, DS; García, MJ; Gomez, P; Lukas, JC; Torres, A, 2006)
"The final population pharmacokinetic model (two-compartmental) included only age and total bodyweight as influencing clearance (CL) and volume of distribution of central compartment (V(1))."	( Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Aumente, D; Buelga, DS; García, MJ; Gomez, P; Lukas, JC; Torres, A, 2006)
"A methotrexate population pharmacokinetic model has been developed for ALL children."	( Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Aumente, D; Buelga, DS; García, MJ; Gomez, P; Lukas, JC; Torres, A, 2006)
" Intraperitoneal FU exposure (AUC) after IP treatment was >1000-fold plasma AUC after IP treatment (regional pharmacokinetic advantage), and >100-fold plasma AUC after intravenous treatment (regional therapeutic advantage)."	( A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. Brown, CB; Chester, JD; Dunham, R; Farrugia, D; Finan, PJ; Halstead, F; Joel, SP; King, J; Seymour, MT; Slevin, ML; Trigonis, I; Wilson, G, 2008)
" Part 1 was designed to determine the OTR and part 2 was the pharmacokinetic part of the study."	( Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Beijnen, JH; Boot, H; Keessen, M; Koch, KM; Pandite, L; Richel, DJ; Schellens, JH; Siegel-Lakhai, WS; Smith, DA; Versola, M; Vervenne, WL, 2007)
" Co-administration of lapatinib increased the area under the plasma concentration-time curve of SN-38, the active metabolite of irinotecan, by an average of 41%; no other pharmacokinetic interactions were observed."	( A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C, 2007)
" The pharmacokinetic parameters were analysed after logarithmic transformation according to a general linear model."	( A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007)
" Three sequential skin biopsies were obtained in selected patients to assess the pharmacodynamic effects on EGFR signaling of FOLFIRI alone and with EKB-569."	( Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C, 2008)
" Chemotherapy alone interferes with pharmacodynamic markers, an observation to be taken into account in future studies of targeted agents with chemotherapy."	( Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C, 2008)
"To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)."	( Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008)
"Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities."	( Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008)
"To evaluate 5-fluorouracil (5-FU) and 5-fluoro-5,6-dihydrouracil (5-FDHU) pharmacokinetics and disease-free survival (DFS) in colorectal cancer patients given 5-FU-based adjuvant chemotherapy within a nonrandomized, retrospective, pharmacokinetic study."	( 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Amatori, F; Bocci, G; Danesi, R; Del Tacca, M; Di Donato, S; Di Paolo, A; Falcone, A; Federici, F; Iannopollo, M; Lastella, M; Lencioni, M; Orlandini, C; Ricci, S, 2008)
" Individual plasma concentrations of 5-FU and 5-FDHU were determined on day 1 of the first cycle with a validated high performance liquid chromatography method, and the main pharmacokinetic variables were determined."	( 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Amatori, F; Bocci, G; Danesi, R; Del Tacca, M; Di Donato, S; Di Paolo, A; Falcone, A; Federici, F; Iannopollo, M; Lastella, M; Lencioni, M; Orlandini, C; Ricci, S, 2008)
" Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation."	( Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009)
" Pharmacokinetic evaluation suggested continuous exposure to 5-FU by means of oral UFT/LV administration in this combination."	( Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009)
" There were no significant differences in the main pharmacokinetic parameters between the two arms except a lower area under the plasma concentration-time curve and a smaller apparent steady-state volume of distribution (Vss) when GSH was coadministered."	( Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Airoldi, M; Cattel, L; Drescher, A; Jaehde, U; Milla, P; Weber, G, 2009)
" Pharmacokinetic analysis was performed on blood, plasma and plasma ultrafiltrable by ICP-MS (Inductively Coupled Plasma Mass Spectrometry)."	( Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. Balacescu, L; Balacescu, O; Berindan-Neagoe, IB; Burz, C; Chintoanu, M; Cristea, V; Gog, A; Irimie, A; Leucuta, SE; Tanaselia, C; Ursu, M; Vlase, L, 2009)
" The mean Cmax and AUC 0-24 of oxaliplatin increased in a dose-related manner."	( Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. Balacescu, L; Balacescu, O; Berindan-Neagoe, IB; Burz, C; Chintoanu, M; Cristea, V; Gog, A; Irimie, A; Leucuta, SE; Tanaselia, C; Ursu, M; Vlase, L, 2009)
" With a relatively low interpatient variability, it is eliminated triphasically and the mean Cmax and AUC 0-24 increases in a dose-related manner."	( Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. Balacescu, L; Balacescu, O; Berindan-Neagoe, IB; Burz, C; Chintoanu, M; Cristea, V; Gog, A; Irimie, A; Leucuta, SE; Tanaselia, C; Ursu, M; Vlase, L, 2009)
" The median C(max) of FU at each dose level increased significantly with increasing doses of vorinostat, suggesting a pharmacokinetic interaction between FU and vorinostat."	( A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)
"This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation."	( Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Baselga, J; Cervantes, A; Ciardiello, F; Kisker, O; Liebscher, S; Macarulla, T; Martinelli, E; Ramos, FJ; Rivera, F; Rodriguez-Braun, E; Roselló, S; Tabernero, J; Vega-Villegas, ME, 2010)
" No pharmacokinetic interactions were noted between vorinostat and FU."	( A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Diasio, RB; Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Muindi, JR; Wang, K; Zwiebel, JA, 2010)
" 19F magnetic resonance spectroscopy can be used in vivo to measure 5FU's half-life and metabolism to cytotoxic fluoronucleotides."	( Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? Griffiths, JR; Howe, FA; Ladroue, C; Lofts, F; McIntyre, DJ; Stubbs, M, 2011)
" The 5FU half-life was measured in each subject, and averaged spectra were examined for the presence of fluoronucleotides."	( Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? Griffiths, JR; Howe, FA; Ladroue, C; Lofts, F; McIntyre, DJ; Stubbs, M, 2011)
" The study also determined the pharmacokinetic parameters of 5-FU, especially steady-state plasma and bone marrow (BM) concentrations."	( Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. Chen, RR; Cheng, AL; Ho, YF; Lu, WC; Yeh, KH, 2011)
" We conducted a phase II trial to confirm the pharmacokinetic parameters from 3-Tesla dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as surrogate biomarkers of BV + FOLFIRI regimen efficacy in colorectal cancer with liver metastases."	( Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Akiyoshi, K; Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Miyake, M; Nakajima, T; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Tateishi, U; Yamada, Y, 2012)
", Salt Lake City, UT) that measures plasma 5-FU concentration and reports an AUC in mg · h/L has been developed to optimize therapy using pharmacokinetic (PK) dosing."	( Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Grier, CE; Hamilton, SA; Haregewoin, A; Kaldate, RR; McLeod, HL, 2012)
"The primary objective of this study is to evaluate the safety, tolerance, and pharmacokinetic profile of liver-directed therapy with drug-eluting beads irinotecan (DEBIRI) in combination with systemic modified FOLFOX in the treatment of unresectable liver metastases in chemotherapy-naive patients with colorectal cancer."	( Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D, 2012)
" Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18."	( Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D, 2012)
" Alternatively, 5-FU doses can be adjusted based on 5-FU pharmacokinetic (PK) monitoring."	( Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. Beachler, C; El-Deiry, WS; Harvey, HA; Kline, CL; Mackley, HB; McKenna, K; Messaris, E; Poritz, L; Schiccitano, A; Sheikh, H; Sivik, J; Staveley-O'Carroll, K; Stewart, D; Zhu, J, 2014)
"The aim of this study was the evaluation of pharmacokinetic parameters, biomarkers, clinical outcome, and imaging parameters in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI plus sunitinib."	( FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D, 2014)
" Pharmacokinetic parameters, including C max, AUC0-t, t 1/2, V d, and CL, were calculated using non-compartmental models."	( Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. Li, Y; Li, Z; Liu, Y; Shi, S; Wu, J; Yang, C; Zhang, Y; Zhou, J, 2015)
" Plasma was collected for pharmacokinetic (PK) analysis before, during, and after surgery."	( A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. Derwinger, K; Kodeda, K; Odin, E; Taflin, H; Wettergren, Y, 2015)
" Population pharmacokinetic parameters were estimated by the NLME software."	( [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Chen, Y; Gao, P; He, X; Li, J; Niu, C; Wang, C; Wang, Y; Zhang, H, 2014)
" Many authors have described the pharmacokinetic (PK) profile of MTX regarding osteosarcoma under a variety of circumstances."	( Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. Lu, W; Niu, X; Tian, X; Zhang, Q; Zhang, W; Zhao, H; Zhen, J, 2015)
"This phase Ib study evaluated the pharmacokinetic profile and safety of ramucirumab, a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor 2, in combination with irinotecan, levofolinate and 5-fluorouracil (FOLFIRI) in Japanese patients with metastatic colorectal carcinoma (mCRC)."	( Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. Gao, L; Gotoh, M; Nasroulah, F; Ohtsu, A; Yamazaki, K; Yoshino, T; Yoshizuka, N, 2015)
"The effect of individual dose adjustment of 5-fluorouracil (5-FU) based on pharmacokinetic monitoring on the outcome of FOLFOX for metastatic colorectal cancer was analyzed retrospectively."	( [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. Kanda, J; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T, 2016)
" The sample group included 11 patients in whom 5-FU doses were adjusted individually based on pharmacokinetic monitoring according to an algorithm to maintain the area under the curve (AUC) in the range of 20-25 mg·h/L (Group A) and 9 patients in whom 5-FU doses were adjusted conventionally based on body surface area (Group B)."	( [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. Kanda, J; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T, 2016)
"The objective of this phase II study was to evaluate the potential of pharmacokinetic (PK) drug-drug interactions between ramucirumab and irinotecan or its metabolite, SN-38, when administered with folinic acid and 5-fluorouracil (FOLFIRI)."	( Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors. Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D, 2016)
" Study description, pharmacokinetic parameter values and influential covariates are reported."	( Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. Barbolosi, D; Deyme, L; Gattacceca, F, 2019)
" The individualized dosing of CPT-11 is essential to ensure optimal pharmacotherapy in cancer patients, given the wide interindividual pharmacokinetic variability of this drug and its active metabolite SN-38."	( Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019)
" Supported by several demographic data, blood markers and pharmacokinetic parameters resulting from a non-compartmental pharmacokinetic study of CPT-11 and its metabolites (SN-38 and SN-38-G), we use machine learning techniques to predict high degrees of different toxicities (leukopenia, neutropenia and diarrhea) in new patients."	( Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019)
" The elimination half-life slowly improved over the following cycles suggesting a reversible cause responsible for reduced MTX clearance and toxicity during the first cycle."	( Reversible Impaired Methotrexate Clearance After Platinum-Based Chemotherapy for Osteosarcoma. de Haan, J; Oude Munnink, T; Touw, D; van der Meer, A; van Kruchten, M, 2019)
" A population pharmacokinetic approach was used to determine oxaliplatin and 5-fluorouracil pharmacokinetics with and without ibudilast."	( Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. Blinman, PL; Dhillon, HM; Galettis, P; McLachlan, AJ; Proschogo, N; Reuter, SE; Teng, C; Vardy, JL, 2020)
" Pharmacokinetic analysis indicates ibudilast has no significant effect on oxaliplatin pharmacokinetics, and is unlikely to influence pharmacokinetics of 5-fluorouracil."	( Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. Blinman, PL; Dhillon, HM; Galettis, P; McLachlan, AJ; Proschogo, N; Reuter, SE; Teng, C; Vardy, JL, 2020)
" Using pharmacokinetic analysis, it is possible to directly evaluate enzyme activity and consider what kind of enzyme variation causes the increase in the AUC of SN-38."	( Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. Ayukawa, H; Endo, S; Furuse, J; Furuta, T; Hirano, R; Kaneko, S; Kawai, K; Kobayashi, T; Minowa, Y; Nagashima, F; Naruge, D; Okano, N; Shibasaki, H; Yokokawa, A, 2021)
"The aim of the present study was to characterize the pharmacokinetics of irinotecan and its four main metabolites (SN-38, SN-38G, APC and NPC) in metastatic colorectal cancer patients treated with FOLFIRI and FOLFIRINOX regimens and to quantify and explain the inter-individual pharmacokinetic variability in this context."	( Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M, 2021)
" First, fixed and random effects models were selected using statistical and graphical methods; second, the impact of covariates on pharmacokinetic parameters was evaluated to explain the inter-individual variability in pharmacokinetic parameters."	( Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M, 2021)
" Moreover, a direct conversion of NPC into SN-38 had never been described before in a population pharmacokinetic model of irinotecan."	( Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M, 2021)
" However, systematic evaluation of potential pharmacodynamic interactions among multi-drug therapy has not been reported previously."	( FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. Allen-Coyle, TJ; Clynes, M; Conlon, NT; Garner, W; Mager, DE; Niu, J; O'Sullivan, F; Roche, S; Straubinger, RM; Welsch, E, 2022)

Excerpt	Reference
"This paper presents an overview of studies of therapy of head and neck squamous cell carcinoma in which chemotherapy was combined with other modalities."	( Current concepts of chemotherapy combined with other modalities for head and neck cancer. DeWys, WD, 1975)
"38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone."	( A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992)
"In a prospective randomized multicentre trial 139 patients with metastatic colorectal carcinoma (70 men, 69 women; age 35-81 years) were given palliative treatment with fluorouracil (400 mg/m2 daily for 5 days) alone or combined with folic acid (100 mg/m2 before each dose of fluorouracil)."	( [Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma]. Aulbert, E; Burghardt, F; Hausamen, TU; Korsten, FW; Lindemann, W; Löffler, TM; Planker, M; Reis, HE; Schröder, M; Strohmeyer, G, 1992)
"The possibility of a deleterious effect of the unnatural stereoisomer on the modulation of 5-FU led us to carry out a phase I-II study of 5-FU combined with the (6S)-stereoisomer of folinic acid given in high doses for treatment of patients with advanced colorectal carcinoma."	( Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. Goldschmidt, E; Grison, X; Guillot, T; Hannoun, L; Lotz, JP; Machover, D; Marquet, J; Metzger, G; Richaud, J; Zittoun, J, 1992)
" These findings suggested that arterial infusion chemotherapy in combination with biochemical modulation was a safe and effective method for treating cancer patients."	( [Arterial infusion chemotherapy combined with biochemical modulation in cancer patients]. Mai, M; Ogino, T; Suga, T; Takahashi, Y, 1991)
"Clinically, 5-formyltetrahydrofolate (leucovorin, folinic acid, LV) in combination with 5-fluorouracil (5-FU) has been used at various doses, schedules, and routes of administration with therapeutic benefit to patients with advanced colorectal carcinoma and breast carcinoma."	( Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. Rustum, YM, 1989)
" In this study leucovorin (folinic acid, LCV) was added to the MTX/FUra combination with the intention of generating elevated levels of methylenetetrahydrofolate to promote the formation of a stable fluorodeoxyuridylate-thymidylate synthetase ternary complex, thereby augmenting the cytotoxicity of the MTX-FUra sequence."	( Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil. Cadman, E; Danhauser, LL; Heimer, R, 1985)
" Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs."	( Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985)
" This study assesses prospectively the results of liver resection as compared to liver resection combined with pre- and post-operative locoregional chemotherapy-immunotherapy in 40 patients suffering from hepatocellular carcinoma."	( Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Konstantinidou, AE; Lygidakis, NJ; Pothoulakis, J; Spanos, H, )
" The combination with folinic acid as a biomodulatory substance and other cytotoxic drugs has been introduced to render protocols more effective and less toxic."	( Severe cardiotoxicity of high-dose 5-fluorouracil in combination with folinic acid, cisplatin and methotrexate in a 14-year-old boy with nasopharyngeal carcinoma (Schmincke tumor). Blütters-Sawatzki, R; Grathwohl, J; Lampert, F; Mertens, R, )
" Drugs were administered with a programmable-in-time pump by continuous infusion for 5 days."	( Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Bastian, G; Brienza, S; Comisso, M; Etienne, MC; Lévi, F; Massari, C; Metzger, G; Milano, G; Misset, JL; Touitou, Y, 1994)
"To determine the toxicities and potential for dose escalation of intravenous (IV) bolus fluorouracil (5-FU) given with 500 mg/m2/d leucovorin (LCV) and granulocyte-macrophage colony-stimulating factor (GM-CSF)."	( Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. Arbuck, SG; Balis, F; Chen, A; Grem, JL; Hamilton, JM; Jordan, E; McAtee, N; Murphy, RF; Setser, A; Steinberg, S, 1994)
"A starting dose of 425 mg/m2/d of 5-FU with LCV on days 1 to 5 could be safely combined with GM-CSF starting either on day 1 or day 6, with further 5-FU dose escalation according to individual tolerance."	( Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. Arbuck, SG; Balis, F; Chen, A; Grem, JL; Hamilton, JM; Jordan, E; McAtee, N; Murphy, RF; Setser, A; Steinberg, S, 1994)
"This study was conducted to investigate the activity and toxicity of 5fluorouracil folinic acid+mitomycin C combined with alpha 2b interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5fluorouracil by interferon."	( Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993)
"Between June 1990 and April 1991 25 previously untreated patients with advanced colorectal carcinoma were treated with mitomycin C 10 mg/m2 iv bolus on day 1, 5fluorouracil 375 mg/m2 on days 1 to 4 and folinic acid 200 mg/m2 on days 1 to 4 every 4 weeks, combined with alpha 2b interferon 3 million U day continuously."	( Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993)
" The possibility of a deleterious effect of the unnatural stereoisomer on the modulation of 5-FU led us to carry out 2 consecutive phase I-II studies of 5-FU combined with the [6S]-stereoisomer of folinic acid given in high doses for treatment of patients with advanced colorectal carcinoma."	( 5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens. André, T; Goldschmidt, E; Grison, X; Hannoun, L; Lotz, JP; Machover, D; Marquet, J; Metzger, G; Richaud, J; Zittoun, J, 1993)
"5-Fluorouracil (5-FU), when combined with leucovorin (LV) or interferon-alpha (IFN-alpha), may result in improved response rates compared with 5-FU alone in patients with advanced colorectal cancer."	( Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. Burghouts, JT; Croles, JJ; de Mulder, PH; Kamm, Y; Punt, CJ; van Liessum, PA, 1993)
"The efficacy of 5-FU continuous infusion combined with LV and IFN-alpha does not appear to differ significantly from earlier reports on treatment using 5-FU plus LV or 5-FU plus IFN-alpha for patients with colorectal cancer."	( Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. Burghouts, JT; Croles, JJ; de Mulder, PH; Kamm, Y; Punt, CJ; van Liessum, PA, 1993)
"To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups."	( Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996)
"Patients with measurable inoperable or metastatic colorectal cancer were randomized to receive weekly FU 500 mg/m2 by intravenous (IV) bolus combined with high-dose FA 500 mg/m2 (group A) or low-dose FA 20 mg/m2 (group B) by 2-hour infusion."	( Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996)
" Therefore, low-dose FA combined with weekly FU may be considered the preferred treatment for metastatic colorectal cancer."	( Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996)
"The combination of sequential high dose methotrexate and 5-fluorouracil (FU) combined with epirubicin (FEMTX regimen) has shown some clinical efficiency as a first line therapy in advanced gastric cancer."	( Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors. Adenis, A; Bonneterre, J; Leriche, N; Pion, JM; Vanlemmens, L, )
" This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation."	( A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Bailey, N; Boddy, AV; Calvert, AH; Chapman, F; Gumbrell, L; Humphreys, A; Laohavinij, S; Lind, MJ; Newell, DR; Oakley, A; Proctor, M; Robson, L; Simmons, D; Taylor, GA; Thomas, HD; Wedge, SR, 1996)
"To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer."	( Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997)
"These studies demonstrate that the present dose and schedule of AZT in combination with 5-FU + LV has significant activity in metastatic colorectal cancer and that the combination of 5-FU + LV with AZT increases the amount of DNA damage."	( Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break Allegrini, G; Andreuccetti, M; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Malvaldi, G; Pfanner, E, 1997)
" Its combination with other effective and well-tolerated cytotoxics may thus be beneficial."	( Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Aapro, M; Andreoni, G; de Braud, F; De Pas, TM; Goldhirsch, A; Minchella, I; Monti, S; Nolè, F; Zampino, MG, 1997)
"There was no difference in response, survival, or toxicity between these three different leucovorin formulations combined with 5-FU."	( Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. Goldberg, RM; Hatfield, AK; Kahn, M; Knost, JA; Krook, JE; Maillard, JA; Moertel, CG; O'Connell, MJ; Sargent, DJ; Schaefer, PL; Tirona, MT; Wiesenfeld, M, 1997)
" Gastrimmune immunisation may be a therapeutic option for the treatment of colorectal cancer in combination with 5-FU/leucovorin."	( Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. Clarke, PA; Grimes, S; Hardcastle, JD; Justin, TA; Michael, D; Morris, TM; Robinson, G; Watson, SA, 1998)
"To evaluate the antitumor activity in terms of response rate (RR), time to progression (TTP) and survival of paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil (5-FU)/leucovorin in pretreated metastatic breast cancer (MBC)."	( Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study. Achterrath, W; Eberhardt, W; Harstrick, A; Klaassen, U; Lenaz, L; Neumann, K; Philippou Pari, C; Seeber, S; Strumberg, D; Wilke, H, 1998)
"Paclitaxel combined with weekly 24-hour infusional 5-FU/leucovorin is well tolerated in the second line treatment of MBC."	( Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study. Achterrath, W; Eberhardt, W; Harstrick, A; Klaassen, U; Lenaz, L; Neumann, K; Philippou Pari, C; Seeber, S; Strumberg, D; Wilke, H, 1998)
" Taken together, the results clearly demonstrated the ability of IL-15, but not IL-2, to provide significant improvement of the therapeutic index of FUra alone and in combination with LV."	( Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cao, S; Rustum, YM; Troutt, AB, 1998)
" This prospective randomized trial compares low-dose (group 1) and high-dose (group 2) leucovorin, combined with the same dose of 5-FU to determine whether high-dose leucovorin was more beneficial than low-dose on overall survival."	( A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. Blanc, F; Bons-Rosset, F; Fabbro-Peray, P; Gouze, C; Heran, B; Marçais, O; Perney, P; Ribard, D; Veyrac, M; Ychou, M, 1998)
" Preclinical studies indicated an enhancement of the therapeutic index when capecitabine was combined with leucovorin."	( A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Allman, D; Bissett, D; Cassidy, J; Dirix, L; Griffin, T; Osterwalder, B; Reigner, B; Van Oosterom, AT, 1998)
" We then tested the effect of GM-CSF given with a more toxic regimen of 5-FU/LV/IFN-alpha (IFN alpha-2a)."	( A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. Allegra, C; Behan, K; Chen, A; Flemming, D; Grem, JL; Grollman, F; Haller, D; Hamilton, JM; Harold, N; Johnston, PG; Lash, A; Liewehr, D; Monahan, B; Morrison, G; Quinn, M; Shapiro, JD; Steinberg, SM; Takimoto, C; Vaughn, D, 1999)
"To determine the maximum-tolerated dose (MTD) and recommended dose of irinotecan (CPT-11) in combination with fluorouracil (5-FU) and leucovorin (LV), using a biweekly LV5FU2 regimen and increasing doses of CPT-11, and to assess the efficacy of this combination in pretreated patients with colorectal cancer (CRC)."	( Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M, 1999)
" CPT-11 at 180 to 200 mg/m(2) in combination with LV5FU2 has been selected as the recommended dose for further studies."	( Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M, 1999)
"Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life."	( Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000)
"This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer."	( Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. Benter, T; Dörken, B; Hohenberger, P; Köhne, CH; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2000)
" This study was conducted to determine the maximum tolerated dose (MTD) of weekly 5-FU when administered with GM-CSF and high-dose LV."	( Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999)
" We describe the design of a phase II study to investigate the safety and efficacy of UFT/leucovorin combined with mitomycin-C in a larger group of previously untreated patients with metastatic colorectal cancer."	( UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca. Jakobsen, A, 2000)
" Protracted infusional 5-FU has been associated with decreased tumor recurrence and improved survival when combined with postoperative adjuvant pelvic radiotherapy."	( Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin. Haller, DG; Minsky, BD; Rosenthal, DI; Saltz, L; Semple, D, 2000)
"The recommended oral dosage of 5-FU (10 mg/m(2) PO bid) given with eniluracil and leucovorin is approximately 115-fold lower than the reference dosage for 24-hour infusional 5-FU."	( Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. Bi, DQ; Donavan, S; Grem, JL; Grollman, F; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Quinn, MG; Shapiro, J; Takimoto, CH; Zentko, S, 2000)
" The present study was initiated to investigate the efficacy of gemcitabine in combination with 5-FU-FA."	( A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Arning, M; Arnold, D; Herrenberger, J; Huhn, D; Kindler, M; Korsten, EW; Langrehr, J; Musch, R; Oettle, H; Pelzer, U; Reitzig, P; Riess, H; Stroszczynski, C, 2000)
"rhuMAbVEGF can be safely combined with chemotherapy at doses associated with VEGF blockade and without apparent synergistic toxicity."	( Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. Adelman, D; Breed, J; Fyfe, G; Gaudreault, J; Gordon, MS; Holmgren, E; Margolin, K; Novotny, W; Stalter, S, 2001)
" A total of 533 courses were administered with a range of 1-14 in FOLFOX4 and 1-12 in FOLFOX2; dose intensity was 92."	( The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phas Baldelli, AM; Beretta, GD; Cascinu, S; Catalano, V; Curti, C; Giordani, P; Labianca, R; Martignoni, G; Mosconi, S; Pancera, G; Poletti, P; Zaniboni, A, )
"The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with dailyx5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo clinic regimen) in the first-line treatment of metastatic colorectal cancer (CRC) patients."	( A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Balbiani, L; Bella, S; Blajman, C; Cazap, E; Chacón, M; Cóppola, F; Giglio, R; Lastiri, F; Mickiewicz, E; Montiel, M; Perazzo, F; Pujol, F; Recondo, G; Richardet, E; Rodger, J; Schmilovich, A; Simon, J; Van Kooten, M; Vilanova, M; Wasserman, E; Zori Comba, A, 2001)
"Patients with isolated hepatic metastases from colorectal cancer were treated every three weeks with increasing doses of oxaliplatin (4 hours; starting dose 25 mg/m2, escalation in steps of 25 mg/m2) in combination with folinic acid (1 hour, 200 mg/m2) and 5-fluorouracil (2 hour, 600 mg/m2)."	( Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Beckert, B; Beykirch, M; Braess, J; Goecke, E; Hiddemann, W; Kern, W; Lang, N; Schalhorn, A; Stein, J; Stemmler, J; Waggershauser, T, 2001)
"To evaluate the efficacy and safety of oxaliplatin (L-OHP) in combination with leucovorin (LV)-modulated bolus plus infusional 5-fluorouracil (5-FU; de Gramont schedule) every 2 weeks in chemotherapy-naive patients with advanced colorectal cancer (CRC)."	( Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Agelaki, A; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N, 2001)
"The purpose of this study was to evaluate the activity and tolerance of high-dose leucovorin (LV) and infusional 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) as salvage chemotherapy in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes."	( Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracyclin Agelaki, S; Christodoulakis, M; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Stylianou, K; Vamvakas, L, 2001)
"Unusual aspect of the development of oxaliplatin was that substantial evidence of its activity was gathered when used in combination with protracted infusion of 5FU combined with leucovorin, preceeding the formal demonstration of its single activity in this disease."	( [Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer]. André, T; Gramont, AD; Louvet, C; Maindrault-Goebel, F, 2001)
"Fifteen patients with isolated liver metastases of colorectal carcinoma were treated with regional administration of CPT-11 in combination with 5-fluorouracil/folinic acid (5-FU/FA)."	( Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases--a pilot experience. Dvorák, J; Jandík, P; Malírová, E; Megancová, J; Melichar, B; Tousková, M; Voboril, Z, )
" A phase II study was conducted to assess the tolerance and efficacy of CPT-11 in combination with leucovorin-modulated bolus plus infusional 5-FU given according to the de Gramont regimen in chemonaive patients with ACC."	( Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N, 2002)
" A phase II study of sequential high-dose methotrexate and fluorouracil, combined with doxorubicin, as a neoadjuvant chemotherapy was conducted in an attempt to evaluate the efficacy of this regimen in improving the survival of patients with scirrhous gastric cancer."	( Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer. Boku, N; Inoue, K; Kinoshita, T; Konishi, M; Nakagouri, T; Ohtsu, A; Ono, M; Sugitou, M; Takahashi, S; Yoshida, S, 2001)
", Carlsbad, CA) when administered in combination with 5-fluorouracil (5-FU) and leucovorin (LV)."	( Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002)
"When eniluracil is given with 5-FU/LV, DPD inhibition appears to be influenced by schedule, and the time to recovery is much longer than has been observed with eniluracil given alone."	( Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition. Grem, JL; Guo, XD; Harold, N; Keith, B; Quinn, M; Schuler, B; Shapiro, J; Zentko, S, 2002)
"To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)."	( Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002)
" Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone."	( A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors. Beck, J; Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Mayer, F; Schroeder, M; von Pawel, J, 2002)
" Thus, clinical and economic data demonstrate that irinotecan, either in combination with irinotecan plus 5-fluorouracil and folinic acid in the first line setting or as monotherapy in the second line setting, has a major role in the management of metastatic colorectal cancer."	( Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Cunningham, D; Falk, S; Jackson, D, 2002)
" Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen."	( Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002)
"Forty-four patients with advanced colorectal cancer, who had progressed during or within 3 months after completion of chemotherapy with LV/5-FU 24-h infusion (LV/5-FU(24h)) (eight patients) or irinotecan combined with or after LV/5-FU(24h )(36 patients), were treated with L-OHP 85 mg/m(2), 2-h intravenous (i."	( Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002)
" Hyperthermic treatment combined with L-OHP/LV/5-FU showed no unexpected toxicities."	( Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002)
" This phase I study was designed to find the maximum tolerated dose (MTD) of weekly cisplatin in combination with standard doses of gemcitabine (1,000 mg/m(2), 30 min) and 5-FU (750 mg/m(2), 24 h)/folinic acid (200 mg/m(2), 30 min)."	( Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer. Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U, 2002)
"The aim of this study was to evaluate the efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma (T3-T4) when delivered in combination with chemotherapy (oral tegafur-uracil modulated with leucovorin)."	( Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study. Batlle, JF; Carpeño, Jde C; García, AG; Grande, AG; Juberías, AM; Olivar, LM; Piñeiro, EH; Sánchez Santos, ME; Uzcudun, AE; Velasco, JC, 2002)
"Our neoadjuvant radiation therapy protocol is efficient for the preoperative treatment of resectable rectal adenocarcinoma when combined with chemotherapy (oral tegafur-uracil modulated with leucovorin)."	( Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study. Batlle, JF; Carpeño, Jde C; García, AG; Grande, AG; Juberías, AM; Olivar, LM; Piñeiro, EH; Sánchez Santos, ME; Uzcudun, AE; Velasco, JC, 2002)
"This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer."	( Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002)
"Irinotecan combined with the bolus Nordic schedule of 5-FU/FA is active in advanced colorectal cancer with an easily managed safety profile which ensures good schedule compliance."	( Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002)
" Thus, Rofecoxib did not appear to increase antitumor activity and resulted in increased gastrointestinal toxicity when combined with 5-FU/LV."	( Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003)
" One course of nedaplatin, 5-FU and LV combined with radiation was performed alternatively."	( [Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma]. Futami, R; Makino, H; Maruyama, H; Miyashita, M; Miyashita, T; Nomura, T; Sasajima, K; Tajiri, T; Tateno, A, 2003)
"A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy."	( Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003)
" We investigated the maximum tolerated dose (MTD) and pharmacokinetics (PK) of CCI-779 in combination with leucovorin (LV) and 5-fluorouracil (5-FU) in patients with advanced solid tumors."	( Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Boni, J; Bruntsch, U; Peters, M; Punt, CJ; Thielert, C, 2003)
" If CCI-779 is to be used in combination with 5-FU/LV, other doses or schedules of administration will need to be explored."	( Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Boni, J; Bruntsch, U; Peters, M; Punt, CJ; Thielert, C, 2003)
" The use of irinotecan together with raltitrexed is also being investigated, as is its combination with oxaliplatin."	( Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U, 2003)
"Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer."	( A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003)
" This study was designed to evaluate the efficacy and the toxicity of paclitaxel combined with semimonthly 5-FU/Leucovorin for the AGC patients."	( [Preliminary report of semimonthly 5-fluorouracil/leucovorin combined with paclitaxel in treatment of advanced gastric cancer (AGC)]. He, YJ; Hu, PL; Li, YH; Liu, DG; Liu, MZ; Qian, SY; Qiu, HJ; Teng, XY; Tian, WH; Xiang, XJ; Xu, RH; Zhang, B; Zhou, NN; Zhou, ZM, 2003)
"Semimonthly 5-FU/LV combined with paclitaxel has high release rate but comparatively mild toxicity for AGC patients."	( [Preliminary report of semimonthly 5-fluorouracil/leucovorin combined with paclitaxel in treatment of advanced gastric cancer (AGC)]. He, YJ; Hu, PL; Li, YH; Liu, DG; Liu, MZ; Qian, SY; Qiu, HJ; Teng, XY; Tian, WH; Xiang, XJ; Xu, RH; Zhang, B; Zhou, NN; Zhou, ZM, 2003)
" irinotecan/5-FU/LV administered every 2 weeks, combined with HAI pirarubicin 60 mg/m(2) on day 1 every 4 weeks."	( Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003)
"The aim of this study was to define the maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24 h-continuous infusion of 5-flourouracil (FU) plus folinic acid, and to assess the toxicity and activity in patients with previously treated colorectal and gastric cancer."	( Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Bokemeyer, C; Hartmann, JT; Hofheinz, RD; Honecker, F; Käfer, G; Kanz, L; Köhne, CH; Nehls, O; Oechsle, K; Quietzsch, D; Wein, A, 2003)
"This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer."	( Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004)
"Oxaliplatin combined with the bolus Nordic schedule of FU+FA (Nordic FLOX) is a well-tolerated, effective, and feasible bolus schedule as first-line treatment of metastatic colorectal cancer that yields comparable results compared with more complex schedules."	( Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004)
" After the operation, weekly bolus of 5-fluorouracil combined with levofolinate was carried out."	( [A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil]. Inoue, M; Jingu, K; Nakajima, Y; Ochiai, T, 2004)
" Oxaliplatin combined with the bolus Nordic schedule of 5-FU/ FA (Nordic FLOX) appears to be well tolerated, effective and feasible as first-line treatment of metastatic colorectal cancer yielding results comparable with those obtained by more complex schedules."	( Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Dahl, O; Sørbye, H, 2003)
"Several studies have demonstrated the efficacy of systemic oxaliplatin (Oxa) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) for the treatment of colorectal liver metastases (CRLM)."	( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I, )
"We designed a phase II trial using Oxa in combination with 5-FU/FA and mitomycin C (MMC) for HAI treatment of patients with isolated non-resectable CRLM."	( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I, )
"We conclude from our results that Oxa in combination with 5-FU/FA and MMC may be a feasible protocol for HAI treatment without major toxicity, especially avoiding higher grade neurotoxicity."	( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I, )
"The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients."	( Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004)
"The novel molecular agent SAM486A is tolerable and safe in combination with a standard 5-FU regimen in patients with advanced colorectal cancer."	( Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004)
"Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer."	( Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004)
" In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)."	( Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."	( Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"Diarrhoea was dose limiting at 300 mg/m2 irinotecan in combination with 5-fluorouracil and folinic acid, and this was determined to be the maximum tolerated dose."	( Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"This regimen of irinotecan in combination with the Mayo Clinic schedule of bolus 5-fluorouracil/folinic acid every four weeks showed activity as first-line therapy in patients with advanced colorectal cancer."	( Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"To evaluate the efficacy of postoperative intraperitoneal hyperthermic chemoperfusion (IHCP) combined with intravenous chemotherapy for advanced gastric cancer."	( [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004)
"Eighty-two patients with stage II - IV gastric cancer were postoperatively randomized into two groups; 46 patients in treatment group who received IHCP combined with intravenous chemotherapy for three times and 36 patients in control group who received intravenous chemotherapy only for six times."	( [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004)
"Intraperitoneal hyperthermic chemoperfusion combined with intravenous chemotherapy can prolong survival and reduce gastrointestinal side-effect which provides an effective treatment option for advanced gastric cancer."	( [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004)
"This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin in patients with advanced solid tumours, and to identify the maximum tolerated dose and the dose for use in future studies."	( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005)
" was given with 350 mg/m2 5-fluorouracil/20 mg/m2 leucovorin x 5 days q28 days."	( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005)
"We performed radio-frequency ablation (RFA) therapy combined with intra-arterial chemotherapy for a 71-year old female gastric cancer patient with liver metastasis."	( [A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy]. Imaizumi, H; Kamei, K; Kosaka, T; Nakano, Y; Takashima, S; Ueno, K; Usami, K, 2004)
" To evaluate the therapeutic effectiveness and safety of oxaliplatin combined with 5-fluorouracil and leucovorin on the patients with gastric carcinoma after palliative gastric resection, we analyzed all of the cases of gastric adenocarcinoma undergone palliative gastric resection in our Cancer Center in recent years."	( [Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer]. Chen, YB; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ, 2004)
"Our aim was to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended dose of oxaliplatin combined with oral tegafur-uracil and leucovorin."	( Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. Chen, JS; Huang, JS; Liau, CT; Lin, YC; Rau, KM; Wang, HM; Yang, TS, 2005)
"Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer."	( Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. Gnad-Vogt, SU; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Willeke, F; Willer, A, 2005)
" This study is a preliminary clinical investigation to determine if HA could be safely used in combination with 5-fluorouracil (5-FU) and doxorubicin (DOX)."	( Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. Brown, TJ; Ellis, A; Fox, RM; Gibbs, P; Heldin, P; Li, L; Rosenthal, MA; Uren, S; Wong, S, 2005)
"Thirty patients with metastatic cancer were intravenously administered 500 mg/m2 HA in combination with escalating doses of DOX (30-60 mg/m2) or 5-FU (cumulative dose of 1,350-2,250 mg/m2 per cycle)."	( Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. Brown, TJ; Ellis, A; Fox, RM; Gibbs, P; Heldin, P; Li, L; Rosenthal, MA; Uren, S; Wong, S, 2005)
" Here, we describe efficacy and safety results for the third patient cohort in this trial, who received BV combined with FU/LV, and compare them with results for concurrently enrolled patients who received IFL."	( Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005)
"To explore the efficacy and safety of CPT-11 combined with fluoropyrimidine in treatment for advanced or metastatic colorectal carcinoma."	( [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma]. Wu, WQ; Yu, BM, 2005)
" CPT-11 combined with capecitabine are not only more effective, but also its occurrence of side effect is lowered, and are especially high effective for lung metastasis."	( [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma]. Wu, WQ; Yu, BM, 2005)
" Treatment with triple therapy using octreotide, galanin and serotonin appear to be comparable to 5-FU/LV in combination with irinotecan and oxaliplatin."	( Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V, 2005)
"To evaluate the effect and acute toxicity of late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma (NPC)."	( [Late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma]. Feng, LP; Lin, Q; Wu, H; Yang, ZX; Yu, ZH, 2005)
"Ninety-six patients with stage III and IV a NPC were randomly divided into 2 groups: test group (n = 46, undergoing late course conformal radiotherapy combined with chemotherapy) and control group (n = 50, undergoing conventional radiotherapy)."	( [Late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma]. Feng, LP; Lin, Q; Wu, H; Yang, ZX; Yu, ZH, 2005)
"Late course conformal radiotherapy combined with chemotherapy effectively improves the disease control, delays the distant metastasis, and alleviates radioactivity damnification."	( [Late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma]. Feng, LP; Lin, Q; Wu, H; Yang, ZX; Yu, ZH, 2005)
" Bevacizumab is currently approved for the first-line treatment of metastatic CRC and is currently being tested in combination with standard therapies for a range of indications."	( Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Hurwitz, H; Kabbinavar, F, 2005)
" Here, we evaluated the pharmacokinetics of oxaliplatin and 5-FU administered in combination with leucovorin in Korean advanced colorectal cancer patients."	( Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006)
" Between February 2002 and October 2002, 64 patients received UFT 300 mg m(-2) day(-1) and LV 90 mg day(-1) from day 1 to day 14 combined with oxaliplatin 130 mg m(-2) on day 1, every 3 weeks."	( 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006)
"Twice weekly SU5416 can be administered with bolus IFL without unexpected toxicities or altering the pharmacokinetic behavior of the administered drugs."	( Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD, 2006)
"To establish a safe and practical chemotherapeutic regimen using CPT-11 in combination with 5-FU plus leucovorin (5-FU/LV) for patients with metastatic colorectal cancer in an outpatient setting, a phase I clinical trial was conducted."	( A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer. Emi, M; Kawabuchi, Y; Minami, K; Yamaguchi, Y, )
"These results suggest that our treatment regimen using CPT-11 in combination with 5-FU/LV is a safe regimen in an outpatient setting and effective for patients with metastatic colorectal cancer."	( A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer. Emi, M; Kawabuchi, Y; Minami, K; Yamaguchi, Y, )
"To investigate the effect of three-dimensional conformal radiotherapy (3-DCRT) in combination with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer."	( Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. He, C; Hu, JB; Sun, XN; Wang, Q; Xu, J; Yang, QC, 2006)
"Forty-eight patients with unresectable recurrent rectal cancer were randomized and treated by 3-DCRT or 3-DCRT combined with FOLFOX4 chemotherapy between September 2001 and October 2003."	( Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. He, C; Hu, JB; Sun, XN; Wang, Q; Xu, J; Yang, QC, 2006)
"Three-dimensional conformal radio-therapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer is a feasible and effective therapeutic approach, and can reduce distant metastasis rate and improve the survival rate."	( Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. He, C; Hu, JB; Sun, XN; Wang, Q; Xu, J; Yang, QC, 2006)
"To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer."	( [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006)
"Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL."	( A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006)
"Levamisole combined with 5-fluorouracil (5-FU) was previously shown to significantly reduce tumor relapses and improve patient survival when given postoperatively in patients with resected stage III colon cancer."	( Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Krook, JE; Kugler, JW; Mahoney, MR; Morton, RF; O'Connell, MJ; Rayson, S; Rowland, KM; Sargent, DJ; Shepherd, L; Windschitl, HE, 2006)
"Eight hundred seventy-eight patients who had undergone complete surgical resection of high-risk stage II/III colon cancer were stratified by known prognostic factors and randomized to receive 1 of 2 treatment regimens: standard-dose levamisole combined with 5-FU and leucovorin; or high-dose levamisole combined with the same chemotherapy."	( Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Krook, JE; Kugler, JW; Mahoney, MR; Morton, RF; O'Connell, MJ; Rayson, S; Rowland, KM; Sargent, DJ; Shepherd, L; Windschitl, HE, 2006)
"It was not possible to improve the efficacy of surgical adjuvant chemotherapy for patients with high-risk colon cancer by giving levamisole at its maximum tolerated dose in combination with 5-FU and leucovorin."	( Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Krook, JE; Kugler, JW; Mahoney, MR; Morton, RF; O'Connell, MJ; Rayson, S; Rowland, KM; Sargent, DJ; Shepherd, L; Windschitl, HE, 2006)
" We designed a new regimen to evaluate the efficacy and feasibility of weekly low dose CPT-11 combined with 5-FU/l-LV therapy based on an RPMI regimen against advanced and recurrent colorectal cancer."	( [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study]. Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K, 2006)
" After that his general condition recovered, and two cycles of neoadjuvant chemotherapy (NAC) by irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) therapy were performed on an outpatient basis."	( [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)]. Fukada, T; Hasegawa, A; Hashimoto, R; Hayashi, T; Kametaka, H; Kawano, H; Koyama, T; Seike, K; Tanaka, H; Yasuno, K, 2006)
"Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC)."	( Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M, 2007)
"Patients received FOLFIRI every 2 weeks for up to six cycles, comprising a 5-FU/LV regimen combined with irinotecan at 180 mg/m2 (cycle 1), increasing to 220 mg/m2 (cycle 2) and 260 mg/m2 (cycle 3 and subsequent cycles) dependent on toxicity."	( Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M, 2007)
"To evaluate the efficacy and toxicity of oxaliplatin in combination with calcium folinate and fluorouracil (OXA-LV5FU2) regimen as the neoadjuvant chemotherapy in the treatment of patients with advanced gastric cancer."	( [Oxaliplatin in combination with calcium folinate and fluorouracil as neoadjuvant chemotherapy in the treatment of advanced gastric cancer]. Fang, Y; Li, F; Li, J; Wang, YJ, 2006)
"Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, was approved in 2004 for use in combination with intravenous 5-fluorouracil-based chemotherapy for the treatment of metastatic colorectal cancer."	( Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Hochster, HS, 2006)
"The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma."	( Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Berardi, R; Cascinu, S; Ceccarelli, C; Di Fabio, F; Funaioli, C; Giannetta, L; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL; Siena, S, 2007)
" This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer."	( Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006)
"This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with oxaliplatin/5-fluorouracil (5-FU)/leucovorin (FOLFOX4) chemotherapy in patients with advanced colorectal cancer."	( A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Bartel, C; Henry, A; Laurent, D; Masson, E; Poethig, M; Steward, W; Thomas, AL; Trarbach, T; Vanhoefer, U; Wang, J; Wiedenmann, B, 2007)
"The MTD of PTK/ZK in combination with FOLFOX4 in this patient population is 1250 mg daily."	( A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Bartel, C; Henry, A; Laurent, D; Masson, E; Poethig, M; Steward, W; Thomas, AL; Trarbach, T; Vanhoefer, U; Wang, J; Wiedenmann, B, 2007)
"This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)."	( Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007)
" This trial assessed the maximum tolerated dose (MTD), safety, preliminary efficacy, and pharmacokinetics of erlotinib combined with FOLFOX."	( Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J, 2007)
" The objective of this Phase I study was to define the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of imatinib in combination with fluorouracil and leucovorin in patients with chemotherapy-refractory gastrointestinal cancer."	( Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial. Al-Batran, SE; Atmaca, A; Ehninger, G; Hosius, C; Jäger, E; Pauligk, C; Schleyer, E, 2007)
"We conducted a randomised phase II study to compare irinotecan monotherapy with irinotecan in combination with infusional 5-fluorouracil/folinic acid (5-FU/FA) regarding efficacy and safety of these regimens in second-line therapy after failed fluoropyrimidine therapy in patients with metastatic colorectal cancer (mCRC)."	( A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W, 2007)
"Our study confirms that irinotecan alone or in combination with infusional 5-FU/FA is an effective and safe regimen for CRC patients who failed first-line therapies."	( A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W, 2007)
" Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer."	( Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007)
"This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and III colon cancer."	( Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. Atkins, JN; Colangelo, LH; Colman, LK; Conley, BA; Fehrenbacher, L; Findlay, MP; Flynn, PJ; Goodwin, JW; Kuebler, JP; Lanier, KS; Levine, EA; O'Connell, MJ; Petrelli, NJ; Ramanathan, RK; Seay, TE; Smith, RE; Soori, G; Wieand, HS; Wolmark, N; Yothers, G; Zapas, JL, 2007)
"To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)."	( Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007)
"Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second-line treatment for advanced colorectal cancer (CRC)."	( First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007)
"Patients with metastatic EGFR-positive CRC received gefitinib at a dose of 250 mg/day combined with simplified FOLFOX6."	( First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007)
"This phase I study was designed to determine the optimally tolerated regimen (OTR), safety, and clinical activity of lapatinib in combination with FOLFOX4 [oxaliplatin/leucovorin/5-fluorouracil (5-FU)] in patients with solid tumors."	( Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Beijnen, JH; Boot, H; Keessen, M; Koch, KM; Pandite, L; Richel, DJ; Schellens, JH; Siegel-Lakhai, WS; Smith, DA; Versola, M; Vervenne, WL, 2007)
" No dose-limiting toxicities were observed and the OTR was established at 1,500 mg/d lapatinib in combination with the standard FOLFOX4 regimen."	( Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Beijnen, JH; Boot, H; Keessen, M; Koch, KM; Pandite, L; Richel, DJ; Schellens, JH; Siegel-Lakhai, WS; Smith, DA; Versola, M; Vervenne, WL, 2007)
"Lapatinib can be safely administered in combination with the standard FOLFOX4 regimen."	( Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Beijnen, JH; Boot, H; Keessen, M; Koch, KM; Pandite, L; Richel, DJ; Schellens, JH; Siegel-Lakhai, WS; Smith, DA; Versola, M; Vervenne, WL, 2007)
"This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma."	( Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH, 2007)
" Resection of liver metastases from SBA combined with neoadjuvant and adjuvant chemotherapy can result in extended disease-free survival and should undergo further investigation."	( Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report. Eigenbrod, T; Klebl, F; Kullmann, F, 2006)
"This study determined the optimally tolerated regimen (OTR) of oral lapatinib administered in combination with infusional 5-fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) and assessed the safety, tolerability and pharmacokinetics of the combination."	( A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C, 2007)
"To assess the therapeutic efficacy and adverse effects of endogenetic field hyperthermia (EFH) in combination with L-OHP /LV / 5-FU in the treatment of advanced gastric cancer."	( [Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer]. Huang, KH; Lin, XG; Liu, TH; Xie, DR, 2007)
"EFH combined with the chemotherapeutic regimen FOLFOX might improve the therapeutic effect of stage II-IV gastric cancer without obviously increasing the adverse effects."	( [Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer]. Huang, KH; Lin, XG; Liu, TH; Xie, DR, 2007)
"This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC)."	( Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. André, T; Casado, E; Cervantes, A; Ciardiello, F; de Gramont, A; Díaz-Rubio, E; Humblet, Y; Kisker, O; Soulié, P; Tabernero, J; Tortora, G; Valera, JS; Van Cutsem, E; Van Laethem, JL; Verslype, C, 2007)
"Cetuximab in combination with FOLFOX-4 is a highly active first-line treatment for mCRC, showing encouraging RR, mPFS, and mOS values."	( Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. André, T; Casado, E; Cervantes, A; Ciardiello, F; de Gramont, A; Díaz-Rubio, E; Humblet, Y; Kisker, O; Soulié, P; Tabernero, J; Tortora, G; Valera, JS; Van Cutsem, E; Van Laethem, JL; Verslype, C, 2007)
"To determine the recommended dose (RD) of EKB-569, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer (mCRC)."	( Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C, 2008)
"The RD of EKB-569 is 25 mg/day when combined with FOLFIRI and results in complete EGFR inhibition."	( Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C, 2008)
"To evaluate the therapeutic efficacy and adverse reaction of Aidi Injection (ADI) combined with FOLFOX4 regimen for treatment of patients with advanced colorectal cancer, and controlled with those of FOLFOX4 regimen alone."	( [Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone]. Dong, L; Fu, SY; Li, HJ, 2007)
"Oxaliplatin combined with 5-FU/leucovorin or capecitabine was generally well tolerated in elderly patients."	( Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2008)
"To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)."	( Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008)
"This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer."	( Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Arnold, D; Dittrich, C; Herrmann, T; Höhler, T; Lordick, F; Riemann, J; Schmoll, HJ; Seufferlein, T; Wöll, E; Zubel, A, 2008)
" Cetuximab combined with FUFOX was generally well tolerated with the most common grade 3/4 adverse events being diarrhea (27%) and paresthesia (16%)."	( Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Arnold, D; Dittrich, C; Herrmann, T; Höhler, T; Lordick, F; Riemann, J; Schmoll, HJ; Seufferlein, T; Wöll, E; Zubel, A, 2008)
"Gefitinib at a dose of 250 mg daily in combination with weekly 5-fluorouracil at 2,000 mg/m(2) or gefitinib at a dose of 500 mg daily with 5-fluorouracil at 1,600 mg/m(2) plus oxaliplatin has an acceptable safety profile."	( Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP, 2008)
"Oxaliplatin combined with 5-fluorouracil (5-FU), with or without leucovorin (LV), is effective and well tolerated for first-line therapy of advanced colorectal cancer (CRC)."	( A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. Bernard, SA; Bjarnason, GA; Braich, T; Desimone, P; Evars, JP; Hrushesky, WJ; Jolivet, J; Ramanathan, RK, 2008)
"This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC)."	( Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Chang, YF; Chao, TY; Chen, PM; Chiou, TJ; Chiu, CF; Chung, CY; Hwang, WS; Lin, SF, 2008)
"The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin (OXA) in combination with continuous infusional 5-fluorouracil (5-FU) and leucovorin (LV) administered every 2 weeks (modified FOLFOX-4 regimen) in elderly patients with advanced gastric cancer (AGC)."	( Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Fu, Z; Guan, F; Guo, QS; Liu, ZF; Wang, MY; Yang, XG; Zhang, XQ, 2008)
" Oxaliplatin in combination with leucovorin and 5-FU should be considered a feasible chemotherapy regimen for patients with recurrent/metastatic biliary tract carcinoma."	( Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. Cho, JY; Jeung, HC; Lee, DK; Lee, SJ; Lim, JY; Mun, HS; Paik, YH; Yoon, DS, 2008)
" We evaluated TM in combination with irinotecan, 5-fluorouracil, and leucovorin (IFL)."	( A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009)
" The FOLFIRI regimen consisted of irinotecan (180 mg/m(2); day 1) combined with leucovorin (200 mg/m(2)), followed by 5-fluorouracil (400 mg/m(2)) as a bolus and 600 mg/m(2) as a 22-h infusion on days 1 and 2 every 2 weeks."	( Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Bang, YJ; Im, SA; Kim, DY; Kim, JH; Kim, TY; Lee, JS; Lee, KW; Lim, JH; Oh, DY; Seo, MD; Yi, HG, 2008)
" In this study, escalating doses of Bortezomib were administered along with the standard FOLFOX-4 doses, in order to evaluate the dose-limiting toxicity (DLT), toxicity profile and activity of the combination."	( An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009)
" This study was to evaluate the efficacy of three-dimensional conformal gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer."	( [Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer]. Cai, CL; Kang, JB; Li, JG; Nie, Q; Qi, WJ; Wang, B; Zhang, LP, 2008)
"3-D conformal gamma-knife radiotherapy combined with thermochemotherapy is well tolerated and is relatively effective for most patients with locally advanced pancreatic cancer."	( [Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer]. Cai, CL; Kang, JB; Li, JG; Nie, Q; Qi, WJ; Wang, B; Zhang, LP, 2008)
"To evaluate the efficacy of r oxaliplatin plus 5-fluorouracil/leucovorin calcium (LV) combined with concurrent radiotherapy in the treatment of local advanced gastric cancer."	( [Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy for local advanced gastric cancer]. Shao, ZY; Zhang, JD, 2008)
"Radiotherapy combined with concurrent chemotherapy may be an effective and well-tolerated regimen in patients with advanced and metastatic gastric cancer."	( [Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy for local advanced gastric cancer]. Shao, ZY; Zhang, JD, 2008)
"This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers."	( Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, MA; Kim, TY; Kim, WH; Lee, KH; Lee, KW; Lee, MH; Lee, NS; Oh, DY; Park, SR; Song, HS, 2009)
"The objective of this study was to evaluate the efficacy and safety of the POF regimen (biweekly 5-fluorouracil/leucovorin combined with paclitaxel and oxaliplatin) as first-line treatment for advanced gastric cancer (AGC)."	( A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. Chen, L; Fan, NF; Guo, ZQ; Lin, RB; Liu, J; Wang, XJ, 2008)
"A total of 342 patients received irinotecan-based chemotherapy as second-line chemotherapy: FOLFIRI-3 [n = 109, irinotecan 100 mg/m(2) days 1 and 3 combined with leucovorin (LV) 400 mg/m(2) day 1 and 46-h continuous 5-fluorouracil (5-FU) 2000 mg/m(2)], FOLFIRI-1 (n = 112, irinotecan 180 mg/m(2) day 1 combined with LV 400 mg/m(2) day 1, 5-FU bolus 400 mg/m(2) and 46-h continuous 5-FU 2400 mg/m(2)) and other various irinotecan-based regimens (n = 121)."	( Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2009)
" Purposes of this study were to determine the recommended phase II dose of cediranib in combination with standard doses of modified FOLFOX-6 (mFOLFOX-6), and the tolerability, safety, pharmacokinetics, and antitumor activity of this combination in patients with untreated metastatic colorectal cancer."	( Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Chen, E; Gauthier, I; Jonker, D; MacLean, M; Powers, J; Seymour, L; Wells, J, 2009)
" The recommended phase II dose is cediranib at 30 mg daily continuously in combination with standard doses of mFOLFOX-6."	( Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Chen, E; Gauthier, I; Jonker, D; MacLean, M; Powers, J; Seymour, L; Wells, J, 2009)
" Moreover, in combination with 5-fluorouracil modulated by folinic acid (5FU-FA) or with Raltitrexed (RTX), both commonly used in the treatment of this disease, it showed a clear schedule-dependent synergistic antiproliferative interaction as demonstrated by calculating combination indexes."	( Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Avallone, A; Bruzzese, F; Budillon, A; Delrio, P; Di Gennaro, E; Leone, A; Pepe, S; Subbarayan, PR, 2009)
" This phase I/II trial was performed to evaluate the efficacy and safety of continuous infusion of irinotecan combined with UFT plus leucovorin (LV) for metastatic colorectal cancer."	( Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer. Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A, 2009)
"A 24-hour infusion of irinotecan combined with UFT/LV is feasible and active for metastatic colorectal cancer."	( Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer. Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A, 2009)
"This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer."	( Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009)
"We conducted a phase I study to determine the maximum tolerated dose of vorinostat in combination with fixed doses of 5-fluorouracil (FU), leucovorin, and oxaliplatin (FOLFOX)."	( A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)
"The maximum tolerated dose of vorinostat in combination with FOLFOX is 300 mg orally twice daily x 1 week every 2 weeks."	( A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)
"To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study."	( Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Hattori, T; Itoh, K; Komatsu, N; Mine, T; Okuno, K; Shiozaki, H; Yamada, A, 2009)
"This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients."	( [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. Lou, F; Pan, HM; Zhu, YH, 2009)
"The chemotherapy of bevacizumab combined with irinotecan, fluorouracil and leucovorin results in better efficacy in patients with progressive metastatic colorectal cancer."	( [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer]. Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H, 2009)
"Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC)."	( Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009)
"1 months and is comparable to that observed in published phase III and community-based trials using first-line bevacizumab plus FOLFIRI, and to phase III trials using bevacizumab in combination with bolus 5-FU/LV plus IFL."	( Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009)
"Bevacizumab combined with first-line FOLFIRI is an effective and well-tolerated therapy option for patients with metastatic CRC."	( Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009)
"To compare the therapeutic effect and toxicity of chemotherapy, used alone or in combined with Shenqi Fuzheng Injection (SFI), for the treatment of advanced colorectal carcinoma (ACRC)."	( [Effect of Shenqi Fuzheng injection combined with chemotherapy in treating advanced colorectal carcinoma]. Liang, QL; Pan, DC; Xie, JR, 2009)
"One hundred and fifty-two patients with ACRC were equally randomized by digital table, to the treated group, treated by chemotherapy of FOLFOX regimen combined with SFI, and the control group treated by FOLFOX regimen alone."	( [Effect of Shenqi Fuzheng injection combined with chemotherapy in treating advanced colorectal carcinoma]. Liang, QL; Pan, DC; Xie, JR, 2009)
"To investigate the efficiency, time to progression (TTP), overall survival (OS) and toxicity of epirubicin combined with DDP and 5-Fu (PELF regimen) for the treatment of advanced gastric cancer."	( [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer]. Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD, 2009)
"The regimen of epirubicin combined with DDP and 5-Fu is effective, well tolerable and safe for advanced gastric cancer patients either as adjuvant or as palliative therapy."	( [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer]. Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD, 2009)
"Third-generation regimens (MACOP-B [methotrexate/leucovorin (LV)/doxorubicin/cyclophosphamide/vincristine/ prednisone/bleomycin] or VACOP-B [etoposide/LV/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin]) in combination with local radiation therapy seem to improve lymphoma-free survival of primary mediastinal large B-cell lymphoma (PMLBCL)."	( Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Broccoli, A; Brusamolino, E; Cabras, MG; Chiappella, A; Finolezzi, E; Martelli, M; Rossi, A; Salvi, F; Stefoni, V; Zinzani, PL, 2009)
"Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)."	( A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010)
"Axitinib is well tolerated in combination with FOLFOX, FOLFIRI, or FOLFOX plus 2 mg/kg bevacizumab."	( A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010)
"We conducted a phase I clinical trial to determine the maximum tolerated dose (MTD) of daily or twice daily vorinostat x 3 days when combined with fixed doses of 5-fluorouracil (FU) and leucovorin every 2 weeks."	( A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Diasio, RB; Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Muindi, JR; Wang, K; Zwiebel, JA, 2010)
"The MTD of vorinostat in combination with sLV5FU2 is 1,700 mg orally once daily x 3 or 600 mg orally twice daily x 3 days every 2 weeks."	( A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Diasio, RB; Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Muindi, JR; Wang, K; Zwiebel, JA, 2010)
"HAI oxaliplatin combined with systemic 5-fluorouracil, leucovorin, and bevacizumab had antitumor activity in patients with advanced cancer and liver metastases, and the current results indicated that this combination warrants further study."	( A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Bedikian, AY; Camacho, LH; Eng, C; Fu, S; Hong, D; Kurzrock, R; Lim, JA; Ng, C; Tsimberidou, AM; Wallace, M; Wen, S; Wheler, J, 2010)
"Edotecarin (J-107088), a novel inhibitor of topoisomerase I has an additive effect on colon cell lines (HCT-116) when combined with 5-fluorouracil (5-FU)."	( A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Diasio, RB; Douillard, JY; Saif, MW; Sellers, S, 2010)
" His diagnosis was rectal perforation combined with intraperitoneal abscess."	( [A case of rectal cancer combined with intraperitoneal abscess responding completely to uracil/tegafur (UFT) plus oral leucovorin (LV) therapy]. Hamaya, M; Hojyo, K; Honda, A; Kaneko, H; Kawashima, H; Narabashi, K; Noda, S; Okamoto, N; Onoda, K; Yamada, K; Yokote, K, 2010)
"Seventy-eight patients with cTNM stage III or IV (M0) gastric cancer were enrolled and 39 were randomized into the treatment arm (n=39, paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy every two weeks in each cycle) and control group (n=39)."	( [A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer]. Liu, FR; Ma, FY; Ma, SQ; Qu, JJ; Shi, YR, 2010)
"The efficacy of paclitaxel combined with FOLFOX4 as neoadjuvant chemotherapy is high."	( [A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer]. Liu, FR; Ma, FY; Ma, SQ; Qu, JJ; Shi, YR, 2010)
"Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC)."	( Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F, 2010)
" Hazard ratios for progression and death were combined with an inverse variance method based on logarithmic conversion."	( Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F, 2010)
"To investigate the efficacy and toxicity of a short intensive Uracil/Tegafur (UFT) based chemoradiotherapy scheme combined with celecoxib in locally advanced pancreatic cancer."	( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011)
"5 Gy radiotherapy combined with UFT 300 mg/m(2) per day, leucovorin (folinic acid) 30 mg and celecoxib 80 0mg for 28 days concomitant with radiotherapy."	( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011)
"Based on the lack of response, the substantial toxicity of mainly gastro-intestinal origin and the reported mediocre overall and progression free survival, we cannot advise our short intensive chemoradiotherapy schedule combined with celecoxib as the standard treatment."	( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011)
" We conducted this study to investigate its efficacy and safety when combined with chemotherapy in patients with advanced solid tumors."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)
"5 mg/m2 /day as an intravenous infusion for more than 7 days, in combination with chemotherapy."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)
"Our study revealed that toxicity of Endostar combined with chemotherapy in the treatment of solid tumors was tolerable with moderate efficacy."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)
"To compare clinical efficacy and toxicity of irinotecan combined with 5-fluorouracil and leucovorin with those of oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer."	( Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X, 2010)
"Literature search was performed by keywords "irinotecan", "oxaliplatin" and "colorectal cancer" on all randomized controlled trails reported on irinotecan versus oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer in MEDLINE, OVID, Springer, Cochrane Controlled Trials Register (CCTR) and CBMdisc (Chinese Biology and Medicine disc) before January 2010."	( Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X, 2010)
"Both irinotecan and oxaliplatin combined with 5-fluorouracil and leucovorin were effective in the first-line therapy of advanced colorectal cancer."	( Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X, 2010)
"Interstitial lung disease in patients with colorectal cancer during chemotherapy combined with bevacizumab is rare."	( Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K, 2011)
"0 mg/kg q2w, concomitantly with a combination of capecitabine and oxaliplatin (XELOX) and FOLFOX-4 (oxaliplatin in combination with infusional 5-FU/LV), respectively, in patients with metastatic colorectal cancer (mCRC)."	( A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Abt, M; Burns, I; Chen, E; Goldstein, D; Major, P; McKendrick, J; Rittweger, K; Robinson, B; Zhi, J, 2011)
" BV in combination with XELOX and FOLFOX-4 was generally well tolerated with no unexpected safety signals and no deaths."	( A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Abt, M; Burns, I; Chen, E; Goldstein, D; Major, P; McKendrick, J; Rittweger, K; Robinson, B; Zhi, J, 2011)
"The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37."	( A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G, 2012)
" Treatment regimen: irinotecan (80 mg/m²) as 1-h infusion followed by 5-FU (2000 mg/m²) combined with FA (500 mg/m²) as 24-h infusion (d1, 8, 15, 22, 29, 36, qd 57)."	( Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011)
"This Phase I study investigated the safety, tolerability and pharmacokinetics of cediranib (20 or 30 mg) in combination with mFOLFOX6 in Japanese patients with previously untreated metastatic CRC."	( Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K, 2012)
"Cediranib (20 or 30 mg) in combination with mFOLFOX6 was considered tolerable according to the protocol-defined criteria, providing justification for the Phase II part of this study."	( Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K, 2012)
"To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients."	( Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. Alkis, N; Benekli, M; Demirci, U; Gumus, M; Isikdogan, A; Kaplan, MA; Koca, D; Ozdemir, NY; Sevinc, A; Uncu, D; Unek, T; Yetisyigit, T; Yilmaz, U, )
"MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients."	( Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. Alkis, N; Benekli, M; Demirci, U; Gumus, M; Isikdogan, A; Kaplan, MA; Koca, D; Ozdemir, NY; Sevinc, A; Uncu, D; Unek, T; Yetisyigit, T; Yilmaz, U, )
"To evaluate the efficacy and safety of yiqi zhuyu decoction (YZD) combined with oxaliplatin plus 5-flurouracil/leucovorin (FOLFOX-4) in the patients with metastatic colorectal cancer (MCRC)."	( Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. Cao, B; Deng, WL; Li, ST; Li, Z, 2011)
"YZD combined with FOLFOX-4 chemotherapy significantly improved OS in this first-line trial in the patients with MCRC and significantly decreased grade 3/4 AEs."	( Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. Cao, B; Deng, WL; Li, ST; Li, Z, 2011)
"In this phase II, double-blind, placebo-controlled study, 172 patients with metastatic CRC were randomised to receive once-daily cediranib (20 or 30 mg) or placebo, each combined with modified FOLFOX6 (mFOLFOX6)."	( Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K, 2012)
"To evaluate the safety and efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) in the treatment of HER2-positive advanced gastric cancer."	( [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. Chen, QQ; Gao, XP; Li, W; Pan, SY; Sun, J, 2011)
"Trsatuzumab combined with FOLFIRI regimen is effective, safe and well tolerated for treatment of HER2-positive advanced gastric cancer."	( [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. Chen, QQ; Gao, XP; Li, W; Pan, SY; Sun, J, 2011)
"We evaluated the efficacy and safety of bolus 5-fluorouracil (5-FU) and leucovorin combined with weekly paclitaxel (FLTAX) in advanced gastric cancer (GC) patients."	( Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer. Hamaguchi, T; Iwasa, S; Kato, K; Kobayashi, K; Matsubara, J; Nagai, Y; Nakajima, TE; Nakayama, N; Shimada, Y; Takagi, S; Tsuji, A; Yamada, Y; Yoshioka, A, 2011)
"The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit."	( Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S, 2012)
"This dose escalation, uncontrolled phase I study evaluated the tolerability, pharmacokinetics (PK), and antitumor activity of oral sorafenib 100, 200, or 400 mg twice daily (bid, continuous regimen) in combination with 5-fluorouracil/leucovorin (5-FU/LCV, intravenous infusion or bolus) in patients with advanced, solid tumors."	( Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S, 2012)
"To observe the efficacy, side effects and impact on the quality of life of Aidi Injection combined with leucovorin calcium/5-fluorouracil/oxaliplatin (FOLFOX4 regimen) in the treatment of advanced colorectal cancer patients."	( A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Huang, XE; Li, CG; Li, Y; Tang, JH; Xu, HX, 2011)
"Aidi injection combined with FOLFOX4 is associated with reduced toxicity of chemotherapy, enhanced clinical benefit response and improved quality of life of patients with advanced colorectal cancer."	( A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Huang, XE; Li, CG; Li, Y; Tang, JH; Xu, HX, 2011)
"The overall toxicity of oxaliplatin and continuous 5-FU/leucovorin infusion in combination with radiation was well tolerated."	( Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study. Baek, JH; Jung, DH; Kwon, KA; Lee, KC; Lee, SH; Lee, WS; Shin, DB; Sym, SJ, 2013)
"Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU."	( A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012)
"Fifty seven patients with mCRC and no previous chemotherapy for metastatic disease were randomized to receive LV/Na or LV/Ca with irinotecan or oxaliplatine combined with infusional 5-FU."	( A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012)
"This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6)."	( A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J, 2012)
" No clinically significant drug-drug interactions were apparent between sunitinib, its metabolite SU12662, and mFOLFOX6."	( A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J, 2012)
"Sunitinib combined with mFOLFOX6 had acceptable tolerability."	( A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J, 2012)
"The efficacy and tolerability of bevacizumab every 2 or 4 weeks using the same dosage in combination with biweekly FOLFIRI were retrospectively evaluated in metastatic colorectal cancer (mCRC) patients in the first-line and second-line therapy."	( Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R, 2012)
" The patients had received biweekly FOLFIRI in combination with bevacizumab 5 mg/kg every 2 weeks or every 4 weeks schedule for various reasons in individual patients."	( Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R, 2012)
"Bevacizumab 5 mg/kg every 2 weeks or every 4 weeks in combination with biweekly FOLFIRI had similar efficacy and tolerability in mCRC."	( Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R, 2012)
"To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas."	( Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013)
"Patients were treated in two matuzumab dose groups with the first cohort of patients receiving 400 mg matuzumab in combination with PLF."	( Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013)
"Matuzumab, in combination with PLF, demonstrated an acceptable safety profile with modest anti-tumor activity."	( Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013)
" FOLFOX4 combined with panitumumab therapy was initiated 1 month after the operation."	( [A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab]. Asano, T; Hattori, M; Kamiya, I; Negita, M; Takagi, D; Uemura, T, 2012)
" This study compared the safety and efficacy of hepatic resection (HR) combined with RFA versus HR alone after effective chemotherapy in patients with initially unresectable CRLM."	( Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Kikuchi, K; Kuroki, H; Mima, K; Miyamoto, Y; Nakagawa, S; Okabe, H; Sakamoto, Y; Watanabe, M, 2013)
" Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy."	( Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012)
"The maximum planned dose of oxaliplatin at 100 mg/m(2) per dose in combination with 5-FU and leucovorin was safe and well tolerated and in this patient population."	( A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Arceci, RJ; Bagatell, R; Boklan, J; Christians, U; Duncan, T; Gore, L; Herzog, C; Hunger, SP; Ivy, SP; Macy, ME; Narendren, A; Rolla, K; Trippett, T; Whitlock, J, 2013)
" In the USA, the approval of cetuximab has been recently expanded to include the first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer (mCRC) when used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin [folinic acid])."	( Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. Lyseng-Williamson, KA, 2012)
"In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle."	( Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Amler, LC; Baranda, JC; Bayraktar, S; Flores, AM; MacIntyre, J; Montero, A; Portera, C; Raja, R; Rocha Lima, CM; Royer-Joo, S; Stern, H; Wallmark, J, 2012)
" This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities."	( A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer. Copeman, M; Gibbs, P; Gouillou, M; Jefford, M; Lipton, L; Lynch, K; McArthur, G; Michael, M; Tebbutt, NC; Zalcberg, J, 2013)
"This prospective observational study assessed the efficacy of bevacizumab in combination with chemotherapy as preoperative treatment to downsize tumours for radical resection in patients with unresectable metastatic colorectal cancer (mCRC)."	( Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J, 2013)
" Preoperative treatment consisted of bevacizumab (5 mg/kg) combined with oxaliplatin- or irinotecan-based chemotherapy, which was followed by surgery in patients showing clinical benefit."	( Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J, 2013)
"The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen."	( Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013)
" However, the value of FAK combined with JWA for GC patients as a biomarker has not been studied."	( High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients. Chen, Y; He, S; Li, A; Qiang, F; Røe, OD; Tan, Y; Wang, S; Wu, X; Xia, X; Zhang, J; Zhou, J; Zhou, Y, 2013)
"Pazopanib combined with FOLFOX6 or reduced CapeOx was adequately tolerated in this patient population."	( An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS, 2013)
" The multitargeted kinase inhibitor, regorafenib, was combined with chemotherapy as first- or second-line treatment of mCRC to assess safety and pharmacokinetics (primary objectives) and tumor response (secondary objective)."	( Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D, 2013)
"Regorafenib had acceptable tolerability in combination with chemotherapy, with increased exposure of irinotecan and SN-38 but no significant effect on 5-fluorouracil or oxaliplatin pharmacokinetics."	( Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D, 2013)
" We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC."	( A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J, 2013)
") or placebo, combined with mFOLFOX6 (oxaliplatin 85 mg/m(2); levo-leucovorin 200 mg/m(2); fluorouracil 400 mg/m(2) bolus and 2400 mg/m(2) continuous infusion) every 14 days."	( Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013)
" These results do not support further development of sorafenib in combination with mFOLFOX6 in molecularly unselected patients with mCRC."	( Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013)
" Patients with histologically proven gastrointestinal neuroendocrine carcinoma who were treated with irinotecan combined with 5-fluorouracil and leucovorin in a first-line setting were eligible for analysis."	( First-line irinotecan combined with 5-fluorouracil and leucovorin for high-grade metastatic gastrointestinal neuroendocrine carcinoma. Du, Z; Li, Q; Wang, Y; Wen, F; Zhou, Y, )
"The results demonstrated that irinotecan combined with 5-fluorouracil and leucovorin is an active regimen with acceptable toxicity for patients with metastatic high-grade gastointestinal neuroendocrine carcinoma that merits further investigation in prospective trials."	( First-line irinotecan combined with 5-fluorouracil and leucovorin for high-grade metastatic gastrointestinal neuroendocrine carcinoma. Du, Z; Li, Q; Wang, Y; Wen, F; Zhou, Y, )
"The purpose of this study is to observe and compare the preliminary efficacy and side effects of docetaxel, 5-fluorouracil and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy for the treatment of advanced gastric cancer."	( Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma. Kan, W; Ke, Z; Pengjun, Z; Qinghua, D; Ruzhen, Z; Shenglin, M; Xiadong, L; Zhibing, W, )
"Retrospectively analyzed 101 patients with advanced gastric cancer receiving docetaxel, 5-fluorouracil, leucovorin and cisplatin intravenous chemotherapy or intravenous administration of docetaxel, 5-fluorouracil and leucovorin combined with cisplatin hyperthermic intraperitoneal perfusion chemotherapy, 49 patients in intravenous chemotherapy (VC) group, 52 patients in hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) group."	( Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma. Kan, W; Ke, Z; Pengjun, Z; Qinghua, D; Ruzhen, Z; Shenglin, M; Xiadong, L; Zhibing, W, )
" We present the treatment rationale and protocol for an ongoing randomized multicenter placebo-controlled phase II study designed to evaluate the efficacy and safety of MetMAb combined with bevacizumab and mFOLFOX-6 (5-fluoruracil, leucovorin, and oxaliplatin)."	( Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Bendell, JC; Ervin, TJ; Gallinson, D; Hack, SP; Phan, SC; Saleh, MN; Singh, J; Vallone, M; Wallace, JA, 2013)
"Eligible patients with previously untreated mCRC are randomized 1:1 to either mFOLFOX-6 combined with bevacizumab and placebo followed by 5-fluorouracil/leucovorin plus bevacizumab and placebo or mFOLFOX6, bevacizumab plus MetMAb followed by 5 FU/LV, bevacizumab, and MetMAb."	( Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Bendell, JC; Ervin, TJ; Gallinson, D; Hack, SP; Phan, SC; Saleh, MN; Singh, J; Vallone, M; Wallace, JA, 2013)
"The study objectives were to evaluate the safety, tolerability, and preliminary efficacy of multiple doses of dulanermin in combination with modified FOLFOX6 and bevacizumab in previously untreated patients with locally advanced, recurrent, or metastatic colorectal cancer."	( A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Ashkenazi, A; Kapp, AV; Kozloff, MF; Messersmith, WA; Peddi, PF; Portera, CC; Royer-Joo, S; Wainberg, ZA, 2013)
"The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen."	( Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014)
"The benefits of aflibercept in combination with FOLFIRI in patients with mCRC previously treated with oxaliplatin were maintained across the specified patient subgroups, including in patients with or without prior bevacizumab treatment."	( Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014)
" Here, we evaluate the safety and pharmacokinetics of efatutazone combined with FOLFIRI (5-fluorouracil, levo-leucovorin, and irinotecan) as second-line chemotherapy in Japanese patients with mCRC."	( Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S, 2014)
"50 mg (the recommended dose [RD] of efatutazone monotherapy) twice daily in combination with FOLFIRI in a 3-9 patient cohort."	( Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S, 2014)
"Efatutazone combined with FOLFIRI demonstrates an acceptable safety profile and evidence of disease stabilization in Japanese patients with mCRC."	( Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S, 2014)
" Seven electronic databases were searched for randomized controlled trials (RCTs) of FOLFOX4 combined with HMs compared to FOLFOX4 alone."	( FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review. Chen, M; May, BH; Xue, CC; Zhang, AL; Zhou, IW, 2014)
", in a week-on/week-off schedule, combined with FOLFIRI or FOLFOX."	( Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J, 2014)
"Axitinib administered in a week-on/week-off schedule combined with FOLFIRI or FOLFOX is supported by (18)FLT-PET data and was well tolerated in patients with gastrointestinal tumours."	( Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J, 2014)
"This phase I study investigated the safety, dose-limiting toxicity, and efficacy in three cohorts all treated with the mTOR inhibitor everolimus that was delivered (1) in combination with 5-fluorouracil with leucovorin (5-FU/LV), (2) with mFOLFOX6 (5-FU/LV + oxaliplatin), and (3) with mFOLFOX6 + panitumumab in patients with refractory solid tumors."	( A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Bernard, S; Davies, JM; Dees, EC; Goldberg, RM; Ivanova, A; Keller, K; McRee, AJ; O'Neil, BH; Sanoff, HG, 2014)
" In the present study, we investigated the efficacy of treatment with systemic gemcitabine (GEM) combined with HAIC with cisplatin (CDDP), 5-fluorouracil (5-FU), and isovorin in patients with advanced ICC."	( Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study. Harima, Y; Hidaka, I; Ishikawa, T; Marumoto, M; Marumoto, Y; Saeki, I; Sakaida, I; Segawa, M; Takami, T; Terai, S; Uchida, K; Urata, Y; Yamaguchi, Y; Yamasaki, T, )
"Seven patients with advanced ICC, who received systemic GEM combined with HAIC with CDDP, 5-FU, and isovorin were studied."	( Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study. Harima, Y; Hidaka, I; Ishikawa, T; Marumoto, M; Marumoto, Y; Saeki, I; Sakaida, I; Segawa, M; Takami, T; Terai, S; Uchida, K; Urata, Y; Yamaguchi, Y; Yamasaki, T, )
"Although this is a pilot study, we suggest that systemic GEM combined with HAIC with CDDP, 5-FU, and isovorin, may be a useful therapy for patients with advanced ICC."	( Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study. Harima, Y; Hidaka, I; Ishikawa, T; Marumoto, M; Marumoto, Y; Saeki, I; Sakaida, I; Segawa, M; Takami, T; Terai, S; Uchida, K; Urata, Y; Yamaguchi, Y; Yamasaki, T, )
"To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin."	( [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer]. Abad, A; Echave, M; Frías, C; Giménez, E; Joulain, F; Lamas, MJ; Naoshy, S; Oyagüez, I; Pericay, C; Rubio, M, 2014)
" In the cost-effectiveness analysis Euros 38,931/LYG was obtained with aflibercept in combination with FOLFIRI versus FOLFIRI."	( [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer]. Abad, A; Echave, M; Frías, C; Giménez, E; Joulain, F; Lamas, MJ; Naoshy, S; Oyagüez, I; Pericay, C; Rubio, M, 2014)
"Aflibercept in combination with FOLFIRI increased overall survival versus FOLFIRI, so it is an effective strategy in the treatment of patients with mCRC."	( [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer]. Abad, A; Echave, M; Frías, C; Giménez, E; Joulain, F; Lamas, MJ; Naoshy, S; Oyagüez, I; Pericay, C; Rubio, M, 2014)
"The aim of this retrospectively study was to evaluate the clinical efficacy of Aidi injection (ADI) combined with FOLFOX4 chemothreapy regimen in the treatment of advanced colorectal carcinoma."	( Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma. Li, Y; Nan, H; Wang, T; Wang, Y; Zhang, C; Zhang, X, 2014)
" Of the included 121 cases, 58 subjects received the treatment of ADI combined with FOLFOX4 chemotherapy (experiment group) and the other 63 cases received the FOLFOX4 chemotherapy alone (control group)."	( Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma. Li, Y; Nan, H; Wang, T; Wang, Y; Zhang, C; Zhang, X, 2014)
"ADI combined with FOLFOX4 chemotherapy can improve the quality of life and decrease some of the toxicity related to chemotherapy in patients with advanced colorectal cancer."	( Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma. Li, Y; Nan, H; Wang, T; Wang, Y; Zhang, C; Zhang, X, 2014)
"In this study, we compared the efficacy and safety of the oral fluoropyrimidine S-1 as monotherapy or in combination with leucovorin as the second-line treatment for patients with metastatic pancreatic cancer whose disease had progressed on gemcitabine treatment."	( S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y, 2014)
" Patients randomly received S-1 or S-1 in combination with leucovorin (SL arm) in 21-day cycles."	( S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y, 2014)
"This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer."	( Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). Alonso, V; Cirera, L; Fernandez-Plana, J; Mendez, M; Pericay, C; Quintero, G; Saigi, E; Salgado, M; Salud, A, 2014)
" This study aimed to evaluate the drug safety and tolerability of continuous intravenous infusion (CIV) of endostar in combination with modified FOLFOX6 (mFOLFOX6) as an initial therapy in advanced colorectal cancer patients."	( Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cao, J; Chen, Z; Guo, W; Ji, D; Li, J; Li, W; Lv, F; Qiu, L; Wang, J; Xia, Z; Zhang, S; Zhang, W, 2015)
" Primary outcomes were dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CIV endostar in combination with mFOLFOX6."	( Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cao, J; Chen, Z; Guo, W; Ji, D; Li, J; Li, W; Lv, F; Qiu, L; Wang, J; Xia, Z; Zhang, S; Zhang, W, 2015)
"Endostar in combination with mFOLFOX6 was generally safe and well tolerated."	( Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cao, J; Chen, Z; Guo, W; Ji, D; Li, J; Li, W; Lv, F; Qiu, L; Wang, J; Xia, Z; Zhang, S; Zhang, W, 2015)
"The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process."	( The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015)
" Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen."	( Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015)
" We assessed the efficacy and safety of ramucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients with disease progression during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine."	( Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin Bodoky, G; Chang, SC; Ciuleanu, TE; Clingan, PR; Cohn, AL; Garcia-Alfonso, P; Garcia-Carbonero, R; Grothey, A; Kim, TW; Lonardi, S; Nasroulah, F; Obermannova, R; Portnoy, DC; Prausová, J; Simms, L; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yoshino, T, 2015)
" Curcumin may provide added benefit in subsets of patients when administered with FOLFOX, and is a well-tolerated chemotherapy adjunct."	( Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Berry, DP; Brown, K; Cai, H; Dennison, A; Garcea, G; Greaves, P; Griffin-Teal, N; Higgins, JA; Howells, LM; Irving, G; Iwuji, C; James, MI; Karmokar, A; Lloyd, DM; Metcalfe, M; Morgan, B; Patel, SR; Steward, WP; Thomas, A, 2015)
"To explore the clinical efficacy and toxic and side effects of recombinant human endostatin (rh- endostatin/endostar) combined with chemotherapy in the treatment of advanced gastric cancer."	( Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer. Gao, SR; Li, LM; Wang, AR; Wang, GM; Xia, HP; Xu, HY, 2015)
"Preliminary observations show that endostar (once every other day) combined with chemotherapy is effective in the treatment of advanced gastrointestinal cancer, with low toxic effects, good tolerance, deserving further study."	( Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer. Gao, SR; Li, LM; Wang, AR; Wang, GM; Xia, HP; Xu, HY, 2015)
" This novel siRNA based drug was studied, in combination with chemotherapy, as targeted therapy for Locally Advanced Pancreatic Cancer (LAPC)."	( RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A, 2015)
" In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (mFOL- FOX6) or capecitabine/oxaliplatin (XELOX)."	( Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer. Akyol, M; Alacacioglu, A; Cokmert, S; Demir, L; Dirican, A; Kucukzeybek, Y; Oktay Tarhan, M; Varol, U; Vedat Bayoglu, I; Yildiz, I; Yildiz, Y, )
"Our results show that XELOX is a safe and effective alternative to mFOLFOX6 when combined with bevacizumab as first-line treatment for mCRC patients."	( Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer. Akyol, M; Alacacioglu, A; Cokmert, S; Demir, L; Dirican, A; Kucukzeybek, Y; Oktay Tarhan, M; Varol, U; Vedat Bayoglu, I; Yildiz, I; Yildiz, Y, )
"Aiming at exploring clinical curative effect of oxaliplatin combined with flurouracil in the treatment of gastrointestinal tumor, this study divided 60 patients with gastrointestinal tumor into control and observation groups, each containing 30 patients."	( Clinical curative effect of oxaliplatin combined with flurouracil in the treatment of gastrointestinal tumor. Feng, W; Li, B; Liu, Y; Wang, J; Xu, D; Zhuang, J, 2015)
" The remission rate, control rate and time to disease progression were compared among patients receiving cetuximab combined with different chemotherapy regimens in different periods."	( [Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma]. Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T, 2015)
"Cetuximab in combination with oxaliplatin-based chemotherapy is recommended as the first-line application in the treatment of metastatic colorectal carcinoma patients, because it is helpful to improve the rate of disease control."	( [Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma]. Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T, 2015)
"The aim is to evaluate the preliminary efficacy and side effects of paclitaxel, 5-fluorouracil, and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) as postoperative adjuvant therapy for patients of locally advanced gastric cancer (GC) at high risk for recurrence after curative resection."	( Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer. Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z, 2014)
"Cisplatin HIPEC combined with paclitaxel, 5-fluorouracil, and leucovorin intravenous chemotherapy regimen could improve the survival rate and decrease the postoperative recurrence of locally advanced GC."	( Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer. Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z, 2014)
"Bevacizumab combined with modified FOLFOX6 is a standard regimen for colorectal cancer."	( Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. Cao, J; Hu, X; Li, T; Lv, F; Ni, C; Ragaz, J; Sun, S; Wang, B; Wang, L; Wang, Z; Wu, Z; Xie, J; Zhang, J; Zhang, S, 2015)
"5 mg/kg every three weeks, was administered with modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 on day 1, followed by 5-FU 2400 mg/m2 intravenous infusion over 46 hours every 2 weeks) to patients who failed at least 1 chemotherapy regimen in the metastatic setting."	( Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. Cao, J; Hu, X; Li, T; Lv, F; Ni, C; Ragaz, J; Sun, S; Wang, B; Wang, L; Wang, Z; Wu, Z; Xie, J; Zhang, J; Zhang, S, 2015)
" Preclinical evidence suggests that the scheduling of bevacizumab may be crucial to optimize its combination with chemo-radiotherapy."	( Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Comella, P; Delrio, P; Granata, V; Iaffaioli, VR; Leone, A; Marone, P; Muto, P; Pecori, B; Petrillo, A; Romano, C; Romano, G; Tatangelo, F, 2015)
"These results highlights the relevance of bevacizumab scheduling to optimize its combination with preoperative chemo-radiotherapy in the management of LARC."	( Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Comella, P; Delrio, P; Granata, V; Iaffaioli, VR; Leone, A; Marone, P; Muto, P; Pecori, B; Petrillo, A; Romano, C; Romano, G; Tatangelo, F, 2015)
"Patients with advanced solid tumors received oral BKM120 daily combined with standard doses of mFOLFOX6 every 2 weeks of a 28 day cycle."	( A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK, 2015)
"The MTD of BKM120 in combination with standard doses of mFOLFOX6 was 40 mg daily, which is well below the 100 mg daily dose proven effective and tolerable both as a single agent and in combination with other chemotherapeutics."	( A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK, 2015)
" Herein, we critically discuss the current data on the efficacy and safety profile of bevacizumab in combination with fluoropyrimidine-based chemotherapy for first-line and maintenance treatment of metastatic CRC and briefly comment on existing controversies and future perspectives."	( Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. Grapsa, D; Saif, MW; Syrigos, K, 2015)
" This phase I trial sought to determine the maximum tolerable dose (MTD) of bevacizumab and sorafenib combined with standard cytotoxic therapy for advanced gastrointestinal (GI) cancers."	( Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016)
"A standard 3 + 3 trial design utilized 3 escalating sorafenib dose levels: (1) 200 mg daily, days 3-7, 10-14; (2) 200 mg twice daily, days 3-6, 10-13; and (3) 200 mg twice daily, days 3-7, 10-14 combined with standard dose FOLFIRI (5-fluouracil, leucovorin, and irinotecan) and bevacizumab (5 mg/kg), repeated every 14 days."	( Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016)
" The MTD was determined to be dose level 2: sorafenib 200 mg twice daily, days 3-6, 10-13 combined with FOLFIRI and bevacizumab at standard doses."	( Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016)
"The MTD of this regimen is sorafenib 200 mg twice daily, days 3-6, 10-13 combined with standard doses of FOLFIRI and bevacizumab."	( Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016)
"High-dose FOLFIRI combined with cetuximab yielded high response rates and enabled complete resection of class II hepatic metastases in most patients."	( High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT). Buc, E; Chatelut, E; De la Fouchardière, C; Mendoza, C; Mineur, L; Pezet, D; Phelip, JM; Quesada, JL; Rivoire, M; Roblin, X, 2016)
" In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported."	( Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016)
"UFT/LV (3 weeks of therapy and 1 week without) combined with biweekly bevacizumab is a tolerable and effective treatment option for elderly patients (aged ≥ 75 years) with metastatic colorectal cancer."	( Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016)
" We conducted a phase I study of lenalidomide in combination with FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) in patients with advanced cancer."	( Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Falchook, G; Fu, S; Hong, DS; Naing, A; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Ye, Y, 2016)
"Lenalidomide in combination with FOLFOX was well tolerated."	( Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Falchook, G; Fu, S; Hong, DS; Naing, A; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Ye, Y, 2016)
" We aimed to establish the safety, tolerability, and recommended phase 2 oral dose of the CCR2 inhibitor PF-04136309 in combination with FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil)."	( Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Belt, BA; Cusworth, BM; DeNardo, DG; Fields, RC; Fowler, KJ; Goedegebuure, SP; Hawkins, WG; Lim, KH; Linehan, DC; Lockhart, AC; Nieman, RK; Nywening, TM; Panni, RZ; Sanford, DE; Strasberg, SM; Suresh, R; Tan, BR; Toriola, AT; Wang-Gillam, A; Worley, LA; Yano, M, 2016)
" Patients were allocated to receive either FOLFIRINOX alone (oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), and bolus fluorouracil 400 mg/m(2), followed by 2400 mg/m(2) 46-h continuous infusion), administered every 2 weeks for a total of six treatment cycles, or in combination with oral PF-04136309, administered at a starting dose of 500 mg twice daily in a standard 3 + 3 dose de-escalation design."	( Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Belt, BA; Cusworth, BM; DeNardo, DG; Fields, RC; Fowler, KJ; Goedegebuure, SP; Hawkins, WG; Lim, KH; Linehan, DC; Lockhart, AC; Nieman, RK; Nywening, TM; Panni, RZ; Sanford, DE; Strasberg, SM; Suresh, R; Tan, BR; Toriola, AT; Wang-Gillam, A; Worley, LA; Yano, M, 2016)
"CCR2-targeted therapy with PF-04136309 in combination with FOLFIRINOX is safe and tolerable."	( Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Belt, BA; Cusworth, BM; DeNardo, DG; Fields, RC; Fowler, KJ; Goedegebuure, SP; Hawkins, WG; Lim, KH; Linehan, DC; Lockhart, AC; Nieman, RK; Nywening, TM; Panni, RZ; Sanford, DE; Strasberg, SM; Suresh, R; Tan, BR; Toriola, AT; Wang-Gillam, A; Worley, LA; Yano, M, 2016)
" We found that cetuximab, in combination with chemotherapy, fostered ICD in CRC cells, which we measured via the endoplasmic reticulum (ER) stress response and an increase in phagocytosis by dendritic cells."	( The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG, 2016)
"The aim of this study is to discuss the curative effect of introperitoneal hyperthermic perfusion chemotherapy(IHPC) combined with systemic neoadjuvant chemotherapy on the gastric cancer patients with peritoneal carcinomatosis."	( [Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis]. Chen, Y; Guo, Y; Suo, J; Wang, D; Xing, Y; Zhang, Y, 2016)
"Sixty-four patients received IHPC combined with systemic chemotherapy."	( [Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis]. Chen, Y; Guo, Y; Suo, J; Wang, D; Xing, Y; Zhang, Y, 2016)
"IHPC combined with systemic chemotherapy is an effective therapeutic method for gastric cancer patients with peritoneal carcinomatosis in terms of reducing preoperative tumor load and achieving radical resection."	( [Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis]. Chen, Y; Guo, Y; Suo, J; Wang, D; Xing, Y; Zhang, Y, 2016)
"Research has indicated that some Chinese herb injections (CHIs) might be beneficial in combination with chemotherapy, including remedies that might be used as effective chemosensitizers and radiosensitizers, or as palliative therapy."	( Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer. Ge, L; Mao, L; Shen, XP; Tian, JH; Wang, YF; Yang, KH; Zhang, J; Zhang, JH, 2016)
" Standard pairwise meta-analysis and Bayesian network meta-analysis were performed to compare the efficacy and safety of different CHIs combined with FOLFOX."	( Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer. Ge, L; Mao, L; Shen, XP; Tian, JH; Wang, YF; Yang, KH; Zhang, J; Zhang, JH, 2016)
" More studies are required to confirm the efficacy of CHIs in combination with FOLFOX for advanced CRC."	( Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer. Ge, L; Mao, L; Shen, XP; Tian, JH; Wang, YF; Yang, KH; Zhang, J; Zhang, JH, 2016)
"The objective of this phase II study was to evaluate the potential of pharmacokinetic (PK) drug-drug interactions between ramucirumab and irinotecan or its metabolite, SN-38, when administered with folinic acid and 5-fluorouracil (FOLFIRI)."	( Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors. Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D, 2016)
"There was no PK drug-drug interaction between ramucirumab and irinotecan or its metabolite, SN-38."	( Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors. Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D, 2016)
"To analyze the preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy."	( [Preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy]. Li, SD; Li, XJ; Shi, JH, 2016)
"Mecobalamin combined with glutathione can significantly reduce the incidence and severity of neurotoxicity induced by FOLFOX4 chemotherapy, therefore, worthy of clinical application."	( [Preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy]. Li, SD; Li, XJ; Shi, JH, 2016)
"Advantages of neoadjuvant chemotherapy combined with monoclonal antibodies for treating patients with resectable colorectal cancer liver metastasis (CLM) have not been established."	( The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Deguchi, T; Inagaki, H; Ishigure, K; Kanda, M; Kataoka, M; Kondo, A; Kondo, K; Matsui, T; Matsuoka, H; Oba, K; Sakamoto, J; Sato, M; Sato, Y; Shibata, Y; Takahashi, T; Takano, N; Tanaka, C; Tanaka, H, 2017)
"Neoadjuvant therapy using FOLFOX/XELOX combined with monoclonal antibodies did not improve PFS, although it was administered safely and had less adverse effects after liver resection."	( The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Deguchi, T; Inagaki, H; Ishigure, K; Kanda, M; Kataoka, M; Kondo, A; Kondo, K; Matsui, T; Matsuoka, H; Oba, K; Sakamoto, J; Sato, M; Sato, Y; Shibata, Y; Takahashi, T; Takano, N; Tanaka, C; Tanaka, H, 2017)
" This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan."	( Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016)
"Eligible patients were randomly assigned to receive mFOLFOX-6 alone (mFOLFOX-6) or in combination with ramucirumab 8 mg/kg IV (RAM+mFOLFOX-6) or icrucumab 15 mg/kg IV (ICR+mFOLFOX-6) every 2 weeks."	( Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016)
" In vivo experiments confirmed the enhanced antitumor activity of the 5-FU + NaLV simultaneous combination with a good toxicity profile, whereas the sequential combination with CaLV failed to potentiate 5-FU activity."	( Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. Bocci, G; Danesi, R; Di Desidero, T; Di Paolo, A; Orlandi, P, 2017)
"One-hundred twenty-seven patients were randomly assigned to parsatuzumab, 400 mg, or placebo, in combination with mFOLFOX6 plus bevacizumab, 5 mg/kg."	( Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Anderson, M; Argiles, G; Braiteh, F; Chang, I; Chen, D; Funke, R; García-Carbonero, R; Gore, I; Hegde, P; Hurwitz, H; Jassem, J; McCall, B; Rhee, I; Rivera, F; Stroh, M; Tebbutt, N; van Cutsem, E; Wainberg, ZA; Wakshull, E; Ye, W, 2017)
"The CONCERT study (observational cohort study of patients with metastatic colorectal cancer initiating chemotherapy in combination with bevacizumab) aimed to describe patient characteristics, bevacizumab use, its efficacy in terms of progression-free survival (PFS) and overall survival (OS), and its safety in patients with metastatic colorectal cancer (mCRC) treated in daily medical practice."	( Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). André, T; Asselain, B; Bennouna, J; Ducreux, M; Phelip, JM, 2017)
" Patients with mCRC initiating bevacizumab combined with chemotherapy were included and followed up for ≤ 36 months."	( Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). André, T; Asselain, B; Bennouna, J; Ducreux, M; Phelip, JM, 2017)
" Bevacizumab was mainly started at 5 mg/kg every 2 weeks (95%) and mostly combined with FOLFIRI (leucovorin, 5-fluorouracil, irinotecan; 68."	( Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). André, T; Asselain, B; Bennouna, J; Ducreux, M; Phelip, JM, 2017)
"Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient."	( Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Atkins, JN; Benson, AB; Berry, S; Bertagnolli, MM; Blanke, C; El-Khoueiry, AB; Fruth, B; Goldberg, RM; Greene, C; Hochster, HS; Innocenti, F; Lenz, HJ; Mayer, RJ; Meyerhardt, JA; Mulkerin, DL; Niedzwiecki, D; O'Neil, BH; O'Reilly, EM; Polite, BN; Schilsky, RL; Schrag, D; Venook, AP; Watson, P, 2017)
"This phase I/II study was designed to determine the maximum tolerated dose of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors and to evaluate the safety and efficacy of this combination for patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach."	( A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Bendell, J; Flores, M; Hemphill, B; Kurkjian, C; Pant, S; Patel, M; Thompson, D, 2017)
" The expansion dose was established as tivantinib 360 mg BID in combination with FOLFOX."	( A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Bendell, J; Flores, M; Hemphill, B; Kurkjian, C; Pant, S; Patel, M; Thompson, D, 2017)
"Surgical resection combined with adjuvant chemotherapy is considered as the gold-standard treatment for advanced colorectal cancer patients."	( Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. Chen, L; Huang, L; Lin, X; Xie, Y; Zheng, Q, 2017)
" Among these patients, 71 patients received first-line treatment only (non-DC-CIK group), while the other 71 patients who had similar demographic and clinical characteristics received a DC-CIK cell infusion combined with first-line treatment (DC-CIK group)."	( Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. Chen, L; Huang, L; Lin, X; Xie, Y; Zheng, Q, 2017)
"Our results showed that patients with advanced colorectal cancer might benefit from DC-CIK immunotherapy combined with first-line therapy by significantly prolonging 5-year OS and PFS."	( Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. Chen, L; Huang, L; Lin, X; Xie, Y; Zheng, Q, 2017)
"PRODIGE 41-BEVANEC is an academic randomized, phase II study designed to evaluate the efficacy of bevacizumab in combination with FOLFIRI after failure of CT1 in unknown primary NEC and GEP-NEC."	( Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study. Assenat, E; Bouarioua, N; Cadiot, G; Coriat, R; Dahan, L; Dubreuil, O; Elhajbi, F; Ferru, A; Gangloff, A; Granger, V; Hautefeuille, V; Hentic, O; Kurtz, JE; Le Malicot, K; Lepage, C; Lepere, C; Lievre, A; Lombard-Bohas, C; Malka, D; Roquin, G; Scoazec, JY; Smith, D; Walter, T, 2018)
" We report 2 patients with para-aortic lymph node metastasis treated with 4 courses each of FOLFOX6 and FOLFIRI in combination with bevacizumab, which led to a complete response."	( [Five-Year Survival of Two Patients with Para-Aortic Lymph Node Metastasis Treated with Four FOLFOX6and Four FOLFIRI Courses in Combination with Bevacizumab]. Ohara, H; Yamamoto, H, 2018)
"To investigate the efficacy of paclitaxel combined with a leucovorin and 5-fluorouracil regimen (PLF regimen; q2w) as neoadjuvant chemotherapy (NCT) for advanced gastric cancer."	( Retrospective study on efficacy of a paclitaxel combined with a leucovorin and fluorouracil regimen for advanced gastric cancer. Chen, Q; Lin, X; Shi, C; Wang, X; Yang, B, 2019)
" We compared tolerability and efficacy of the two different chemotherapy regimens; 5-FU/leucovorin (LV) versus cisplatin with capecitabine (XP) combined with radiotherapy (RT) in the adjuvant therapy of the lymph node positive locally advanced gastric cancer."	( Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer. Bilici, A; Erkol, B; Figen, M; Surmelioglu, A; Tilki, M; Ustaalioglu, BBO; Uyar, S, 2018)
" Group 2 (n = 58) received 5-FU/LV combined with RT postoperatively."	( Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer. Bilici, A; Erkol, B; Figen, M; Surmelioglu, A; Tilki, M; Ustaalioglu, BBO; Uyar, S, 2018)
" Patients were randomly assigned (1:1) to either BEVZ92 or reference bevacizumab (5 mg/kg on day 1 of each cycle every 2 weeks) in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or fluorouracil, leucovorin, and irinotecan (FOLFIRI)."	( Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. Abdalla, KC; Bondarenko, I; Del Campo García, A; Franke, F; Huerga, C; Melo Cruz, F; Mendonça Bariani, G; Millán, S; Ostwal, V; Paravisini, A; Peredpaya, S; Rahuman, SA; Ramesh, A; Roca, E; Romera, A; Shah, P; Shparyk, Y, 2018)
"Our results suggest that BEVZ92 and reference bevacizumab are pharmacokinetically bioequivalent and have no appreciable differences in efficacy, immunogenicity, and safety profiles as first-line treatment in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer."	( Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. Abdalla, KC; Bondarenko, I; Del Campo García, A; Franke, F; Huerga, C; Melo Cruz, F; Mendonça Bariani, G; Millán, S; Ostwal, V; Paravisini, A; Peredpaya, S; Rahuman, SA; Ramesh, A; Roca, E; Romera, A; Shah, P; Shparyk, Y, 2018)
" In this phase I study, we evaluated the safety of ip PTX combined with 5-fluorouracil, folinic acid, oxaliplatin, and bevacizumab (mFOLFOX6-bevacizumab) or capecitabine, oxaliplatin, and bevacizumab (CapeOX-bevacizumab) for colorectal cancer with peritoneal metastasis."	( Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019)
"The adverse events of mFOLFOX6-bevacizumab or CapeOX-bevacizumab in combination with ip PTX were considered similar to those described in previous studies of oxaliplatin-based treatment alone."	( Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019)
"In order to reduce the frequency and the severity of oxaliplatin-related sensory-neuropathy and preserve antitumor efficacy, we performed alternating 4 mFOLFOX6 and 4 FOLFIRI cycles, in combination with bevacizumab, in patients with metastatic colorectal cancer."	( [A Case of a Patient with Rectum Cancer with Multiple Metastases, Who Was Able to Undergo Conversion Therapy Using Alternating mFOLFOX6 and FOLFIRI Regimens in Combination with Alternating Cetuximab and Bevacizumab]. O'hara, H; Yamamoto, H, 2018)
"Polypharmacy of elderly oncology patients and fragmented medication management are well-known risk factors for drug-drug interactions (DDIs)."	( Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019)
" The studies observed patients with wild-type [Kirsten] rat sarcoma viral oncogene homolog ([K]RAS/RAS) metastatic colorectal cancer (mCRC), who had been treated with panitumumab in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in the first line or with panitumumab combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the second line following fluoropyrimidine-based chemotherapy."	( Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC. Bjorklof, K; Buchler, T; Csoszi, T; Demonty, G; Hebart, H; Kafatos, G; Kiehl, M; Koukakis, R; Kuhn, A; Tomasek, J, 2019)
" We report a potential drug-drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt."	( HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases. El-Sayed, D; Kang-Birken, SL; Prichard, J, )
" To test this hypothesis, we analyzed CEA and CA19-9 serum levels in patients with advanced colorectal cancer who received cetuximab in combination with chemotherapy."	( The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. Dai, G; Gou, M; Jia, J; Qian, N; Yang, F; Zhang, P, 2019)
"CEA and CA19-9 are useful indicators of therapeutic curative effect from cetuximab combined with first-line chemotherapy."	( The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. Dai, G; Gou, M; Jia, J; Qian, N; Yang, F; Zhang, P, 2019)
"This study explores the effect of preoperative radiotherapy combined with FOLFOX chemotherapy on patients with locally advanced colon cancer (LACC)."	( Clinical Evaluation of Preoperative Radiotherapy Combined with FOLFOX Chemotherapy on Patients with Locally Advanced Colon Cancer. Guo, Z; Li, S; Qiao, W; Yu, W; Zhou, J, 2019)
" This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer."	( Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019)
"gov, NCT01506167) that recruited patients with metastatic colorectal cancer scheduled to receive bevacizumab in combination with first-line chemotherapy as part of routine clinical practice."	( ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Baijal, S; Chau, I; Cunningham, D; Ellis, R; Harrison, M; Khakoo, S; Ograbek, A; Pedley, I; Raouf, S; Ross, P; Steward, W; Tahir, S, 2019)
" In the NAPOLI-1 trial, liposomal irinotecan in combination with fluorouracil (nal-iri/5FU) was shown to improve overall survival when compared to fluorouracil alone for metastatic pancreatic cancer."	( Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Arango, MJ; Noonan, AM; Porter, K; Reardon, J; Tossey, JC; VanDeusen, JB, 2019)
"This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy (HBOT) in patients with metastatic pancreatic cancer."	( Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer. Iyikesici, MS, 2020)
" We hypothesized that pelareorep in combination with pembrolizumab and chemotherapy in patients with PDAC would be safe and effective."	( Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B, 2020)
"This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic adenocarcinoma."	( Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C, 2020)
"Eligible patients were randomized 2:1 to either eryaspase in combination with gemcitabine or mFOLFOX6 (eryaspase arm), or to gemcitabine or mFOLFOX6 alone (control arm)."	( Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C, 2020)
"Eryaspase in combination with chemotherapy is associated with improvements in OS and PFS, irrespective of ASNS expression in second-line advanced pancreatic adenocarcinoma."	( Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C, 2020)
"To compare the clinical efficacy and safety of FOLFOX6 regimen and docetaxel-cisplatin-fluorouracil (DCF) regimen as neoadjuvant chemotherapy (NACT) combined with radical gastrectomy in treating advanced gastric cancer."	( A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer. Li, E; Liu, Y; Shao, H; Tai, Q; Zhao, R, )
"The clinical data of 96 patients with advanced gastric cancer admitted and subjected to NACT combined with radical gastrectomy in our hospital from September 2013 to September 2017 were collected, and the patients were divided into FOLFOX6 group (n=48) and DCF group (n=48) according to the NACT regimens received."	( A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer. Li, E; Liu, Y; Shao, H; Tai, Q; Zhao, R, )
"The FOLFOX6 regimen and DCF regimen as NACT combined with radical gastrectomy have curative effects in treating locally advanced gastric cancer, preferable clinical response rate and disease control rate can be obtained, and the adverse reactions of the chemotherapy are tolerable."	( A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer. Li, E; Liu, Y; Shao, H; Tai, Q; Zhao, R, )
" The following study aims to determine whether cetuximab combined with FOLFOX-4 is a cost-effective regimen for patients with specific RAS wt mCRC in China."	( Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. Ding, H; Fang, L; Gao, P; Huang, L; Wang, H; Ye, W; Zhu, Z, 2020)
"Despite the survival benefit, cetuximab combined with FOLFOX-4 is not a cost-effective treatment for the first-line regime of patients with RAS wt mCRC in China."	( Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. Ding, H; Fang, L; Gao, P; Huang, L; Wang, H; Ye, W; Zhu, Z, 2020)
" Particularly, the expression of tumour-suppressing gene Ccdc80 was induced by vactosertib and further induced by vactosertib in combination with nal-IRI/5-FU/LV."	( Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. An, H; Heo, JS; Hong, CP; Hong, E; Kang, JM; Kim, SJ; Lee, S; Ooshima, A; Park, J; Park, JO; Park, S; Park, SH, 2020)
"We demonstrated in this study that dose escalation using IMRT in combination with platin-based chemotherapy as a definitive treatment for esophageal carcinoma is safe and results in higher loco-regional and control survival when compared to previously reported data."	( Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. Carrère, N; Dalmasso, C; Guimbaud, R; Izar, F; Lusque, A; Modesto, A; Moyal, E; Rives, M; Vieillevigne, L, 2020)
" The drug combination administered at clinical doses resulted in significantly higher antagonistic interactions compared to the low-dose optimized drug combination (ODC)."	( Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. Nowak-Sliwinska, P; Ramzy, GM; Rausch, M; Zoetemelk, M, 2020)
" Against this backdrop, the efficacy of nanoliposomal irinotecan(nal-IRI)in combination with fluorouracil and folinic acid(FF)for progressive metastatic pancreatic cancer after previous gemcitabine therapy was confirmed in Europe in 2015 ahead of Japan."	( [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer]. Ueno, M, 2020)
" The data sources were the VELOUR (Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen) and RAISE (Ramucirumab Versus Placebo in Combination With Second-Line FOLFIRI in Patients With Metastatic Colorectal Carcinoma That Progressed During or After First-Line Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine) trials, which compared FOLFIRI alone with AFL or RAM in second-line treatment for mCRC."	( Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. Kashiwa, M; Matsushita, R, 2020)
"AtezoTRIBE is a prospective, open label, phase II, comparative trial in which initially unresectable and previously untreated mCRC patients, irrespective of microsatellite status, are randomized in a 1:2 ratio to receive up to 8 cycles of FOLFOXIRI/bevacizumab alone or in combination with atezolizumab, followed by maintenance with bevacizumab plus 5-fluoruracil/leucovorin with or without atezolizumab according to treatment arm until disease progression."	( AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. Antoniotti, C; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Brunella, DS; Corallo, S; Cremolini, C; Falcone, A; Grassi, E; Lonardi, S; Marmorino, F; Morano, F; Moretto, R; Pietrantonio, F; Racca, P; Rossini, D; Salvatore, L; Tamberi, S; Tamburini, E; Tortora, G, 2020)
"IORT using the INTRABEAM radiation system combined with portal vein infusion chemotherapy is promising for select patients with PVTT."	( INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. Han, M; He, Y; Liang, H; Shao, Z; Song, X, 2020)
" with mCRC RAS/BRAF mutated, in first line will receive nivolumab in combination with FOLFOXIRI/bevacizumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks."	( Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). Antonuzzo, L; Bergamo, F; Berselli, A; Bordonaro, R; Damato, A; Iachetta, F; Maiello, E; Nasti, G; Normanno, N; Pinto, C; Romagnani, A; Tonini, G; Zaniboni, A, 2020)
"We describe our experience with serial uterine artery embolization (UAE) combined with standard weekly methotrexate and a eight-day methotrexate/folinic acid (MTX/FA) treatment regimen in the management of placenta accreta spectrum (PAS) disorder at 7 weeks of gestation."	( Successful treatment of placenta accreta spectrum disorder using management strategy of serial uterine artery embolization combined with standard weekly and a 8-day methotrexate/folinic acid regimens at 7 weeks of gestation. Chou, MM; Chuang, SW; Lu, YA; Yuan, JC, 2020)
"Early diagnosis of the PAS disorder could result in better obstetric outcome through earlier intervention using serial UAE combined with standard weekly and a eight day MTX//FA regimen in the first trimester of pregnancy."	( Successful treatment of placenta accreta spectrum disorder using management strategy of serial uterine artery embolization combined with standard weekly and a 8-day methotrexate/folinic acid regimens at 7 weeks of gestation. Chou, MM; Chuang, SW; Lu, YA; Yuan, JC, 2020)
" Although the survival benefits when combined with chemotherapy have been determined, there are no studies comparing the two agents with chemotherapy in the second-line treatment."	( The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience. Almuradova, E; Çakar, B; Doğanavşargil, B; Gürsoy, P; Harman, M; Karabulut, B; Karateke, M; Sezak, M, 2021)
" In this phase II study, we prospectively analyzed the efficacy and safety of raltitrexed combined with S-1 (RS regimen) in the treatment of mCRC after the failure of conventional chemotherapy."	( A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. Chen, Z; Guo, W; Huang, M; Li, W; Qiu, L; Wang, C; Wang, Y; Yang, Y; Zhang, W; Zhang, X; Zhang, Z; Zhao, X; Zhu, X, 2021)
"The use of sodium levofolinate (Na-Lev) is safe in combination with continuous infusion 5-fluorouracil in patients with gastrointestinal tumors treated with the FOLFIRI regimen."	( Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen. Bartolini, G; Crudi, L; Donati, C; Foca, F; Frassineti, GL; Masini, C; Matteucci, L; Monti, M; Pagan, F; Passardi, A; Rapposelli, I; Ruscelli, S; Sbaffi, S; Sullo, F; Valgiusti, M, 2021)
"The objectives of this study were to compare the safety profiles of sodium levofolinate (Na-Lev) and calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) in the FOLFIRI regimen and to measure the organizational impact of the introduction of Na-Lev on drug production and administration."	( Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen. Bartolini, G; Crudi, L; Donati, C; Foca, F; Frassineti, GL; Masini, C; Matteucci, L; Monti, M; Pagan, F; Passardi, A; Rapposelli, I; Ruscelli, S; Sbaffi, S; Sullo, F; Valgiusti, M, 2021)
"Bevacizumab combined with S-1 and raltitrexed demonstrated positive antitumor efficacy and acceptable toxicity."	( Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Yang, Y; Zhou, YW, 2021)
" In the present study, we assessed the activity and safety of bevacizumab combined with S-1 and raltitrexed."	( Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Yang, Y; Zhou, YW, 2021)
"Bevacizumab combined with S-1 and raltitrexed showed promising antitumor activity and safety in refractory mCRC."	( Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Yang, Y; Zhou, YW, 2021)
" We conducted this phase Ib/II study to assess the safety and efficacy of anti-PD-1 antibody camrelizumab in combination with FOLFOX4 for treatment-naive advanced hepatocellular carcinoma (aHCC)."	( Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Chen, Z; Li, H; Liu, Y; Meng, Z; Qin, S; Ren, Z; Wang, L; Xiong, J; Zhang, X; Zou, J, 2021)
"Camrelizumab combined with FOLFOX4 for first-line treatment of patients with aHCC showed good safety and tolerability, with promising preliminary antitumor activity."	( Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Chen, Z; Li, H; Liu, Y; Meng, Z; Qin, S; Ren, Z; Wang, L; Xiong, J; Zhang, X; Zou, J, 2021)
" Irreversible electroporation (IRE) is a nonthermal ablative technique that provides an alternative in patients with LAPC and can be safely combined with chemotherapy."	( Irreversible Electroporation (IRE) Combined With Chemotherapy Increases Survival in Locally Advanced Pancreatic Cancer (LAPC). Astras, G; Davakis, S; Dimitrokallis, N; Felekouras, E; Karamouzis, MV; Kountourakis, P; Moris, D; Oikonomou, D; Papalampros, A; Papamichael, D; Petrou, AS; Schizas, D, 2021)
"Napabucasin 240 mg BID in combination with FOLFIRI and bevacizumab was tolerated, with a manageable safety profile in Japanese patients with metastatic CRC."	( Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer. Bando, H; Iino, S; Kadowaki, S; Kageyama, R; Kawazoe, A; Masuishi, T; Muro, K; Taniguchi, H; Yoshino, T, 2021)
"It is necessary to systematically evaluate the clinical efficacy and safety of bevacizumab (BEV) combined with 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX) regimen in the treatment of advanced colorectal cancer."	( The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis. Chen, D; Liu, W; Wang, X; You, J; Zhang, H; Zhang, S, 2021)
"We searched the PubMed et al databases for randomized controlled trials (RCTs) on the BEV combined with the FOLFOX regimen in the treatment of advanced colorectal cancer up to January 20, 2021."	( The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis. Chen, D; Liu, W; Wang, X; You, J; Zhang, H; Zhang, S, 2021)
"BEV combined with the FOLFOX regimen is more effective than the FOLFOX regimen alone in the treatment of advanced colorectal cancer, but it may also increase the risk of gastrointestinal adverse reactions."	( The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis. Chen, D; Liu, W; Wang, X; You, J; Zhang, H; Zhang, S, 2021)
"To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC)."	( Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022)
" In total, 75 and 43 patients received FOLFOX or FOLFIRI, respectively, in combination with panitumumab (53%) or cetuximab (47%)."	( Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022)
"This study shows that with an appropriate design, including reduced doses, vulnerable older patients best tolerate chemotherapy when combined with anti-EGFR antibodies."	( Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022)
"Traditional Chinese medicine injections (TCMJs) combined with FOLFOX4 regimen could achieve favorable effects in the treatment of gastric cancer."	( Efficacy and safety of traditional Chinese medicine injections combined with FOLFOX4 regimen for gastric cancer: A protocol for systematic review and network meta-analysis. Du, X; Jiang, L; Ouyang, J; Zhang, Y, 2021)
"PubMed, Web of Science, Scopus, Cochrane Library, Embase, China Scientific Journal Database, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Data were searched to identify randomized controlled trials which focused on TCMJs combined with FOLFOX4 against gastric cancer from its inception to September 2021."	( Efficacy and safety of traditional Chinese medicine injections combined with FOLFOX4 regimen for gastric cancer: A protocol for systematic review and network meta-analysis. Du, X; Jiang, L; Ouyang, J; Zhang, Y, 2021)
"The conclusion of this systematic review will provide evidence for selecting an optimal TCMJ combined with FOLFOX4 for patients with gastric cancer."	( Efficacy and safety of traditional Chinese medicine injections combined with FOLFOX4 regimen for gastric cancer: A protocol for systematic review and network meta-analysis. Du, X; Jiang, L; Ouyang, J; Zhang, Y, 2021)
"Doublet or triplet chemotherapy regimens in combination with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mAb), such as cetuximab or panitumumab, or the anti-vascular endothelial growth factor mAb bevacizumab, are the current recommended standard of care therapies for unresectable metastatic colorectal cancer (mCRC)."	( Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A, 2022)
"To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy."	( Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022)
" They provided informed consent and were treated with apatinib combined with FOLFIRI according to the scheduled regimen until disease progression or unacceptable toxicity occurred."	( Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022)
"Apatinib combined with FOLFIRI for the first-line treatment of advanced unresectable mCRC showed good efficacy and safety."	( Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022)
"To evaluate the safety and effectiveness of aflibercept in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with metastatic colorectal cancer (mCRC) who progressed with oxaliplatin-containing regimen."	( Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY, 2023)
"Aflibercept in combination with FOLFIRI was effective and showed an acceptable safety profile in Korean patients with mCRC in daily clinical practice."	( Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY, 2023)
" Currently, no trials have investigated the impact of perioperative immunotherapy in combination with chemotherapy for resectable gastric or GEJ adenocarcinoma."	( Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB, 2022)
"GASPAR trial is a multicenter open-label, nonrandomized, phase II trial to evaluate the efficacy and safety of Spartalizumab in combination with the FLOT regimen as perioperative treatment for resectable gastric or GEJ adenocarcinoma."	( Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB, 2022)
"Currently, no trials have investigated the impact of immunotherapy in combination with FLOT chemotherapy as perioperative treatment for resectable gastric or GEJ adenocarcinoma."	( Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB, 2022)
"This multicenter single-arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC)."	( Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. Akazawa, N; Ando, T; Hirata, K; Kagawa, Y; Kato, T; Maeda, H; Mishima, H; Nagasaka, T; Nagata, N; Oba, K; Sakamoto, J; Shiozawa, M; Watanabe, J; Yamada, T; Yokota, M, 2022)
"Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study."	( [The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab]. Colombo, A; Porretto, CM; Rosati, G, 2022)
"This study aimed to investigate the effect of the mFOLFOX6 regimen combined with SHR-1210 on immune function and prognosis in patients with microsatellite instability CRC."	( Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer. Lu, P; Sun, J; Wang, Y; Yao, N, 2022)
" This Phase I/II study examined the toxicity and efficacy of high-dose pulsed AZD8931, an EGFR/HER2/HER3 inhibitor, combined with chemotherapy, in metastatic colorectal cancer (CRC)."	( PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. Barber, PR; Forsyth, S; Gao, F; Hackett, LD; Hartley, JA; Hochhauser, D; Lopes, A; Lowe, HL; Ng, TT; Pearce, S; Propper, DJ; Sarker, D; Saunders, MP; Spanswick, VJ; Weitsman, GE; White, L, 2023)
" FOLFOX or FOLFIRI, each in combination with E+C, were the most active first-line treatments as compared with E+C or to chemotherapy alone."	( Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M, 2023)
"To date, oxaliplatin and irinotecan are used in combination with 5-flourouracil (5-FU) for metastatic colorectal cancer."	( Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells. Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K, 2023)
"The meta-analysis aimed to assess the clinical efficacy of chemotherapeutic triplet-drug regimen combined with anti-EGFR antibody in patients with initially unresectable metastatic colorectal cancer (mCRC)."	( Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis. Dong, W; Jiang, T; Jiang, X; Li, H; Li, Y; Lv, Y; Tian, M; Xiao, J; Yin, Z; Zeng, J, 2023)

Excerpt	Reference
" The therapeutic advantage of combination chemotherapy may reside in the whole organism, reflecting increased bioavailability of drug, reduced dose-limiting toxicity or reduced impairment of host defenses; it may reside in the tumor cells, reflecting the multiple molecular mechanisms of interaction mentioned above."	( Multiple basis of combination chemotherapy. Grindey, GB; Mihich, E, 1977)
"The intestinal absorption and in vivo kinetics of (6S)-[3H]-5-methyl-tetrahydrofolate (5-methyl-H4folate), (6S)-[3H]-5-formyl-H4folate and [3H]folic acid were investigated to determine whether inherent differences exist in the overall bioavailability of these folates in rats."	( Folic acid, 5-methyl-tetrahydrofolate and 5-formyl-tetrahydrofolate exhibit equivalent intestinal absorption, metabolism and in vivo kinetics in rats. Bhandari, SD; Gregory, JF, 1992)
" Recent clinical trials suggest that oral mesna has adequate bioavailability (roughly 50% by urinary thiol measurements) to prevent urotoxicity in high-dose ifosfamide regimens."	( Chemoprotectants for cancer chemotherapy. Dorr, RT, 1991)
" The effect of food on the bioavailability of folinic acid has not yet been studied, though it is most frequently administered orally."	( Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice. Borsi, JD; Moe, PJ; Romslo, I; Sagen, E, 1990)
" Absolute bioavailability was only 4% as a consequence of a significant intestinal first pass effect."	( Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. Cheron, JM; Greiner, PO; Marquet, J; Zittoun, J, 1989)
" Bioavailability was assessed by measuring over 24 hours the blood concentrations of total folates, the parent compound 5-formyltetrahydrofolate, and the metabolite 5-methyltetrahydrofolate, using differential microbiologic assays with Lactobacillus casei and Streptococcus faecalis."	( Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration. Gutierrez, ML; Leese, PT; McGuire, BW; Sia, LL; Stokstad, EL, 1988)
" Absolute bioavailability of the 200-mg oral dose of leucovorin based on AUC was 31% compared with that of the iv dose (6,848 vs."	( Absorption kinetics of orally administered leucovorin calcium. Gutierrez, ML; Haynes, JD; Kisicki, JC; McGuire, BW; Sia, LL; Stokstad, EL, 1987)
"Biochemical investigations show a decreased bioavailability of 5-methyl-tetrahydrofolic acid in vitamin B12 deficient human cell cultures and bone marrow cells."	( [Vitamin B12 as a regulator and methotrexate as an antagonist of folic acid metabolism. Pathophysiologic and clinical aspects]. Sauer, H, 1983)
" These results indicate that zinc deficiency in pregnant rats decreases folate bioavailability of folinic acid, folate polyglutamates and, to a lesser extent, that of folate monoglutamate."	( Zinc deficiency and dietary folate metabolism in pregnant rats. Blache, D; Coudray, C; Faure, P; Favier, A; Favier, M; Roussel, AM, 1993)
"The bioequivalence and bioavailability of oral and intravenous formulations of levoleucovorin and leucovorin were studied, and the absolute bioavailabilities of levoleucovorin and leucovorin tablet formulations were determined."	( Bioequivalence of oral and injectable levoleucovorin and leucovorin. DeVito, JM; Johnson, JB; Kozloski, GD; Tonelli, AP, 1993)
" It has been suggested that this drug may be given by the subcutaneous route and that following a short infusion the bioavailability is similar to that observed after intravenous administration."	( Bioavailability of subcutaneous 5-fluorouracil: a case report. Carlin, W; Dunlop, DJ; Eatock, MM; Soukop, M; Watson, DG, 1996)
" Trials of new combinations are warranted to take advantage of the pharmacokinetic properties and oral bioavailability of UFT and leucovorin."	( Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Belón, J; Blanco, E; Espinosa, E; Feliu, J; Garcia Alfonso, P; Garcia Girón, C; Garrido, P; González Barón, M; Jara, C; Ruiz, A; Vincent, JM; Zamora, P, 1997)
"It has been suggested that colon cancer risk in ulcerative colitis (UC) is correlated to a reduced bioavailability of folate."	( Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. Biasco, G; Calabrese, C; Di Febo, G; Gionchetti, P; Miglioli, M; Miniero, R; Paganelli, GM; Pironi, L; Rivolta, G; Santucci, R; Zannoni, U, 1997)
" The pharmacokinetics and bioavailability of 1954U89 were examined in male beagle dogs and male CD rats."	( The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. Deangelis, DV; Studenberg, SD; Wargin, WA; Woolley, JL, 1997)
" In addition, we sought to determine whether coadministration of UFT and leucovorin alters the bioavailability of these agents."	( Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Birkhofer, MJ; Meropol, NJ; Noel, D; Sonnichsen, DS, 1997)
"28 hours and the oral bioavailability in 12 matched subjects was 83."	( Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. Hum, M; Kamen, BA; Marling-Cason, M; Ratliff, AF; Rose, K; Wilson, J; Winick, N, 1998)
"We conclude that AMT has good oral bioavailability and that, when given on a q12 hour x two weekly schedule, the MTD is 2 mg/m2 with delayed LV rescue."	( Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. Hum, M; Kamen, BA; Marling-Cason, M; Ratliff, AF; Rose, K; Wilson, J; Winick, N, 1998)
" In addition, a three-treatment by three-period crossover bioavailability comparison of oral LV 30 mg plus UFT 200 mg versus either LV or UFT alone was scheduled for the 8 days preceding the first cycle of therapy."	( Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999)
" However, the great interpatient variability observed in UFT and LV pharmacology may have obscured true bioavailability effects in this small patient population."	( Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999)
" No correlation was found between the degree of gastrointestinal damage and the presumed bioavailability of co-trimoxazole as estimated from serum levels of trimethoprim and sulphamethoxazole."	( Gastrointestinal damage induced by cytostatic treatment does not affect the bioavailability of co-trimoxazole. Höglund, P; Johnsson, A; Ljungberg, B; Nilsson-Ehle, I; Nyhlén, A, )
" The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump."	( A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000)
" Promising new agents: 5-FU prodrugs and inhibitors of dihydropyrimidine dehydrogenase (DPD) are promising chemotherapeutic agents with good oral bioavailability which can be combined with other drugs (leucoverin) with acceptable toxicity."	( [Metastatic colorectal cancer: new therapeutics]. Brion, N; Paule, B, )
" Numerous active 5-FU schedules are in clinical use, but erratic oral bioavailability has historically mandated intravenous administration."	( Oral therapy for colorectal cancer: how to choose. Damjanov, N; Meropol, NJ, 2000)
"The reduced bioavailability of chemotherapeutic agents is one of the reasons that explains the limited efficacy of adjuvant chemotherapy in high grade glioma patients."	( The effect of anticonvulsant drugs on blood levels of methotrexate. Defanti, CA; Landonio, G; Riva, M; Siena, S, 2000)
"The oral administration of 5-fluorouracil (5-FU) is hindered by erratic bioavailability due to catabolism of 5-FU by the enzyme dihydropyrimidine dehydrogenase (DPD) in the gastrointestinal tract."	( Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001)
" The effect of food on the oral bioavailability of UFT (2 x 100 mg capsules; dose in terms of FT) and leucovorin (2 x 15 mg tablets) was evaluated in a single-dose, randomized, two-way crossover study."	( Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001)
" The pharmacokinetic parameters and relative bioavailability were investigated for domestic LV tablet and capsule vs an imported tablet."	( High-performance liquid chromatographic method for determination of leucovorin in plasma: validation and application to a pharmacokinetic study in healthy volunteers. Chen, J; Cheng, WB; Duan, GL; Li, D; Zheng, LX, 2002)
" Milk folate is entirely bound by an excess of folate-binding protein (FBP), prompting speculation that FBP may affect the bioavailability of the limited folate supply."	( Dietary interactions influence the effects of bovine folate-binding protein on the bioavailability of tetrahydrofolates in rats. Jones, ML; Nixon, PF; Treloar, T, 2003)
" This is probably attributable to the low systemic bioavailability of Oxa."	( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I, )
"The orally bioavailable matrix metalloproteinase inhibitor MMI270 reduces tumour growth metastasis in preclinical models."	( A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Blackey, R; Cassidy, J; Choi, L; Devlin, M; Eatock, M; Johnson, J; Morrison, R; Owen, S; Twelves, C, 2005)
" It is well known that the microflora in the colon produce large quantities of folate that approach or exceed recommended dietary intakes; however, there is no direct evidence of the bioavailability of this pool in humans."	( Folate is absorbed across the colon of adults: evidence from cecal infusion of (13)C-labeled [6S]-5-formyltetrahydrofolic acid. Aufreiter, S; Fazili, Z; Gregory, JF; Kamalaporn, P; Kim, YI; Marcon, N; O'Connor, DL; Pencharz, PB; Pfeiffer, CM, 2009)
" In this single-dose, randomized, two-way crossover study, we investigated the effects of a low-fat Japanese meal on the pharmacokinetics and oral bioavailability of UFT (2 x 100-mg capsules; dose in terms of tegafur) and leucovorin (1 x 25-mg tablet)."	( Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer. Furuhata, T; Hosokawa, Y; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K; Sasaki, K; Tsuruma, T, 2009)
" Folinic acid (leucovorin, LV) was preferred to folic acid as its bioavailability is higher."	( Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status. Blehaut, H; Conte, M; de Kermadec, FH; de Portzamparc, V; Mircher, C; Poret, G; Ravel, A; Rethore, MO; Sturtz, FG, 2010)
" No differences were noted in the pharmacokinetics of vorinostat at the 800- or 1,400-mg dose-levels, suggesting bioavailability saturation."	( A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Fakih, MG; Groman, A; McMahon, J; Muindi, JR; Wilding, G, 2012)
" Naturally occurring 5-MTHF has important advantages over synthetic folic acid - it is well absorbed even when gastrointestinal pH is altered and its bioavailability is not affected by metabolic defects."	( Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Panzavolta, G; Scaglione, F, 2014)
" Because the oral bioavailability of 5-FU is unpredictable and highly variable, 5-FU is commonly administered intravenously."	( Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Magdy, T; Nies, AT; Schwab, M; Zanger, UM, 2015)

Excerpt	Reference
"Fifty-one patients with nonmetastatic gestational trophoblastic neoplasms (NMGTN) were treated with either 4 or 6 mg/kg methotrexate (MTX) and citrovorum factor (CF) rescue to determine if the higher dosage could reduce the number of courses of chemotherapy required to achieve remission."	( Methotrexate with citrovorum factor rescue for nonmetastatic gestational trophoblastic neoplasms. Berkowitz, RS; Goldstein, DP, 1979)
" Progressive increases in the calcium leucovorin dosage on any schedule reduced both toxicity and the antitumor effect of methotrexate in each model."	( Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Dorick, DM; Moccio, DM; Sirotnak, FM, 1978)
" Significant linear correlations have been obtained between methotrexate dosage and concentrations in plasma at 6 and 24 hours after the initiation of the therapy."	( Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion. Kim, PY; Lantin, E; Romsdahl, MM; Sutow, WW; van Eys, DC; Wang, YM, 1978)
" The dosage of methotrexate was sequentially escalated to produce mucositis (the usual dose-limiting toxicity)."	( Adjuvant methotrexate and leucovorin in head and neck squamous cancer. Two-year follow-up of a pilot project. Applebaum, E; Bytell, DE; DeWys, WD; Sisson, GA; Taylor, SG, 1978)
" All dogs tolerated E g of methotrexate/m2 of body surface, but granulocytopenia precluded escalation beyond this dosage in 4 dogs."	( High-dose methotrexate and leucovorin rescue in dogs with osteogenic sarcoma. Cotter, SM; Parker, LM, 1978)
"We used MTX as single drug treatment on the basis of an incremental dosage schedule, with doses increased from 250 mg/m2 to 750 mg/m2 or from 5 to 10 g, at intervals of 10 days."	( [Results and pharmacokinetic aspects of methotrexate therapy in high doses]. Breyer, S; Graninger, W; Jaschek, I; Lenzhofer, R; Moser, K, 1979)
" The optimal dosage and duration of the two agents are yet to be determined."	( High-dose methotrexate with folinic acid rescue. Bender, JF; Fortner, CL; Grove, WR, 1977)
"Cytocidal activity of a drug is dependent on both drug dosage and duration of exposure."	( Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate. Cohen, HJ; Jaffe, N, 1978)
" Results indicate that the method should be usful in the future in assisting individualization of dosage regimens and in the study of the pharmacokinetics and metabolism of MTX in cancer patients."	( A radioimmunoassay for methotrexate and its comparison with spectrofluorimetric procedures. Blum, MR; Loeffler, LJ; Nelsen, MA, 1976)
" After early dosage modifications, serious toxic side effects were rare in this group of patients who had had extensive prior therapy."	( Methotrexate (NSC-740) with citrovorum factor (NSC-3590) rescue, alone and in combination with cyclophosphamide (NSC-26271), in ovarian cancer. Barlow, JJ; Piver, MS, 1976)
"In this study, 30 patients with metastatic breast cancer were treated with 5-Fluorouracil (5-FU) and high-dose Folinic acid, using a new sequential dosing schedule."	( Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients. Bellora, G; Bergamino, T; Ciancio, A; Ferrero, A; Katsaros, D; Sismondi, P; Zola, P, 1992)
" In contrast to only four of 56 patients with monotherapy, 14 of 39 with the combination treatment at the initial dosage had severe diarrhea with two treatment-related deaths in this latter group."	( Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial. Günther, E; Hinrichs, HF; Hirschmann, WD; Koniczek, KH; Natt, F; Sondern, W; Steinke, B; Wagner, T; Wander, HE; Werdier, D, 1992)
" The reduction in methotrexate dosage in m-BACOD patients was not associated with an increased incidence of CNS relapse."	( The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. Canellos, GP; Harrington, DP; Jochelson, MS; Klatt, MM; Pinkus, GS; Rosenthal, DS; Shipp, MA; Skarin, AT; Yeap, BY, 1990)
" Eighty-seven percent of treatment courses were given in accordance with protocol dosing and schedule."	( m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. Balcerzak, S; Carden, JO; Coltman, CA; Dahlberg, S; Dana, BW; Fisher, RI; Hartley, K; Hartsock, RJ; Miller, TP, 1990)
" Fifty-five eligible patients were treated at eight dosing levels."	( A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. Bauer, L; Budd, GT; Bukowski, RM; Gibson, V; Inoshita, G; Murthy, S; Prestifilippo, J; Sergi, JS; Yalavarthi, P, 1992)
" in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)."	( Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991)
" Dosage must be adjusted to the results of blood counts."	( [Usefulness of folinic acid in cytopenia induced by antiparasitic drugs in AIDS patients]. Leport, C; Niyongabo, T; Vildé, JL, 1991)
"Maximal dosing of cytotoxic chemotherapy drugs is often limited by the development of severe nonmyelosuppressive toxicities."	( Chemoprotectants for cancer chemotherapy. Dorr, RT, 1991)
"In a previous study (J Clin Oncol 7:1407-1417, 1989), we identified two dosage administration schedules of fluorouracil (5FU) combined with leucovorin that were superior to single-agent 5FU for the treatment of advanced colorectal cancer."	( Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. Gerstner, JB; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1991)
" Dosage of infused MTX was 1,000-2,000 mg per an artery."	( [Intra-arterial infusion of high dose methotrexate therapy in recurrent gliomas]. Hayashi, A; Kyuma, Y, 1990)
"To determine the maximal tolerable dosage of trimetrexate for treatment of pneumocystis pneumonia, 25 patients were treated each day with 45 mg/m2 of trimetrexate and 80 mg/m2 of leucovorin; 10 received 60 mg/m2 and 80 mg/m2; 12 received 60 mg/m2 and 160 mg/m2; and 6 received 90 mg/m2 and 160 mg/m2, respectively."	( Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia. Akil, B; Allegra, CJ; Feinberg, J; Hughlett, C; Lane, HC; Ogata-Arakaki, D; Sattler, FR; Shelhamer, J; Tuazon, CU; Verdegem, TD, 1990)
"Thirty elderly patients suffering from macrocytic anaemia associated with chronic diseases were treated with folinic acid for 25 days at a dosage of 4-8 mg daily."	( [Folinic acid in the treatment of elderly patients with macrocytic anemia]. Criserà, A; Ferrari, MG; Lucchi, R; Sacchetta, AC, 1990)
"Four single-arm trials using methotrexate (M), 5-fluorouracil (5FU), and leucovorin (L) were sequentially performed in metastatic measurable colorectal cancer using different dosing and timing schedules for the three drugs."	( Sequential methotrexate, 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work? Cripps, C; Johnston, J; Maroun, J; Stewart, D; Weinerman, B, 1990)
" Dosing error was excluded, as was the hypothesis that the high concentrations were due to the presence of methotrexate-specific antibodies."	( Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma. Bowles, MR; Buttsworth, JA; Grimes, DJ; Nixon, PF; Pond, SM; Ravenscroft, PJ; Thomson, DB; Whiting, RF, )
" The doses and schedule of drug administration were designed to minimize dosage reduction and treatment delay."	( Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. Abeloff, MD; Beveridge, RA; Damron, DJ; Davidson, NE; Donehower, RC; Fetting, JH; Gordon, GG; Waterfield, WC, 1990)
" Neutropenia can also appear after low (prophylactic) dosage of TMP-SMX, and can be prevented by concomitant administration of folinic acid."	( [Neutropenia caused by low-dose trimethoprim-sulfamethoxazole in children with chronic pathology of the urinary tract]. De Manzini, A; Lepore, L; Peratoner, L, )
" Oral administration over 24 hours results in an AUC of 5-CH3 THF equivalent to that obtained after intravenous dosing in the presence of only small amounts of (6R) LV."	( Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. Ratain, MJ; Schilsky, RL, 1990)
"Several different strategies to improve the in vitro cytocidal effect of 5-fluorouracil/leucovorin (5FU/LV), including modulation of dosage and schedule and combination with other cytotoxic agents or biochemical modulators, were examined in the COLO 320DM and Ht-29 cell lines by means of the Bactec system."	( A study of various strategies to enhance the cytotoxic activity of 5-fluorouracil/leucovorin in human colorectal cancer cell lines. Scheithauer, W; Temsch, EM, )
" The authors conclude that: (1) individualized dosing of outpatient MTX-CF chemotherapy for symptomatic EP can be safely managed, even in an indigent population; (2) rupture can occur up to 23 days after chemotherapy initiation; (3) fetal cardiac activity is an absolute contraindication to chemotherapy; (4) chemotherapy in patients with symptoms is of limited value because the disease is too far advanced; therefore, it is essential that the diagnosis of EP be established before symptom onset; and (5) chemotherapy offers no significant immediate advantages to outpatient laparoscopic surgery."	( Outpatient chemotherapy of unruptured ectopic pregnancy. Buster, JE; Ling, FW; Stovall, TG, 1989)
" Groups of tumor bearing mice were treated with saline, leucovorin, 5-fluorouracil or 5-fluourouracil plus leucovorin on an optimal dosage schedule."	( Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Dreyfuss, A; el-Magharbel, I; Frei, E; Holden, SA; Jones, SM; Rosowsky, A; Trites, D; Wright, JE, 1989)
" Despite the 2-fold attenuation of dosage required, antitumor activity of the combination (increased life span, 161%) was approximately twice that obtained with maximum tolerated doses of either agent alone and tumor-free, long-term survivors were obtained."	( Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection. DeGraw, JI; Schmid, FA; Sirotnak, FM, 1989)
" dosage was only half that after oral dosage."	( Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. Cheron, JM; Greiner, PO; Marquet, J; Zittoun, J, 1989)
" The syndrome appears to be associated with high dosage and slow acetylator status."	( Sulphasalazine associated pancytopenia may be caused by acute folate deficiency. Logan, EC; Ryrie, DR; Williamson, LM, 1986)
" The initial rise in serum folate with intravenous and intramuscular dosing represented 5-formyltetrahydrofolate; this fell concomitantly with the appearance of 5-methyltetrahydrofolate."	( Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration. Gutierrez, ML; Leese, PT; McGuire, BW; Sia, LL; Stokstad, EL, 1988)
" At these dosage levels, diarrhea was not a limiting toxicity."	( High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer. Arnold, DJ; Balcueva, EP; Dimitrov, NV; Scholnik, AP; Schwenke, P; Suhrland, LG; Walker, WS, 1988)
" The optimal dosing for MV26PD remains to be determined."	( Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902. Anderson, J; Bloomfield, CD; Cooper, MR; Ginsberg, SJ; Gottlieb, AJ; Hurd, DD; Lachant, NA, 1988)
" Dosage adjustment according to body surface area would seem indicated by the toxicity data, with a 5-FU dose of 1200 mg/m2 body surface area and citrovorum factor 50 mg/m2 being recommended for Phase II trials of this combination of drugs given according to this weekly schedule."	( Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factor. Budd, GT; Bukowski, RM; Schreiber, MJ; Steiger, E; Weick, JK, 1986)
" The toxicities, cumulative VCR dosage, and percentage of ideal dosage observed in 18 patients receiving folinic acid have been compared with those observed in 70 patients who previously received VCR without folinic acid in the same chemotherapy program."	( Clinical trial of folinic acid to reduce vincristine neurotoxicity. Case, LD; Cooper, MR; Jackson, DV; Kaplon, MK; McMahan, RA; Pope, EK; Richards, F; Stuart, JJ; White, DR; Zekan, PJ, 1986)
" It was found that the blood levels of MTX were maintained at 10(-4) M by the dosage of 500 mg/kg, but no higher levels were achieved by increasing dosage."	( Experimental studies on high-dose methotrexate with citrovorum factor chemotherapy for 89Sr-induced osteosarcoma murine model. Tomita, K, 1986)
" Toxicity did not appear to be minimized by attenuation of MTX and/or 5-FU dosage or by increasing the dose and/or duration of LCV."	( Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987)
" Using an intensive adjuvant treatment, the overall toxicity was tolerable allowing the application of the full therapeutic dosage in 95% without any interruptions."	( [Principles of the simultaneous radiation and polychemotherapy in advanced head and neck carcinoma]. Hartenstein, RC; Wendt, TG; Wustrow, TP, 1987)
" This allows an examination of dose-response relationships and comparisons of therapeutic index."	( Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies. Bruckner, HW; Mayer, R; Novak, J; Petrelli, NJ; Stablein, D, 1987)
"5 microM at 5 hours, respectively, after termination of CF dosing in all subjects treated at the 800- and 1600-mg dose schedule."	( Bioavailability of high-dose oral leucovorin. Adelstein, DJ; Blum, MR; Giroski, P; Hines, JD; Rustum, YM; Zakem, MH, 1987)
" From a consideration of the clinical pharmacokinetics of MTX, we suggest other factors that may predispose to the occurrence of marrow toxicity: the presence of hypoalbuminemia, interactions between MTX and other protein bound or weakly acidic drugs, and the repetitive dosing schedule of low dose MTX."	( Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. MacKinnon, SK; Starkebaum, G; Willkens, RF, 1985)
"One hundred and ninety-one cases of acute lymphoblastic leukaemia were entered in a trial in which, for five months, all received cytotoxic therapy with prednisolone, vincristine, mercaptopurine, L-asparaginase, and methotrexate (the latter in high dosage followed by folinic acid)."	( Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (B.C.G.), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen ((Concord trial). Preliminary report to the Medical Research Council by the Leukaemi , 1971)
" 2 patients were treated with MTX single agent therapy at a dosage of up to 750mg/m2 per cycle and a short CF rescue of 48 hours."	( [Methotrexate citrovorum factor therapy in advanced hypernephromas (author's transl)]. Baumgartner, G; Heinz, R; Linemayr, G, 1980)
"Studies on thirty-six psoriatics revealed no differences in acute liver toxicity of four different intermittent dosage schedules of methotrexate with or without addition of leucovorin, as judged by daily determinations of SGOT for one week."	( Methotrexate in psoriasis with and without leucovorin: effect of different dosage schedules on acute liver toxicity. Bjerring, P; Zachariae, H, 1982)
" It is concluded that methotrexate with folinic acid at the dosage used in this study, while less toxic than methotrexate alone, is less effective than methotrexate alone in the induction of remission of nonmetastatic gestational trophoblastic disease."	( Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate--folinic acid. Hammond, CB; Smith, EB; Tyrey, L; Weed, JC, 1982)
" At these dosage levels there were no statistically significant differences in response rate or survival between the two groups."	( High-dose methotrexate in small cell lung cancer. Lack of efficacy in preventing CNS relapse. Capizzi, RL; Carney, C; Delaney, D; Kahn, L; Kirsch, M; Lipper, S; Neijstrom, ES; Rudnick, SA, 1983)
" Six of 19 patients (32%) treated with high-dose infusion responded (one complete response) and four of 18 patients (22%) receiving standard dosage responded (P = ."	( A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. Hauck, WW; Lad, TE; McGuire, WP; Showel, JL; Taylor, SG, 1984)
" Use of the principle of concentration X time in dosage calculations will result in the avoidance of giving unnecessarily high doses of methotrexate."	( Methotrexate. II. Use in pediatric chemotherapy. Lippens, RJ, 1984)
" A comparison of drug dosage in the group receiving TPN and the group receiving standard nutrition is a measure of drug tolerance in these patients."	( A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance. Brennan, MF; Fisher, RI; Popp, MB; Simon, RM, 1981)
" Hypoxanthine protection differed among the cell lines, and the dose-response relationship for protection occurred within the physiologic bone marrow hypoxanthine concentration range."	( Comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines. Browman, GP, 1982)
" The preliminary results of this study support the notion of a dose-response relationship to MTX in advanced squamous cell cancer of the head and neck."	( Methotrexate treatment of advanced head and neck cancers: a dose response evaluation. Fox, RM; Tattersall, MH; Woods, RL, 1981)
" The current phase I study was designed to determine the pharmacokinetic profiles and clinical tolerance of escalating doses of the pure biologically active S-isomer of leucovorin ((S)-LV) given IP with the same dosing schedule of FUDR."	( Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Chan, KK; Israel, VK; Jeffers, S; Jiang, C; Leichman, CG; Leichman, L; Morrow, CP; Muggia, FM; Roman, L; Tulpule, A, 1995)
" Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation."	( Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Allegra, CJ; Grogan, L; Sotos, GA, 1994)
" No significant difference was noted between the "success" and "failure" groups with respect to MTX dose or infusion time, the timing and dosage of folinic acid rescue, the number of courses of MTX, or the mean interval between courses."	( High-dose methotrexate for gestational trophoblastic disease. Covens, A; Elit, L; Gerulath, A; Murphy, J; Osborne, R; Rosen, B; Sturgeon, J, 1994)
" Continuous subcutaneous infusion at the same total dosage over 3 days gave AUC (0-96 hr) values of 134 nmol/mg protein."	( Leucovorin and folic acid regimens for selective expansion of murine 5,10-methylenetetrahydrofolate pools. Alperin, W; Pardo, M; Rosowsky, A; Sayeed-Shah, U; Wright, JE, 1995)
" In this paper, the cellular and clinical pharmacology of 5-FU potentiation by LV are reviewed, and the dosing and administration schedules are discussed in relation to reported clinical trials."	( Role of leucovorin dosing and administration schedule. Jolivet, J, )
" Epirubicin dosage could be increased to 100 mg m-2 in 53 patients (87%), to 110 mg m-2 in 31 patients (51%) and to 120 mg m-2 in 18 cases (30%)."	( Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM Agostara, B; Cariello, S; Colucci, G; Durini, E; Gebbia, V; Giotta, F; Pacilio, G; Pezzella, G; Romito, S; Testa, A, 1995)
" As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats."	( [Chrono-chemotherapy and dose intensity]. Lévi, F, 1995)
" Animals in Groups III and IV received the same drug dosage for six weeks and were operated at different intervals: Group III at one week and Group IV at two weeks after completion of chemotherapy."	( Effect of 5-fluorouracil and leucovorin on the integrity of colonic anastomoses in the rat. Gordon, PH; Hananel, N, 1995)
" Each of these dosage administration schedules has been demonstrated to be superior to single-agent bolus 5FU in previous controlled trials."	( Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Buroker, TR; Gerstner, JB; Gesme, DH; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Schaefer, PL; Wieand, HS, 1994)
"Intensive-course 5FU plus low-dose leucovorin appears to have a superior therapeutic index compared with weekly 5FU plus high-dose leucovorin using the dosage administration schedules applied in this study based on similar therapeutic effectiveness, but lower financial cost, and less need for hospitalization to manage chemotherapy toxicity."	( Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Buroker, TR; Gerstner, JB; Gesme, DH; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Schaefer, PL; Wieand, HS, 1994)
" Carboplatin was given as an outpatient on day 1 at a dosage based on the formula: Dose (mg/m2) = (0."	( Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck. Benner, SE; Dimery, IW; Esparaz, B; Frenning, D; Guillory-Perez, C; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M, 1994)
" Eleven out of 19 patients (58%; 95% CI:34-80%) showed a complete (2 cases) or partial (9 cases) response to this treatment, regardless of the 5dFUR dosage employed."	( Dose-finding study of 5'-deoxy-5-fluorouridine in combination with fixed doses of cisplatin and L-folinic acid for the treatment of advanced or recurrent squamous cell carcinoma of the head and neck. Biglietto, M; Carteni, G; Catalano, G; Comella, G; Comella, P; Della Vittoria Scarpati, M; Palmieri, G; Pandolfi, A; Stampino, CG, )
"We examined the importance of dosing interval between leucovorin (LCV) and 5-fluorouracil (5-FU) on intracellular thymidylate synthase (TS) ternary complex, free TS and total TS protein levels in human MCF-7 breast and NCI H630 colon cancer cell lines."	( The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. Allegra, CJ; Drake, JC; Johnston, PG; Voeller, DM, 1995)
" l-LV was administered intravenously by a 2-hour infusion at a dosage of 250 mg/m2 and 5-FU at a dosage of 600 mg/m2, intravenously via bolus one hour after administration of l-LV had been started."	( [A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. Abe, T; Hirabayashi, N; Kurihara, M; Nakano, S; Ohno, T; Ohta, J; Ohtani, T; Taguchi, T; Takeda, S; Yonemura, Y, 1995)
" Dosing decisions in older patients are difficult and must integrate assessments of organ function, comorbidities, overall physical status, and goals of treatment, in an effort to ensure the best possible outcome for these patients."	( Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Arcangeli, G; Douglass, HO; Driscoll, DL; Meropol, NJ; Petrelli, NJ; Stein, BN, 1995)
" Intermittent dosing and supplementation with leucovorin have been tried in attempts to improve tolerance."	( The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. Bozzette, SA; Forthal, D; Kemper, C; Leedom, J; McCutchan, JA; Richman, DD; Sattler, FR; Tilles, JG, 1995)
" Clinical toxicity, such as headache and gastrointestinal distress, accounted for the observed difference in tolerance between dosing regimens."	( The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. Bozzette, SA; Forthal, D; Kemper, C; Leedom, J; McCutchan, JA; Richman, DD; Sattler, FR; Tilles, JG, 1995)
" Leucovorin use does not improve tolerance for chronic TMP/SMX dosing in AIDS, even among patients taking tablets daily."	( The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. Bozzette, SA; Forthal, D; Kemper, C; Leedom, J; McCutchan, JA; Richman, DD; Sattler, FR; Tilles, JG, 1995)
" Treatment was well tolerated; 4/27 patients experienced > or = ECOG grade 3 toxicity at full 5-FU dosage (500 mg/m2 bolus/infusion)."	( A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H, 1994)
" We were not able to increase 5FU weekly dosage above 700 mg/m2 due to the occurrence of grade 3-4 gastrointestinal toxicity."	( Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. Buccellato, C; Cipolla, C; Comande, S; Curto, G; Gebbia, N; Gebbia, V; Latteri, M; Testa, A; Valenza, R, 1994)
" The dose-response curve was steep, with 3/3 patients treated at a dose of 1,750 mg/m2 developing grade IV diarrhea."	( Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen. Creaven, PJ; Frank, C; Levine, EG; Meropol, NJ; Petrelli, NJ; Proefrock, A; Raghavan, D; Rodriguez-Bigas, M; Rustum, YM; Udvary-Nagy, S, 1994)
" This was associated with delivery of 100% of the planned dosage of vincristine, prednisone, and daunorubicin at induction."	( Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect. Chan, LC; Chan, TK; Chiu, EK; Kwong, YL; Liang, R; Lie, A; Todd, D, 1994)
" Eighty per cent reduction of leucovorin dosage leads to a significant decrease in grade 2 and grade 3 haematological and gastrointestinal toxicity."	( Local and systemic toxicity of intra-hepatic-arterial 5-FU and high-dose or low-dose leucovorin for liver metastases of colorectal cancer. Klotz, HP; Largiadèr, F; Weder, W, 1994)
" A tolerable dosage regimen was radiation at 45 Gy with 4 days of 5-FU plus leucovorin during the first week and 3 days during the last week with postradiation chemotherapy."	( Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. Burch, PA; Cha, SS; Gunderson, LL; Mailliard, JA; Martenson, JA; McKenna, PJ; Moertel, CG, 1994)
"The increased embryotoxicity of pyrimethamine (PYM) with concomitant oral dosing of folic acid (FA) was examined in rats."	( Synergistic embryotoxicity of combination pyrimethamine and folic acid in rats. Chung, MK; Han, SS; Roh, JK, )
" Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)."	( Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994)
" The LV dosage was 30 mg/body (low-dose method) and the FU dosage was 500-750 mg/body."	( [5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994)
" Because of severe mucositis, the final 30 patients were treated with the same dosage of cisplatin but with the deletion on day 6 of leucovorin and 5-fluorouracil."	( Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Elias, A; Frei, E; Kalish, LA; Kass, F; Lynch, TJ; Shulman, L; Skarin, A; Strauss, G; Sugarbaker, D, 1994)
" The addition of IFN-alpha produced more 5-FU-related toxicity compared with a previous study in which the same dosage and schedule of 5-FU plus LV was used."	( Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. Burghouts, JT; Croles, JJ; de Mulder, PH; Kamm, Y; Punt, CJ; van Liessum, PA, 1993)
" An escalating FU dosing schedule was used to achieve equal toxicity."	( A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993)
" If the combination is to be given on a protracted basis, 5-FU must be administered at a much smaller dosage than has been traditionally utilized."	( A phase I trial of protracted 5-fluorouracil infusion and oral calcium leucovorin. Anderson, T; Beatty, PA; Hansen, RM; Quebbeman, EJ, 1993)
" Dosage adjustments for both methotrexate and leucovorin were made as needed, according to a defined protocol."	( Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Bykerk, V; Choquette, D; Esdaile, JM; Hazeltine, M; Kanji, M; Neville, C; Robidoux, L; Shiroky, JB; St-Pierre, A; Zummer, M, 1993)
" In total, 158 courses (median: 4, range: 1 through 16; 81 and 58 courses at, respectively, a 40 and 50 to 55 mg/m2 daily dosage of C) were delivered using a multichannel programmable in-time pump (Intelliject, Aguettant) connected to a double lumen implanted venous side-port."	( Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. Denis, B; Focan, C; Focan-Henrard, D; Kreutz, F; Levi, F, 1995)
" In the dose-response range studied there was no apparent affinity for methotrexate."	( Purification and characterization of folate binding proteins from rat placenta. da Costa, M; Rothenberg, SP, 1996)
" 5FU was given as a 24-hour infusion at a dosage of 4 g/m2 and oral leucovorin at a dosage of 50 mg every 6 hours for four doses, starting with the infusion of 5FU."	( Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. Atkins, JN; Case, LD; Grote, T; McFarland, J; Muss, HB; Richards, F, 1996)
" Patients who received Tomudex spent a substantially shorter time in hospital for dosing and had significantly lower rates of grade 3 and 4 toxicities such as leucopenia and mucositis."	( 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Cunningham, D; Harper, P; Kerr, D; Olver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; Van Cutsem, E; Zalcberg, JR, 1995)
" Individualized 5-FU dosing to obtain higher 5-FU plasma concentrations may be indicated."	( Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. Athanasiadis, I; Dolan, ME; Haraf, DJ; Kies, MS; Kozloff, M; Malone, D; Mick, R; Ratain, MJ; Vokes, EE; Weichselbaum, RR, 1996)
" A further 46 patients (of whom 22 had been previously treated) received the same treatment as above but with a double dosage (500 mg/m2) of MTX."	( Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil. Beneduce, G; Biondi, E; Casaretti, R; Comella, G; Comella, P; Daponte, A; Frasci, G; Gravina, A; Palmieri, G, )
" For lymphoma, CHOP chemotherapy dosage costs are approximately half of those for CDE infusion related to the specific drug regimen and drug dosage used."	( Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges. Anderson, NR; Lokich, JJ; Moore, CL, 1996)
" The principle cost differences between bolus and infusional schedules relate to drug dosage and the toxicity profile."	( Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges. Anderson, NR; Lokich, JJ; Moore, CL, 1996)
" Dosage in subsequent cycles was adjusted according to hematologic toxicity."	( A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Carroll, PR; Ernest, ML; Fippin, LJ; Small, EJ, 1996)
" Two patients developed exacerbation of hepatitis when the dosage of prednisolone was reduced after they had ten weeks of high dose prednisolone."	( Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC, 1996)
" In many countries patients with CRC do not receive chemotherapy because some clinicians perceive that the benefits of such treatment do not compensate for the potential negative effects on patient quality of life in terms of toxicity and inconvenient dosage schedules."	( Colorectal cancer--an undertreated disease. Kemeny, N, 1996)
" Further studies are needed to establish a standard for appropriate dosage and administration of LV."	( [Biochemical modulation applied to experimental cancer chemotherapy]. Nakamura, Y, 1996)
" The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity."	( A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997)
" However, the toxicities observed with this dosage schedule were considerable and further studies are needed to develop a less toxic regimen."	( Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. Buzaid, AC; Cohen, N; Greenberg, BR; Slater, D; Sporn, JR, 1997)
" DHAD dosage could be increased to 18 mg/m2 in 66 out of 317 cycles of chemotherapy (21%)."	( Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy O Caruso, M; Colucci, G; Durini, E; Gebbia, N; Gebbia, V; Giotta, F; Pezzella, G; Riccardi, F; Romito, S, 1997)
") dolasetron dosing regimens in patients receiving their first course of high-dose (> or = 80 mg/m2) cisplatin."	( A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy. Cramer, MB; Hahne, WF; Kasimis, BS; Schulman, P; Stewart, WH; Tapazoglou, E, 1997)
" Optimal dosing and administration strategies remain to be determined."	( A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Machover, D, 1997)
" However, controversy remains regarding the optimal dosing regimen."	( A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Machover, D, 1997)
" In sequence, paclitaxel 200 mg/m2 (3-hour infusion), carboplatin dosed to an area under the concentration-time curve of 6 mg/mL x min, and methotrexate 10 mg/m2, increasing in 10-mg/m2 increments, were administered on day 1 every 21 days."	( Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma. Edelman, MJ; Houston, J; Lauder, I; Meyers, FJ, 1997)
" In addition, 5-FU levels were detectable throughout the 28-day dosing period; however, there was no evidence of significant accumulation of uracil, tegafur, or 5-FU."	( Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Pazdur, R, 1997)
" Dosage was reduced for neutropenia, thrombocytopenia, diarrhea, stomatitis, and dermatitis."	( Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. Goldberg, RM; Hatfield, AK; Kahn, M; Knost, JA; Krook, JE; Maillard, JA; Moertel, CG; O'Connell, MJ; Sargent, DJ; Schaefer, PL; Tirona, MT; Wiesenfeld, M, 1997)
" In rats bearing advanced colorectal tumors, the role of LV dosage was more clearly evident with the weekly 5-FU treatment schedule than with the daily schedule."	( Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. Cao, S; Rustum, YM; Zhang, Z, )
" Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU."	( Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer. Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; DeLena, M; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Lorusso, V; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1998)
" A North American study (study 10) was originally set up to compare two raltitrexed dosage arms (3."	( Mature results from three large controlled studies with raltitrexed ('Tomudex'). Cunningham, D, 1998)
" These include optimization of dosing and schedule of administration, determination of the most effective oxaliplatin-5-fluorouracil/folinic acid combination, definition of the role of new thymidylate synthase inhibitors with respect to oxaliplatin therapy, and identification of the most effective combinations of oxaliplatin with the new anticancer agents that have been recently introduced."	( Oxaliplatin for the treatment of advanced colorectal cancer: future directions. Bekradda, M; Cvitkovic, E; Ducreux, M; Louvet, C, 1998)
" Therefore toxic potentiation of 5-FU due to simultaneous 1-LV dosing is presumed to be concerned with an increased ternary complex (FdUMP-TS-5,10-methylenetetrahydrofolate) formation and a greater extent of TS inhibition."	( Effects of levofolinate calcium on subacute intravenous toxicity of 5-fluorouracil in rats. Fujii, H; Ichimura, A; Murakami, Y; Murata, A; Takagi, H; Tauchi, K; Yamashita, N, 1998)
" Raltitrexed, a thymidylate synthase inhibitor, offers similar antitumoral activity together with a tolerability in comparison to standard 5-fluorouracil based chemotherapy and its simple dosage schedule also contributes to better quality of life."	( [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer]. Bours, V; Fillet, G; Jerusalem, G, 1998)
" Raltitrexed has the added convenience of an every 3 weeks dosing schedule."	( Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998)
" Nine dosage levels ranging from 120 to 3750 mg/m2 were explored."	( High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer. Bertino, JR; Densmore, CL; Fleisher, M; Grant, SC; Heelan, RT; Kris, MG; Krol, G; Miller, VA; Pfister, DG; Pisters, KM; Rigas, JR; Sirotnak, FM; Tong, W; Tyson, LB, 1996)
" Suramin was administered for eight weeks at doses determined by means of a computer-assisted dosing algorithm that used Bayesian pharmacokinetics to maintain suramin plasma concentrations of 200-250 microg/ml."	( Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy. Allegrini, G; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Galli, C; Lencioni, M; Masi, G; Pfanner, E, )
" Weekly dosing of paclitaxel produces notable activity, while maintaining relatively low toxicity in heavily pretreated metastatic breast cancer patients."	( UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer. Dethling, J; Kühnle, H; Lück, HJ; Scholz, U, 1999)
"This phase I study was undertaken to define the maximum tolerated dose, dose-limiting toxicity, and recommended dosage of UFT (uracil and tegafur) plus oral calcium folinate (Orzel) and vinorelbine (Navelbine) in combination treatment of metastatic breast cancer in patients who have received one prior chemotherapy regimen."	( UFT plus oral calcium folinate/vinorelbine for advanced breast cancer. Déporte-Fety, R; Fumoleau, P; Kerbrat, P; Laguerre, B, 1999)
" Dosage in subsequent cycles was adjusted according to toxicity."	( A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. Kantoff, PW; Loughlin, KR; Manola, J; Oh, WK; Richie, JP, 1999)
" There is no apparent reason to change the dosing regimen of prophylactic co-trimoxazole when there is clinical evidence of damage to the gastrointestinal mucosa induced by chemotherapy."	( Gastrointestinal damage induced by cytostatic treatment does not affect the bioavailability of co-trimoxazole. Höglund, P; Johnsson, A; Ljungberg, B; Nilsson-Ehle, I; Nyhlén, A, )
"Combination chemotherapy with multiple drugs (FLMP therapy), in which the drugs were determined based on biochemical modulation and the dosing schedule was established in accordance with the circadian rhythms of the human body, was performed in cases of advanced recurrent gastric cancer."	( [Effect of combination chemotherapy with multiple drugs (FLMP therapy) based on the circadian rhythms of the human body in advanced recurrent gastric cancer]. Iesato, H; Kamoshita, N; Kato, Y; Nagaoka, H; Okabe, T; Yokomori, T, 1999)
" Preoperative chemoradiotherapy consisted of cisplatinum combined chemotherapy and radiotherapy (total dosage of 30-70 Gy)."	( Analysis of postoperative complications after esophagectomy for esophageal cancer in patients receiving neoadjuvant therapy. Eguchi, R; Hayashi, K; Ide, H; Itoh, H; Nakamura, T; Ohta, M; Okamoto, F; Takasaki, K, 1999)
" UFT and other oral 5FU dosing strategies make promising components of combination chemotherapy, deserving further, randomised evaluation."	( Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer. Cresswell, H; Dent, JT; Papamichael, D; Seymour, MT; Slevin, ML; Wilson, G, 1999)
"In the Phase I portion, paclitaxel 200 mg/m(2) (3-hour infusion), carboplatin dosed to an area under the curve (AUC) of 6 mg/mL."	( Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. deVere White, RW; Edelman, MJ; Gandour-Edwards, R; Meyers, FJ; Miller, TR; Williams, SG, 2000)
" The use of 5-FU pro-drugs and/or DPD inhibitors can overcome this absorption problem and allow for oral dosing of fluoropyrimidines."	( Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents. Hoff, PM; Pazdur, R, 1999)
" A dose-response relationship was observed between the radiation dose and the tumor downstaging and local control."	( Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Buie, D; Chan, AK; Heine, J; Jenken, D; Johnson, DR; Langevin, J; Wong, AO, 2000)
" This variability makes effective dosing of 5-FU and related drugs difficult."	( Oral DPD-inhibitory fluoropyrimidine drugs. Diasio, RB, 2000)
" The removal of one administration of vinorelbine at dose levels 3 and 4 has allowed for increased UFT dosage and AUC0-6 h of fluorouracil, with no dose-limiting toxicity reported for these patients."	( UFT/leucovorin plus vinorelbine combination for advanced breast cancer. Bonneterre, J; Déporte, R; Fargeot, P; Fumoleau, P; Kerbrat, P, 2000)
"The recommended oral dosage of 5-FU (10 mg/m(2) PO bid) given with eniluracil and leucovorin is approximately 115-fold lower than the reference dosage for 24-hour infusional 5-FU."	( Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. Bi, DQ; Donavan, S; Grem, JL; Grollman, F; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Quinn, MG; Shapiro, J; Takimoto, CH; Zentko, S, 2000)
" Well dosed 5 FU over a short period of time without folinic acid may be a valuable and inexpensive adjuvant treatment for colorectal cancer."	( Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer. Beauduin, M; Brohée, D; Bury, J; Canon, JL; Focan, C; Focan-Henrard, D; Herman, ML; Lecomte, M; Vindevoghel, A, )
" Three different dosing regimens were investigated in phase I studies: continuous monotherapy, intermittent monotherapy, and intermittent therapy supplemented with leucovorin."	( 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer. Seitz, JF, 2001)
" These data suggest that UFT/leucovorin should not be dosed simultaneously with food."	( Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001)
" Due to a high rate of gastrointestinal side-effects in the initial phase of the trial, the dosage of 5-FU was reduced to 2,200 mg/m2 for all subsequent patients."	( Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. Gassel, HJ; Heinrich, S; Junginger, T; Köhne, CH; Lorenz, M; Mattes, E; Mueller, HH; Saeger, HD; Schramm, H; Staib-Sebler, E; Vetter, G, 2001)
" Alternative lower dosing or other regimens are to be explored to ascertain the value of bolus 5-FU/FA combined with oxaliplatin."	( A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Balbiani, L; Bella, S; Blajman, C; Cazap, E; Chacón, M; Cóppola, F; Giglio, R; Lastiri, F; Mickiewicz, E; Montiel, M; Perazzo, F; Pujol, F; Recondo, G; Richardet, E; Rodger, J; Schmilovich, A; Simon, J; Van Kooten, M; Vilanova, M; Wasserman, E; Zori Comba, A, 2001)
" It can be concluded that the total dose of 5-FU administered is important in planned dosage schedule of adjuvant chemotherapy in colon cancer."	( Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. Ahn, JB; Chung, HC; Jeung, HC; Kim, BS; Kim, NK; Min, JS; Rha, SY; Roh, JK; Shim, KY; Yoo, NC, 2001)
" After completion of the first chemotherapy cycle, LEV was administered orally at a dosage of 150 mg per day on days 1 to 3, once every 2 weeks."	( Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1. Beger, HG; Link, KH; Staib, L, )
" The dosage and administration is referred to the weekly method developed at RPMI."	( [Levofolinate and fluorouracil combination therapy]. Murakami, M; Takeuchi, S, 2001)
" Since 5-FU seems to have dual, mechanisms of cell kill; DNA and RNA directed cytotoxicity, it is important to know how to maximize or improve therapeutic ratio by dosing or scheduling 5-FU administration, even modulating 5-FU with other agents."	( [5-fluorouracil]. Aiba, K, 2001)
" The phenytoin dosage was decreased and the symptoms resolved."	( Phenytoin and fluorouracil interaction. Brodribb, TR; Gilbar, PJ, 2001)
" Dipyridamole was administered at three different dosing schedules (DS) and methods of administration in three groups of patients."	( Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens. Dimitrakopoulos, A; Fotiadis, K; Genatas, K; Karatzas, G; Kosmas, C; Paliaros, P; Polyzos, A; Rokana, S; Tsavaris, N; Vachiotis, P; Vadiaka, M, )
" Capecitabine in therapeutic dosage regimens generally has acceptable tolerability."	( Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Goa, KL; McGavin, JK, 2001)
" As a result, both the host tolerance and antitumor efficacy of 5-fluorouracil (5-FU) and oxaliplatin (L-OHP), like 30 other anticancer drugs, vary largely according to the dosing time in laboratory rodents."	( Chronotherapy of colorectal cancer. Giacchetti, S, 2002)
"This study determined the effect of different weekly dosing schedules of 5-fluorouracil (5-FU)/leucovorin (LV)/eniluracil on dihydropyrimidine dehydrogenase (DPD) activity and plasma uracil levels."	( Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition. Grem, JL; Guo, XD; Harold, N; Keith, B; Quinn, M; Schuler, B; Shapiro, J; Zentko, S, 2002)
" In addition to a more favorable safety profile, the 300 mg/m(2) dosage offered improved dose-intensity compared with the initial dosage."	( Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. Amadori, D; Cruciani, G; Giovanis, P; Marangolo, M; Nicolini, M; Oliverio, G; Panzini, I; Pasquini, E; Ravaioli, A; Rossi, A; Tassinari, D; Turci, D; Zumaglini, F, 2002)
"In this study, we propose a simple population-based Bayesian approach for predicting MTX plasma concentration from a limited number of samples, so as to adapt both duration and dosage of the rescue agent to be used next."	( Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. Bonnier, P; Ciccolini, J; Durand, A; Hadjaj, D; Lejeune, C; Merite, N; Monjanel-Mouterde, S; Piana, P, 2002)
" The use of BIA may lead to improved dosing with FU."	( Relationships between body composition parameters and fluorouracil pharmacokinetics. Ferrari, M; Ferrazzi, E; Gusella, M; Padrini, R; Toso, S, 2002)
" 5-FU dosage was fixed at 1,600 mg/m2 while docetaxel was evaluated at weekly 1-hour infusion dosages of 30, 40 and 50 mg/m2 to determine the MTD."	( A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002)
" At a docetaxel dosage of 50 mg/m2 per week, the dose-limiting events of grade 4 febrile neutropenia and grade 3 hypomagnesemia occurred."	( A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002)
" The treatment was interrupted if grade 3/4 toxicity appeared and was resumed at the same dosage on recovery."	( Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial. Antón-Torres, A; Aparicio, J; Aranda, E; Bretón, JJ; Carrato, A; Díaz-Rubio, E; Fernández-Martos, C; Navarro, M; Rivera, F; Sastre, J, 2001)
" In order to improve the therapeutic index of systemic chemotherapy for these patients, we designed a weekly MP-HDFL protocol, which took advantage of the low toxicity of the infusional dosing schedule for cisplatin and 5-fluorouracil (5-FU), and double biochemical modulation of 5-FU by methotrexate and leucovorin."	( A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemi Bu, CF; Cheng, AL; Hsu, C; Hsu, CH; Lin, CC; Lu, YS; Yang, CH; Yeh, KH, )
" The present results have no clinical implications for the use of capecitabine and argue against the value of therapeutic drug monitoring for dosage adjustment."	( Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003)
" But the usage and dosage of this therapy should be further studied."	( [Tolerance of human body to simultaneous infusion of 5-fluorouracil and calcium folinate]. Chen, JY; Chen, LT; Lin, Q; Peng, XZ; Zhang, H, 2003)
"Simultaneous continuous infusion of 5-FU and CF can enhance the dosage of 5-FU, and has a better efficacy to advanced digestive tract, head and neck cancers."	( [Tolerance of human body to simultaneous infusion of 5-fluorouracil and calcium folinate]. Chen, JY; Chen, LT; Lin, Q; Peng, XZ; Zhang, H, 2003)
"To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV)."	( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003)
"A pharmacokinetic model for ftorafur and 5FU was developed and should be useful to further study drug interactions and establish dosing guidelines."	( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003)
" Leucovorin (LV) dosage was fixed at 500 mg/m(2)."	( Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Fleming, GF; Hong, AM; Meyerson, A; Ratain, MJ; Schilsky, RL; Schumm, LP; Vogelzang, NJ, 2003)
" These DLTs included grade 3 fatigue (n = 3), grade 2 neutropenia precluding weekly dosing (n = 1), grade 3 thrombocytopenia (n = 1) and grade 3 mental status changes (n = 1)."	( Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Fleming, GF; Hong, AM; Meyerson, A; Ratain, MJ; Schilsky, RL; Schumm, LP; Vogelzang, NJ, 2003)
" The purpose of this study was to evaluate the efficacy and toxicity of a modified TPFL regimen (m-TPFL) for locally advanced SCCHN, consisting of a modified dosage with docetaxel, cisplatin, 5-FU and l-leucovorin (l-LV) designed for Japanese patients."	( Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Sasaki, S; Taniguchi, M; Watanabe, A, 2003)
" Because of the high impact on cost-effectiveness each more expensive chemo-therapy schedule with higher overall dosage should first prove its superior clinical efficacy."	( Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study. Koperna, T; Semmler, D, )
"Chemotherapy with oxaliplatin, fluorouracil (5-FU) and leucovorin (LV) has proven efficacy in patients with advanced colorectal carcinoma (CRC), although the optimal dosage and administration schedule are still unclear."	( Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer. Chiara, S; Gozza, A; Heouaine, A; Lionetto, R; Nobile, MT; Pastrone, I; Percivale, PL; Rosso, R; Sanguineti, O; Taveggia, P, )
" Eight episodes of grade II or III stomatitis were observed and were responsible for dosage modifications of TMTX and 5-FU."	( Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004)
"We evaluated the optimal dosage schedule for combined oral chemotherapy using uracil/tegafur (UFT) and leucovorin (LV) in Yoshida sarcoma-bearing rats."	( Preliminary study of the optimal dosing schedule for oral UFT/leucovorin chemotherapy. Ishikawa, K; Kamijo, A; Makuuchi, H; Murayama, C; Nakamura, T; Sadahiro, S; Saguchi, T; Suzuki, T; Yasuda, S, )
"Administration of UFT/LV for 5 days of the week seemed to exhibit superior antitumor activity, with no increase in the incidence of adverse effects, as compared with the consecutive daily dosing schedule."	( Preliminary study of the optimal dosing schedule for oral UFT/leucovorin chemotherapy. Ishikawa, K; Kamijo, A; Makuuchi, H; Murayama, C; Nakamura, T; Sadahiro, S; Saguchi, T; Suzuki, T; Yasuda, S, )
" Leucovorin dosage was adjusted according to creatinine clearance."	( High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Campbell, M; Joannon, P; Oviedo, I; Tordecilla, J, 2004)
" Dosage was reduced at any time if toxicity NCI CTC grade III/IV was observed."	( Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004)
"Prednisone dosage (25 mg/d) was tapered to 0 mg/d within 24 weeks and was adjusted if flare-ups occurred."	( Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Caporali, R; Cimmino, MA; Ferraccioli, G; Gerli, R; Klersy, C; Montecucco, C; Salvarani, C, 2004)
"Follow-up was short, and a high dose of folinic acid and a relatively high starting dosage of prednisone were used."	( Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Caporali, R; Cimmino, MA; Ferraccioli, G; Gerli, R; Klersy, C; Montecucco, C; Salvarani, C, 2004)
" The results of growth curve analyses replicated these findings and suggested a significant adverse effect of cumulative dosage of intrathecal methotrexate on estimated Wechsler Performance IQ."	( Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. Barrowman, NJ; Dunlap, H; Halton, JM; Hsu, E; Keene, DL; Kuehn, SM; Matzinger, MA; Montour-Proulx, I, 2005)
"The incidence of 5-fluorouracil (5-FU)-related cardiotoxicity seems to be dosage and schedule dependent."	( Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Alakavuklar, MN; Barutca, S; Kundak, I; Meydan, N; Oztop, I; Yavuzsen, T; Yilmaz, U, 2005)
" Morbidity is a significant limitation of this procedure, usually related to the extent of surgery, and hematological toxicity, which is considered as dependent upon the chemotherapy dosage alone."	( Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. Boige, V; Elias, D; Estphan, G; Laplanche, A; Malka, D; Pocard, M; Raynard, B, 2005)
" Recent treatment schedules vary markedly in terms of timing, dosing and scheduling of MTX and/or leukovorin, which may leave us uncertain with ideas such as "how should we best use HDMTX and LV?" or "why are we still using such by industry recommended doses of MTX?" The answer of how best to incorporate HDMTX and/or LV into ALL treatment plans is still not known and further clinical and pharmacological studies dealing with still controversial systemic MTX issue are actual even now, after more than 5 decades of clinical experiences with the MTX in pediatric oncology."	( High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Bajciová, V; Gregorová, V; Kadlecová, V; Mendelová, D; Sterba, J; Valík, D, 2005)
" In the high 5-FU group, seven of 14 patients (50%) received < or =80% of the planned chemotherapy dose during the first cycle due to dosage reductions whilst treatment delays occurred in 10/14 patients."	( Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T, 2006)
" A decrease of dosage or abundance of continuation was done during the course due to complications."	( [Five cases of locally advanced rectal cancer or local recurrence performed intra-arterial infusion chemotherapy via the internal iliac artery]. Agata, T; Aoyama, H; Funabashi, M; Hanai, T; Kamano, T; Katsuno, H; Koide, Y; Maeda, K; Masumori, K; Noro, T; Sato, H, 2005)
" The treatment schedule modification, omitting the 5-FU dosing on day 8, considerably improved treatment compliance, reducing the incidence of febrile neutropenia, diarrhea, and asthenia."	( Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006)
" 5-fluoruracil 750 mg sq m(-1), leucovorin 75 mg sq m(-1), epirubicin 45 mg sq m(-1), carboplatin 225 mg sq m(-1) were administered every 3 weeks into celiac axis for three cycles (FLEC regimen), then gemcitabine at the dosage of 1 g sq m(-1) on days 1, 8 and 15 every 4 weeks for 3 months (FLECG regimen)."	( Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T, 2006)
" The dose intensity of gemcitabine of the 35 patients with 5-FU dosage set at MTD was 593 mg/m2 per week."	( Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. Chang, JY; Chao, Y; Chen, LT; Cheng, AL; Chuang, TR; Hsu, C; Hsu, CH; Jan, CM; Liu, TW; Shiah, HS; Whang-Peng, J; Yu, WL, 2006)
"In this study, we attempted to determine the efficacy and toxicity of decreasing dosage of irinotecan plus 5-fluorouracil (5-FU) and leucovorin (LV) in the treatment of advanced colorectal cancer."	( Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and leucovorin (LV) in the treatment of advanced and/or metastatic colorectal cancer: a phase II study. Chueh, TC; Huang, JS; Lai, CH; Lan, YJ; Liaw, CC; Wang, CH; Yen, CL; You, YT, )
"Palifermin administered at the indicated dosing regimen (40 microg/kg for 3 consecutive days) before chemotherapy was well tolerated and resulted in a statistically significant and clinically meaningful reduction in the incidence of WHO grade 2 or higher OM in patients with metastatic CRC."	( Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006)
" The proposed model could be used in Bayesian algorithms with a limited sampling strategy to estimate the systemic exposure of individual patients to methotrexate and adapt both folinic acid rescue and methotrexate dosing accordingly."	( Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Aumente, D; Buelga, DS; García, MJ; Gomez, P; Lukas, JC; Torres, A, 2006)
" We also performed a dose-response study with folinic acid and determined the impact of maternal folate supplementation on Folr1 nullizygous cardiac development."	( Cardiovascular abnormalities in Folr1 knockout mice and folate rescue. Finnell, RH; Gelineau-van Waes, J; Merriweather, M; Schwartz, RJ; Scott, M; Wlodarczyk, BJ; Yu, W; Zhu, H, 2007)
"Our study shows that low LBM is a significant predictor of toxicity in female patients administered 5-FU using the convention of dosing per unit of body surface area."	( Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Baracos, VE; Butts, CA; McCargar, LJ; Mourtzakis, M; Mulder, KE; Prado, CM; Reiman, T; Sawyer, MB; Scarfe, AG, 2007)
" We were unable to demonstrate a significant dose-response relationship for renal damage in the tested dose range."	( Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer. Belka, C; Bokemeyer, C; Budach, W; Hehr, T; Kollmannsberger, C; Welz, S, 2007)
" The dosing regimen recommended in clinic trial is 8 mg/m(2)."	( [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007)
" The dosage of FOLFOX 4 was reduced after three courses due to neutropenia and diarrhea."	( [A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy]. Fujisawa, M; Ishibiki, Y; Ishiyama, S; Kitabatake, T; Kojima, K; Machida, M; Nakayama, Y; Nitta, S; Ono, S; Shinjou, K; Urao, M, 2007)
"Cisplatin (DDP) in large dosage impairs renal functions, while the impact of fractionated low dose DDP on renal functions is unclear."	( [Effects of fractionated low dose Cisplatin on renal functions of patients with gastric carcinoma]. Jin, ML; Li, J; Li, Y; Shen, L, 2007)
" Although this patient could accept it relatively safely without any severe side effect, the optimal dosage and the timing of hemodialysis for inoperable metastatic colorectal cancer patients should be determined by a further study using more cases."	( [Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. Ehara, K; Hasebe, S; Hashimoto, M; Hayashi, M; Igarashi, M; Ito, T; Katori, H; Kinoshita, Y; Matoba, S; Matsuda, M; Mine, S; Moriyama, J; Sato, M; Sawada, T; Toda, S; Tsutsumi, K; Udagawa, H; Ueno, M; Watanabe, G; Yokoyama, T, 2008)
"A phase III, multicenter, randomized study compared conventional dosing of fluorouracil (FU) plus folinic acid with pharmacokinetically guided FU dose adjustment in terms of response, tolerability, and survival."	( Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008)
" Those centres that did not use routine dosing of folinic acid post transplant chose not to do so on the grounds that they believed that it was not efficacious or may increase the risk of GVHD."	( Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand. Bhurani, D; Kerridge, I; Schifter, M, 2008)
" The setting of dosage was differed in two hospitals."	( [Comparative survey on current status and the differences of treatment using modified FOLFOX6 regimen in patients with colorectal cancer in two general hospitals]. Anami, S; Fujii, C; Fukunaga, M; Furukawa, H; Kitada, N; Morimoto, S; Morita, S; Takara, K; Watari, M; Yamasaki, H; Yokoyama, T, 2008)
" In contrast, a similar dosing regimen but at a lower dose (0."	( Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Cool, JC; Fan, C; Foster, BK; Scherer, MA; Shandala, T; Tapp, H; Xian, CJ, 2009)
" Capecitabine was given at an oral dosage of 825 mg/m(2)bid on each day of the radiotherapy period with the first daily dose applied 2 h before irradiation, followed by surgery 6 weeks later."	( Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Budach, W; Debus, J; Dunst, J; Hinke, A; Hoelscher, T; Mose, S; Reese, T; Roedel, C; Rudat, V; Wulf, J; Zuehlke, H, 2008)
" The dosing regimen was continued up to 10 weeks."	( Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: intervention of folic and folinic acid. Jena, GB; Padmanabhan, S; Ramarao, P; Tripathi, DN; Vikram, A, 2009)
" Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy."	( Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Inaba, Y; Matsuo, K; Muro, K; Najima, M; Sato, Y; Shitara, K; Takahari, D; Ura, T; Yamaura, H; Yokota, T, 2009)
"Etoposide 50 mg/m(2), UFT 250 mg/m(2) and leucovorin 90 mg (fixed dose) were dosed in 3 gifts approximately 8h apart for 14 days followed by 1 week rest every 3 weeks until progressive disease (PD)."	( Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R, 2009)
" Additionally, no dosage decrease was required, and only 4 cycles were withheld for 1 week because of neutropenia."	( Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer. Hatzopoulos, A; Heras, P; Karagiannis, S; Kritikos, K; Kritikos, N; Mitsibounas, D; Xourafas, V, )
" Alternative vorinostat dosing schedules may be needed for optimal down-regulation of TS expression."	( A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)
" Of the total 368 cycles administered, 68 suffered administration delays and 22 had the dosage reduced."	( [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. de la Rubia, A; Díaz-Carrasco, MS; Fernández-Lobato, B; Marín, M; Pareja, A; Vila, N, )
"The use of the FOLFOX4 regimen has been adjusted to uses with some solid scientific evidence, but its toxicity has limited its use and has made administering the planned dosage levels difficult."	( [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. de la Rubia, A; Díaz-Carrasco, MS; Fernández-Lobato, B; Marín, M; Pareja, A; Vila, N, )
" The CPT-11 dosage was 150 mg/m(2)."	( [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. Fukuoka, T; Hatano, N; Imamura, Y; Morita, Y; Usui, H; Yokoyama, S, 2009)
" CoFactor was developed as a more active replacement of leucovorin to potentially allow reduced dosing of 5-FU."	( Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer. Bouvet, M; Costantini, CL; Reid, TR, )
" But even with an 85 mg/m(2) dose, mFOLFOX6 therapy could be continued by extending the dosing interval."	( [The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy]. Fujita, M; Kataoka, Y; Katayama, T; Koide, T; Matsuda, H; Okuda, M; Yamagishi, Y, 2009)
" Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy."	( Folate in depression: efficacy, safety, differences in formulations, and clinical issues. Fava, M; Mischoulon, D, 2009)
"FOLFOX4 (SWIFT1) and mFOLFOX6 (SWIFT2) regimens complying with the international standard dosage and schedule can also be administered safely and effectively in Japan."	( Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study. Ikenaga, M; Kato, T; Kondo, K; Mishima, H; Nagata, N; Nakao, A; Oba, K; Okuyama, Y; Sakamoto, J; Shibata, Y; Tanemura, H, )
"9%, respectively, compared with dosing on an empty stomach."	( Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer. Furuhata, T; Hosokawa, Y; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K; Sasaki, K; Tsuruma, T, 2009)
" As the drug is orally administered, capecitabine permits greater convenience and flexibility in dosing by eliminating the need for continuous infusion and its potential complications."	( Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. Boehm, KA; Cartwright, T; McCollum, D, 2010)
" When chemotherapy with S-1 or UFT/LV started from the micrometastasis stage, not the advanced macroscopic metastasis stage, anti-LNM efficacy of S-1 was significantly higher than that of UFT/LV at the dosage in which antitumor activity of the two drugs against primary subcutaneous tumor was comparable."	( Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV. Hirai, T; Ito, Y; Kato, T; Kodera, Y; Nakanishi, H; Nakao, A, 2010)
"The aim of this study was to evaluate the protective effect of calcium folinate (CF) applied in 10% of the methotrexate (MTX) dosage against morphologic and steroid-receptor damage induced by MTX in rat endosalpinx."	( Protective effect of calcium folinate against methotrexate-induced endosalpinx damage in rats. Chen, YP; Wang, HC; Yang, XJ; Zhao, J; Zheng, FY, 2011)
" The regimen of pre-op CCRT was a radiation dosage of 45 Gy in 20 fractions and oral tegafur-uracil (UFUR) and leucovorin."	( The impact of preoperative chemoradiotherapy on advanced low rectal cancer. Chang, SC; Chen, WS; Jiang, JK; Kao, PS; Lee, RC; Liang, WY; Lin, JK; Lin, TC; Wang, HS; Wang, LW; Yang, SH, 2010)
" The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients."	( Update on capecitabine alone and in combination regimens in colorectal cancer patients. Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S, 2010)
" The aim of this investigation was to evaluate the performance of a clinical decision support system and Bayesian forecasting algorithm in the prediction of MTX concentrations and assessment of LV dosing requirements in pediatric and young adult patients with cancer based on the current practice at the Children's Hospital of Philadelphia."	( Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Barrett, JS; Dombrowsky, E; Jayaraman, B; Narayan, M, 2011)
" Despite this, 150 mg/m(2) CPT is widely prescribed and is the maximum dosage covered by Japanese health insurance."	( Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y, 2011)
"5 and 50 mg/day) and continuous daily dosing (CDD; 37."	( A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G, 2012)
"FOLFOX plus bevacizumab therapy can be given safely to hemodialytic patients with no reduction in the dose of oxaliplatin if hemodialysis is performed soon after the administration of oxaliplatin and the dosing interval is extended to 3 weeks."	( Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Chiba, T; Ezoe, Y; Horimatsu, T; Mashimo, Y; Miyamoto, S; Morita, S; Muto, M, 2011)
" Concomitant 5-FU/LCV resulted in no clinically relevant changes in the area under the plasma concentration-time curve in the dosing interval (AUC(0-12)) and maximum plasma concentration (C(max)) of sorafenib (100-400 mg bid) at steady state."	( Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S, 2012)
"5, and 50 mg/day) on three schedules: 2 weeks on, 2 weeks off (2/2); 4 weeks on, 2 weeks off (4/2); or continuous daily dosing (CDD)."	( A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J, 2012)
" standard body-surface-area (BSA) dosing in a FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimen in metastatic colorectal cancer (mCRC)."	( Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Asevoaia, A; Boisdron-Celle, M; Capitain, O; Gamelin, E; Morel, A; Poirier, AL, 2012)
"Efficacy and tolerability of PK-adjusted FOLFOX dosing was much higher than traditional BSA dosing in agreement with previous reports for 5-FU monotherapy PK-adjusted dosing."	( Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Asevoaia, A; Boisdron-Celle, M; Capitain, O; Gamelin, E; Morel, A; Poirier, AL, 2012)
"The efficacy and tolerability of bevacizumab every 2 or 4 weeks using the same dosage in combination with biweekly FOLFIRI were retrospectively evaluated in metastatic colorectal cancer (mCRC) patients in the first-line and second-line therapy."	( Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R, 2012)
" However, our study clearly points out the need for determination of optimum biological dosing interval of bevacizumab in well-designed, prospective, randomized trials."	( Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R, 2012)
" Data on folinic acid dosage and duration were analyzed along with SCT parameters using univariate and multivariate statistics."	( Folinic acid supplementation in higher doses is associated with graft rejection in pediatric hematopoietic stem cell transplantation. Harila-Saari, A; Lindqvist, H; Remberger, M; Sundin, M; Winiarski, J, 2013)
" The cost of drug acquisition was calculated based on dosage data and the mean number of treatment cycles from the pivotal studies NO16966 and NO16967."	( Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. Gibbs, P; Hack, SP; Kerr, A; Price, T; Stokes, L; Todd, C; Tran, G, 2013)
" We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6)."	( Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. Asaka, M; Kato, K; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Muto, S; Nakatsumi, H; Oba, K; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2012)
"43) with conventionally dosed therapy."	( Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cheng, C; Crews, KR; Evans, WE; Howard, SC; Jeha, S; McCormick, J; Panetta, JC; Pauley, JL; Pei, D; Pui, CH; Relling, MV; Ribeiro, R; Rubnitz, J; Sandlund, JT, 2013)
" The experimental arm's dosage schedule was paclitaxel 60 mg/m2 (intravenous infusion) on days 1, 8 and 15 and S-1 80-120 mg/d (oral administration) on days 1-14."	( A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013)
"Traditional post-surgical chemotherapy for pancreatic cancer is notorious for its devastating side effects due to the high dosage required."	( Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery. Chen, H; Deng, X; Jin, J; Li, H; Peng, C; Shen, B; Zhan, Q; Zhang, X, 2013)
" We started combination chemotherapy with 5-fluorouracil, Leucovorin and oxaliplatin(modified FOLFOX6)at a 20% lower than standard dosage for safety."	( [A case of metastatic colorectal cancer with icterus due to multiple liver metastases treated effectively by FOLFOX plus bevacizumab]. Fukuda, K; Koja, S; Terasawa, T; Yasuda, K, 2013)
"5 or 9 mg/kg/d given on days 1 to 3 of each 14-day cycle along with standard dosing of modified FOLFOX6 plus bevacizumab."	( A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Ashkenazi, A; Kapp, AV; Kozloff, MF; Messersmith, WA; Peddi, PF; Portera, CC; Royer-Joo, S; Wainberg, ZA, 2013)
" The subsequent 14 patients were treated with a dulanermin dosage of 9 mg/kg/d."	( A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Ashkenazi, A; Kapp, AV; Kozloff, MF; Messersmith, WA; Peddi, PF; Portera, CC; Royer-Joo, S; Wainberg, ZA, 2013)
"6%) while 5 patients had extended-interval dosage (17."	( Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013)
" With current dosing regimens, axitinib plus FOLFOX or FOLFIRI seems to be less well tolerated than bevacizumab-based regimens."	( Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013)
"We evaluated week-on/week-off axitinib dosing plus chemotherapy in patients with gastrointestinal tumours, including tumour thymidine uptake by fluorine-18 3'-deoxy-3'-fluorothymidine positron emission tomography ((18)FLT-PET)."	( Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J, 2014)
") axitinib 7 mg (n=3) or 10 mg (n=18) for 7 days followed by a 7-day dosing interruption; serial (18)FLT-PET scans were performed before day 1 and on days 7, 10, and 14."	( Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J, 2014)
"3%); alteration and complete recovery (31%) or sustained deterioration (45%), possibly due to inadequate chronotherapy dosing and/or timing."	( The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA, 2014)
"An IO dosing schedule had a significant benefit on both TTF and TTP versus CO dosing in this trial despite the very attenuated sample."	( Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Alberts, S; Ansari, R; Childs, BH; Chowhan, N; Grothey, A; Hainsworth, JD; Hart, L; Hochster, HS; Keaton, M; Ramanathan, RK; Rowland, K, 2014)
"Oral UFT plus leucovorin given by either dosage schedule is a very safe regimen for adjuvant chemotherapy."	( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial. Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014)
" Sequential blood samples were collected at regular intervals over 24 h after dosing and were analyzed using a validated high-performance liquid chromatography (HPLC) method."	( Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. Li, Y; Li, Z; Liu, Y; Shi, S; Wu, J; Yang, C; Zhang, Y; Zhou, J, 2015)
" A common dosage of leucovorin in adjuvant and palliative settings is 60 mg/m(2)."	( Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages. Derwinger, K; Odin, E; Taflin, H; Wettergren, Y, 2014)
" Further studies are needed to establish whether higher dosage yields a better treatment response."	( Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages. Derwinger, K; Odin, E; Taflin, H; Wettergren, Y, 2014)
" A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC."	( Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Ayer, T; Chen, Q; El-Rayes, BF; Flowers, CR; Goldstein, DA; Harvey, RD; Howard, DH; Lipscomb, J, 2014)
"Thirty-two patients scheduled for colon resection were randomized to receive Modufolin® or Isovorin® at dosage of 60 or 200 mg/m²."	( A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. Derwinger, K; Kodeda, K; Odin, E; Taflin, H; Wettergren, Y, 2015)
"Seven patients with metastases confined to the liver were included and stratified into two groups, depending of dosage of systemic chemotherapy."	( Fluorouracil, leucovorin and irinotecan combined with intra-arterial hepatic infusion of drug-eluting beads preloaded with irinotecan in unresectable colorectal liver metastases: side effects and results of a concomitant treatment schedule. Clinical inves Badzek, S; Golem, H; Gorsic, I; Kekez, D; Librenjak, N; Perkov, D; Plestina, S; Prejac, J; Smiljanic, R, )
"The efficacy of the biweekly combination of cetuximab with FOLFOX-4 in patients with wild-type KRAS tumours supports the administration of cetuximab in a dosing regimen more convenient for patients and healthcare providers."	( Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). Alonso, V; Cirera, L; Fernandez-Plana, J; Mendez, M; Pericay, C; Quintero, G; Saigi, E; Salgado, M; Salud, A, 2014)
" Future strategies should focus on investigating the immunomodulatory effects of chemotherapy in conjunction with TroVax, understanding the optimal dosing and schedule of the combination, and examining potential predictive biomarkers to determine which patients may benefit from immunotherapy from those who do not."	( TroVax in colorectal cancer. Cen, P; Rowe, J, 2014)
" Rescue dosage of leucovorin in variant group was higher than that in wild-type group [(312."	( [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Chen, Y; Gao, P; He, X; Li, J; Niu, C; Wang, C; Wang, Y; Zhang, H, 2014)
" Standard dosage of mFOLFOX6 was used."	( Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cao, J; Chen, Z; Guo, W; Ji, D; Li, J; Li, W; Lv, F; Qiu, L; Wang, J; Xia, Z; Zhang, S; Zhang, W, 2015)
" This report explores the relationship between glucarpidase dosage and patient outcomes in pediatric oncology patients."	( Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Cheng, C; Crews, KR; Jeha, S; Molinelli, AR; Navid, F; Relling, MV; Scott, JR; Stewart, CF; Swanson, HD; Ward, DA; Zhou, Y, 2015)
"No significant relationship was found between glucarpidase dosage (units/kg) and percent decrease in methotrexate plasma concentrations measured by TDx (P > 0."	( Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Cheng, C; Crews, KR; Jeha, S; Molinelli, AR; Navid, F; Relling, MV; Scott, JR; Stewart, CF; Swanson, HD; Ward, DA; Zhou, Y, 2015)
" An adaptive reduction in chemotherapy dosage was required in 2 patients due to hematological toxicity, and a delay in chemotherapy cycles was required for 3 patients."	( FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J, 2015)
" The median total dosage of oxaliplatin was 811."	( Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). Goto, K; Hasegawa, J; Inoue, K; Ishigure, K; Kotaka, M; Manaka, D; Matsui, T; Oba, K; Ohtsu, A; Saji, S; Sakamoto, J; Shinozaki, K; Touyama, T; Watanabe, T; Yoshino, T, 2015)
" No difference in other treatment toxicity was observed between the two groups, and patients exhibited high compliance in dosing administration."	( Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J, 2015)
" During HIPEC in Colliseum technique Oxaliplatin was given in a dosage of 200 mg/m2 and Docetaxel in a dosage of 80 mg/m2."	( Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer. . Hotopp, T; Müller, H; Tofeili, A; Wutke, K, 2014)
"Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area."	( Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015)
" Spatially defined projected light photopolymerization of hydrogels with embedded active compounds is introduced as a flexible and cost-efficient method for producing multiplexed dosing assays."	( Multiplexed Dosing Assays by Digitally Definable Hydrogel Volumes. Andresen, TL; Chernyy, S; Faralli, A; Larsen, EK; Larsen, NB; Melander, F, 2016)
" Capecitabine plus oxaliplatin could be economically reasonable if full dosing occurred ≥76% of the time (base case 42%)."	( Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers. Aspinall, SL; Chatta, G; Cunningham, FE; Good, CB; Passero, V; Smith, KJ; Soni, A; Zhao, X, 2014)
"Adverse events seen with chemotherapy consisted of grade 2 leukopenia in 1 patient, but there were no cases of delayed administration or dosage reduction due to grade 2 neurotoxicity."	( Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery. Arimitsu, H; Hirano, A; Koda, K; Kosugi, C; Matsuo, K; Shiragami, R; Shuto, K; Suzuki, M; Tanaka, K; Yamazaki, M; Yasuda, H, 2015)
"To (a) assess potential patient-specific factors related to adherence to mCRC chemotherapy regimens and (b) compare adherence with IV versus oral dosage forms."	( Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer. Anderson, S; Seal, BS; Shermock, KM, 2016)
" The median cumulative dosage capecitabine was lower for patients treated with CAPOX (163,744 mg/m(2), interquartile range [IQR] 83,397-202,858 mg/m(2)) than for patients treated with CapMono (189,195 mg/m(2), IQR 111,667-228,125 mg/m(2), P = 0."	( Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients. Creemers, GJ; Janssen-Heijnen, ML; Lemmens, VE; Maas, HA; Pruijt, JF; Razenberg, LG; van Erning, FN, 2016)
"CAPOX is associated with significantly more grade III-V toxicities than CapMono, which had a pronounced impact on the cumulative dosage received and completion of all planned cycles."	( Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients. Creemers, GJ; Janssen-Heijnen, ML; Lemmens, VE; Maas, HA; Pruijt, JF; Razenberg, LG; van Erning, FN, 2016)
" This relationship favors new treatment strategies with white blood cell growth factors or chemotherapy dosing based on muscle value."	( Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A, 2016)
" We propose that changes in dosing procedures could improve the delivery and therapeutic index for methotrexate and other folic acid-targeted drug conjugates and imaging agents."	( Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin. Banaszak Holl, MM; Boutom, SM; Chen, J; Frey, C; Marsh, EN; Merzel, RL; Shedden, K, 2017)
" Potential correlation between treatment modalities (regimen, dosage and route of administration of L-OHP, and injection timing for dexamethasone administration) and HSRs was assessed."	( Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer. Ando, Y; Hayashi, T; Ikeda, Y; Ito, K; Kawada, K; Kumazawa, S; Maeda, K; Matsuoka, H; Murai, S; Ohta, H; Shiouchi, H; Yamada, S; Yasuda, K, 2017)
" Risk factors for MEN included older age (>60 years), chronic kidney disease, and high initial dosage of MTX without folic acid supplementation."	( Methotrexate-induced epidermal necrosis: A case series of 24 patients. Chen, CB; Chen, TJ; Chung, WH; Huang, YH; Hui, RC; Hung, SI; Lu, YT; Wang, CW; Wang, KH; Yang, LC, 2017)
" To reduce the risk of MEN, physicians should avoid prescribing MTX to high-risk patients and titrate the dosage slowly upward with folic acid supplementation."	( Methotrexate-induced epidermal necrosis: A case series of 24 patients. Chen, CB; Chen, TJ; Chung, WH; Huang, YH; Hui, RC; Hung, SI; Lu, YT; Wang, CW; Wang, KH; Yang, LC, 2017)
"Methotrexate has a wide dosing range."	( A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration. Cerminara, Z; Duffy, A; Gilmore, S; Nishioka, J; Trovato, J, 2019)
"We performed a secondary analysis of a completed multicenter trial that investigated PK-guided 5FU dosing in patients receiving mFOLFOX6 +/- bevacizumab for colorectal cancer."	( The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018)
"Although our results did not confirm the impact of low skeletal muscle on PKs of 5FU, further research exploring the impact of body composition on chemotherapy PKs and related toxicities is warranted with the potential for alternative dosing strategies in sarcopenic patients to reduce unnecessary toxicities while maintaining efficacy."	( The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018)
" However, the toxicity and limited dosing of currently available molecular inducers have largely inhibited translation to clinical settings."	( Regulation of T cell proliferation with drug-responsive microRNA switches. Chen, YY; Smolke, CD; Wong, RS, 2018)
" Dosing and completion of prescribed chemotherapy were assessed on the subset of patients who received all therapy at MSK."	( Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. Cercek, A; Crane, CH; Garcia-Aguilar, J; Gollub, MJ; Gonen, M; Guillem, JG; Nash, GM; Paty, PB; Reidy, DL; Roxburgh, CSD; Saltz, LB; Segal, NH; Seier, K; Shia, J; Smith, JJ; Stadler, ZK; Strombom, P; Temple, LKF; Vakiani, E; Varghese, A; Weiser, MR; Wu, AJ; Yaeger, R, 2018)
" A 76-year-old African-American woman with a history of bullous pemphigoid on methotrexate therapy presented with lower extremity cellulitis, developing oral and cutaneous erosions during hospitalization after daily dosage of methotrexate."	( Acute mucocutaneous methotrexate toxicity with marked tissue eosinophilia. Borda, LJ; Milikowski, C; Ross, A; Villada, G, 2018)
" Dosage was more often reduced in patients receiving FOLFOX based therapy."	( Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. Evert, M; Fest, P; Fichtner-Feigl, S; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Munker, S; Ott, C; Reng, M; Schlitt, HJ; Schnoy, E; Stroszczynski, C; Teufel, A; Vogelhuber, M; Wiggermann, P, 2018)
"Contrary to our expectations, the need to reduce chemotherapy dosage due to side effects does not indicate a worse prognosis in our retrospective analysis."	( Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. Evert, M; Fest, P; Fichtner-Feigl, S; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Munker, S; Ott, C; Reng, M; Schlitt, HJ; Schnoy, E; Stroszczynski, C; Teufel, A; Vogelhuber, M; Wiggermann, P, 2018)
"To review the evidence for benefits and harms of folate (folic acid or folinic acid) supplementation on methotrexate (MTX) treatment for rheumatoid arthritis (RA), to assess whether or not folate supplementation would reduce MTX toxicity or reduce MTX benefits, and to decide whether a higher MTX dosage is essential."	( Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis: A Systematic Review. Guan, W; He, Y; Hu, W; Li, T; Liu, L; Liu, S; Liu, X; Lu, J; Wang, C; Wang, P; Xuan, Y; Zhang, L; Zhang, Y, 2019)
" Hyperammonemia induced by 5-FU is relatively rare, with a reported incidence of 5-9%; however, caution is required with high dosage regimens of 5-FU that are currently recommended for colorectal cancer therapy because hyperammonemia is an important side effect."	( [A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer]. Funahashi, K; Kagami, S; Tamura, A; Yoshino, Y, 2018)
" The individualized dosing of CPT-11 is essential to ensure optimal pharmacotherapy in cancer patients, given the wide interindividual pharmacokinetic variability of this drug and its active metabolite SN-38."	( Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019)
" Here, we investigated a safe and efficient dosing schedule of oxaliplatin in folinic acid, fluorouracil, and oxaliplatin (FOLFOX) regimen by monitoring total and free platinum concentrations in plasma."	( Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report. Cai, X; Fang, W; Gu, Y; Li, X; Wang, D; Wang, J; Wang, Y; Xu, L; Zhao, F, 2019)
" These data indicate that the use of modified dosing FOLFIRINOX in advanced PC pts older than 75 appears to maintain similar toxicity and efficacy when compared to younger pts."	( Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Fogelman, DR; Hess, KR; Ho, L; Javle, MM; Mizrahi, JD; Overman, MJ; Pant, S; Raghav, KPS; Rogers, JE; Shroff, RT; Varadhachary, GR; Wolff, RA, 2020)
" Demographics, clinical and dosing characteristics, and treatment outcomes were collected."	( Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Ahn, D; Barzi, A; Bekaii-Saab, T; Corvino, FA; Mamlouk, K; Miksad, R; Pulgar, S; Surinach, A; Torres, AZ; Valderrama, A; Wang, S, 2020)
"04) and a higher chemotherapy dosage (P = ."	( Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020)
" Evaluation of pharmacogenomically dosed perioperative gFOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and UGT1A1 genotype-directed irinotecan) to optimize efficacy while limiting toxic effects may have value."	( Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. Allen, K; Alpert, L; Catenacci, DVT; Chase, L; de Wilton Marsh, R; Ferguson, MK; Gordon, B; Hart, J; Karrison, T; Kindler, HL; Kipping-Johnson, K; Liao, CY; Lomnicki, S; Markevicius, U; Maron, SB; Moore, K; Narula, S; Peterson, B; Polite, BN; Posner, MC; Prachand, VN; Racette, C; Rampurwala, MM; Roggin, KK; Setia, N; Siddiqui, UD; Turaga, K; Xiao, SY, 2020)
"In this study, perioperative pharmacogenomically dosed gFOLFIRINOX was feasible, providing downstaging with PRG 1 in more than one-third of patients and an R0 resection rate in 92% of patients."	( Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. Allen, K; Alpert, L; Catenacci, DVT; Chase, L; de Wilton Marsh, R; Ferguson, MK; Gordon, B; Hart, J; Karrison, T; Kindler, HL; Kipping-Johnson, K; Liao, CY; Lomnicki, S; Markevicius, U; Maron, SB; Moore, K; Narula, S; Peterson, B; Polite, BN; Posner, MC; Prachand, VN; Racette, C; Rampurwala, MM; Roggin, KK; Setia, N; Siddiqui, UD; Turaga, K; Xiao, SY, 2020)
" This pharmacokinetic/pharmacodynamic (PK/PD) study was performed to determine the effect of different G-CSF regimens on the incidence and duration of neutropenia following FOLFIRINOX administration in order to propose an optimal G-CSF dosing schedule."	( Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach. Bengrine-Lefevre, L; Ghiringhelli, F; Macaire, P; Paris, J; Schmitt, A; Vincent, J, 2020)
" Final model estimates were used to simulate different G-CSF dosing schedules for 1000 virtual subjects."	( Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach. Bengrine-Lefevre, L; Ghiringhelli, F; Macaire, P; Paris, J; Schmitt, A; Vincent, J, 2020)
" Our findings underscore the relevance of the clinically applied LV regimen and highlight the potential of this model to further optimize modifications in dosing and timing of Leucovorin on oral mucosa cells."	( Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia. Clevers, H; de Jonge, R; Driehuis, E; Heil, SG; Jansen, G; Kolders, S; Lin, M; Muller, IB; Oosterom, N; Pieters, R; van den Heuvel-Eibrink, MM, 2020)
" We aimed to improve FOLFOXIRI by optimization of the dosing and the sequence of drug administration."	( Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. Nowak-Sliwinska, P; Ramzy, GM; Rausch, M; Zoetemelk, M, 2020)
" Other dosing schedules or combinations may be evaluated."	( Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S, 2020)
" Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation."	( Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021)
" Screening patients for dihydropyrimidine dehydrogenase deficiency prior to 5-FU administration may facilitate an individualized strategy for optimal dosing and safety."	( 5-Fluorouracil Rechallenge After Cardiotoxicity. Almnajam, M; Desai, A; Kim, AS; Mohammed, T; Patel, KN, 2020)
"5, 5, or 10 μg/kg) + 5-flurouracil/leucovorin/oxaliplatin (FOLFOX), dosed per manufacturers prescribing information, until tumor progression."	( Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Aljumaily, R; Autio, KA; Bauer, TM; Bendell, J; Falchook, GS; Hecht, JR; Hung, A; Infante, JR; Javle, M; Leveque, J; Naing, A; Oft, M; Pant, S; Papadopoulos, KP; Patel, MR; Rao, S; Ratti, N; VanVlasselaer, P; Verma, R; Wainberg, ZA; Wong, DJ, 2021)
" Whereas reductions of NTx dosage was more common in elderly patients in comparison 1 (p = 0."	( Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the Ceyhan, GO; Damm, M; Kordes, M; Maggino, L; Moir, J; Rosendahl, J; Schorn, S; Weniger, M, 2020)
" Folinic acid dosage was 2 mg/kg up to 50 mg per day for the entire course of the study."	( Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial. Akhondzadeh, S; Batebi, N; Fakour, Y; Hasanzadeh, A; Moghaddam, HS; Mohammadi, MR, 2021)
" LV is very potent in the prevention of neurotoxicity and administration of LV could protect the normal cells, but the dosage and duration of LV should be according to the MTX concentration."	( How to rescue high-dose methotrexate induced nephrotoxicity and literature review about hemodiafiltration? Ding, N; Gao, L; Gao, LH; Wang, XB; Wang, Z; Yang, YY; Zhang, LP, 2020)
" Dose reduction was defined as any decrease from initial dose; dose delay was any dosing delay >3 days from target date."	( Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. Bekaii-Saab, T; Belanger, B; Blanc, JF; Chen, LT; de Jong, FA; Macarulla, T; Mirakhur, B; Siveke, JT, 2021)
" Further optimization in terms of dosing and timing will enhance clinical potential of this combination strategy for patients."	( Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Guo, J; Huang, L; Liu, Y; Sun, D; Yu, Z; Zou, Y, 2021)
" The anamnesis revealed that he had been taken the prescribed dosage of MTX daily, instead of weekly."	( Bowel perforation due to methotrexate therapeutic error: an insidious adverse reaction. Cirronis, M; Locatelli, CA; Novara, E; Perlini, S; Persiano, T, 2021)
" Further approaches taken to improve the efficacy of 5-FU chemotherapy regimens have focused on optimising the route and dosing schedules and regulating folate metabolism."	( Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. de Gramont, A; Glimelius, B; Marshall, J; Stintzing, S; Yoshino, T, 2021)
" The optimal dosage and duration of FA rescue remain controversial."	( Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort. Aarnivala, H; Banerjee, J; Harila-Saari, A; Niinimäki, R; Pokka, T; Vepsäläinen, K, 2022)
" Additionally, universal dosing and timing guidelines are lacking."	( Role of folinic acid in methotrexate-based prophylaxis of graft-versus-host disease following hematopoietic stem cell transplantation. AlJohani, NI, 2021)
"FOLFIRINOX and FOLFOXIRI are combination chemotherapy treatments that incorporate the same drug cocktail (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) but exploit an altered dosing regimen when used in the management of pancreatic and colorectal cancer, respectively."	( A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction. Callan, B; Callan, JF; Gao, J; Griffith, DM; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M, 2021)
" Metabolic activity, citrulline levels and cytokine/chemokine production were measured to determine the optimal dosage and incubation time."	( Development of a self-limiting model of methotrexate-induced mucositis reinforces butyrate as a potential therapy. da Silva Ferreira, AR; Garssen, J; Harmsen, HJM; Harthoorn, LF; Hartog, A; Ten Klooster, JP; Tissing, WJE; van Bergenhenegouwen, J; van der Aa, SAJ; Wardill, HR; Wehkamp, T, 2021)
" While the recommended dosing schedule for the triplet chemotherapy regimen with 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) in combination with bevacizumab is well established, the optimal dosing of FOLFOXIRI in combination with anti-EGFR agents is unknown."	( Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A, 2022)
"To describe the management and outcome of a dog following a 10-fold dosing error of vincristine."	( Successful management and recovery of a dog with immune-mediated thrombocytopenia following vincristine overdose. Blong, AE; Poirier, M; Walton, RAL, 2022)
" However, with the emergence of conditions where folate metabolism and transport are disrupted, such as folate receptor alpha autoantibody (FRαAb)-induced folate deficiency, it is critical to find a folate form that is effective and safe for pharmacologic dosing for prolonged periods."	( Absorption and Tissue Distribution of Folate Forms in Rats: Indications for Specific Folate Form Supplementation during Pregnancy. Arning, E; Bobrowski-Khoury, N; Bottiglieri, T; Quadros, EV; Sequeira, JM, 2022)
"High-dose methotrexate (HDMTX) is active against various malignancies; it possesses serious toxicities and is associated with patient characteristics, dosage regimens, comedications, and physiological status."	( Leucovorin (folinic acid) rescue for high-dose methotrexate: A review. Jiang, R; Mei, S; Zhao, Z, 2022)
"Original FOLFIRINOX (oFFX) is more toxic than other regimens for patients with metastatic pancreatic cancer (mPC); therefore, a modified FFX (mFFX) regimen with a reduced dosage has been used in Japanese clinical practice."	( Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Tsuruta, N; Ueda, Y; Ureshino, N, 2023)
" Treatment was started with 30 mg of prednisolone, and the dosage was gradually decreased."	( [A Case of Unilateral Interstitial Lung Disease in a Patient Treated with Oxaliplatin, 5-Fluorouracil, and Leucovorin]. Aisaki, K; Aoki, K; Doumoto, Y; Funatsu, K; Hosaka, M; Kimura, T; Kobori, S; Minoshima, K; Ushiku, H; Wakabayashi, M; Yoshida, H, 2022)
" Logistic regression analysis explored the relationship between BSA or weight adjusted MTX dosing and: (i) CR to first-line chemotherapy; (ii) incidence of disease relapse."	( Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia. Cushen, BF; Hancock, BW; Hills, A; Kandiah, K; Palmer, JE; Parker, VL; Singh, K; Tidy, JA; Winter, MC, 2023)
"In LR-GTN patients, BSA and weight adjusted MTX-FA dosing did not influence CR to first-line chemotherapy or the incidence of disease relapse."	( Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia. Cushen, BF; Hancock, BW; Hills, A; Kandiah, K; Palmer, JE; Parker, VL; Singh, K; Tidy, JA; Winter, MC, 2023)
"In the treatment of LR-GTN, dose individualisation using BSA or weight is not required, and fixed dosing continues to be preferred as the UK standard."	( Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia. Cushen, BF; Hancock, BW; Hills, A; Kandiah, K; Palmer, JE; Parker, VL; Singh, K; Tidy, JA; Winter, MC, 2023)
" Pharmacokinetic parameters (maximum plasma concentration, time to maximum concentration, area under the plasma concentration-time curve over the dosing interval, area under the plasma concentration-time curve from time 0 to infinity, terminal elimination half-life, and terminal rate constant) of 3 preparations were calculated."	( Three-Period Bioequivalence Study of Sodium Levofolinate Injection With Calcium Levofolinate for Injection and Sodium Folinate for Injection in Healthy Chinese Subjects. Chen, X; Huang, Y; Jia, Y; Liu, G; Liu, R; Qiu, B; Shen, J; Wang, C, 2023)
" Pharmacokinetic-guided (PKG) dosing has demonstrated beneficial effects in other tumors, but scarce data is available in pancreatic cancer."	( Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma. Aldaz, A; Arbea, L; Chopitea, A; Martí-Cruchaga, P; Pardo, F; Ponz-Sarvise, M; Rodríguez-Rodríguez, J; Rotellar, F; Sala-Elarre, P; Subtil, JC; Urrizola, A; Vilalta-Lacarra, A; Zozaya, G, 2023)
" 5-Fluorouracil (5-FU) dosage was adjusted throughout neoadjuvant treatment according to pharmacokinetic parameters and Irinotecan (CPT-11) pharmacokinetic variables were retrospectively estimated."	( Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma. Aldaz, A; Arbea, L; Chopitea, A; Martí-Cruchaga, P; Pardo, F; Ponz-Sarvise, M; Rodríguez-Rodríguez, J; Rotellar, F; Sala-Elarre, P; Subtil, JC; Urrizola, A; Vilalta-Lacarra, A; Zozaya, G, 2023)

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
5-formyltetrahydrofolic acid	A formyltetrahydrofolic acid in which the formyl group is located at position 5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Folate metabolism ( Folate metabolism )	20	39
formylTHF biosynthesis II	0	27
Folate metabolism	1	56
Biochemical pathways: part I	0	466

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1665 (16.20)	18.7374
1990's	1900 (18.49)	18.2507
2000's	2598 (25.28)	29.6817
2010's	3095 (30.11)	24.3611
2020's	1020 (9.92)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3,248 (29.56%)	5.53%
Reviews	1,002 (9.12%)	6.00%
Case Studies	1,661 (15.12%)	4.05%
Observational	90 (0.82%)	0.25%
Other	4,987 (45.39%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (705)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma[NCT00041132]	Phase 2	56 participants (Actual)	Interventional	2002-09-30	Completed
Randomized Phase II Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer[NCT01283204]	Phase 2	180 participants (Actual)	Interventional	2010-03-09	Completed
A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL)[NCT00262925]	Phase 2	12 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to slow accrual)
A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer[NCT01308086]	Phase 3	2,000 participants (Actual)	Interventional	2010-10-31	Active, not recruiting
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer[NCT05836584]	Phase 2	240 participants (Anticipated)	Interventional	2024-06-08	Recruiting
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair[NCT02912559]	Phase 3	700 participants (Anticipated)	Interventional	2017-10-16	Active, not recruiting
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer[NCT02890355]	Phase 2	123 participants (Actual)	Interventional	2016-09-01	Active, not recruiting
Efficacy and Safety of Alternating Systemic and Hepatic Artery Infusion Therapy Versus Systemic Chemotherapy Alone As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer: A Randomized, Parallel-Group, Open-Labelled, Active-Contro[NCT02529774]	Phase 2/Phase 3	432 participants (Anticipated)	Interventional	2015-09-30	Not yet recruiting
A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer[NCT04761614]	Phase 1	13 participants (Actual)	Interventional	2021-04-02	Active, not recruiting
A Randomized Phase II Study of PEP02 or Irinotecan in Combination With Leucovorin and 5-Fluorouracil in Second Line Therapy of Metastatic Colorectal Cancer[NCT01375816]	Phase 2	55 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to efficacy interim analysis as per protocol)
ESSAI DE PHASE III RANDOMISE EVALUANT LE FOLFOX AVEC OU SANS DOCETAXEL (TFOX) EN 1ère LIGNE DE CHIMIOTHERAPIE DES ADENOCARCINOMES OESO-GASTRIQUES LOCALEMENT AVANCES OU METASTATIQUES[NCT03006432]	Phase 3	507 participants (Actual)	Interventional	2016-12-19	Active, not recruiting
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status[NCT01835041]	Phase 1	21 participants (Actual)	Interventional	2013-04-30	Completed
PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma[NCT02366819]	Phase 4	36 participants (Anticipated)	Interventional	2014-12-11	Recruiting
Phase I Trial of Radioimmunotherapy (Y-90 M5A) in Combination With FOLFIRI and Bevacizumab Chemotherapy for Metastatic Colorectal Carcinoma[NCT01205022]	Phase 1	3 participants (Actual)	Interventional	2011-04-30	Completed
Phase II Clinical Trial to Evaluate the Efficacy of Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal Cancer Who Have Received FOLFOX + Panitumumab in First-line[NCT03751176]	Phase 2	31 participants (Actual)	Interventional	2018-11-08	Active, not recruiting
Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)[NCT03518112]	Phase 2	6 participants (Actual)	Interventional	2018-04-18	Terminated(stopped due to Due to Competing Studies)
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis[NCT00488605]	Phase 3	0 participants (Actual)	Interventional	2023-08-01	Withdrawn(stopped due to This is a duplicate record and the sponsor has registered the study.)
A Stratified Phase II Study of Neoadjuvant Chemotherapy Given Before SCPRT as Treatment for Patients With MRI-Staged Operable Rectal Cancer at High Risk of Metastatic Relapse[NCT01263171]	Phase 2	60 participants (Actual)	Interventional	2012-04-30	Completed
Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroeso[NCT04662710]	Phase 3	890 participants (Anticipated)	Interventional	2020-12-30	Active, not recruiting
Trial Evaluating the Efficacy and Tolerance of Perioperative Chemotherapy With 5FU-Cisplatin-Cetuximab in Adenocarcinomas of the Stomach and Gastroesophageal Junction. Phase II Single Arm, Multicenter.[NCT01360086]	Phase 2	65 participants (Actual)	Interventional	2011-06-30	Completed
S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma: a Multi-center, Open-labeled, Randomized Controlled Trial[NCT01364376]		583 participants (Actual)	Interventional	2011-06-30	Completed
Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receivi[NCT01442649]	Phase 2	133 participants (Actual)	Interventional	2010-12-31	Completed
Phase 2 Study of Hepatic Arterial Infusion With Oxaliplatin, Folinic Acid and 5 Fluorouracil Alone or in Combination With Intravenous Chemotherapy in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Colorectal Cancer[NCT02345746]	Phase 2	0 participants (Actual)	Interventional	2012-12-31	Withdrawn(stopped due to patient population)
A Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI + Panitumumab as First-line Treatment in Elderly Patients With RAS/BRAF Wild-type Unresectable Metastatic Colorectal Cancer and Good Performance Status[NCT03142516]	Phase 2	20 participants (Actual)	Interventional	2017-10-31	Completed
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or Stage IIIC Colorectal Cancer: A Randomized Controlled Clinical Research[NCT05200299]	Phase 2	100 participants (Anticipated)	Interventional	2022-02-01	Recruiting
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer[NCT03941093]	Phase 3	284 participants (Actual)	Interventional	2019-05-10	Active, not recruiting
Timing of Rectal Cancer Response to Chemoradiation[NCT00335816]	Phase 2	248 participants (Anticipated)	Interventional	2008-08-31	Active, not recruiting
Avelumab Added to FOLFIRI Plus Cetuximab Followed by Avelumab Maintenance in Patients With Previously Untreated RAS Wild-type Colorectal Cancer. The Phase II FIRE-6 Study[NCT05217069]	Phase 2	57 participants (Actual)	Interventional	2019-09-27	Active, not recruiting
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse[NCT04546399]	Phase 2	550 participants (Anticipated)	Interventional	2020-12-04	Suspended(stopped due to Other - FDA Partial Clinical Hold)
Randomised, Multicentre, Phase II Pilot Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Populat[NCT03279289]	Phase 2	170 participants (Actual)	Interventional	2017-10-25	Completed
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer[NCT01333033]	Phase 2	257 participants (Actual)	Interventional	2011-07-31	Completed
An Open Randomized Single Site Pharmacokinetic and Pharmacodynamic Study, of Calciumfolinat 60 mg/m², 200 mg/m² or 500 mg/ m² in Blood, Tumor and Adjacent Mucosa From Patients With Colon Cancer[NCT02959541]		48 participants (Actual)	Interventional	2016-09-30	Active, not recruiting
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies[NCT01383343]	Phase 1	17 participants (Actual)	Interventional	2011-08-31	Completed
A Randomized Phase II Study of Comparing S-1/Leucovorin With sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer[NCT01193452]	Phase 2	100 participants (Anticipated)	Interventional	2010-08-31	Recruiting
A Phase II Clinical Trial of High Dose Vitamin D3 Supplementation in Combination With FOLFOX + Bevacizumab in the 1st Line Treatment of Metastatic Colorectal Cancer[NCT01198548]	Phase 2	10 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Lack of funding)
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma [NCT00096278]	Phase 3	2,710 participants (Actual)	Interventional	2004-09-15	Completed
Intensive Chemotherapy And Immunotherapy In Patients With Newly Diagnosed Primary CNS Lymphoma[NCT00098774]	Phase 2	47 participants (Actual)	Interventional	2004-10-31	Completed
Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months)[NCT00096135]		168 participants (Actual)	Interventional	2004-11-30	Completed
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274]	Phase 3	3,397 participants (Actual)	Interventional	2004-02-29	Completed
A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and[NCT02037048]	Phase 2	63 participants (Anticipated)	Interventional	2014-02-10	Active, not recruiting
Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients With Metastatic Colorectal Cancer[NCT00098787]	Phase 2	247 participants (Actual)	Interventional	2005-09-08	Completed
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer[NCT00059930]	Phase 1	38 participants (Actual)	Interventional	2003-01-31	Active, not recruiting
A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Plac[NCT00399035]	Phase 3	1,254 participants (Actual)	Interventional	2006-11-30	Completed
A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors[NCT02319018]	Phase 1	14 participants (Actual)	Interventional	2015-08-27	Completed
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)[NCT00792948]	Phase 2	97 participants (Actual)	Interventional	2009-09-01	Active, not recruiting
Randomized Phase 2 Study Comparing Second Look Laparoscopy to Standard Follow up in Patients With no Radiologic Evidence of Disease at 6 Months After Complete Resection of Colorectal Mucinous Carcinoma[NCT01628211]	Phase 2	140 participants (Anticipated)	Interventional	2012-04-30	Recruiting
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled,[NCT03192644]	Phase 3	162 participants (Anticipated)	Interventional	2017-07-01	Recruiting
Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced Hepatocellular Carcinoma[NCT02436044]		0 participants	Expanded Access		Approved for marketing
A Multi-center Randomized Controlled Trial: Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer[NCT02402972]	Phase 3	700 participants (Anticipated)	Interventional	2015-02-28	Recruiting
A Phase IB Study FOLFIRINOX and NIS793 in Patients With Pancreatic Cancer[NCT05417386]	Phase 1	50 participants (Anticipated)	Interventional	2022-08-09	Recruiting
Comparative Analysis of Immune Profile Following Neoadjuvant Chemotherapy in Colorectal Liver Metastases (CRLM): A Prospective Pilot Clinical Trial[NCT03698461]	Phase 2	20 participants (Actual)	Interventional	2019-05-15	Active, not recruiting
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG[NCT01256398]	Phase 2	66 participants (Actual)	Interventional	2010-12-14	Completed
A Randomized Controlled Study of the Efficacy of Hepatic Arterial Perfusion Chemotherapy Concurrently Compared to Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable Intermediate and Advanced HCC[NCT06041477]	Phase 3	540 participants (Anticipated)	Interventional	2023-09-30	Recruiting
Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab[NCT05319639]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2023-02-16	Recruiting
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not [NCT04456699]	Phase 3	335 participants (Actual)	Interventional	2020-08-19	Completed
Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism[NCT04060030]	Phase 2	80 participants (Anticipated)	Interventional	2020-10-08	Recruiting
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin[NCT03388190]	Phase 2	80 participants (Actual)	Interventional	2018-05-29	Active, not recruiting
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas[NCT03504423]	Phase 3	528 participants (Actual)	Interventional	2018-11-09	Completed
To Observe the Pathological Remission Rate and Safety of FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer With a Single-arm, Open, Prospective Phase II Exploratory Clinical Study[NCT05018182]	Phase 2	69 participants (Anticipated)	Interventional	2021-08-02	Recruiting
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Canc[NCT05008809]	Phase 3	507 participants (Anticipated)	Interventional	2021-12-06	Recruiting
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia[NCT02723994]	Phase 2	171 participants (Actual)	Interventional	2016-09-30	Active, not recruiting
A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver[NCT02063529]	Phase 2	101 participants (Actual)	Interventional	2014-02-28	Completed
Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer[NCT02235324]	Phase 2	0 participants (Actual)	Interventional	2015-03-31	Withdrawn(stopped due to Lack of funding)
Short-course Radiotherapy Versus Chemoradiotherapy, Followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients[NCT04246684]	Phase 3	702 participants (Anticipated)	Interventional	2020-10-15	Active, not recruiting
A Phase II Randomized Study of SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer[NCT03443492]	Phase 2	130 participants (Anticipated)	Interventional	2018-03-26	Enrolling by invitation
An Open-label, Multicenter, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.[NCT03127124]	Phase 1/Phase 2	64 participants (Anticipated)	Interventional	2018-02-27	Suspended(stopped due to IRB Recommendation)
Phase II Randomized Controlled Trial of FOLFOXIRI Compared to FOLFOX in First Line Treatment of Chemo-naive Metastatic Colorectal Cancer[NCT02128425]	Phase 2	162 participants (Anticipated)	Interventional	2014-04-30	Recruiting
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT01399684]	Phase 2	127 participants (Actual)	Interventional	2011-11-30	Completed
A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051), and Transplantation for Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG[NCT00039377]	Phase 2	58 participants (Actual)	Interventional	2002-04-30	Completed
Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer[NCT00154102]	Phase 3	1,221 participants (Actual)	Interventional	2004-05-31	Completed
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.[NCT05945823]	Phase 2	26 participants (Anticipated)	Interventional	2023-07-13	Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Nivolumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G[NCT06093425]	Phase 3	950 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)[NCT02112916]	Phase 3	847 participants (Actual)	Interventional	2014-10-04	Active, not recruiting
Orzel (UFT+Leucovorin) as First-Line Therapy for Metastatic Breast Cancer[NCT00005608]	Phase 2	0 participants	Interventional	2000-02-29	Terminated(stopped due to Drug was pulled from the market.)
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones[NCT03007147]	Phase 3	475 participants (Anticipated)	Interventional	2017-08-08	Recruiting
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)[NCT02981628]	Phase 2	80 participants (Anticipated)	Interventional	2017-06-19	Active, not recruiting
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)[NCT02101853]	Phase 3	669 participants (Actual)	Interventional	2014-12-17	Active, not recruiting
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma[NCT00408005]	Phase 3	1,895 participants (Actual)	Interventional	2007-01-22	Active, not recruiting
Phase I Clinical Trial With LBH589 and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU Based Chemotherapy[NCT01238965]	Phase 1	7 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Adverse Events)
High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)[NCT00075725]	Phase 3	3,154 participants (Actual)	Interventional	2003-12-29	Completed
[NCT01160419]	Phase 2	49 participants (Anticipated)	Interventional	2009-12-31	Active, not recruiting
Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study[NCT01230983]	Phase 3	573 participants (Actual)	Interventional	1996-06-30	Completed
A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin[NCT03464968]	Phase 2	120 participants (Actual)	Interventional	2015-07-29	Completed
SAMSUNG MEDICAL CENTER[NCT03110510]	Phase 2	0 participants (Actual)	Interventional	2019-09-06	Withdrawn(stopped due to institution problem)
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab[NCT01164215]	Phase 1	76 participants (Actual)	Interventional	2010-02-28	Completed
A Single Centre, Open-label, Parallel-group, Single Oral Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pyrimethamine in Healthy Japanese and Caucasian Male Subjects[NCT03258762]	Phase 1	14 participants (Actual)	Interventional	2017-09-25	Completed
Adjuvant Modified FOLFOXIRI Versus mFOLFOX6 in Patients With Postoperative MRD Positive Stage II-III Colorectal Cancer: A Multicenter, Open Lable Randomized Phase 3 Study (AFFORD)[NCT05427669]	Phase 3	340 participants (Anticipated)	Interventional	2022-10-09	Not yet recruiting
A Randomized Phase II Trial of Capecitabine and Temozolomide (CAPTEM) or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of Predictive Role of Positron Emission Tomography (PET) Imaging and Biological Markers[NCT03387592]	Phase 2	112 participants (Anticipated)	Interventional	2017-03-06	Recruiting
Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma[NCT01167725]	Phase 3	340 participants (Anticipated)	Interventional	2010-08-31	Active, not recruiting
Randomized, Double Blind Phase II Study of FOLFOX/Bevacizumab Combined With MK-0646 Versus FOLFOX/Bevacizumab Combined With Placebo in First-Line Treatment of Metastatic Colorectal Cancer[NCT01175291]	Phase 2	0 participants (Actual)	Interventional	2010-09-30	Withdrawn(stopped due to treatment deemed ineffective so accrual was closed)
A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy[NCT01205711]	Phase 2	111 participants (Actual)	Interventional	2010-04-30	Completed
Optimizing Ultrasound Enhanced Delivery of Therapeutics[NCT04821284]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2021-12-06	Recruiting
A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic Cancer[NCT04141995]	Phase 2	20 participants (Anticipated)	Interventional	2021-02-12	Recruiting
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma[NCT03611556]	Phase 1/Phase 2	213 participants (Actual)	Interventional	2018-06-21	Completed
A Phase II Trial of Radioimmunotherapy (Y-90 M5A) Following Hepatic Resection and FOLFIRI or FOLFOX Chemotherapy [+/-BEVACIZUMAB], or Xelox for Metastatic Colorectal Carcinoma to the Liver[NCT01320683]	Phase 2	1 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Slow accrual.)
Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer[NCT01298570]	Phase 2	181 participants (Actual)	Interventional	2011-04-07	Completed
Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A11/UGT1A11 or UGT1A11/UGT1A11/UGT1A1*28: Prospective, Phase II, Multicenter Study[NCT00628810]	Phase 2	86 participants (Actual)	Interventional	2007-01-31	Completed
[NCT02870036]	Phase 1	243 participants (Anticipated)	Interventional	2016-10-31	Recruiting
A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus [NCT00778102]	Phase 2	80 participants (Actual)	Interventional	2008-10-31	Completed
A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER[NCT00719797]	Phase 3	509 participants (Actual)	Interventional	2008-07-31	Completed
Phase I Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients With Primary Central Nervous Lymphoma (PCNSL)[NCT00727831]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2008-07-31	Completed
Pilot Study of FOLFOX6 Plus Sir-Spheres® Microspheres (Chemo-radiotherapy) in Combination With Bevacizumab (Avastin) as a First Line Treatment in Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma[NCT00735241]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2008-07-31	Withdrawn(stopped due to Withdrawn by the study sponsor.)
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy[NCT00967616]	Phase 2	100 participants (Actual)	Interventional	2009-09-30	Completed
Feasibility and Dose Discovery Analysis of Zoledronic Acid With Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma[NCT00742924]	Phase 1	24 participants (Actual)	Interventional	2008-08-31	Completed
A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/2; Protocol No. P04722)[NCT00954512]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2009-09-25	Terminated(stopped due to This study was terminated for business reasons.)
A Multi Center Phase II Study of 5-Fluorouracil/ Folinic Acid Plus Gemcitabine in Patients With Advanced Pancreatic Cancer.[NCT00919282]	Phase 2	78 participants (Actual)	Interventional	1997-09-30	Completed
A Randomized Phase II Study of Two Dose-Levels of Vorinostat in Combination With 5-FU and Leucovorin in Patients With Refractory Metastatic Colorectal Cancer[NCT00942266]	Phase 2	58 participants (Actual)	Interventional	2009-07-31	Completed
A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer[NCT00668863]	Phase 2	71 participants (Actual)	Interventional	2008-05-31	Completed
Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer[NCT00769405]	Phase 3	264 participants (Actual)	Interventional	2008-02-29	Completed
Phase II Study of Oxaliplatin in Combination With 5-fluorouracil (5-FU) and Folinic Acid (FA) in Patients Who Have Failed First-line Treatment for Locally Advanced or Metastatic Cervical Cancer.[NCT00782041]	Phase 2	11 participants (Actual)	Interventional	2003-01-31	Terminated(stopped due to protocol violation)
Maintenance and Reinduction Chemotherapy With Avastin in Metastatic Colon Cancer: The MARTHA (SICOG 0803) Trial[NCT00797485]	Phase 3	672 participants (Anticipated)	Interventional	2008-07-31	Recruiting
"PsyCARE Trial - Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis : A Prospective Randomised Controlled Trial "[NCT05796401]	Phase 3	500 participants (Anticipated)	Interventional	2023-06-15	Not yet recruiting
Randomized Phase II Study Assessing the Efficacy and Safety of 2 Therapeutic Strategies Combining Bevacizumab With Chemotherapy: De-escalation Versus Escalation in Patients With Non-pretreated Unresectable Metastatic Colorectal Cancer[NCT02842580]	Phase 2	20 participants (Actual)	Interventional	2016-09-30	Terminated(stopped due to Inclusion rythm too slow.)
A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors[NCT00957905]	Phase 2	36 participants (Actual)	Interventional	2009-06-30	Completed
Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer[NCT02785146]	Phase 3	230 participants (Anticipated)	Interventional	2016-06-30	Recruiting
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab[NCT04164069]	Phase 1	9 participants (Anticipated)	Interventional	2020-09-02	Active, not recruiting
A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer[NCT00343408]	Phase 1	31 participants (Actual)	Interventional	2005-11-29	Completed
A Study to Characterize and Evaluate Biomarkers of Chemotherapy in Patients With Metastatic Colorectal Cancer In The First-line Setting[NCT03532711]		264 participants (Actual)	Observational	2012-01-01	Completed
A Phase II Study Assessing Tumor Blood Flow as Measured by Dynamic Contrast Enhanced MRI in Patients With Metastatic Colorectal Cancer Receiving FOLFOX Alone Versus Patients Randomized to Receive FOLFOX Plus Bevacizumab at 5mg/kg or 10mg/kg.[NCT00602329]	Phase 2	5 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Due to Poor accrual)
PFL-Alpha Chemotherapy Followed by Surgery or FHX for Early Stage Esophageal Cancer - A Pilot Project[NCT00004897]	Phase 2	0 participants	Interventional	1999-10-31	Terminated(stopped due to Institutional Review Board requested termination - all patients deceased and no new accrual.)
Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma[NCT00004231]	Phase 2	0 participants	Interventional	1999-10-31	Completed
A Pilot and Feasibility Study of PD-1 Blockade With Nivolumab in Combination With Chemotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma[NCT03970252]	Early Phase 1	36 participants (Anticipated)	Interventional	2019-07-24	Recruiting
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia[NCT02730546]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2016-06-24	Active, not recruiting
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation[NCT04595864]	Phase 3	40 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab[NCT03300609]	Phase 3	4 participants (Actual)	Interventional	2018-02-27	Terminated(stopped due to Insufficient Accrual)
Randomised Study to Investigate FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab as First-line Treatment of BRAF-mutated Metastatic Colorectal Cancer[NCT04034459]	Phase 2	109 participants (Actual)	Interventional	2016-11-25	Active, not recruiting
Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internist[NCT02578368]	Phase 3	271 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer[NCT02047474]	Phase 2	46 participants (Actual)	Interventional	2014-03-25	Active, not recruiting
Role of Folinic Acid in Improving the Adaptive Skills and Language Impairment in Children With Autism Spectrum Disorder[NCT05013164]	Phase 2	44 participants (Actual)	Interventional	2020-10-01	Completed
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer: a Randomized Phase II Trial[NCT03280407]	Phase 2	124 participants (Anticipated)	Interventional	2017-03-01	Recruiting
Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer[NCT02128243]	Phase 2	242 participants (Actual)	Interventional	2014-09-30	Completed
Single-arm Phase II Study of Maintenance Therapy With Aflibercept After First-line Treatment With FOLFIRI Plus Aflibercept in Metastatic Colorectal Cancer Patients[NCT02129257]	Phase 2	73 participants (Actual)	Interventional	2014-05-26	Completed
The Purpose of This Study is to Evaluate the Effectiveness of MB-6 as Adjuvant Therapy in Reducing Neutropenia When Given Oxaliplatin-based Chemotherapy in Patients With Stage 3 Colorectal Cancer Previously Treated With Surgery.[NCT02135887]		184 participants (Anticipated)	Observational	2013-11-04	Recruiting
A Prospective, Open-lable, Multicenter, Randomized, Controlled Phase II Clinical Trial to Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer[NCT03567629]	Phase 2	130 participants (Anticipated)	Interventional	2018-05-29	Active, not recruiting
A Randomized, Parallel Control Trial to Compare mFOLFOX Versus mFOLFIRI Versus FOLFPTX (a Combination of Paclitaxel, Fluorouracil) as First-line Treatment in Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction[NCT03045770]		150 participants (Anticipated)	Interventional	2017-02-10	Not yet recruiting
A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-[NCT02337946]	Phase 2	164 participants (Actual)	Interventional	2014-10-16	Completed
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium[NCT04060017]	Phase 2	80 participants (Anticipated)	Interventional	2020-09-22	Recruiting
Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder[NCT02839915]	Phase 2	134 participants (Anticipated)	Interventional	2020-08-13	Recruiting
A Phase II Study of Metformin Plus Modified FOLFOX 6 in Patients With Metastatic Pancreatic Cancer[NCT01666730]	Phase 2	50 participants (Actual)	Interventional	2013-02-21	Completed
Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)[NCT00103285]	Phase 3	5,377 participants (Actual)	Interventional	2005-04-11	Completed
An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer[NCT00707889]	Phase 2	159 participants (Actual)	Interventional	2008-10-31	Completed
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver[NCT00019760]	Phase 2	0 participants	Interventional	1999-04-30	Completed
The Effect of Oral Folinic Acid Rescue Therapy on Pemetrexed Induced Neutropenia: A Randomized Open-label Trial[NCT06010277]	Phase 4	50 participants (Anticipated)	Interventional	2023-02-06	Recruiting
A Phase I/II Clinical Trial of FOLFOX Bevacizumab Plus Botensilimab and Balstilimab (3B-FOLFOX) in Patients With MSS Metastatic Colorectal Cancer[NCT05627635]	Phase 1/Phase 2	86 participants (Anticipated)	Interventional	2023-05-03	Recruiting
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)[NCT04248452]	Phase 3	314 participants (Anticipated)	Interventional	2020-05-26	Recruiting
A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470]	Phase 3	1,226 participants (Actual)	Interventional	2007-11-30	Completed
Folate Absorption Across the Large Intestine, Study #2: Capsule Study[NCT00941174]	Phase 1	9 participants (Actual)	Interventional	2008-09-30	Completed
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)[NCT00098839]	Phase 1/Phase 2	134 participants (Actual)	Interventional	2005-02-28	Completed
A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk)[NCT00974792]	Phase 2	150 participants (Anticipated)	Interventional	2006-01-31	Recruiting
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB T[NCT00057811]	Phase 2	97 participants (Actual)	Interventional	2004-06-30	Completed
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)[NCT00061945]	Phase 1/Phase 2	302 participants (Actual)	Interventional	2003-06-30	Completed
A Pilot Study of Neoadjuvant Chemotherapy With Selective Use of Radiation for Locally Advanced Rectal Cancer[NCT00462501]		35 participants (Actual)	Interventional	2007-03-31	Completed
Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT00449163]	Phase 2	25 participants (Actual)	Interventional	2006-03-01	Terminated(stopped due to Study terminated by University of Miami Institutional Review Board)
Multi-Centre Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone, As Adjuvant Treatment After Resection Of Liver Metastases For Colorectal Cancer.[NCT00143403]	Phase 3	321 participants (Actual)	Interventional	2001-12-31	Completed
Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma[NCT00004228]	Phase 3	393 participants (Actual)	Interventional	2000-06-30	Completed
A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer[NCT00003298]	Phase 2	39 participants (Actual)	Interventional	1999-06-01	Completed
Hepatic Resection Followed by Concurrent Adjuvant Portal Vein Infusion of Fluorodeoxyuridine and Systemic 5-Fluorouracil and Folinic Acid for Metastatic Colorectal Carcinoma[NCT00002842]	Phase 2	49 participants (Actual)	Interventional	1994-09-30	Completed
Characterization and Research of Predictive Markers of Neurotoxicity During Treatment With Oxaliplatin in Colorectal Carcinoma: a Genetic and Proteomic Approach. Phase II Multicenter Study[NCT00884767]	Phase 2	206 participants (Anticipated)	Interventional	2007-09-30	Recruiting
Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer[NCT00905047]	Phase 3	89 participants (Actual)	Interventional	2005-09-30	Completed
FIRE-5 -Study: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation[NCT04034173]	Phase 2	120 participants (Anticipated)	Interventional	2019-08-01	Not yet recruiting
A Phase II Study Of Systemic High-Dose Methotrexate For The Treatment Of Glioblastoma Multiforme In Newly Diagnosed Patients With Measurable Disease[NCT00082797]	Phase 2	36 participants (Anticipated)	Interventional	2005-07-12	Completed
A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer[NCT00004860]	Phase 2	0 participants	Interventional	2000-10-09	Completed
A Randomized Investigation of Side Effects to FOLFOXIRI in Combination With Tocotrienol or Placebo as First Line Treatment of Metastatic Colorectal Cancer[NCT02705300]	Phase 2	70 participants (Actual)	Interventional	2016-05-06	Active, not recruiting
NEO-adjuvant Chemo-Immunotherapy in Pancreatic Cancer[NCT06094140]	Phase 2	20 participants (Anticipated)	Interventional	2022-05-20	Recruiting
FLOX + Cetuximab (Erbitux®): First Line Treatment for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor, A Phase II Study[NCT00660582]	Phase 2	152 participants (Actual)	Interventional	2008-04-30	Completed
Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression[NCT00660894]	Phase 3	1,535 participants (Actual)	Interventional	2008-04-30	Completed
A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)[NCT00873093]	Phase 2	148 participants (Actual)	Interventional	2009-03-31	Completed
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity[NCT02779283]	Phase 1	7 participants (Actual)	Interventional	2016-01-13	Completed
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies[NCT02333188]	Phase 1	50 participants (Actual)	Interventional	2014-12-31	Completed
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma[NCT04949256]	Phase 3	862 participants (Anticipated)	Interventional	2021-07-28	Recruiting
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom[NCT03914625]	Phase 3	6,720 participants (Anticipated)	Interventional	2019-07-03	Recruiting
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan-1 Levels[NCT03117972]	Phase 2	177 participants (Anticipated)	Interventional	2017-08-04	Active, not recruiting
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study[NCT00515216]	Phase 2	26 participants (Actual)	Interventional	2007-08-31	Completed
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study[NCT00514020]	Phase 2	33 participants (Actual)	Interventional	2007-08-31	Completed
A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With a[NCT00500292]	Phase 2	109 participants (Actual)	Interventional	2007-03-31	Completed
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation[NCT00303628]	Phase 3	355 participants (Actual)	Interventional	2006-05-11	Terminated(stopped due to The study was terminated before reaching its accrual goal due to slow accrual.)
Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer[NCT00467142]	Phase 2	62 participants (Actual)	Interventional	2007-01-23	Completed
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)[NCT04952753]	Phase 2	205 participants (Actual)	Interventional	2021-11-15	Active, not recruiting
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Phase III, Randomized, Controlled Study Comparing the Efficacy and Safety of mFOLFOX6 + Bevacizumab Therapy vs. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Wi[NCT02394834]		757 participants (Actual)	Observational	2015-05-29	Active, not recruiting
A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma[NCT01897454]	Phase 2	23 participants (Actual)	Interventional	2012-01-27	Terminated(stopped due to Study was terminated due to slower than anticipated accrual)
A Open Label, Non Randomized, Phase Two Trial in Metastatic Colorectal Cancer (mCRC) With the Combination of m FOLFIRI Plus Aflibercept as First Line Treatment: MINOAS Trial[NCT02624726]	Phase 2	31 participants (Actual)	Interventional	2016-01-31	Active, not recruiting
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab With Either FOLFOX, OPTIMOX or XELOX[NCT00499369]	Phase 3	72 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to Due to inadequate accrual, study was terminated and limited outcome data was reported.)
A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-label Phase I Part to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With FOLFOX Followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Ass[NCT00494221]	Phase 1/Phase 2	172 participants (Actual)	Interventional	2007-06-30	Completed
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome[NCT02676323]	Phase 1	19 participants (Actual)	Interventional	2016-05-03	Terminated(stopped due to Slow accrual)
A Randomized Trial Investigating the Role of FOLFOX-4 Regimen Duration (3 Versus 6 Months) and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer[NCT00646607]	Phase 3	3,756 participants (Actual)	Interventional	2007-06-30	Completed
An Open Labeled Phase 2 Study of Gemcitabine in Combination With Cisplatin, 5-FU (24h CI) and Folinic Acid in Patients With Inoperable Esophageal Cancer[NCT00759226]	Phase 2	92 participants (Actual)	Interventional	2002-07-31	Completed
Clinical Phase II Study Evaluating Systemic Chemotherapy in Combination With Cetuximab as Adjuvant Treatment in Patients With Completely Surgically Resected Peritoneal Carcinomatosis of Colorectal Origin[NCT00766142]	Phase 2	18 participants (Actual)	Interventional	2007-05-01	Terminated(stopped due to In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such, eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown down considerably, and the trial was stopped.)
Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer[NCT00851084]	Phase 2	268 participants (Actual)	Interventional	2009-02-28	Completed
Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease[NCT00865709]	Phase 2	198 participants (Actual)	Interventional	2009-03-31	Completed
A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors[NCT02574663]	Phase 1	66 participants (Actual)	Interventional	2015-09-11	Completed
A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile[NCT00737373]	Phase 2	143 participants (Actual)	Interventional	2007-08-31	Completed
A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia[NCT00764907]	Phase 3	4,000 participants (Anticipated)	Interventional	2002-11-30	Recruiting
A Phase I Study of BBI608 Administered With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer[NCT02641873]	Phase 1	4 participants (Actual)	Interventional	2015-12-31	Completed
A Two-arm Phase II Randomised Trial of Intermittent Chemotherapy Plus Continuous Cetuximab and of Intermittent Chemotherapy Plus Intermittent Cetuximab in First Line Treatment of Patients With K-ras-normal (Wild-type) Metastatic Colorectal Cancer[NCT00640081]	Phase 2	169 participants (Actual)	Interventional	2007-07-31	Completed
A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT)[NCT00785421]	Phase 2/Phase 3	312 participants (Actual)	Interventional	2004-04-30	Completed
seconD-line Folfiri/aflIbercept in proSpecTIvely Stratified, Anti-EGFR resistaNt, Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status[NCT04252456]		150 participants (Anticipated)	Interventional	2018-04-23	Recruiting
Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer[NCT01718873]	Phase 3	230 participants (Actual)	Interventional	2012-05-31	Completed
A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients[NCT02573220]	Phase 1	0 participants (Actual)	Interventional	2015-06-30	Withdrawn(stopped due to Study terminated by PI due to inability to accrue.)
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB.[NCT00720512]	Phase 3	184 participants (Actual)	Interventional	2008-06-30	Terminated
Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.[NCT00861094]	Phase 2/Phase 3	266 participants (Actual)	Interventional	2008-03-31	Completed
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal/Gastroesophageal Junction Adenocarcinoma (PHOX)[NCT06078709]	Phase 2	99 participants (Anticipated)	Interventional	2023-11-20	Recruiting
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in Locally Advanced Resectable Rectal Cancer: A Randomized, Non-Comparative Phase II Study[NCT00865189]	Phase 2	91 participants (Actual)	Interventional	2007-10-23	Completed
A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615]	Phase 2	252 participants (Actual)	Interventional	2009-02-28	Completed
Does Folinic Acid Supplementation Decrease Homocysteine Concentrations in Newborns[NCT00877227]	Phase 1	37 participants (Actual)	Interventional	2003-01-31	Completed
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer: A Multicenter, Prospective, Randomized Controlled Cohort Study (FINE Trial)[NCT05954078]	Phase 3	340 participants (Anticipated)	Interventional	2023-07-31	Recruiting
Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma[NCT02293109]	Phase 1	10 participants (Actual)	Interventional	2015-12-17	Completed
A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen[NCT00615056]	Phase 2	171 participants (Actual)	Interventional	2008-03-31	Completed
Phase 3 Study of Adjuvant Chemoradiotherapy of Advanced Resectable Rectal Cancer Comparing Modulation of 5-FU With Folinic Acid or With Interferon-alpha[NCT01060501]	Phase 3	796 participants (Actual)	Interventional	1992-07-31	Completed
Multimodality Management of Head and Neck Cancer: A Phase II Trial of Induction Chemotherapy, Organ Preservation Surgery, and Concurrent Chemoradiotherapy[NCT00544414]	Phase 2	31 participants (Actual)	Interventional	2000-06-07	Active, not recruiting
Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer[NCT00026273]	Phase 3	0 participants	Interventional	2001-01-31	Completed
Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer[NCT00952029]	Phase 2/Phase 3	492 participants (Actual)	Interventional	2010-03-31	Completed
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafe[NCT02928224]	Phase 3	702 participants (Actual)	Interventional	2016-10-13	Completed
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer[NCT00321685]	Phase 2	57 participants (Actual)	Interventional	2006-07-25	Completed
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)[NCT00720109]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2008-07-14	Completed
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)[NCT04233866]	Phase 2	176 participants (Actual)	Interventional	2020-08-26	Active, not recruiting
A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer[NCT01867892]	Phase 2	86 participants (Anticipated)	Interventional	2013-06-30	Enrolling by invitation
A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer[NCT01888978]	Phase 2	19 participants (Actual)	Interventional	2012-12-31	Completed
A Randomized Phase II Trial of Induction Regimen With mFOLFOX6 and Ziv-aflibercept for First-line Therapy of Metastatic Colorectal Cancer Followed by Continuation Regimen With 5-FU/LV Alone or With Ziv-aflibercept Until Disease Progression[NCT01889680]	Phase 2	0 participants (Actual)	Interventional	2014-11-30	Withdrawn
Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan & Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel & MitomycinC), When Used in Combination With Vitamin C, in Patients With Advanced Pancreatic Cancer[NCT01905150]	Phase 2	34 participants (Actual)	Interventional	2014-07-31	Completed
Hypofractionated Radiotherapy Combined With Chemotherapy and Toripalimab for Locally Recurrent Rectal Cancer: a Single-arm, Two-cohort, Phase II Trial (TORCH-R)[NCT05628038]	Phase 2	93 participants (Anticipated)	Interventional	2022-08-18	Recruiting
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esop[NCT02625610]	Phase 3	499 participants (Actual)	Interventional	2015-12-24	Completed
A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma[NCT02022358]	Phase 2	34 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to Recruitment almost complete, has been slow and challenging)
Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence[NCT00005979]	Phase 3	0 participants	Interventional	1998-07-22	Completed
A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies[NCT00005988]	Phase 1	5 participants (Actual)	Interventional	2000-02-29	Completed
Phase II Study Evaluating the Combination of 5-Fluorouracil, Leucovorin, Oxaliplatin, and Herceptin in the Treatment of Patients With Metastatic Colorectal Cancer Who Have Progressed After 5-FU and/or Irinotecan-Containing Therapy[NCT00006015]	Phase 2	26 participants (Actual)	Interventional	2000-05-31	Terminated(stopped due to lack of sufficient accrual)
A Multicenter, Open-Label, Randomized, Three-Arm Study Of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) Or Oxaliplatin Or A Combination Of (5-Fu) LV + Oxaliplatin As Second-Line Treatment Of Metastatic Colorectal Carcinoma[NCT00008281]	Phase 3	0 participants	Interventional	2000-10-31	Active, not recruiting
Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients[NCT00000643]	Phase 2	150 participants	Interventional		Completed
Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii[NCT00000973]	Phase 1	26 participants	Interventional		Completed
FOCUS 3 - A Study to Determine the Feasibility of Molecular Selection of Therapy Using KRAS, BRAF and Topo-1 in Patients With Metastatic or Locally Advanced Colorectal Cancer[NCT00975897]	Phase 2/Phase 3	3,240 participants (Anticipated)	Interventional	2009-07-31	Completed
A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS[NCT00001014]	Phase 3	302 participants	Interventional		Completed
Study Of The Survival Without Degradation To The Quality Of Life During Chemotherapy For Metastatic Breast Cancer In Women[NCT00010075]	Phase 2	0 participants	Interventional	2000-01-31	Active, not recruiting
A Randomized, Multicenter, Phase II Study Of Bolus/Infusion 5-FU/LV (de Gramont Regimen) Versus Oxaliplatin And Bolus/Infusion 5-FU/LV (de Gramont Regimen) As Third-Line Treatment Of Patients With Metastatic Colorectal Carcinoma[NCT00016198]	Phase 2	0 participants	Interventional	2001-05-31	Completed
A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients With Metastatic Colorectal Carcinoma Previously Treated With Irinotecan (CPT-11)[NCT00016978]	Phase 2	40 participants (Actual)	Interventional	2001-04-30	Completed
A Phase II Trial of Neoadjuvant Cisplatin-Fluorouracil-Docetaxel Chemotherapy, Surgery, and Intraperitoneal (IP) Floxuridine (FUdR) Plus Leucovorin in Patients With Locally Advanced Gastric Cancer[NCT00006038]	Phase 2	0 participants	Interventional	2000-02-29	Completed
Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver [NCT00153998]	Phase 2	135 participants (Actual)	Interventional	2004-11-30	Completed
A Phase I, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor.[NCT04689100]	Phase 1	259 participants (Anticipated)	Interventional	2017-04-11	Recruiting
A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Me[NCT00182715]	Phase 3	2,421 participants (Anticipated)	Interventional	2005-03-31	Active, not recruiting
Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers[NCT00537121]	Phase 1	23 participants (Actual)	Interventional	2006-11-30	Completed
Randomized Phase III Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)[NCT00190515]	Phase 3	1,101 participants (Actual)	Interventional	2003-02-28	Completed
A Multicentre Randomised Phase II Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)[NCT01050426]	Phase 2	17 participants (Actual)	Interventional	2009-03-31	Terminated(stopped due to Data from other trials failed to demonstrate meaningful survival advantage)
A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach and Gastroesophageal Junction[NCT00525785]	Phase 2	58 participants (Actual)	Interventional	2004-01-31	Completed
A Phase 3, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Surufatinib Plus Toripalimab Versus FOLFIRI as a Secondline Treatment in Patients With Advanced Neuroendocrine Carcinoma[NCT05015621]	Phase 3	194 participants (Anticipated)	Interventional	2021-09-18	Recruiting
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies[NCT00381680]	Phase 3	275 participants (Actual)	Interventional	2007-03-31	Completed
A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients With Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor[NCT00321828]	Phase 2	90 participants (Actual)	Interventional	2006-03-31	Completed
Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative[NCT00068692]	Phase 3	225 participants (Actual)	Interventional	2003-10-15	Completed
A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment[NCT00457691]	Phase 3	768 participants (Actual)	Interventional	2007-06-30	Completed
Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181]	Phase 3	86 participants (Actual)	Interventional	2003-05-31	Completed
NEoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed (NEEDS Trial)[NCT04460352]	Phase 3	1,020 participants (Anticipated)	Interventional	2020-11-27	Recruiting
Post-Approved Phase III Study of 1-LV/5FU Therapy[NCT00195572]	Phase 3	200 participants (Anticipated)	Interventional	2002-05-31	Completed
A Prospective Study of Short Infusion of Ziv-Aflibercept in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer[NCT01941173]		0 participants (Actual)	Interventional	2014-01-31	Withdrawn(stopped due to Lack of accrual)
A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma[NCT02344810]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2015-03-06	Withdrawn(stopped due to The study did not open to accrual. No start date and no completion dates.)
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors[NCT02720068]	Phase 1	576 participants (Anticipated)	Interventional	2016-05-02	Active, not recruiting
Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma[NCT00335140]	Phase 2	26 participants (Actual)	Interventional	2007-08-23	Terminated(stopped due to slow accrual)
Phase II Study of the Efficacy of Amifostine (Ethyol) in Reducing the Incidence and Severity of Oxaliplatin-Induced Neuropathy in Patients With Colorectal Cancer[NCT00601198]	Phase 2	4 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Funding support withdrawn)
An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status[NCT01228734]	Phase 3	553 participants (Actual)	Interventional	2010-09-09	Completed
A Phase I Clinical Trial of MEK162 in Combination With FOLFOX in Patients With Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy[NCT02041481]	Phase 1	26 participants (Actual)	Interventional	2014-06-30	Completed
A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity[NCT00005860]	Phase 1	0 participants	Interventional	2000-04-30	Completed
Study of Second Look Surgery With or Without Chemotherapy Intraperitoneally, in the Event of Risk of Intraperitoneal Recurrence[NCT00005944]	Phase 2	0 participants	Interventional	1999-07-01	Terminated(stopped due to insuffisient recruitment)
A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All[NCT00005977]	Phase 3	83 participants (Actual)	Interventional	2000-09-30	Completed
Phase III Study of An Optimized LV-5FU-Oxaliplatin Regimen in Metastatic Colorectal Cancer. C99-1.[NCT00006468]	Phase 3	0 participants	Interventional	2000-01-31	Active, not recruiting
Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer[NCT00006786]	Phase 2	0 participants	Interventional	2000-11-30	Completed
Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11[NCT00006103]	Phase 3	400 participants (Actual)	Interventional	2000-07-31	Completed
Randomized Therapeutic Study Comparing Tumor Resection Followed Immediately by Intraperitoneal Chemotherapy and Systemic Chemotherapy VS Systemic Chemotherapy Alone for the Treatment of Colorectal Cancer Metastatic to the Peritoneum[NCT00006112]	Phase 2	0 participants	Interventional	1996-01-31	Active, not recruiting
Alternation of FOLFOX6 (Oxaliplatin - Leucovorin - Fluorouracil) and FOLFIRI (Irinotecan - Leucovorin - Fluorouracil) as Second Line Treatment of Metastatic Colorectal Cancer[NCT00006115]	Phase 2	0 participants	Interventional	1999-04-30	Active, not recruiting
A Phase I Study of PS-341 in Combination With 5-FU/LV in Solid Tumors[NCT00007878]	Phase 1	30 participants (Actual)	Interventional	2000-09-30	Completed
A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS[NCT00000966]	Phase 1	45 participants	Interventional		Completed
Vitamin B12 and Folinic Acid Supplementation in Mitochondrial DNA Deletion Syndromes[NCT06186154]	Phase 1	25 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment of Stage III and High-risk Stage II Resected Colon Cancer Patients With Adjuvant FOLFOXIRI and/or Post-adjuvant Trifluridine/Tipiracil[NCT05062889]	Phase 2	477 participants (Anticipated)	Interventional	2023-05-17	Recruiting
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)[NCT04210115]	Phase 3	700 participants (Anticipated)	Interventional	2020-02-28	Recruiting
Randomized Phase II Trial of Cetuximab/Bevacizumab (CB) as Palliative First-Line Therapy in Patients With Advanced Colorectal Cancer Followed by FOLFOX+CB vs. FOLFOX+B[NCT00571740]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to The study was not activated)
A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer[NCT00192075]	Phase 2	84 participants (Actual)	Interventional	2003-06-30	Completed
Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)[NCT00587873]	Phase 2	18 participants (Actual)	Interventional	1994-03-31	Completed
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies[NCT01643499]	Phase 1	79 participants (Actual)	Interventional	2012-03-26	Completed
Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients.[NCT03721653]	Phase 2	218 participants (Actual)	Interventional	2018-11-30	Completed
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma[NCT01959139]	Phase 1/Phase 2	126 participants (Actual)	Interventional	2014-01-23	Active, not recruiting
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)[NCT01190930]	Phase 3	9,350 participants (Actual)	Interventional	2010-08-09	Active, not recruiting
Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer[NCT02270606]	Phase 1	14 participants (Actual)	Interventional	2014-12-04	Completed
Quadruplet 1st Line Treatment of CAPOXIRI Plus Bevacizumab Versus FOLFOXIRI Plus Bevacizumab for mCRC, Multicenter Randomised Phase II Study (QUATTRO-II)[NCT04097444]	Phase 2	112 participants (Anticipated)	Interventional	2019-10-11	Recruiting
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies[NCT02419495]	Phase 1	221 participants (Actual)	Interventional	2015-06-26	Active, not recruiting
An Open Label, Multicenter, Single Arm, Phase 1/2 Trial of Metronomic 5-fluorouracil in Combination With Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.[NCT02620800]	Phase 1	12 participants (Actual)	Interventional	2016-01-18	Completed
Neoadjuvant mFOLFOXIRI Plus Bevacizumab Versus Induction FOLFOX Followed by Concomitant Chemoradiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer: Multicenter Randomized Phase III Trial[NCT04215731]	Phase 3	500 participants (Anticipated)	Interventional	2020-03-27	Recruiting
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies[NCT05292664]	Phase 1	92 participants (Anticipated)	Interventional	2023-03-29	Recruiting
Phase I Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies[NCT00625092]	Phase 1	17 participants (Actual)	Interventional	2007-10-31	Completed
A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies[NCT00610948]	Phase 1	74 participants (Actual)	Interventional	2008-03-31	Completed
Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission[NCT00002514]	Phase 3	1,929 participants (Actual)	Interventional	1993-05-07	Completed
Evaluation and Comparison of the Efficacy of a New Standard Pre-operative Chemotherapy for Stage II and III Colorectal Cancer According to the FOLFOX4 Regimen With Routine Chemoradiation Therapy[NCT05378919]	Phase 2	250 participants (Anticipated)	Interventional	2015-06-01	Recruiting
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies[NCT00627666]	Phase 2	52 participants (Anticipated)	Interventional	2003-01-31	Completed
Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese Patients With Metastatic Pancreatic Cancer, Which Progressed or Recurred After Prior Gemcitabine-Based Therapy[NCT02697058]	Phase 2	84 participants (Actual)	Interventional	2016-03-30	Completed
A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.[NCT02658214]	Phase 1	32 participants (Actual)	Interventional	2016-04-28	Completed
A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer[NCT00654160]	Phase 1	7 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers[NCT01229111]	Phase 2	14 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Lack of Drug Supply)
Primary Surgery Plus Single Course Methotrexate Versus Primary Methotrexate for Treatment of Gestational Trophoblastic Neoplasms in Low Risk Cases Above 40y: a Randomized Controled Trial[NCT02606539]	Phase 2/Phase 3	20 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Phase II Study Evaluating the Efficacy and Safety of cétuximab Associated With the Protocol FOLFIRINOX (LV5FU Simplified Combined With Irinotecan and Oxaliplatin) in the First Line Treatment in Patients With Metastatic Colorectal Cancer Expressing EGFR or[NCT00556413]	Phase 2	42 participants (Actual)	Interventional	2005-09-30	Completed
Effect of Folic Acid on Homocysteine Levels and Flow-mediated Dilation in HIV and HIV-HCV Coinfected Patients: a Randomized Controlled Trial[NCT02810275]	Phase 3	69 participants (Actual)	Interventional	2012-10-31	Completed
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit[NCT01183780]	Phase 3	1,072 participants (Actual)	Interventional	2010-12-02	Completed
Phase II Multicenter Study of the Impact of the Therapeutic Sequence of Radiochemotherapy (50 Gy + Capecitabine + Oxaliplatin + Cetuximab) Followed by Total Mesorectal Excision Surgery Then Post-surgery Chemotherapy (FOLFOX 4 + Cetuximab) in Synchronous L[NCT00541112]	Phase 2	19 participants (Actual)	Interventional	2007-10-29	Terminated(stopped due to Toxicity and lack of efficacy)
Phase II Study Evaluating the Effectiveness of the Association of Chemotherapy LV5FU2 Simplified and Cetuximab With Intra-arterial Hepatic Chemotherapy Using Oxaliplatin in Patients With Colorectal Cancer and Nonresectable Hepatic Metastases[NCT00544349]	Phase 2	45 participants (Anticipated)	Interventional	2006-10-31	Completed
Phase II Study of 5FU/Folinic Acid and Irinotecan as Second or Third Line Treatment in Patients With Metastatic, Unresectable, Colorectal Cancer[NCT00075595]	Phase 2	0 participants	Interventional	2002-06-30	Active, not recruiting
Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis[NCT00276757]		376 participants (Anticipated)	Interventional	2001-04-30	Completed
Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV[NCT00006050]	Phase 2	0 participants	Interventional	1999-04-04	Completed
Randomized Phase II Study of First-Line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS And BRAF Wild-Type Metastatic Colorectal Cancer Elderly Patients[NCT02904031]	Phase 2	180 participants (Anticipated)	Interventional	2016-07-31	Active, not recruiting
A Phase I Study to Evaluate the Safety and Tolerability of Irinotecan Liposome in Combination With Oxaliplatin and 5-FU/LV in the Treatment of Advanced Pancreatic Cancer[NCT04796948]	Phase 1	41 participants (Actual)	Interventional	2021-04-08	Active, not recruiting
The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828]		176 participants (Anticipated)	Interventional	2019-08-02	Recruiting
Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors[NCT00091312]	Phase 3	1,976 participants (Anticipated)	Interventional	2004-06-30	Active, not recruiting
Bevacizumab Plus mFOLFOXIRI or mFOLFOX-6 as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer: a Randomised, Open-label, Phase 3 Trial[NCT04230187]	Phase 3	528 participants (Anticipated)	Interventional	2020-06-01	Recruiting
Gleevec (Imatinib) Plus Multi-Agent Chemotherapy For Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia[NCT00618501]	Phase 2	50 participants (Anticipated)	Interventional	2005-10-31	Completed
Phase 2 Study to Improve Tolerance of Chemotherapy Involving Cetuximab and Multidrug FOLFIRI, With Pharmacokinetic and Pharmacogenetic Studies, in Patients With Metastatic Colorectal Cancer[NCT00559741]	Phase 2	80 participants (Anticipated)	Interventional	2005-10-31	Completed
A ComboMATCH Treatment Trial: FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations[NCT05564403]	Phase 2	66 participants (Anticipated)	Interventional	2024-05-07	Recruiting
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma[NCT03798626]	Phase 1	167 participants (Actual)	Interventional	2019-05-22	Active, not recruiting
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB[NCT03337087]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2018-11-02	Active, not recruiting
A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis[NCT00408551]	Phase 2	20 participants (Anticipated)	Interventional	2005-11-30	Recruiting
Feasibility Study of mFOLFOX6 (Oxaliplatin Combined With l-Leucovorin (l-LV) and 5-Fluorouracil) in Patients With Advanced Colorectal Cancer[NCT00209703]	Phase 2	30 participants	Interventional	2005-01-31	Terminated
Randomized Phase III Clinical Study Comparing Postoperative UFT+LV, UFT+LV/UFT and UFT+LV+PSK/UFT+PSK Therapies for Stage III Colorectal Cancer[NCT00209742]	Phase 3	340 participants (Anticipated)	Interventional	2005-04-30	Active, not recruiting
A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer[NCT00212589]	Phase 3	60 participants	Interventional	2002-12-31	Completed
[NCT01851941]	Phase 2	52 participants (Actual)	Interventional	2004-10-31	Completed
Treatment of Acute Lymphoblastic Leukemia in Children[NCT00400946]	Phase 3	800 participants (Actual)	Interventional	2005-04-30	Completed
AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer[NCT01862003]	Phase 2	24 participants (Actual)	Interventional	2014-05-31	Completed
Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial[NCT01867697]	Phase 2	173 participants (Actual)	Interventional	2012-05-31	Completed
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)[NCT00557193]	Phase 3	218 participants (Actual)	Interventional	2008-01-15	Active, not recruiting
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial[NCT02934464]	Phase 3	280 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Open Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of IMC-11F8 in Combination With 5-FU/FA and Oxaliplatin (mFOLFOX-6) in Patients With Treatment-naïve, Locally-advanced or Metastatic Colorectal Cancer[NCT00835185]	Phase 2	44 participants (Actual)	Interventional	2007-08-31	Completed
An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies[NCT00000714]	Phase 3	0 participants	Interventional		Completed
A Randomized Phase III Trial of Paclitaxel, Carboplatin and Etoposide Vs. 5-Fluorouracil and Folinic Acid in the Treatment of Patients With Adenocarcinoma of Unknown Primary Site[NCT00003558]	Phase 3	140 participants (Anticipated)	Interventional	1998-08-31	Active, not recruiting
Phase IB/Randomized Phase II Study of Folfirinox Plus AMG-479 (Ganitumab) or Placebo in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma[NCT01473303]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2012-08-31	Withdrawn(stopped due to CALGB 81003 closed about a week after it was activated because of withdrawal of support. No patients were registered on this study.)
Randomized Phase II Trial Evaluating the Feasibility and Tolerance of the Combination of FOLFOX With Cetuximab and the Combination of FOLFOX With Cetuximab and Bevacizumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Colore[NCT00438737]	Phase 2	100 participants (Anticipated)	Interventional	2007-01-31	Active, not recruiting
An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid Tumors[NCT05148195]	Phase 2	110 participants (Anticipated)	Interventional	2021-12-22	Recruiting
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)[NCT04068103]	Phase 2/Phase 3	1,408 participants (Anticipated)	Interventional	2019-12-16	Recruiting
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement[NCT02828358]	Phase 2	78 participants (Actual)	Interventional	2017-04-01	Active, not recruiting
A Pilot Study of the Efficacy of the Chop-Montak Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma[NCT00513188]		0 participants (Actual)	Interventional	2007-02-28	Withdrawn
Oxaliplatin-CPT-11-5-FU-Leucovarin + Bevacizumab and Cetuximab (OCFL-BC) as a Combination Regimen for Systemic Treatment of Advanced Colorectal Carcinoma With Potentially Resectable Liver and/or Lung Metastases. A Phase II Study[NCT00513266]	Phase 2	35 participants (Anticipated)	Interventional	2007-06-30	Active, not recruiting
Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers[NCT00524186]	Phase 1	23 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to PI left institute)
Phase II Randomized Study Comparing FOLFIRINOX + Panitumumab Versus mFOLFOX6 + Panitumumab in Metastatic Colorectal Cancer Patients Selected by RAS and B-RAF Status From Circulating DNA Analysis[NCT02980510]	Phase 2	219 participants (Actual)	Interventional	2016-12-31	Active, not recruiting
An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib[NCT01289821]	Phase 2	54 participants (Actual)	Interventional	2011-02-28	Completed
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia[NCT00550992]		445 participants (Anticipated)	Interventional	2006-01-31	Recruiting
"Frontline Chemotherapy Reinforced for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX"[NCT00557102]	Phase 2	24 participants (Actual)	Interventional	2007-09-30	Completed
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unr[NCT03504397]	Phase 3	566 participants (Actual)	Interventional	2018-06-21	Active, not recruiting
Phase II, Multicenter Study Evaluating G-CSF as Primary Prophylaxis for Neutropenia Associated With First-line Chemotherapy Regimen FOLFIRI and Bevacizumab in Patients With Metastatic Colorectal Cancer Who Are Homozygous for UGT1A1*28 Polymorphism, the Pr[NCT00541125]	Phase 2	20 participants (Actual)	Interventional	2007-11-30	Completed
Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer[NCT00559676]	Phase 4	200 participants (Anticipated)	Interventional	2005-03-31	Completed
A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon[NCT00378716]	Phase 3	1,608 participants (Actual)	Interventional	1997-02-28	Completed
Randomized Phase II Trial Of Neoadjuvant Combined Modality Therapy For Locally Advanced Rectal Cancer[NCT00081289]	Phase 2	146 participants (Actual)	Interventional	2004-03-31	Completed
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies[NCT03221400]	Phase 1/Phase 2	340 participants (Anticipated)	Interventional	2017-08-29	Recruiting
A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Color[NCT01383707]	Phase 2	77 participants (Actual)	Interventional	2011-08-12	Completed
A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer[NCT02246049]	Phase 2	69 participants (Actual)	Interventional	2014-05-31	Completed
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia[NCT03488225]	Phase 2	4 participants (Actual)	Interventional	2018-03-28	Terminated(stopped due to the study was closed early due to competing trials)
A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma[NCT02539537]	Phase 3	171 participants (Actual)	Interventional	2015-10-23	Active, not recruiting
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study[NCT02345460]	Phase 2	1 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to Competing studies)
TREATMENT OF ADULT PATIENTS WITH RELAPSING ACUTE LYMPHOCYTIC LEUKEMIA, A MULTICENTER TRIAL[NCT00002532]	Phase 2	0 participants	Interventional	1993-01-31	Active, not recruiting
A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4)[NCT00002700]	Phase 3	392 participants (Anticipated)	Interventional	1995-08-31	Completed
A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018]	Phase 2	54 participants (Actual)	Interventional	1997-09-30	Completed
A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594]	Phase 3	1,691 participants (Actual)	Interventional	1998-10-31	Completed
A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver[NCT00003834]	Phase 2	44 participants (Actual)	Interventional	1999-03-31	Completed
A Phase II Trial of Docetaxel, Cisplatin, 5-FU, and Leucovorin for Carcinoma of the Nasopharnyx[NCT00004164]	Phase 2	0 participants	Interventional	1999-08-31	Active, not recruiting
Phase II Study of Oxaliplatin and 5 Fluorouracil in the Treatment of Advanced Ovarian Cancer[NCT00004206]	Phase 2	0 participants	Interventional	1999-09-30	Active, not recruiting
A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer[NCT00005586]	Phase 3	2,500 participants (Anticipated)	Interventional	1997-10-31	Completed
[NCT00378456]		0 participants	Interventional		Completed
Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as N[NCT01802645]	Phase 2	91 participants (Actual)	Interventional	2013-03-31	Active, not recruiting
A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer[NCT01068327]	Phase 1	46 participants (Actual)	Interventional	2007-11-05	Completed
Phase II Study Of 5FU-Irinotecan-Cisplatin As First-Line Treatment In Patients With Metastatic Carcinoma Of The Esophagus[NCT00075738]	Phase 2	0 participants	Interventional	2003-10-31	Active, not recruiting
Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00098982]	Phase 1	16 participants (Actual)	Interventional	2004-09-30	Completed
Phase II Study of Recurrent Ganglionic Colorectal Cancer Not Accessible By Surgery Treated Using Chemotherapy With Simplified FOLFOX7 Followed By Radiotherapy Combined With 5FU and Oxaliplatin[NCT00268333]	Phase 2	39 participants (Anticipated)	Interventional	2005-08-31	Completed
Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors[NCT00416767]	Phase 2	20 participants (Actual)	Interventional	2004-05-31	Completed
A Multi-Center Phase Ib Study of Oxaliplatin (NSC #266046) in Combination With Fluorouracil and Leucovorin in Pediatric Patients With Advanced Solid Tumors[NCT00281944]	Phase 1	42 participants (Actual)	Interventional	2005-09-30	Completed
Phase I Study of High Dose Methotrexate With Simultaneous Trimetrexate and Leucovorin in Patients With Recurrent Osteosarcoma[NCT00119301]	Phase 1	18 participants (Anticipated)	Interventional	2005-04-30	Completed
Phase II Trial Of Irinotecan + 5-Fluorouracil + Leucovorin + Oxaliplatin As First-Line Treatment For Metastatic Colorectal Cancer[NCT00080951]	Phase 2	14 participants (Actual)	Interventional	2004-03-31	Completed
An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Oxaliplatin and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors[NCT00080990]	Phase 1	46 participants (Actual)	Interventional	2004-02-29	Completed
Preoperative Radiotherapy With or Without Concurrent Chemotherapy (5-Fluorouracil and Leucovorin) in T3-4 Rectal Cancers - Randomized Trial[NCT00296608]	Phase 3	762 participants (Actual)	Interventional	1993-04-30	Completed
A Randomized Pilot Study of the Activation of the Hemostatic Pathway by FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer[NCT00323011]	Phase 2	5 participants (Actual)	Interventional	2006-05-31	Terminated(stopped due to drug not available)
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver[NCT02885753]	Phase 3	348 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia[NCT00039130]	Phase 2	105 participants (Actual)	Interventional	2002-05-31	Completed
A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon[NCT00425152]	Phase 3	2,151 participants (Actual)	Interventional	1989-07-31	Completed
Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer[NCT00085163]	Phase 3	0 participants	Interventional	2004-03-31	Completed
"Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma."[NCT02143219]	Phase 2	72 participants (Actual)	Interventional	2014-07-31	Completed
Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927]	Phase 3	568 participants (Anticipated)	Interventional	2007-01-31	Active, not recruiting
A Phase II Combination Trial of PS-341 and 5-FU/LV in Gastric and/or GE Junction Adenocarcinoma[NCT00103103]	Phase 2	0 participants	Interventional	2005-03-31	Terminated
A Phase II Trial of Isolated Hepatic Perfusion (IHP) and Systemic FOLFOX4 for Subjects With Metastatic Unresectable Colorectal Cancers of the Liver With ≥ 40% Hepatic Tumor Burden[NCT00103298]	Phase 2	0 participants	Interventional	2004-12-31	Completed
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients With Colorectal Cancer and Other Solid Tumors[NCT00138177]	Phase 1	54 participants (Actual)	Interventional	2005-07-31	Completed
Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients[NCT00112658]	Phase 2/Phase 3	342 participants (Actual)	Interventional	2004-11-30	Completed
A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma[NCT00449137]	Phase 1	13 participants (Actual)	Interventional	2005-06-30	Completed
5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.[NCT00145314]	Phase 3	571 participants (Actual)	Interventional	2005-05-31	Completed
Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer[NCT00497107]	Phase 3	300 participants (Anticipated)	Interventional	2007-07-31	Recruiting
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers[NCT04535401]	Phase 1	90 participants (Anticipated)	Interventional	2021-08-13	Active, not recruiting
RACE-trial: Neoadjuvant Radiochemotherapy Versus Chemotherapy for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A Randomized Phase III Joint Study of the AIO, ARO and DGAV[NCT04375605]	Phase 3	342 participants (Actual)	Interventional	2020-06-03	Active, not recruiting
mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer Patients After Preoperative Treatment With Oxaliplatin (FANTASTIC): a Multicenter, Phase 3 Randomized Controlled Trial[NCT04338191]	Phase 3	638 participants (Anticipated)	Interventional	2020-04-01	Recruiting
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gast[NCT03505320]	Phase 2	143 participants (Anticipated)	Interventional	2018-06-29	Recruiting
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation[NCT00653068]	Phase 3	70 participants (Actual)	Interventional	2008-12-08	Active, not recruiting
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy[NCT05640726]	Phase 2	30 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
Post-Approved Phase III Study of 1-LV/5FU Therapy[NCT00195585]	Phase 3	650 participants	Interventional	2002-10-31	Completed
A Phase III Study to Evaluate the 3-year Disease-free Survival in Patients With Locally Advanced Colon Cancer Receiving Either Perioperative or Postoperative Chemotherapy With FOLFOX or CAPOX Regimens[NCT02572141]	Phase 3	738 participants (Anticipated)	Interventional	2015-01-01	Active, not recruiting
A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of MTX in Patients With Active RA Who Have Failed Previous TNF-α Antagonists[NCT01217814]	Phase 2	16 participants (Actual)	Interventional	2010-11-30	Terminated(stopped due to Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns)
A Prospective Randomised Open Label Trial of Oxaliplatin/Fluoropyrimidine Versus Oxaliplatin/Fluoropyrimidine Plus Cetuximab Pre and Post Operatively in Patients With Resectable Colorectal Liver Metastasis Requiring Chemotherapy[NCT00482222]	Phase 3	340 participants (Anticipated)	Interventional	2007-02-28	Recruiting
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer: A Randomized Phase II Trial of the German Rectal Cancer Study Group[NCT02363374]	Phase 2	311 participants (Actual)	Interventional	2015-03-25	Completed
Study to Determine the Maximum Tolerated Time of Infusion for High-Dose Methotrexate, Administered as a Continuous Intravenous Infusion at a Dose of 6g/m² Per 24 Hours of Infusion Time[NCT00513981]	Phase 1	36 participants (Anticipated)	Interventional	2007-03-31	Completed
A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094]	Phase 3	49 participants (Actual)	Interventional	2003-06-30	Completed
Pilot Study of Correlation Between Molecular Phenotype and Response to Two Independent Treatment Regimens, Carboplatin and Paclitaxel vs. 5-Fluorouracil and Oxaliplatin Chemotherapy in Patients With Localized Esophageal Adenocarcinoma[NCT02392377]	Phase 2	1 participants (Actual)	Interventional	2015-02-28	Terminated(stopped due to Slow accrual)
A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry[NCT03009058]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-05-24	Terminated(stopped due to Commercial reasons)
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction[NCT01611857]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2012-07-31	Completed
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. [NCT00336024]	Phase 3	91 participants (Actual)	Interventional	2007-08-06	Active, not recruiting
A Phase II Study of Weekly 24-hour Infusion 5-fluoro-deoxyuridine (FUdR)/Leucovorin With Oxaliplatin and Docetaxel (Taxotere) as First-line Treatment in Patients With Metastatic Gastric Adenocarcinoma (IIT# 14065)[NCT00448682]	Phase 2	25 participants (Actual)	Interventional	2005-06-30	Terminated
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.[NCT00002102]		0 participants	Interventional		Completed
Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy[NCT01533740]		31 participants (Actual)	Observational	2012-03-31	Completed
A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin[NCT00002618]	Phase 3	242 participants (Anticipated)	Interventional	1994-12-31	Completed
Induction Intensification in Infant ALL: A Children's Oncology Group Study[NCT00002756]	Phase 2	221 participants (Actual)	Interventional	1996-06-30	Completed
A Phase Ib/II Study of AK112 and AK119 in Combination With or Without Chemotherapy in the Treatment of Patients With Advanced Microsatellite Stabilized (pMMR/MSS) Colorectal Cancer[NCT05846867]	Phase 1/Phase 2	72 participants (Anticipated)	Interventional	2023-05-10	Not yet recruiting
A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer[NCT00385970]	Phase 3	380 participants (Anticipated)	Interventional	2006-03-31	Active, not recruiting
Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study[NCT00006479]	Phase 3	0 participants	Interventional	2000-09-30	Active, not recruiting
A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer[NCT00003049]	Phase 3	100 participants (Anticipated)	Interventional	1997-05-31	Completed
Randomized Phase III Study of Preoperative Chemotherapy Followed by Surgery Versus Surgery Alone in Locally Advanced Gastric Cancer (cT3 and cT4NxM0)[NCT00004099]	Phase 3	144 participants (Actual)	Interventional	1999-07-31	Terminated(stopped due to low accrual)
Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer[NCT00008060]	Phase 3	0 participants	Interventional	2000-05-31	Completed
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294]	Phase 1	0 participants	Interventional	2000-08-31	Completed
A Phase IB Study in Patients With Metastatic Colorectal Cancer to Evaluate Pharmacodynamic Effects of Erlotinib and Safety and Efficacy of Erlotinib in Combination With Modified FOLFOX6 (mFOLFOX6) and Bevacizumab[NCT00118261]	Phase 1	17 participants (Actual)	Interventional	2005-03-31	Completed
Phase I Study Of Weekly Paclitaxel In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies[NCT00009828]	Phase 1	0 participants (Actual)	Interventional	1999-12-31	Withdrawn
A Phase I Study of Weekly Gemcitabine in Combination With Infusional 5-Fluorouracil and Oral Calcium Leucovorin in Adult Cancer Patients[NCT00019513]	Phase 1	108 participants (Anticipated)	Interventional	1998-08-31	Completed
Osteosarcoma: Outcome of Therapy Based on Histologic Response. A Collaborative Effort of the POB/NCI, Texas Children's Hospital and University of Oklahoma.[NCT00019864]	Phase 2	100 participants (Anticipated)	Interventional	2000-03-31	Terminated
A Phase I & Pharmacologic Trial Of Sequential Irinotecan As A 24-Hour IV Infusion, Leucovorin, & Flurouracil As A 48-Hour IV Infusion In Adult Cancer Patients[NCT00020488]	Phase 1	0 participants	Interventional	2001-02-28	Completed
Pilot Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Combination With Irinotecan, Fluorouracil, and Leucovorin, and in Patients With Newly Diagnosed Stage IV Colorectal Carcinoma[NCT00020917]	Phase 2	0 participants	Interventional	2001-02-28	Completed
Phase I Study of Flavopiridol in Combination With 5-Fluorouracil, Leucovorin and Irinotecan in Patients With Advanced Malignancies[NCT00021073]	Phase 1	90 participants (Anticipated)	Interventional	2001-05-31	Completed
A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2[NCT00023998]	Phase 2	80 participants (Actual)	Interventional	2001-07-31	Completed
Mechanisms of Antifolate Efficacy in Arthritis[NCT00000395]	Phase 2	40 participants (Actual)	Interventional	1996-09-30	Completed
A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS[NCT00000674]		30 participants	Interventional		Completed
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma[NCT00000689]	Phase 1	18 participants	Interventional		Completed
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis[NCT00000794]	Phase 2	100 participants	Interventional		Completed
Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics[NCT00000998]	Phase 1	50 participants	Interventional		Completed
A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS[NCT00001013]	Phase 3	364 participants	Interventional		Completed
The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia[NCT00016302]		100 participants (Actual)	Interventional	2001-04-30	Completed
Time Finding Study of Chronomodulated Irinotecan, 5 Fluorouracil, Leucovorin and Oxaliplatin as First or Second Chemotherapy Line Against Metastatic Colorectal Cancer[NCT00039208]	Phase 2	0 participants	Interventional	2002-02-28	Completed
A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma[NCT00040690]	Phase 2	120 participants (Anticipated)	Interventional	2008-11-30	Completed
An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Irinotecan (CPT-11) and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors[NCT00042874]	Phase 1	77 participants (Actual)	Interventional	2002-05-31	Completed
A Randomized, Double-blind, Single-dummy, Parallel-controlled, Multicentre, Phase III Clinical Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treat[NCT05074589]	Phase 3	298 participants (Actual)	Interventional	2018-01-25	Completed
A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer[NCT00052585]	Phase 2	50 participants (Actual)	Interventional	2002-10-31	Terminated(stopped due to Administratively complete.)
A Phase I/II Study of Oblimersen Sodium (G3139, Genasense) in Combination With Oxaliplatin, 5FU and Leucovorin (FOLFOX4) Regimen in Advanced Colorectal Cancer[NCT00055822]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2002-10-31	Completed
European Study Group For Pancreatic Cancer - Trial 3[NCT00058201]	Phase 3	1,030 participants (Anticipated)	Interventional	2001-07-31	Completed
Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer[NCT00066274]	Phase 2	0 participants	Interventional	2002-07-23	Completed
Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed[NCT00070213]	Phase 3	460 participants (Actual)	Interventional	2003-09-30	Completed
A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study[NCT00072553]	Phase 2	0 participants	Interventional	2003-09-30	Active, not recruiting
A Multi-centre, Randomised, Parallel Group, Open-label, Phase II, Single-stage Selection Trial of Liposomal Irinotecan (Nal-IRI) and 5-fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-line Therapy in Patients With Progressive Poorly Differentiated [NCT03837977]	Phase 2	102 participants (Anticipated)	Interventional	2018-11-13	Active, not recruiting
Phase I Study Of Oral Etoposide In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies[NCT00009815]	Phase 1	0 participants (Actual)	Interventional	1999-12-31	Withdrawn
Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma[NCT00009893]	Phase 2	42 participants (Actual)	Interventional	2001-05-31	Completed
Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas[NCT00010088]	Phase 2	0 participants	Interventional	1999-01-31	Active, not recruiting
Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL)[NCT00275106]	Phase 3	600 participants (Anticipated)	Interventional	2004-09-30	Terminated(stopped due to Withdrawn due to an excess of toxic deaths)
A Non-Randomized Multicenter Phase I/II Study Of Active Specific Immunotherapy In Patients With Stage II and Stage III Colon Cancer[NCT00016133]	Phase 1/Phase 2	0 participants	Interventional	2001-03-31	Completed
Phase II Study in Patients With Metastatic Colorectal Carcinoma Previously Treated With Oxaliplatin (OXAL) or a Combination of Irinotecan (CPT-11) and OXAL[NCT00016952]	Phase 2	19 participants (Actual)	Interventional	2001-04-30	Completed
A Phase II Study Of Intensive Induction Chemotherapy Followed By Autologous Stem Cell Transplantation Plus Immunotherapy For Mantle Cell Lymphoma[NCT00020943]	Phase 2	79 participants (Actual)	Interventional	2001-06-30	Completed
A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051)[NCT00022737]	Phase 3	220 participants (Actual)	Interventional	2002-10-31	Completed
A Phase II Study of Local Excision Alone or Local Excision Plus Adjuvant Chemoradiation Therapy for Small Distal Rectal Cancers[NCT00023751]	Phase 2	320 participants (Actual)	Interventional	2001-07-31	Completed
A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum[NCT00023868]	Phase 3	0 participants	Interventional	2001-11-01	Terminated(stopped due to redesign)
A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer[NCT00026364]	Phase 1	22 participants (Actual)	Interventional	2001-11-30	Completed
A Phase III Prospective Random Assignment Trial of Regional and Systemic Chemotherapy With or Without Initial Isolated Hepatic Perfusion for Patients With Metastatic Unresectable Colorectal Cancers of the Liver[NCT00020501]	Phase 3	0 participants	Interventional	2001-03-31	Completed
A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metast[NCT00021281]	Phase 3	0 participants	Interventional	2000-12-31	Active, not recruiting
Phase II Study: Hyperfractionated Pre-Op Chemo-Radiation for Locally Advanced Rectal Cancer[NCT00021398]	Phase 2	23 participants (Actual)	Interventional	1996-07-31	Completed
A Phase I/II Study Of OSI-774 In Combination With Oxaliplatin, And 5-Fluourouracil In Patients With Metastatic Colorectal Carcinoma[NCT00049101]	Phase 1/Phase 2	0 participants	Interventional	2002-08-31	Completed
Intensive Induction Therapy for Children With Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse[NCT00049569]		126 participants (Anticipated)	Interventional	2003-01-31	Completed
A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)[NCT00025142]	Phase 2	0 participants	Interventional	2001-07-31	Completed
Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer[NCT00025337]	Phase 3	880 participants (Actual)	Interventional	2001-09-30	Completed
Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma[NCT00027833]	Phase 2	0 participants	Interventional	2001-12-31	Active, not recruiting
Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Met[NCT00423696]	Phase 2	145 participants (Actual)	Interventional	2006-03-23	Completed
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer[NCT00060411]	Phase 1	24 participants (Actual)	Interventional	2003-06-30	Completed
A Phase III Trial of Modified FOLFOX6 Versus CAPOX, With Bevacizumab (NSC-704865) or Placebo, as First-Line Therapy in Patients With Previously Untreated Advanced Colorectal Cancer[NCT00070122]	Phase 3	2,200 participants (Actual)	Interventional	2004-04-30	Terminated(stopped due to Administratively complete.)
A Phase II Feasibility Translational Research Trial of Induction Chemotherapy Followed by Concomitant Chemoradiation in Patients With Clinical T4 Rectal Cancer[NCT00070434]	Phase 2	0 participants (Actual)	Interventional	2004-08-31	Withdrawn(stopped due to poor accrual)
A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin®) Plus 5-Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancers That Have Progressed After Standard Chemotherapy[NCT00066846]	Phase 2	0 participants	Interventional	2003-08-31	Completed
Oxaliplatin (NSC 266046) in Combination With 5-Fluorouracil and Leucovorin (FOLFOX4) for Patients Who Have Not Received Prior Chemotherapy for Advanced Colorectal Cancer[NCT00039611]		0 participants	Interventional	2002-05-31	Completed
CLOCC Trial (Chemotherapy + Local Ablation Versus Chemotherapy) Randomized Phase II Study Of Local Treatment Of Liver Metastases By Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone In Patients With Unresectable Colorectal Liver Metastas[NCT00043004]	Phase 2	119 participants (Actual)	Interventional	2002-05-31	Terminated(stopped due to low accrual)
A Phase I Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Advanced Malignancy[NCT00043121]	Phase 1	50 participants (Actual)	Interventional	2002-06-30	Completed
A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma[NCT00045539]	Phase 2	0 participants	Interventional	2002-10-31	Completed
A Phase I Pharmacologic Trial Of Infusional UCN-01 Given With A Weekly Schedule Of 5-Fluorouracil And Leucovorin[NCT00042861]	Phase 1	0 participants	Interventional	2002-08-31	Completed
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum[NCT00056030]	Phase 2	73 participants (Anticipated)	Interventional	2004-12-31	Completed
Multicenter, Randomized Controlled Trial Designed to Evaluate the Efficacy and Safety of Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Raltitrexed or Oxaliplatin Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)[NCT02965248]	Phase 3	147 participants (Anticipated)	Interventional	2016-11-30	Recruiting
5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03).[NCT00046995]	Phase 3	800 participants (Anticipated)	Interventional	2001-05-31	Active, not recruiting
A Randomized, Prospective Study Comparing Three Regimens Of Eloxatin ™ Plus Fluoropyrimidine For Evaluation Of Safety And Tolerability In First Line Treatment Of Patients With Advanced Colorectal Cancer (Tree Study)[NCT00062426]	Phase 3	0 participants	Interventional	2003-05-31	Completed
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors[NCT02009449]	Phase 1	350 participants (Actual)	Interventional	2013-11-15	Active, not recruiting
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. A Pan-European Prospective Multicenter Double Single Arm Cohort Study.[NCT06068023]		400 participants (Anticipated)	Observational	2023-07-01	Recruiting
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma[NCT04205968]	Phase 2	94 participants (Anticipated)	Interventional	2020-06-01	Recruiting
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage[NCT01670084]	Phase 2	0 participants (Actual)	Interventional	2012-12-31	Withdrawn(stopped due to No Accrual)
The TRIPLETE Study RANDOMIZED PHASE III STUDY OF TRIPLET mFOLFOXIRI PLUS PANITUMUMAB Versus mFOLFOX6 PLUS PANITUMUMAB AS INITIAL THERAPY FOR UNRESECTABLE RAS AND BRAF WILDTYPE METASTATIC COLORECTAL CANCER PATIENTS[NCT03231722]	Phase 3	435 participants (Actual)	Interventional	2017-09-13	Completed
Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer[NCT01279681]	Phase 3	32 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Slow accrual)
Phase II Study of Gamma Interferon (IFN-γ) Added to Bolus + Infusional 5-Fluorouracil (5-FU) and Leucovorin (LV) +/- Bevacizumab (BV) in Metastatic Colorectal Carcinoma[NCT00786643]	Phase 2	48 participants (Actual)	Interventional	2006-02-28	Completed
Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment[NCT01276379]	Phase 2	221 participants (Actual)	Interventional	2011-01-31	Completed
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma[NCT05677490]	Phase 3	382 participants (Anticipated)	Interventional	2023-01-23	Recruiting
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial[NCT03777813]	Phase 2	120 participants (Anticipated)	Interventional	2018-12-05	Recruiting
Study of Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer and Efficacy Prediction[NCT01832948]	Phase 2	30 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX[NCT00268398]	Phase 3	284 participants (Actual)	Interventional	2002-07-31	Completed
Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2[NCT00274872]	Phase 2/Phase 3	600 participants (Anticipated)	Interventional	2004-01-31	Active, not recruiting
Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen[NCT01640782]	Phase 3	1,100 participants (Actual)	Interventional	2005-02-28	Completed
A PHASE II Study of GM-CSF As Pre- And Post-operative Adjuvant Therapy For Stage II And III Colon Cancer[NCT00262808]	Phase 2	50 participants (Anticipated)	Interventional	2004-03-31	Completed
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: A Pilot Study[NCT00416819]		10 participants (Actual)	Interventional	2003-09-30	Completed
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group[NCT04495088]	Phase 3	818 participants (Anticipated)	Interventional	2020-09-30	Recruiting
Open, Multi-center Phase I/II Trial With Mitomycin C in Combination With 5-Fluorouracil and Folinic Acid in Pretreated Patients With Metastatic Gastrointestinal Cancer[NCT00289445]	Phase 1/Phase 2	0 participants	Interventional	1999-09-30	Completed
Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer[NCT00303771]	Phase 3	282 participants (Actual)	Interventional	2003-06-30	Completed
Phase I/II Study of CT-2106 in Combination With Infusional 5-fluorouracil/Folinic Acid (5-FU/FA)(de Gramont Schedule) as Second Line in Patients With Metastatic Colorectal Cancer Failing an Oxaliplatin Plus 5-FU/FA Regimen[NCT00291785]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2004-01-31	Completed
One-year Double-blind Placebo-controlled Phase 2-3 Study to Evaluate the Effect of Oral Folinic Acid Treatment (1mg/kg/d) on the Psychomotor Development of Young Down Syndrome Patients[NCT00294593]	Phase 2/Phase 3	120 participants	Interventional	2000-10-31	Completed
Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study[NCT00300404]	Phase 3	40 participants	Interventional	2002-01-31	Completed
Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression[NCT00303758]	Phase 3	202 participants (Actual)	Interventional	2005-10-31	Completed
Explorative Trial to Investigate Catumaxomab (Anti-EpCAM x Anti-CD3) for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas Prior to Gastrectomy[NCT01504256]	Phase 2	42 participants (Anticipated)	Interventional	2011-10-31	Completed
An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma[NCT01506167]		719 participants (Actual)	Observational	2012-07-06	Completed
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients With Metastatic HER2-Negative,[NCT01662869]	Phase 3	564 participants (Actual)	Interventional	2012-11-30	Completed
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)[NCT02162563]	Phase 3	564 participants (Anticipated)	Interventional	2014-07-31	Recruiting
An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients With Metastatic Colorectal Cancer[NCT00862784]	Phase 2	48 participants (Actual)	Interventional	2009-04-30	Completed
Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency[NCT01715363]	Phase 2	3 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Recruitment difficulties)
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer[NCT05253651]	Phase 3	400 participants (Anticipated)	Interventional	2022-10-24	Recruiting
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Ma[NCT00217737]	Phase 3	3,610 participants (Anticipated)	Interventional	2005-09-06	Active, not recruiting
[NCT01758666]		40 participants (Anticipated)	Interventional	2012-09-30	Active, not recruiting
Short-term Folinic Acid Supplementation Improves Vascular Reactivity in HIV-infected Individuals: a Randomized Trial[NCT01768182]		30 participants (Actual)	Interventional	2009-08-31	Completed
An Open Label, Multicenter, Dose Finding, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Receiving Folotyn® (Pralatrexate)[NCT01789723]	Phase 1	0 participants (Actual)	Interventional	2013-03-31	Withdrawn
A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.[NCT01814501]	Phase 2	16 participants (Actual)	Interventional	2013-02-01	Active, not recruiting
An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Receiving Folotyn® (Pralatrexate)[NCT01820091]	Phase 1	0 participants (Actual)	Interventional	2013-04-30	Withdrawn
An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer[NCT02384850]	Phase 1	10 participants (Actual)	Interventional	2015-03-31	Terminated
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer[NCT01498289]	Phase 2	213 participants (Actual)	Interventional	2012-02-29	Completed
Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSF[NCT02620865]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2015-12-31	Completed
Intermittent or Continuous Panitumumab Plus FOLFIRI for First-line Treatment of Patients With RAS/B-RAF Wild-type Metastatic Colorectal Cancer: a Randomized Phase 2 Trial[NCT04425239]	Phase 2	151 participants (Actual)	Interventional	2018-05-21	Completed
Open, Randomized, Controlled, Multicenter Phase III Study Comparing CMAB009 Plus FOLFIRI Versus FOLFIRI Alone as First-line Treatment for Epidermal Growth Factor Receptor-expressing, RAS/BRAF Wild-type, Metastatic Colorectal Cancer[NCT03206151]	Phase 3	520 participants (Actual)	Interventional	2017-12-12	Active, not recruiting
Phase II Study of Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin,Leucovorin and 5-Fluorouracil[NCT02987699]	Phase 2	54 participants (Anticipated)	Interventional	2016-11-30	Recruiting
A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen[NCT01882868]	Phase 2	62 participants (Actual)	Interventional	2013-07-31	Completed
An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression[NCT01280643]		3 participants (Actual)	Interventional	2010-03-31	Terminated(stopped due to Slow accrual)
A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer[NCT06107413]	Phase 2	206 participants (Anticipated)	Interventional	2023-11-12	Recruiting
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia[NCT00002103]		0 participants	Interventional		Completed
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer[NCT03152370]	Phase 1	29 participants (Actual)	Interventional	2017-05-17	Completed
Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma[NCT00002463]	Phase 2	4 participants (Actual)	Interventional	1989-02-28	Completed
FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY[NCT00002523]	Phase 3	1,011 participants (Actual)	Interventional	1993-04-30	Completed
Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II[NCT00002571]	Phase 2	52 participants (Actual)	Interventional	1994-06-30	Completed
LSA5 PROTOCOL FOR THE TREATMENT OF ADVANCED PEDIATRIC AND ADOLESCENT NON-HODGKIN'S LYMPHOMA (NHL)[NCT00002691]	Phase 2	0 participants	Interventional	1995-08-31	Completed
PALLIATIVE LOCAL CHEMOTHERAPY FOR NON-RESECTABLE LIVER METASTASES FROM COLORECTAL CARCINOMA, A RANDOMISED PHASE III STUDY[NCT00002793]	Phase 3	336 participants (Anticipated)	Interventional	1991-01-31	Active, not recruiting
Chemotherapy, Radiotherapy, and Azidothymidine for AIDS-Related Primary CNS Lymphoma[NCT00000723]		45 participants	Interventional		Terminated
Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases[NCT01442935]	Phase 2	256 participants (Actual)	Interventional	2011-02-28	Completed
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized[NCT01443065]	Phase 2	162 participants (Actual)	Interventional	2011-01-31	Completed
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study[NCT05802056]	Phase 1	15 participants (Anticipated)	Interventional	2023-11-29	Recruiting
A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma[NCT05688215]	Phase 1/Phase 2	56 participants (Anticipated)	Interventional	2023-03-07	Recruiting
A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia[NCT00591123]	Phase 2	38 participants (Actual)	Interventional	2007-12-31	Completed
Induction Chemotherapy With Taxotere, Cisplatin and 5-Fluorouracil Followed by Concomitant Cetuximab and Radiation for Locoregionally Advanced Squamous Cell Cancer of the Head and Neck: A Phase II Trial[NCT01467115]	Phase 2	1 participants (Actual)	Interventional	2010-03-31	Completed
A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unr[NCT05678257]	Phase 2	171 participants (Anticipated)	Interventional	2023-04-18	Recruiting
A Randomised Phase II/III Trial of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy for Resectable Gastric Cancer[NCT01924819]	Phase 2/Phase 3	574 participants (Actual)	Interventional	2009-09-30	Active, not recruiting
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chem[NCT01926236]	Phase 3	162 participants (Actual)	Interventional	2014-02-28	Completed
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment[NCT03428958]	Phase 1/Phase 2	225 participants (Anticipated)	Interventional	2018-10-16	Recruiting
A Folinic Acid Intervention for ASD: Links to Folate Receptor-alpha Autoimmunity & Redox Metabolism[NCT01602016]	Phase 2	99 participants (Actual)	Interventional	2012-05-31	Terminated(stopped due to Non-compliance)
mFOLFOX6 Combined With Dalpiciclib(SHR6390) in Patients With Metastatic Colorectal Cancer (FIND): A Single-arm, Phase IIa Study.[NCT05480280]	Phase 2	18 participants (Anticipated)	Interventional	2022-07-20	Recruiting
A Phase II/I Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status[NCT03699319]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2018-12-07	Active, not recruiting
A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome[NCT00002002]		0 participants	Interventional		Completed
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma[NCT01231399]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2012-02-29	Completed
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma[NCT00000658]	Phase 3	250 participants	Interventional		Completed
A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia[NCT00000724]	Phase 3	0 participants	Interventional		Completed
A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to[NCT00000730]	Phase 3	240 participants	Interventional		Terminated
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 Alone in Locally Advanced Colorectal Cancer: a Randomized Control Phase II Study (OPTICAL-2)[NCT05571644]	Phase 2	82 participants (Anticipated)	Interventional	2022-12-15	Not yet recruiting
HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate Versus Nab-paclitaxel in Combination With Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer: an Open, Randomized, Multicenter Phase III Trial.[NCT05751850]	Phase 3	522 participants (Anticipated)	Interventional	2023-06-13	Recruiting
A Study of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia[NCT00002434]		0 participants	Interventional		Completed
Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer[NCT00002476]	Phase 3	0 participants	Interventional	1990-01-31	Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494]	Phase 2	134 participants (Actual)	Interventional	1992-05-31	Completed
Pilot Study in AIDS-Related Lymphomas[NCT00002524]	Phase 2	46 participants (Actual)	Interventional	1993-06-30	Completed
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome[NCT00002578]	Phase 2	35 participants (Anticipated)	Interventional	1994-08-31	Completed
A RANDOMISED TRIAL OF INTRAVENOUS VERSUS INTRAHEPATIC ARTERIAL 5-FU AND LEUCOVORIN FOR COLORECTAL LIVER METASTASES[NCT00002692]	Phase 3	312 participants (Anticipated)	Interventional	1994-12-31	Active, not recruiting
TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY[NCT00002704]	Phase 2	156 participants (Actual)	Interventional	1996-01-31	Completed
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER[NCT00002716]	Phase 3	135 participants (Actual)	Interventional	1996-01-31	Completed
RANDOMIZED PHASE II STUDY OF A WEEKLY 24H-INFUSION OF HIGH-DOSE 5-FU PLUS OR MINUS FOLINIC ACID (HD-FU/FA) VERSUS HD-FU/FA PLUS BIWEEKLY CISPLATIN VERSUS FAMTX (5-FU/ADRIAMYCIN/METHOTREXATE) IN ADVANCED GASTRIC CANCER, AN EORTC/AIO INTERGROUP TRIAL[NCT00002722]	Phase 2	135 participants (Anticipated)	Interventional	1996-01-31	Completed
A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma[NCT00002590]	Phase 2	221 participants (Actual)	Interventional	1994-07-31	Completed
RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA[NCT00002896]	Phase 3	774 participants (Anticipated)	Interventional	1993-09-30	Active, not recruiting
Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia Testing Increased Doses of Daunorubicin During Induction, and Cytarabine During Consolidation, Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradia[NCT00003700]	Phase 2	163 participants (Actual)	Interventional	1999-01-31	Completed
Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children[NCT01576705]	Phase 3	175 participants (Actual)	Interventional	2012-04-02	Completed
A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach[NCT00003862]	Phase 2	0 participants	Interventional	1999-11-30	Completed
A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma[NCT00004102]	Phase 2	0 participants	Interventional	1999-01-31	Completed
Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid[NCT00004150]	Phase 3	0 participants	Interventional	1999-03-31	Completed
A Randomized, Open-Label, Multicenter Phase III Study of 5-FU/Leucovorin With or Without Concomitant SU5416 in Patients With Metastatic Colorectal Cancer[NCT00004252]	Phase 3	0 participants	Interventional	1999-11-30	Completed
ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study[NCT00005596]	Phase 3	1,076 participants (Actual)	Interventional	2000-04-30	Completed
A Phase I Study of Oxaliplatin, CPT-11, 5-FU and Leucovorin in Patients With Solid Tumors[NCT00005068]	Phase 1	0 participants	Interventional	2000-01-31	Completed
Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma[NCT00052910]	Phase 3	546 participants (Actual)	Interventional	2002-12-31	Completed
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI in Patients With Ras Mutant Positive Metastatic Colorectal Cancer, Either Newly Diagnosed or Previously Treated.[NCT01322815]	Phase 2	11 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Poor accrual rate)
A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00265850]	Phase 3	2,334 participants (Actual)	Interventional	2005-11-30	Completed
An Open Labelled Phase III Adjuvant Trial of Disease-free Survival in Patients With Resected Pancreatic Ductal Adenocarcinoma Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic T[NCT05314998]	Phase 3	394 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Bes[NCT00492999]	Phase 2	64 participants (Anticipated)	Interventional	2007-05-31	Active, not recruiting
Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer[NCT01679327]	Phase 2	100 participants (Anticipated)	Interventional	2012-03-31	Recruiting
Clinical Efficacy of Chemotherapy Combined With Cytokine-induced Killer in Treatment of Patients With Colon Cancer[NCT03084809]	Phase 4	46 participants (Actual)	Interventional	2012-05-06	Completed
Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290]	Phase 2	67 participants (Actual)	Interventional	2013-11-08	Completed
Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case[NCT01991873]	Phase 2	387 participants (Actual)	Interventional	2014-04-30	Completed
A Randomised Phase III Trial Comparing Hepatic Arterial Injection of Yttrium-90 Resin Microspheres (SIR-spheres) Plus Systemic Maintenance Therapy Versus Systemic Maintenance Therapy Alone for Patients With Unresectable Liver Metastases From Colorectal Ca[NCT01895257]	Phase 3	162 participants (Anticipated)	Interventional	2013-08-31	Recruiting
Phase III Study in mCRC Patients With RAS/BRAF Wild Type Tissue and RAS Mutated in LIquid BIopsy to Compare in First-line Therapy FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb Study)[NCT04776655]	Phase 3	280 participants (Anticipated)	Interventional	2021-04-30	Recruiting
A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advance[NCT02588105]	Phase 1	84 participants (Actual)	Interventional	2015-11-10	Completed
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer[NCT04745988]	Phase 2	43 participants (Anticipated)	Interventional	2021-11-11	Recruiting
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.[NCT03192618]	Phase 3	290 participants (Anticipated)	Interventional	2017-07-01	Recruiting
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer[NCT00100841]	Phase 2	66 participants (Actual)	Interventional	2004-11-30	Completed
Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patient[NCT04617457]	Phase 2	150 participants (Anticipated)	Interventional	2021-10-10	Recruiting
Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances[NCT01729481]	Phase 2	150 participants (Actual)	Interventional	2012-07-31	Active, not recruiting
Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer[NCT01212822]	Phase 2	20 participants (Actual)	Interventional	2011-04-27	Completed
A Phase 1b Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Product in Japanese Subjects With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab,[NCT01286818]	Phase 1	6 participants (Actual)	Interventional	2011-02-28	Completed
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence[NCT00317408]		96 participants (Anticipated)	Interventional	2004-04-30	Active, not recruiting
A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies[NCT00001016]	Phase 3	0 participants	Interventional		Completed
Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia[NCT00002120]	Phase 1	20 participants	Interventional		Completed
AUTOLOGOUS, ALLOGENEIC, OR SYNGENEIC BONE MARROW TRANSPLANTATION IN HODGKIN'S DISEASE, NON-HODGKIN'S LYMPHOMA, AND MULTIPLE MYELOMA[NCT00002552]	Phase 2	40 participants (Anticipated)	Interventional	1993-10-31	Completed
A Phase III Study of Immediate Versus Delayed Chemotherapy for Asymptomatic Advanced Colorectal Cancer[NCT00002570]	Phase 3	67 participants (Actual)	Interventional	1994-07-15	Completed
Phase II Trial of Trimetrexate and Leucovorin in The Treatment of Recurrent Childhood Acute Lymphoblastic Leukemia[NCT00002738]	Phase 2	25 participants (Anticipated)	Interventional	1996-01-31	Completed
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members[NCT00000703]		45 participants	Interventional		Completed
A Study of Neutrexin (Trimetrexate Glucuronate) With Leucovorin Protection for Pediatric Patients (Ages 2-12) With Pneumocystis Carinii Pneumonia[NCT00002317]		0 participants	Interventional		Completed
Postoperative Evaluation of 5-FU by Bolus Injection vs. 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT vs. Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT P[NCT00002551]	Phase 3	1,917 participants (Actual)	Interventional	1994-03-31	Completed
EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY[NCT00002816]	Phase 3	120 participants (Anticipated)	Interventional	1996-12-31	Completed
PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME[NCT00002557]	Phase 2	3 participants (Anticipated)	Interventional	1993-06-30	Active, not recruiting
A Randomised Trial Comparing Pre-Operative Radiotherapy and Selective Post-Operative Chemoradiotherapy in Rectal Cancer[NCT00003422]	Phase 3	1,800 participants (Anticipated)	Interventional	1998-01-31	Completed
Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole Versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer[NCT00002593]	Phase 3	1,135 participants (Actual)	Interventional	1994-12-31	Completed
Phase II Trial of Trimetrexate (Neutrexin), 5-Fluorouracil and Leucovorin in Metastatic Colorectal Cancer[NCT00003446]	Phase 2	0 participants	Interventional	1997-12-31	Completed
A Phase I Study of Continuous Oral Administration of SCH 66336 and 5-Fluorouracil/Leucovorin (5FU/LV) in Patients With Advanced Cancer[NCT00003956]	Phase 1	25 participants (Anticipated)	Interventional	1999-04-30	Completed
Multicentre Phase III Comparing To Therapeutic Sequence: Folfiri Following of Folfox6 (Group A) and Folfox6 Following Of (Group B) For Metastatic Colorectal Cancer[NCT00003260]	Phase 3	109 participants (Anticipated)	Interventional	1998-01-31	Active, not recruiting
TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FI[NCT00002665]	Phase 2	50 participants (Anticipated)	Interventional	1995-07-31	Completed
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age.[NCT00002785]	Phase 2	0 participants	Interventional	1996-07-31	Completed
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc[NCT00003728]	Phase 3	1,500 participants (Anticipated)	Interventional	1998-12-31	Active, not recruiting
A Phase II Window Study of Trimetrexate With Simultaneous Leucovorin Protection in the Treatment of Newly Diagnosed Patients With Metastatic Osteosarcoma[NCT00003776]	Phase 2	0 participants	Interventional	1998-12-31	Completed
A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU[NCT00005036]	Phase 3	560 participants (Actual)	Interventional	1999-11-30	Completed
A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid [NCT02379091]	Phase 2	108 participants (Actual)	Interventional	2014-12-17	Completed
CHEMOTHERAPY CHOICES IN ADVANCED COLORECTAL CANCER: A RANDOMISED TRIAL COMPARING 2 DURATIONS AND 3 SYSTEMIC CHEMOTHERAPY REGIMENS IN THE PALLIATIVE TREATMENT OF ADVANCED COLORECTAL CANCER[NCT00002893]	Phase 3	900 participants (Anticipated)	Interventional	1995-06-30	Active, not recruiting
Phase I/II Study of 5-Fluorouracil/Folinic Acid/Gemcitabine in Patients With Advanced Colorectal Carcinoma[NCT00003001]	Phase 1/Phase 2	63 participants (Anticipated)	Interventional	1997-04-30	Active, not recruiting
Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma[NCT00003799]	Phase 1	20 participants (Anticipated)	Interventional	1999-05-31	Completed
Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer[NCT00003835]	Phase 3	1,260 participants (Anticipated)	Interventional	1999-05-31	Completed
Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin[NCT00003925]	Phase 1	36 participants (Anticipated)	Interventional	1998-05-31	Completed
A Phase I Study of Low Dose Continuous Infusion Topotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Malignancies[NCT00003331]	Phase 1	30 participants (Anticipated)	Interventional	1998-01-31	Completed
CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer[NCT00004885]	Phase 3	430 participants (Actual)	Interventional	1999-07-31	Completed
A Phase II, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of RO5520985 (Vanucizumab) Plus FOLFOX Versus Bevacizumab Plus FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT02141295]	Phase 2	197 participants (Actual)	Interventional	2014-06-30	Terminated
T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation[NCT00005641]	Phase 2	0 participants	Interventional	1997-09-30	Terminated(stopped due to low study accrual)
PROTOCOL FOR THE TREATMENT OF MALIGNANT NON-TESTICULAR GERM CELL TUMORS[NCT00002489]	Phase 2	0 participants	Interventional	1991-10-31	Completed
MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93)[NCT00002531]	Phase 2	0 participants	Interventional	1993-01-31	Active, not recruiting
A PHASE II TRIAL OF NEOADJUVANT CISPLATIN-FLUOROURACIL CHEMOTHERAPY, SURGERY, AND INTRAPERITONEAL (IP) FLOXURIDINE (FUdR) PLUS LEUCOVORIN IN PATIENTS WITH GASTRIC CANCER[NCT00002783]	Phase 2	50 participants (Anticipated)	Interventional	1996-05-31	Completed
Modulation of 5-Fluorouracil With Trimetrexate and Leucovorin in Advanced Pancreatic Cancer[NCT00002955]	Phase 2	21 participants (Actual)	Interventional	1995-08-31	Completed
Adjuvant Chemoimmunotherapy for Colorectal Cancer[NCT00003063]	Phase 3	1,050 participants (Anticipated)	Interventional	1991-11-30	Active, not recruiting
A Prospective Study of FOLFIRI Plus Panitumumab in Extended RAS Wild Type and BRAF Wild Type Metastatic Colorectal Cancer With Acquired Resistance to Prior Cetuximab (or Panitumumab) Plus Irinotecan-Based Therapy and Who Failed at Least One Subsequent Non[NCT02508077]	Phase 2	1 participants (Actual)	Interventional	2016-02-16	Terminated(stopped due to Poor Accrual)
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (NORMAL-R)[NCT02641691]	Phase 2	20 participants (Actual)	Interventional	2016-05-27	Completed
Phase II Study of AVELUMAB and CETUXIMAB and Modified FOLFOXIRI as Initial Therapy for RAS Wild-type Unresectable Metastatic Colorectal Cancer Patients[NCT04513951]	Phase 2	58 participants (Anticipated)	Interventional	2020-04-01	Active, not recruiting
A Pilot Study of Intravenous Ascorbic Acid and Folfirinox in the Treatment of Advanced Pancreatic Cancer[NCT02896907]	Early Phase 1	8 participants (Actual)	Interventional	2016-10-18	Completed
Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study[NCT04927780]	Phase 3	378 participants (Anticipated)	Interventional	2021-09-07	Recruiting
Phase III Intergroup Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection, Followed by 5-FU/Leucovorin for Patients With Colon Cancer[NCT00002525]	Phase 3	859 participants (Actual)	Interventional	1993-10-01	Terminated(stopped due to The study was stopped before reaching its accrual goal due to slow accrual)
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotep[NCT00003273]	Phase 2	0 participants (Actual)	Interventional	1997-11-30	Withdrawn
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma[NCT00002835]	Phase 3	116 participants (Actual)	Interventional	1995-10-30	Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN[NCT00002865]	Phase 2	25 participants (Actual)	Interventional	1995-04-30	Completed
Irinotecan and 5-Fluorouracil/Leucovorin for Patients With Colorectal Carcinoma and Other Refractory Tumors[NCT00004005]	Phase 2	12 participants (Actual)	Interventional	1998-09-30	Completed
A Phase II Study of PN-401, 5-FU and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach[NCT00004233]	Phase 2	65 participants (Actual)	Interventional	2001-02-28	Completed
Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis[NCT00004317]	Phase 4	600 participants (Anticipated)	Interventional	2000-07-31	Recruiting
ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study[NCT00003783]	Phase 2	36 participants (Actual)	Interventional	1999-03-31	Completed
A Phase II Study of CPT-11 and 5-FU/LCV in Patients With Previously Untreated Gastric Adenocarcinoma[NCT00005607]	Phase 2	0 participants	Interventional	2000-02-29	Active, not recruiting
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma ([NCT04363801]	Phase 2	232 participants (Anticipated)	Interventional	2020-07-29	Recruiting
An Examination of Changes in Urinary Metabolites With Use of Folinic Acid in Children With Autism Spectrum Disorder (ASD)[NCT03771560]	Phase 2/Phase 3	18 participants (Actual)	Interventional	2018-02-15	Completed
A Phase II Clinical Trial Evaluating Overall Survival With Therasphere® In Conjunction With 2nd-Line FOLFOX In Patients With Gemcitabine-Refractory Pancreatic Carcinoma With Liver Metastases[NCT01581307]	Phase 2	9 participants (Actual)	Interventional	2012-04-30	Completed
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia[NCT01535053]	Phase 3	57 participants (Actual)	Interventional	2012-06-18	Completed
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction[NCT01307956]	Phase 2	11 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial)
FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL) Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer: a Phase II Trial by the FNF Team.[NCT03222089]	Phase 2	0 participants (Actual)	Interventional	2017-07-20	Withdrawn(stopped due to Another study enrolling the similar group of patient are ongoing)
PRIMIER*: Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI-724 as First Line Treatment for Metastatic Colorectal Cancer[NCT02413853]	Phase 2	0 participants (Actual)	Interventional	2015-11-30	Withdrawn(stopped due to Study drug supply issues)
An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin® Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients[NCT01987102]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2013-12-31	Completed
Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma[NCT00002471]	Phase 2	0 participants	Interventional	1990-02-28	Completed
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Soli[NCT05714553]	Phase 1/Phase 2	91 participants (Anticipated)	Interventional	2023-03-08	Recruiting
Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.[NCT01700569]	Phase 1	24 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to changing the standard of care)
A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age With[NCT01412879]	Phase 2	53 participants (Actual)	Interventional	2011-11-30	Completed
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer: the BRANCH Trial[NCT01481545]	Phase 2	62 participants (Actual)	Interventional	2006-12-31	Completed
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma[NCT00982592]	Phase 2	124 participants (Actual)	Interventional	2009-09-30	Completed
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I[NCT02553460]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2016-01-29	Active, not recruiting
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor[NCT00084838]	Phase 2	25 participants (Actual)	Interventional	2003-02-28	Completed
An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, With or Without Voraxaze Treatment[NCT00634504]	Phase 1	20 participants (Actual)	Interventional	2008-05-31	Completed
Front-line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study. (SUREMETS)[NCT00936832]	Phase 2	0 participants (Actual)	Interventional	2009-04-30	Withdrawn(stopped due to because the sunitinib showed futility in anotehr trial)
A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regime[NCT00112918]	Phase 3	3,451 participants (Actual)	Interventional	2004-12-31	Completed
Cetuximab and Envafolimab Plus mFOLFOXIRI Versus Cetuximab Plus mFOLFOX6/FOLFIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer: A Randomized Controlled Phase II Trial (CEIL)[NCT05959356]	Phase 2	198 participants (Anticipated)	Interventional	2023-11-09	Active, not recruiting
A Phase II, Prospective, Multicenter Study of Cadonilimab in Combination With FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer.[NCT05839470]	Phase 2	20 participants (Anticipated)	Interventional	2023-11-19	Recruiting
A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04999332]	Phase 2	58 participants (Anticipated)	Interventional	2021-12-10	Recruiting
NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic C[NCT04539808]	Phase 2	60 participants (Anticipated)	Interventional	2021-05-27	Recruiting
A Randomised Study to Assess the Efficacy of Cetuximab Rechallenge in Patients With Metastatic Colorectal Cancer (RAS Wild-type) Responding to First-line Treatment With FOLFIRI Plus Cetuximab[NCT02934529]	Phase 3	673 participants (Actual)	Interventional	2015-03-31	Active, not recruiting
A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX[NCT00381862]	Phase 2	54 participants (Actual)	Interventional	2006-06-30	Completed
A Phase I, Randomised, Open-Label, Single-Dose, Two-Treatment, Two-Way Crossover, Two-Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination With Anti-Cancer Ag[NCT05383352]	Phase 1	122 participants (Anticipated)	Interventional	2022-05-30	Recruiting
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations[NCT02883049]	Phase 3	5,937 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
A Phase II Study Of Neo-Adjuvant Chemotherapy And Radiation In Patients With Locally Advanced Pancreatic Cancer[NCT00089024]	Phase 2	29 participants (Actual)	Interventional	2004-02-25	Completed
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)[NCT01270438]	Phase 2	0 participants (Actual)	Interventional	2010-12-31	Withdrawn
A Single-Blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin® (60 or 200mg/m2) Compared to Levoleucovorin (60 or 200mg/m2) in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer[NCT01681472]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2012-09-30	Completed
A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-[NCT04919226]	Phase 3	202 participants (Anticipated)	Interventional	2021-12-21	Recruiting
PHASE I TRIAL OF POST-OPERATIVE COMBINED ORAL UFT PLUS LEUCOVORIN AND RADIATION THERAPY FOR RECTAL CANCER[NCT00002801]	Phase 1	30 participants (Anticipated)	Interventional	1996-04-30	Completed
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL)[NCT00003215]	Phase 3	400 participants (Anticipated)	Interventional	1997-04-30	Completed
A Phase II Study of Oxaliplatin in Combination With Fluorouracil and Leucovorin in Carcinoma of the Esophagus and Gastric Cardia[NCT00004127]	Phase 2	35 participants (Actual)	Interventional	2000-02-29	Completed
First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287]	Phase 3	554 participants (Anticipated)	Interventional	1998-03-31	Completed
A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia[NCT00003305]	Phase 2	75 participants (Anticipated)	Interventional	1997-07-31	Completed
A Phase I Study of Docetaxel Plus 5-FU, Cisplatin and Leucovorin in Patients With Advanced Solid Tumors[NCT00004913]	Phase 1	0 participants	Interventional	2000-01-31	Completed
A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931]	Phase 3	2,472 participants (Anticipated)	Interventional	2000-02-29	Completed
ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study[NCT00005585]	Phase 3	838 participants (Actual)	Interventional	2000-04-30	Completed
Development of a Novel Folic Acid Wound Dressing to Enhance Nitric Oxide Bioactivity Required for Diabetic Foot Ulcer Wound Healing[NCT04723134]	Phase 2	30 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Protocol for Patients With Newly Diagnosed Better Risk Acute Lymphoblastic Leukemia (ALL): A POG Pilot Study[NCT00003671]	Phase 2	59 participants (Actual)	Interventional	1998-12-31	Completed
Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma[NCT00392834]	Phase 2	34 participants (Actual)	Interventional	2006-09-30	Completed
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH)[NCT00588536]	Phase 2	5 participants (Actual)	Interventional	1995-01-31	Completed
A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas[NCT02015819]	Phase 1	16 participants (Actual)	Interventional	2014-10-07	Completed
A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-R[NCT02506842]	Phase 3	300 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)[NCT04094688]	Phase 3	455 participants (Actual)	Interventional	2019-09-30	Active, not recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy[NCT03959085]	Phase 3	4,772 participants (Anticipated)	Interventional	2019-10-31	Recruiting
Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab[NCT02138617]	Phase 2	100 participants (Actual)	Interventional	2014-05-31	Active, not recruiting
Mature B-Cell Lymphoma And Leukemia Study III[NCT01046825]	Phase 2/Phase 3	128 participants (Actual)	Interventional	2010-09-09	Active, not recruiting
Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer[NCT01871571]	Phase 2	17 participants (Actual)	Interventional	2013-08-02	Active, not recruiting
Phase I / II Dose Escalation of Oxaliplatin Via a Laparoscopic Approach of Aerosol Pressurized Intraperitoneal Chemotherapy for Nonresectable Peritoneal Metastases of Digestive Cancers (Stomach, Hail and Colorectal)[NCT03294252]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2017-05-24	Terminated(stopped due to The 34 patients included had all completed their treatment period under the protocol and the data could be collected to assess the main objective and the secondary objectives before the last theoretical follow-up.)
Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients[NCT02069704]	Phase 1	142 participants (Actual)	Interventional	2014-10-29	Completed
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer[NCT05610163]	Phase 2	312 participants (Anticipated)	Interventional	2022-12-08	Recruiting
A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)[NCT05546411]	Phase 2	8 participants (Actual)	Interventional	2023-01-06	Terminated(stopped due to Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are stopping all clinical development of NIS793 in pancreatic cancer, effective immediately.)
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer[NCT04340141]	Phase 3	352 participants (Anticipated)	Interventional	2020-07-01	Recruiting
A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer[NCT02394795]	Phase 3	823 participants (Actual)	Interventional	2015-05-29	Completed
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma[NCT05546853]	Phase 1	52 participants (Anticipated)	Interventional	2023-03-28	Recruiting
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative G[NCT01590719]	Phase 2	123 participants (Actual)	Interventional	2012-07-31	Completed
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer[NCT00851045]	Phase 2	17 participants (Actual)	Interventional	2009-10-31	Completed
Phase I Study of Ursodeoxycholic Acid (Ursodiol)in Combination With 5-Fluorouracil, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Cancer[NCT00873275]	Phase 1	11 participants (Actual)	Interventional	2009-03-11	Active, not recruiting
"A Phase II Study of Liposomial IrinoTecan (Nal-IRI) With 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer nITRo Trial"[NCT03528785]	Phase 2	67 participants (Anticipated)	Interventional	2018-03-02	Recruiting
Biomarkers and Clinical Outcomes in Localized Rectal Adenocarcinoma Treated With Neoadjuvant Therapy[NCT04418895]	Phase 2	0 participants (Actual)	Interventional	2021-08-13	Withdrawn(stopped due to lack of resources)
International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma[NCT00006455]	Phase 3	885 participants (Actual)	Interventional	1999-11-26	Completed
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents[NCT03020030]	Phase 3	560 participants (Actual)	Interventional	2017-03-03	Active, not recruiting
An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer[NCT01133990]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2010-03-04	Terminated(stopped due to The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not tolerable, hence no efficacy analysis was conducted.)
A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)[NCT01900431]	Phase 2	58 participants (Actual)	Interventional	2013-10-31	Completed
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer[NCT02042443]	Phase 2	53 participants (Actual)	Interventional	2014-02-28	Completed
The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study[NCT02506231]	Phase 2/Phase 3	160 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Asso[NCT01964755]	Phase 2	6 participants (Actual)	Interventional	2009-04-21	Terminated(stopped due to Investigator Decision)
FOLFOX Via Hepatic Artery Infusion Chemotherapy (HAI) Plus Systemic Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A[NCT05727163]	Phase 2	194 participants (Anticipated)	Interventional	2022-07-29	Recruiting
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer. A Randomized Phase II Marker Trial[NCT04245865]	Phase 2	74 participants (Anticipated)	Interventional	2020-06-26	Recruiting
First-line FOLFOX-4 Plus Panitumumab Followed by 5-FU/LV Plus Panitumumab or Single-agent Panitumumab as Maintenance Therapy in Patients With RAS Wild-type, Metastatic Colorectal Cancer: the VALENTINO Study[NCT02476045]	Phase 2	224 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer[NCT01765582]	Phase 2	280 participants (Actual)	Interventional	2013-01-23	Terminated
Phase II Trial of FOLFOXIRI + Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer[NCT02497157]	Phase 2	45 participants (Anticipated)	Interventional	2015-05-21	Completed
A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic Cancer[NCT01959672]	Phase 2	11 participants (Actual)	Interventional	2013-09-06	Completed
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Irinotecan and Its Metabolite SN-38 When Coadministered With Folinic Acid and 5 Fluorouracil in Patients With Advanced Malignant Solid Tumors[NCT01634555]	Phase 2	29 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00002525 (4) [back to overview]	5-year Overall Survival Rate in Patients With Dukes' B3/C Disease
NCT00002525 (4) [back to overview]	5-year Overall Survival Rate in Patients With Dukes' B2 Disease
NCT00002525 (4) [back to overview]	5-year Disease-free Survival Rate in Patients With Dukes' B3/C Disease
NCT00002525 (4) [back to overview]	5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease
NCT00002842 (1) [back to overview]	2 Year Disease-free Survival .
NCT00003298 (4) [back to overview]	Best Confirmed Response to Neoadjuvant Therapy
NCT00003298 (4) [back to overview]	Grade 3 or Higher Toxicity Incidence on Step 1
NCT00003298 (4) [back to overview]	Overall Survival
NCT00003298 (4) [back to overview]	Progression Free Survival
NCT00004228 (2) [back to overview]	Percentage of Patients With Overall Survival as Assessed by Time to Death
NCT00004228 (2) [back to overview]	Event-free Survival
NCT00039130 (3) [back to overview]	2 Year Event Free Survival
NCT00039130 (3) [back to overview]	Complete Response Rate
NCT00039130 (3) [back to overview]	2 Year Overall Survival
NCT00039377 (5) [back to overview]	Disease Free Survival
NCT00039377 (5) [back to overview]	Overall Survival
NCT00039377 (5) [back to overview]	5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups
NCT00039377 (5) [back to overview]	Number of Participants Who Achieved a BCR-ABL Response at 12 Months
NCT00039377 (5) [back to overview]	5 Year Overall Survival for Autologous & Allogeneic Transplant Groups
NCT00041132 (3) [back to overview]	Progression-free Survival
NCT00041132 (3) [back to overview]	Response
NCT00041132 (3) [back to overview]	Overall Survival
NCT00052910 (2) [back to overview]	Overall Survival
NCT00052910 (2) [back to overview]	Disease Free Survival
NCT00057811 (4) [back to overview]	Minimal Residual Disease
NCT00057811 (4) [back to overview]	Response Rate
NCT00057811 (4) [back to overview]	Toxic Death
NCT00057811 (4) [back to overview]	Grade ≥ 3 Stomatitis
NCT00061945 (6) [back to overview]	Disease-free Survival, for Only Complete Response Patients
NCT00061945 (6) [back to overview]	Number of Participants Achieving Complete Remission
NCT00061945 (6) [back to overview]	Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)
NCT00061945 (6) [back to overview]	Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]	Overall Survival
NCT00061945 (6) [back to overview]	Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)
NCT00068692 (4) [back to overview]	Failure Pattern
NCT00068692 (4) [back to overview]	Proportion of Sphincter Preservation
NCT00068692 (4) [back to overview]	3-year Overall Survival Rate
NCT00068692 (4) [back to overview]	3-year Disease Free Survival
NCT00075725 (7) [back to overview]	Correlation of Early Marrow Response Status With MRD Positive.
NCT00075725 (7) [back to overview]	Correlation of Early Marrow Response Status With MRD Negative.
NCT00075725 (7) [back to overview]	Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).
NCT00079274 (6) [back to overview]	Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)
NCT00079274 (6) [back to overview]	Disease-free Survival (Arms A and D: Wild-type KRAS Patients)
NCT00079274 (6) [back to overview]	Disease-free Survival (Arms A and D: Mutant KRAS Patients)
NCT00079274 (6) [back to overview]	Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)
NCT00079274 (6) [back to overview]	Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)
NCT00079274 (6) [back to overview]	Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)
NCT00081289 (18) [back to overview]	Number of Participants With Grade 3+ Treatment-related Adverse Events
NCT00081289 (18) [back to overview]	Number of Participants With Grade 3+ Treatment-related Adverse Events Postoperatively
NCT00081289 (18) [back to overview]	Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Completion of Post-operative Chemotherapy
NCT00081289 (18) [back to overview]	Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Two Years
NCT00081289 (18) [back to overview]	Change From Baseline in QLQ-C30 Global Health Status Score at Completion of Post-operative Chemotherapy
NCT00081289 (18) [back to overview]	Change From Baseline in QLQ-C30 Global Health Status Score at Two Years
NCT00081289 (18) [back to overview]	Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Completion of Chemoradiation
NCT00081289 (18) [back to overview]	Disease-free Survival Rate at 4 Years
NCT00081289 (18) [back to overview]	Distant Failure Rate at 4 Years
NCT00081289 (18) [back to overview]	Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Post-operative Chemotherapy
NCT00081289 (18) [back to overview]	Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Completion of Chemoradiation
NCT00081289 (18) [back to overview]	Change From Baseline in QLQ-C30 Global Health Status Score at Completion of Chemoradiation
NCT00081289 (18) [back to overview]	Pathologic Complete Response Rate
NCT00081289 (18) [back to overview]	Second Primary Rate at 4 Years
NCT00081289 (18) [back to overview]	Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Two Years
NCT00081289 (18) [back to overview]	Local-regional Failure Rate at 4 Years
NCT00081289 (18) [back to overview]	Number of Participants With Grade 3+ Treatment-related Adverse Events Preoperatively
NCT00081289 (18) [back to overview]	Survival Rate at 4 Years
NCT00084838 (19) [back to overview]	Grade 3-4 Pain Events
NCT00084838 (19) [back to overview]	Grade 3-4 Neurology Events
NCT00084838 (19) [back to overview]	Grade 3-4 Muscloskeletal Events
NCT00084838 (19) [back to overview]	Grade 3-4 Metabolic/Laboratory Events
NCT00084838 (19) [back to overview]	Grade 3-4 Infection/Febrile Neutropenia Events
NCT00084838 (19) [back to overview]	Grade 3-4 Hepatic Events
NCT00084838 (19) [back to overview]	Grade 3-4 Hemorrhage Events
NCT00084838 (19) [back to overview]	Grade 3-4 Gastrointestinal Events
NCT00084838 (19) [back to overview]	Grade 3-4 Dermatology Events
NCT00084838 (19) [back to overview]	Grade 3-4 Constitutional Events
NCT00084838 (19) [back to overview]	Grade 3-4 Blood/Bone Marrow Events
NCT00084838 (19) [back to overview]	Grade 3-4 Auditory/Hearing Events
NCT00084838 (19) [back to overview]	Grade 3-4 Allergy/Immunology
NCT00084838 (19) [back to overview]	2-yr Overall Survival
NCT00084838 (19) [back to overview]	Grade 3-4 Cardiovascular Events
NCT00084838 (19) [back to overview]	Pre-Radiation Therapy Chemotherapeutic Response
NCT00084838 (19) [back to overview]	Grade 3/4 Events
NCT00084838 (19) [back to overview]	Grade 3-4 Renal/Genitourinary Events
NCT00084838 (19) [back to overview]	Grade 3-4 Pulmonary Events
NCT00089024 (2) [back to overview]	Surgical Exploration
NCT00089024 (2) [back to overview]	Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment
NCT00096135 (1) [back to overview]	Event-free Survival
NCT00096278 (2) [back to overview]	Disease-free Survival
NCT00096278 (2) [back to overview]	Survival
NCT00098774 (4) [back to overview]	4 Year Overall Survival Rate
NCT00098774 (4) [back to overview]	Complete Response Rate After Remission Induction
NCT00098774 (4) [back to overview]	4 Year Progression Free Rate
NCT00098774 (4) [back to overview]	Change From Baseline in Mini-Mental Status Evaluation at 4 Months
NCT00098787 (3) [back to overview]	Progression-Free Survival (PFS)
NCT00098787 (3) [back to overview]	Overall Survival (OS)
NCT00098787 (3) [back to overview]	Objective Response Rate
NCT00098839 (4) [back to overview]	Event-free Survival Rate
NCT00098839 (4) [back to overview]	Pharmacokinetics
NCT00098839 (4) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01%
NCT00098839 (4) [back to overview]	Remission Re-induction (CR2) Rate
NCT00100841 (2) [back to overview]	Progression Free Survival Rate
NCT00100841 (2) [back to overview]	Severe Adverse Event (SAE) Rate
NCT00103285 (10) [back to overview]	Optimal Time Point for Advance Health Related Quality of Life Intervention
NCT00103285 (10) [back to overview]	Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)
NCT00103285 (10) [back to overview]	Event-free Survival (EFS) for SR-High Patients.
NCT00103285 (10) [back to overview]	Event-Free Survival Probability According to MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]	Overall Survival Probability (OS) According to Induction Day 29 MRD Status
NCT00103285 (10) [back to overview]	Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]	Health-related Quality of Life Relative to Physical, Social and Emotional Impairment
NCT00103285 (10) [back to overview]	Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]	Early Marrow Status (EMS) by MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]	Event-free Survival (EFS) for SR-Low Patients
NCT00112918 (6) [back to overview]	Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis
NCT00112918 (6) [back to overview]	Overall Survival in Stage III Cancer Patients - Time to Event
NCT00112918 (6) [back to overview]	Disease-free Survival in Stage III Cancer Patients - Time to Event
NCT00112918 (6) [back to overview]	Overall Survival in Stage III Cancer Patients - Number of Events
NCT00112918 (6) [back to overview]	Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis
NCT00112918 (6) [back to overview]	Disease-free Survival in Stage III Cancer Patients - Number of Events
NCT00143403 (2) [back to overview]	Overall Survival Rates
NCT00143403 (2) [back to overview]	Disease Free Survival (DFS)
NCT00154102 (15) [back to overview]	Disease Control Rate - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]	Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]	Participants With No Residual Tumor After Metastatic Surgery
NCT00154102 (15) [back to overview]	Best Overall Response Rate - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]	Overall Survival Time (KRAS Wild-Type Population)
NCT00154102 (15) [back to overview]	Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]	Overall Survival Time (OS)
NCT00154102 (15) [back to overview]	Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]	Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]	Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
NCT00154102 (15) [back to overview]	Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
NCT00154102 (15) [back to overview]	Safety - Number of Patients Experiencing Any Adverse Event
NCT00154102 (15) [back to overview]	Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]	Overall Survival Time (KRAS Mutant Population)
NCT00154102 (15) [back to overview]	Duration of Response - Independent Review Committee (IRC) Assessments
NCT00192075 (11) [back to overview]	Progression-Free Survival - Avastin Subgroup
NCT00192075 (11) [back to overview]	Tumor Response - Avastin Subgroup
NCT00192075 (11) [back to overview]	Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)
NCT00192075 (11) [back to overview]	Toxicity - Avastin Subgroup
NCT00192075 (11) [back to overview]	Progression-Free Survival
NCT00192075 (11) [back to overview]	Overall Survival
NCT00192075 (11) [back to overview]	Duration of Response - A+FOLFOX4 - Avastin Subgroup
NCT00192075 (11) [back to overview]	Duration of Response
NCT00192075 (11) [back to overview]	Survival at 12 Months and 24 Months - Avastin Subgroup
NCT00192075 (11) [back to overview]	Time to Progressive Disease - Avastin Subgroup
NCT00192075 (11) [back to overview]	Time to Progressive Disease
NCT00262925 (2) [back to overview]	Complete Response Rate
NCT00262925 (2) [back to overview]	Overall Survival
NCT00265850 (2) [back to overview]	Overall Survival
NCT00265850 (2) [back to overview]	Progression-free Survival (PFS)
NCT00303628 (6) [back to overview]	Patterns of Failure
NCT00303628 (6) [back to overview]	Change in Rectal Function Between Baseline and 12 Months
NCT00303628 (6) [back to overview]	5-year Disease-free Survival Rate
NCT00303628 (6) [back to overview]	5-year Overall Survival Rate
NCT00303628 (6) [back to overview]	Change in Oxaliplatin-related Neurotoxicity Between Baseline and 12 Months
NCT00303628 (6) [back to overview]	Proportion of Patients Who Completed 12 Cycles of Treatment
NCT00321685 (5) [back to overview]	Resection Rate for T4 Rectal Cancers
NCT00321685 (5) [back to overview]	Resection Rate for T3 Rectal Cancers
NCT00321685 (5) [back to overview]	Pathologic Complete Response Rate
NCT00321685 (5) [back to overview]	5-year Recurrence-free Survival Rate
NCT00321685 (5) [back to overview]	5-year Overall Survival Rate
NCT00321828 (1) [back to overview]	Major Morbidity Related to the Intact Primary Tumor
NCT00335140 (1) [back to overview]	Complete Response Rate - Locally Reviewed
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Diabetes Insipidus
NCT00336024 (10) [back to overview]	Rates of Nutritional Toxicities
NCT00336024 (10) [back to overview]	Rates of Gastrointestinal Toxicities
NCT00336024 (10) [back to overview]	Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).
NCT00336024 (10) [back to overview]	Percentage of Participants With Event Free Survival (EFS)
NCT00336024 (10) [back to overview]	Percentage of Participants With Any Acute Adverse Events
NCT00336024 (10) [back to overview]	Number of Participants With Secondary Malignancies
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Low Somatomedin C
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Central Hypothyroidism
NCT00381680 (6) [back to overview]	Event Free Survival. EFS
NCT00381680 (6) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00381680 (6) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00381680 (6) [back to overview]	Adjusted Event Free Survival
NCT00381680 (6) [back to overview]	Event Free Survival (EFS)
NCT00381680 (6) [back to overview]	Frequency and Severity of Adverse Effects
NCT00381862 (1) [back to overview]	Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.
NCT00392834 (1) [back to overview]	Overall Survival (OS) at 1 Year
NCT00399035 (7) [back to overview]	Rate of Resection of Liver Metastases
NCT00399035 (7) [back to overview]	Best Percentage Change in Tumour Size
NCT00399035 (7) [back to overview]	Duration of Response
NCT00399035 (7) [back to overview]	Overall Response Rate
NCT00399035 (7) [back to overview]	Overall Survival
NCT00399035 (7) [back to overview]	Progression-free Survival
NCT00399035 (7) [back to overview]	Time to Wound Healing Complications
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival by Bone Marrow Day 18 Status
NCT00400946 (10) [back to overview]	Induction Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]	Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]	Post-Induction Nadir Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]	5-year Disease-Free Survival by CNS Directed Treatment Group
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival by MRD Day 32 Status
NCT00400946 (10) [back to overview]	Asparaginase-Related Toxicity Rate
NCT00400946 (10) [back to overview]	Induction Infection Toxicity Rate
NCT00400946 (10) [back to overview]	Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]	Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)
NCT00408005 (8) [back to overview]	Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00449163 (4) [back to overview]	Rate of Toxicity in Study Participants
NCT00449163 (4) [back to overview]	Overall Survival up to 2 Years
NCT00449163 (4) [back to overview]	Median Progression-free Survival in Months
NCT00449163 (4) [back to overview]	Response Rate (Complete Response and Partial Response)
NCT00457691 (8) [back to overview]	Number of Participants With Overall Confirmed Objective Response
NCT00457691 (8) [back to overview]	Duration of Response (DR)
NCT00457691 (8) [back to overview]	Overall Survival (OS)
NCT00457691 (8) [back to overview]	Progression-free Survival (PFS)
NCT00457691 (8) [back to overview]	Change From Baseline in European Quality of Life (EuroQol) EQ-5D Self-Report Questionnaire
NCT00457691 (8) [back to overview]	Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)
NCT00457691 (8) [back to overview]	Change From Baseline in MDASI-GI Symptom Interference Score
NCT00457691 (8) [back to overview]	Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Assessment Inventory of Gastrointestinal Symptoms (MDASI-GI) Symptom Intensity Score
NCT00462501 (1) [back to overview]	Complete Pathologic Response
NCT00467142 (2) [back to overview]	Percentage of Participants in Objective Response (Partial or Complete Responses)
NCT00467142 (2) [back to overview]	Median Duration of Response
NCT00494221 (5) [back to overview]	Objective Tumour Response Rate
NCT00494221 (5) [back to overview]	Overall Survival
NCT00494221 (5) [back to overview]	Progression Free Survival
NCT00494221 (5) [back to overview]	Best Percentage Change in Tumour Size
NCT00494221 (5) [back to overview]	Duration of Response
NCT00499369 (2) [back to overview]	Progression-free Survival (PFS)
NCT00499369 (2) [back to overview]	Toxicity
NCT00500292 (1) [back to overview]	Number of Patients With an Objective Disease Progression Event
NCT00514020 (1) [back to overview]	"Number of Patients With Each Response in Good Risk Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]2/2 or TSER2/3 Genotype [Low TS Expression])"
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]	Progression-free Survival (PFS)
NCT00515216 (18) [back to overview]	Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]	Disease Control Rate (DCR)
NCT00515216 (18) [back to overview]	Overall Response Rate (ORR)
NCT00515216 (18) [back to overview]	Overall Survival
NCT00525785 (1) [back to overview]	Complete Pathologic Response Rate
NCT00544414 (2) [back to overview]	Overall Response
NCT00544414 (2) [back to overview]	Progression-free Survival
NCT00557193 (10) [back to overview]	Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00557193 (10) [back to overview]	Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00561470 (5) [back to overview]	Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria
NCT00561470 (5) [back to overview]	Number of Participants With Adverse Events (AE)
NCT00561470 (5) [back to overview]	Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay
NCT00561470 (5) [back to overview]	Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)
NCT00561470 (5) [back to overview]	Overall Survival (OS)
NCT00588536 (1) [back to overview]	Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX.
NCT00591123 (2) [back to overview]	Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.
NCT00591123 (2) [back to overview]	Toxicity of the Combination of FOLFOX, 5-FU, and Erlotinib
NCT00615056 (6) [back to overview]	Overall Survival (OS)
NCT00615056 (6) [back to overview]	Duration of Response (DR)
NCT00615056 (6) [back to overview]	Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal
NCT00615056 (6) [back to overview]	Change From Baseline in MD Anderson Symptoms Inventory Diarrhea (MDASI-D) Symptom Severity Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal
NCT00615056 (6) [back to overview]	Progression Free Survival (PFS)
NCT00615056 (6) [back to overview]	Percentage of Participants With Objective Response (OR)
NCT00634504 (1) [back to overview]	Pharmacokinetics (PK) of Leucovorin
NCT00653068 (4) [back to overview]	Toxic Death
NCT00653068 (4) [back to overview]	Overall Survival (OS)
NCT00653068 (4) [back to overview]	Event-free Survival
NCT00653068 (4) [back to overview]	Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy
NCT00668863 (15) [back to overview]	Terminal Phase Elimination Half-life (t1/2) of Irinotecan
NCT00668863 (15) [back to overview]	Clearance of Irinotecan
NCT00668863 (15) [back to overview]	Apparent Oral Clearance (CL/F) of Sunitinib
NCT00668863 (15) [back to overview]	Percentage of Participants Who Presented Objective Response: Objective Response Rate (ORR)
NCT00668863 (15) [back to overview]	Plasma Concentration at Steady State (Css) of 5-FU
NCT00668863 (15) [back to overview]	Volume of Distribution at Steady State (Vss) of Irinotecan
NCT00668863 (15) [back to overview]	Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC 0-24) of Sunitinib
NCT00668863 (15) [back to overview]	Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC Last) and Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC ∞) of Irinotecan
NCT00668863 (15) [back to overview]	Maximum Observed Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of Sunitinib.
NCT00668863 (15) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Irinotecan
NCT00668863 (15) [back to overview]	Progression-Free Survival (PFS)
NCT00668863 (15) [back to overview]	Duration of Response (DR)
NCT00668863 (15) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE).
NCT00668863 (15) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Irinotecan
NCT00668863 (15) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Sunitinib
NCT00720109 (5) [back to overview]	Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00720109 (5) [back to overview]	Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00720109 (5) [back to overview]	Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00720109 (5) [back to overview]	Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]	Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00742924 (1) [back to overview]	Limiting Toxicity
NCT00766142 (4) [back to overview]	Median Progression-free Survival (PFS) Time
NCT00766142 (4) [back to overview]	Overall Survival (OS) Time
NCT00766142 (4) [back to overview]	Mean Number of Adverse Events Per Patient, Within 30 Days of Surgery
NCT00766142 (4) [back to overview]	30-day Mortality Rate
NCT00778102 (14) [back to overview]	Percentage of Participants With Complications Related to First Resective Surgery
NCT00778102 (14) [back to overview]	Percentage of Participants With Complete or Major Histopathological Response
NCT00778102 (14) [back to overview]	Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0
NCT00778102 (14) [back to overview]	Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor
NCT00778102 (14) [back to overview]	Percentage of Participants Experiencing Relapse Following Curative Resection
NCT00778102 (14) [back to overview]	Percentage of Participants Experiencing Death or Disease Progression
NCT00778102 (14) [back to overview]	Overall Survival (OS)
NCT00778102 (14) [back to overview]	Percentage of Participants With Complications Related to Second Resective Surgery
NCT00778102 (14) [back to overview]	Percentage of Participants Who Died
NCT00778102 (14) [back to overview]	Time to Resection
NCT00778102 (14) [back to overview]	Relapse-Free Survival (RFS)
NCT00778102 (14) [back to overview]	Progression-Free Survival (PFS)
NCT00778102 (14) [back to overview]	Percentage of Participants With Histopathological Response
NCT00778102 (14) [back to overview]	Time to Response
NCT00786643 (3) [back to overview]	Best Response (BR)
NCT00786643 (3) [back to overview]	Early Response Rate (RR) (Stratum 1 Only)
NCT00786643 (3) [back to overview]	Time to Progression
NCT00792948 (3) [back to overview]	Overall Survival (OS)
NCT00792948 (3) [back to overview]	Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
NCT00792948 (3) [back to overview]	Continuous Complete Remission (CCR) Rate
NCT00835185 (12) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) or Death
NCT00835185 (12) [back to overview]	Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-∞)] of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]	Clearance (CL) of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]	Duration of Response
NCT00835185 (12) [back to overview]	Half-Life (t1/2) of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]	Kirsten Rat Sarcoma (KRAS) Mutation Status
NCT00835185 (12) [back to overview]	Serum Anti-IMC-11F8 Antibody Assessment (Immunogenicity)
NCT00835185 (12) [back to overview]	Maximum Concentration (Cmax) of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]	Volume of Distribution (Vss) of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]	Overall Survival (OS)
NCT00835185 (12) [back to overview]	Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response )
NCT00835185 (12) [back to overview]	Progression-Free Survival (PFS)
NCT00851084 (6) [back to overview]	Overall Objective Response Rate (ORR)
NCT00851084 (6) [back to overview]	Overall Survival (OS)
NCT00851084 (6) [back to overview]	Progression Free Survival (PFS)
NCT00851084 (6) [back to overview]	Progression Free Survival (PFS) Rate at 12 Months
NCT00851084 (6) [back to overview]	Immunogenicity of Intravenous (IV) Aflibercept
NCT00851084 (6) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAE)
NCT00862784 (7) [back to overview]	Number of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs)
NCT00862784 (7) [back to overview]	Serum Anti-IMC-1121B (Immunogenicity) at Day 1
NCT00862784 (7) [back to overview]	Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]
NCT00862784 (7) [back to overview]	Progression-Free Survival (PFS)
NCT00862784 (7) [back to overview]	Duration of Response
NCT00862784 (7) [back to overview]	Overall Survival (OS)
NCT00862784 (7) [back to overview]	Number of Participants With IMC-1121B (Ramucirumab)-Related Adverse Events (AEs)
NCT00865189 (11) [back to overview]	Number of Cycles of Radiotherapy
NCT00865189 (11) [back to overview]	Overall Survival
NCT00865189 (11) [back to overview]	Percentage of Participants Who Died
NCT00865189 (11) [back to overview]	Percentage of Participants With Second Cancer, Local or Regional Recurrence, Distant Metastasis, or Death
NCT00865189 (11) [back to overview]	Percentage of Participants With Surgery
NCT00865189 (11) [back to overview]	Percentage of Participants With Tumor Sterilization Defined by ypT0-N0
NCT00865189 (11) [back to overview]	Percentage of Participants With Tumor Down-Staging (ypT0-pT2)
NCT00865189 (11) [back to overview]	Percentage of Participants With Local and Distant Recurrences
NCT00865189 (11) [back to overview]	Disease-Free Survival (DFS)
NCT00865189 (11) [back to overview]	Number of Cycles of Chemotherapy
NCT00865189 (11) [back to overview]	Number of Cycles of Induction Chemotherapy
NCT00865709 (5) [back to overview]	Time to Progression (TTP)
NCT00865709 (5) [back to overview]	Progression-Free Survival (PFS)
NCT00865709 (5) [back to overview]	Overall Survival (OS)
NCT00865709 (5) [back to overview]	Overall Response
NCT00865709 (5) [back to overview]	Duration of Response
NCT00873093 (7) [back to overview]	Severe Adverse Events (SAE) Rate.
NCT00873093 (7) [back to overview]	Toxic Death Rate
NCT00873093 (7) [back to overview]	Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy
NCT00873093 (7) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00873093 (7) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 2
NCT00873093 (7) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00873093 (7) [back to overview]	Event Free Survival
NCT00942266 (7) [back to overview]	Overall Survival
NCT00942266 (7) [back to overview]	Disease Control Rate (Stable Disease or Objective Response)
NCT00942266 (7) [back to overview]	Toxicity
NCT00942266 (7) [back to overview]	Vorinostat Pharmacokinetics
NCT00942266 (7) [back to overview]	Response Rate
NCT00942266 (7) [back to overview]	Median Progression-free Survival
NCT00942266 (7) [back to overview]	Fluorouracil Steady-state Pharmacokinetics
NCT00954512 (2) [back to overview]	Part 2: Number of Participants With Each Type of Response Evaluation Criteria in Solid Tumors (RECIST)-Determined Overall Best Response
NCT00954512 (2) [back to overview]	Part 1: Number of Participants Who Experienced One or More Adverse Events (AEs)
NCT00957905 (1) [back to overview]	Objective Response Rate
NCT00967616 (5) [back to overview]	Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
NCT00967616 (5) [back to overview]	Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
NCT00967616 (5) [back to overview]	Best Overall Response and Objective Response Rate Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
NCT00967616 (5) [back to overview]	Median Overall Progression-Free Survival Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
NCT00967616 (5) [back to overview]	Median Overall Progression-Free Survival: Sensitivity Analysis Including Clinical Progression After Administration of CS-7017 and Irinotecan, Leucovorin, and 5-Fluorouracil After Failure of First-line Therapy of Metastatic Colorectal Cancer
NCT00982592 (5) [back to overview]	Median Progression-free Survival (PFS)
NCT00982592 (5) [back to overview]	Objective Response Rate
NCT00982592 (5) [back to overview]	Overall Survival
NCT00982592 (5) [back to overview]	Incidence of Toxicities (Grade 3 and Higher)
NCT00982592 (5) [back to overview]	Incidence of Toxicities (grades1 and 2)
NCT01133990 (5) [back to overview]	Phase 1b: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)
NCT01133990 (5) [back to overview]	Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter
NCT01133990 (5) [back to overview]	Phase 1b: Number of Participants With Clinically Significant Changes in Physical Examinations
NCT01133990 (5) [back to overview]	Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)
NCT01133990 (5) [back to overview]	Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
NCT01183780 (7) [back to overview]	Overall Survival (OS)
NCT01183780 (7) [back to overview]	Percentage of Participants Achieving an Objective Response (Objective Response Rate)
NCT01183780 (7) [back to overview]	Percentage of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
NCT01183780 (7) [back to overview]	Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab
NCT01183780 (7) [back to overview]	Progression-free Survival (PFS) Time
NCT01183780 (7) [back to overview]	Change From Baseline in EuroQol- 5D (EQ-5D)
NCT01183780 (7) [back to overview]	Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Right
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Left
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Right
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Left
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Right
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Left
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]	Overall Survival (OS) for B-LLy Patients
NCT01190930 (41) [back to overview]	Event Free Survival (EFS) for B-LLy Patients
NCT01190930 (41) [back to overview]	Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization
NCT01190930 (41) [back to overview]	DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional
NCT01190930 (41) [back to overview]	DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]	DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care
NCT01190930 (41) [back to overview]	Sample Collection of Central Path Review Slides in B-LLy Patients
NCT01212822 (4) [back to overview]	Progression Free Survival
NCT01212822 (4) [back to overview]	Overall Survival
NCT01212822 (4) [back to overview]	Complete and Partial Response to Neoadjuvant Therapy Based on the Response Evaluation Criteria in Solid Tumors (RECIST)
NCT01212822 (4) [back to overview]	Disease-free Survival
NCT01217814 (1) [back to overview]	Pharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab
NCT01228734 (5) [back to overview]	Overall Survival (OS) Time
NCT01228734 (5) [back to overview]	Progression Free Survival (PFS) Time
NCT01228734 (5) [back to overview]	Time to Treatment Failure (TTF)
NCT01228734 (5) [back to overview]	Number of Subjects With Curative Surgery of Liver Metastases
NCT01228734 (5) [back to overview]	Best Overall Response Rate (ORR)
NCT01229111 (4) [back to overview]	The Response Rate of Patients Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
NCT01229111 (4) [back to overview]	Estimation of Overall Survival
NCT01229111 (4) [back to overview]	Progression Free Survival
NCT01229111 (4) [back to overview]	Tabulation of the Toxicity Profile of the Combination Therapy
NCT01231399 (4) [back to overview]	Overall Survival
NCT01231399 (4) [back to overview]	Number of Subject With Overall Response
NCT01231399 (4) [back to overview]	Progression-free Survival
NCT01231399 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Everolimus
NCT01256398 (6) [back to overview]	Disease Free Survival (DFS)
NCT01256398 (6) [back to overview]	Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]	Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]	Overall Survival (OS)
NCT01256398 (6) [back to overview]	Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]	Response
NCT01276379 (5) [back to overview]	Response Duration
NCT01276379 (5) [back to overview]	Progression Free Survival
NCT01276379 (5) [back to overview]	Overall Survival
NCT01276379 (5) [back to overview]	Frequency of Adverse Events
NCT01276379 (5) [back to overview]	Secondary Biomarkers Analysis
NCT01279681 (4) [back to overview]	Overall Survival
NCT01279681 (4) [back to overview]	Response Rate, Defined as the Percentage of Patients in Each Arm Who Have an Objective Status of Complete Response or Partial Response, Confirmed by a Second Assessment Measured at Least 6 Weeks From the Initial Assessment
NCT01279681 (4) [back to overview]	Number of Participants With Grade 3 Adverse Events At Least Possibly Related to Treatment
NCT01279681 (4) [back to overview]	Progression-Free Survival
NCT01286818 (9) [back to overview]	Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events
NCT01286818 (9) [back to overview]	Steady State Volume of Distribution (Vss) of Ramucirumab
NCT01286818 (9) [back to overview]	Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]
NCT01286818 (9) [back to overview]	Area Under the Curve (AUC) of Ramucirumab
NCT01286818 (9) [back to overview]	Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period
NCT01286818 (9) [back to overview]	Number of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)
NCT01286818 (9) [back to overview]	Half Life (t1/2) of Ramucirumab
NCT01286818 (9) [back to overview]	Clearance (CL) of Ramucirumab
NCT01286818 (9) [back to overview]	Maximum Concentration (Cmax) of Ramucirumab
NCT01289821 (6) [back to overview]	Duration of Response (DOR)
NCT01289821 (6) [back to overview]	Disease Control (DC)
NCT01289821 (6) [back to overview]	Overall Survival (OS)
NCT01289821 (6) [back to overview]	Progression-free Survival (PFS)
NCT01289821 (6) [back to overview]	Objective Response (OR)
NCT01289821 (6) [back to overview]	Duration of Stable Disease (DOSD)
NCT01298570 (4) [back to overview]	Overall Survival (OS)
NCT01298570 (4) [back to overview]	Percentage of Patients With Severe Adverse Events
NCT01298570 (4) [back to overview]	Progression Free Survival (PFS)
NCT01298570 (4) [back to overview]	Drug Metabolism
NCT01307956 (4) [back to overview]	Progression-free Survival
NCT01307956 (4) [back to overview]	Overall Survival
NCT01307956 (4) [back to overview]	Number of Patients Who Can Undergo Resection
NCT01307956 (4) [back to overview]	Complete Pathological Response (pCR) Rate
NCT01322815 (1) [back to overview]	Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients)
NCT01333033 (5) [back to overview]	pCR Compared Between Induction Treatment Arms Among PET/CT Responders
NCT01333033 (5) [back to overview]	PET/CT Response Between Treatment Arms
NCT01333033 (5) [back to overview]	Progression Free Survival (PFS) Among PET/CT Non-responders Within Each Induction Treatment Group
NCT01333033 (5) [back to overview]	Complete Pathological Response (pCR) of PET/CT Non-responders
NCT01333033 (5) [back to overview]	pCR Compared Among Non-responders Between Induction Treatment Arms if Treatment Regimens Are Found to be Efficacious
NCT01383707 (6) [back to overview]	Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS)
NCT01383707 (6) [back to overview]	Overall Survival (OS)
NCT01383707 (6) [back to overview]	Progression-Free Survival (PFS)
NCT01383707 (6) [back to overview]	Percentage of Participants Achieving No Residual Tumor (R0)/Surgical Margin With Microscopic Residual Tumor (R1) Liver Resection
NCT01383707 (6) [back to overview]	Disease-free Interval (DFI)
NCT01383707 (6) [back to overview]	Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set
NCT01412879 (4) [back to overview]	Progression-Free Survival (PFS) at 2 Years
NCT01412879 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT01412879 (4) [back to overview]	Response Rate (Complete and Partial Response)
NCT01412879 (4) [back to overview]	5-year Overall Survival (OS)
NCT01481545 (7) [back to overview]	Percentage of Patients With Complete Tumor Regression Rate (TRG1)
NCT01481545 (7) [back to overview]	Patients With Metastatic Lymphnodes at Pathology Exam After Surgery
NCT01481545 (7) [back to overview]	Overall Survival (OS)
NCT01481545 (7) [back to overview]	Number of Patients With Sphincter Preservation
NCT01481545 (7) [back to overview]	Progression Free Survival (PFS)
NCT01481545 (7) [back to overview]	Number of Participants With Adverse Events
NCT01481545 (7) [back to overview]	Clinical Response Rate
NCT01498289 (6) [back to overview]	PFS Variation by ERCC1
NCT01498289 (6) [back to overview]	Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT01498289 (6) [back to overview]	Progression-free Survival (PFS) in High-ERCC1 Patients
NCT01498289 (6) [back to overview]	PFS in Low-ERCC1 Participants
NCT01498289 (6) [back to overview]	Overall Survival (OS)
NCT01498289 (6) [back to overview]	Overall Response Rate (ORR)
NCT01535053 (6) [back to overview]	Patient-reported Quality of Life (QOL) After Baseline Visit.
NCT01535053 (6) [back to overview]	Patient-reported Quality of Life (QOL) at Baseline
NCT01535053 (6) [back to overview]	Percentage of Participants With Complete Response
NCT01535053 (6) [back to overview]	The Number of Participants With Post Protocol Multi-agent Chemotherapy Treatment for Each Arm.
NCT01535053 (6) [back to overview]	The Number of Participants With Post Protocol Surgical Treatment for Each Arm.
NCT01535053 (6) [back to overview]	Number of Participants With CTCAE v4 Graded Adverse Events With Low-risk Gestational Trophoblastic Neoplasia by Arm
NCT01576705 (2) [back to overview]	GMDS (Griffiths Mental Development Scale)
NCT01576705 (2) [back to overview]	BL (Brunet Lezine Revised Scale)
NCT01581307 (3) [back to overview]	Rate of Progression Free Survival (PFS)
NCT01581307 (3) [back to overview]	Median Overall Survival (OS)
NCT01581307 (3) [back to overview]	Overall Response Rate (ORR)
NCT01611857 (4) [back to overview]	Time to Progression in Phase II Dose Expansion
NCT01611857 (4) [back to overview]	The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation
NCT01611857 (4) [back to overview]	Progression Free Survival in Phase II Dose Expansion
NCT01611857 (4) [back to overview]	Overall Survival in Phase II Dose Expansion
NCT01634555 (6) [back to overview]	Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Irinotecan and Its Metabolite SN-38 From Time Zero to Infinity [AUC(0-∞)] in Cycle 1
NCT01634555 (6) [back to overview]	Pharmacokinetics: Cmax of Ramucirumab (IMC-1121B)
NCT01634555 (6) [back to overview]	Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)
NCT01634555 (6) [back to overview]	Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Irinotecan and Its Metabolite SN-38 in Cycle 1
NCT01634555 (6) [back to overview]	Pharmacokinetics: Dose-Normalized Cmax of Irinotecan and Its Metabolite SN-38 in Cycle 2
NCT01634555 (6) [back to overview]	Pharmacokinetics: Dose-Normalized AUC(0-∞) of Irinotecan and Its Metabolite SN-38 in Cycle 2
NCT01666730 (5) [back to overview]	Median Overall Survival (OS)
NCT01666730 (5) [back to overview]	Response Rate (RR) Objective Tumor Response Based on Computed Tomography (CT) Scans or Magnetic Resonance Imaging (MRI) Scans According to Response Evaluation Criteria in Solid Tumors (RECIST)
NCT01666730 (5) [back to overview]	Progression Free Survival According to RECIST 1.1 Criteria
NCT01666730 (5) [back to overview]	Clinical Benefit Rate (CBR) Based on Computed Tomography (CT) Scans or Magnetic Resonance Imaging (MRI) Scans According to RECIST
NCT01666730 (5) [back to overview]	Number of Grade 3 and 4 Toxicities According to NCI CTCAE Version 4.0
NCT01681472 (43) [back to overview]	T(Last) of [6S]-5-THF
NCT01681472 (43) [back to overview]	T(Last) of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]	T(Last) of [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]	Cmax of [6S]-5-methyl-THF in Plasma
NCT01681472 (43) [back to overview]	T(Last) of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]	Concentration of [6S]-5-methyl-THF in Tumor Tissue
NCT01681472 (43) [back to overview]	Concentration of [6S]-5-THF in Adjacent Mucosa Tissue
NCT01681472 (43) [back to overview]	Concentration of [6S]-5-THF in Tumor Tissue
NCT01681472 (43) [back to overview]	T(1/2) of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]	T(1/2) of [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]	T(1/2) of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]	Tmax of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]	T(1/2) of [6S]-5-THF
NCT01681472 (43) [back to overview]	S-Folate Concentration
NCT01681472 (43) [back to overview]	Number of AEs Per Severity
NCT01681472 (43) [back to overview]	Homocystein Concentration
NCT01681472 (43) [back to overview]	Gene Expression Ratios (Mucosa:Tumor)
NCT01681472 (43) [back to overview]	Correlation of Gene Expression in Tumor and Adjacent Mucosa
NCT01681472 (43) [back to overview]	AUC(0-2h) of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]	AUC(0-2h) of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]	AUC(0-2h) of [6S]-5-THF
NCT01681472 (43) [back to overview]	AUC(0-2h) of [6SR]-5-formyl-THF
NCT01681472 (43) [back to overview]	AUC(Last) of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]	AUC(Last) of [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]	AUC(Last) of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]	AUC(Last) of [6S]-5-THF
NCT01681472 (43) [back to overview]	Cmax of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]	Cmax of [6S]-5-formyl-THF in Plasma
NCT01681472 (43) [back to overview]	Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-THF
NCT01681472 (43) [back to overview]	Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]	Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]	Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]	Cmax of [6S]-5-THF in Plasma
NCT01681472 (43) [back to overview]	Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue
NCT01681472 (43) [back to overview]	Concentration of [6R]-5,10-methylene-THF in Tumor Tissue
NCT01681472 (43) [back to overview]	Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue
NCT01681472 (43) [back to overview]	Concentration of [6S]-5-formyl-THF in Tumor Tissue
NCT01681472 (43) [back to overview]	Concentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue
NCT01681472 (43) [back to overview]	Change in S-Folate Concentration From Screening
NCT01681472 (43) [back to overview]	Change in Homocystein Concentration From Screening
NCT01681472 (43) [back to overview]	Tmax of [6S]-5-THF
NCT01681472 (43) [back to overview]	Tmax of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]	Tmax of [6S]-5-formyl-THF
NCT01718873 (5) [back to overview]	Disease Control Rate
NCT01718873 (5) [back to overview]	Overall Survival
NCT01718873 (5) [back to overview]	Toxic Effects
NCT01718873 (5) [back to overview]	Objective Response Rate
NCT01718873 (5) [back to overview]	Progression-free Survival (PFS)
NCT01765582 (7) [back to overview]	Time to PFS2
NCT01765582 (7) [back to overview]	Overall Survival (OS)
NCT01765582 (7) [back to overview]	Percentage of Participants With Adverse Events
NCT01765582 (7) [back to overview]	Percentage of Participants With Overall Response During First-Line Therapy (ORR1)
NCT01765582 (7) [back to overview]	Progression-Free Survival During First-Line Therapy (PFS1)
NCT01765582 (7) [back to overview]	Proportion of Participants Considered by the Investigator to be Unresectable on Study Enrollment Who Subsequently Underwent Attempted Curative Resections of Metastases
NCT01765582 (7) [back to overview]	Proportion of Participants Who Underwent Liver Metastases Resections
NCT01882868 (27) [back to overview]	Area Under the Concentration Time Curve (AUC) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Area Under the Concentration Time Curve From Time 0 to 14 Days Post Start of Infusion (AUC0-14 Day) for Free and VEGF-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Area Under the Concentration Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Free and VEGF-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Area Under the Concentration Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Free and Vascular Endothelial Growth Factor (VEGF)-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Terminal Elimination Half-life (t1/2z) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Time to Reach Maximum Plasma Concentration Observed (Tmax) for Free and VEGF-Bound Aflibercept in Cycle 1: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Terminal Elimination Half-life (t1/2z) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Steady State Drug Concentration (Css) for 5-FU: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Total Body Clearance (CL) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]	Total Body Clearance (CL) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Total Body Clearance (CL) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Volume of Distribution at the Steady State (Vss) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]	Volume of Distribution at the Steady State (Vss) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Aflibercept Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay
NCT01882868 (27) [back to overview]	Active Metabolite SN-38 / Irinotecan Ratio on Area Under the Concentration Time Curve (Rmet): Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Area Under the Concentration Time Curve (AUC) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]	Area Under the Concentration Time Curve (AUC) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Area Under the Concentration Time Curve From Time 0 to 14 Days Post Start of Infusion (AUC0-14 Day) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]	Clearance at Steady State (CLss) for 5-FU: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT01882868 (27) [back to overview]	Overall Survival (OS)
NCT01882868 (27) [back to overview]	Percentage of Participants With Overall Response
NCT01882868 (27) [back to overview]	Progression Free Survival (PFS)
NCT01897454 (7) [back to overview]	Percentage of Participants Achieving R0 Resection (R0 Resection Rate)
NCT01897454 (7) [back to overview]	Overall Response Rate
NCT01897454 (7) [back to overview]	Overall Survival (OS)
NCT01897454 (7) [back to overview]	Percentage of Patients Able to Undergo Resection
NCT01897454 (7) [back to overview]	Progression Free Survival (PFS)
NCT01897454 (7) [back to overview]	Toxicities Associated With Chemotherapy and Radiotherapy
NCT01897454 (7) [back to overview]	Vascular Reconstruction
NCT01900431 (8) [back to overview]	Percent Change From Baseline in CRT at Week 16
NCT01900431 (8) [back to overview]	Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 16
NCT01900431 (8) [back to overview]	Change From Baseline in Central Retinal Thickness (CRT) At Week 16
NCT01900431 (8) [back to overview]	Change From Baseline in VH Scale at Week 16
NCT01900431 (8) [back to overview]	Percentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 16
NCT01900431 (8) [back to overview]	Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16
NCT01900431 (8) [back to overview]	Percentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 16
NCT01900431 (8) [back to overview]	Pharmacokinetics (PK) Assessment: Serum Functional Sarilumab Concentration
NCT01928290 (7) [back to overview]	Time to Progression (TTP)
NCT01928290 (7) [back to overview]	Number of Participants With an Objective Response
NCT01928290 (7) [back to overview]	Progression Free Survival
NCT01928290 (7) [back to overview]	Overall Survival (OS)
NCT01928290 (7) [back to overview]	Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events
NCT01928290 (7) [back to overview]	Duration of Response
NCT01928290 (7) [back to overview]	Clinical Benefit Rate
NCT01959139 (5) [back to overview]	Progression Free Survival (PFS) (Phase II)
NCT01959139 (5) [back to overview]	Phase II: Overall Survival
NCT01959139 (5) [back to overview]	Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOX
NCT01959139 (5) [back to overview]	Objective Tumor Response Rate (Confirmed and Unconfirmed, Complete and Partial)
NCT01959139 (5) [back to overview]	Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT01959672 (5) [back to overview]	Distant Failure-free Survival
NCT01959672 (5) [back to overview]	Overall Survival
NCT01959672 (5) [back to overview]	Surgical Complete Resection (Negative Margin) Rate
NCT01959672 (5) [back to overview]	Number of Participants With CA-125-Specific T-cell Signal.
NCT01959672 (5) [back to overview]	Number of Participants With Progressive Disease,
NCT01964755 (6) [back to overview]	One-Year Rate of Failure-Free Survival (FFS)
NCT01964755 (6) [back to overview]	One-year Rate of Overall Survival
NCT01964755 (6) [back to overview]	Rate of Complete Response to Protocol Therapy
NCT01964755 (6) [back to overview]	HIV Viral Load in Positive Subjects Before, During and After Protocol Therapy
NCT01964755 (6) [back to overview]	Rate of Toxicity Related to Protocol Therapy
NCT01964755 (6) [back to overview]	T-Cell Subset Levels in Peripheral Blood in Positive Participants Before, During and After Protocol Therapy
NCT01987102 (14) [back to overview]	Number of AEs Per Severity (All Courses)
NCT01987102 (14) [back to overview]	Number of Grade A1, Grade A2, Grade B, Grade C, or Grade D Excretion Toxicities as Listed in the MTX-toxicity Management Instructions
NCT01987102 (14) [back to overview]	Number of Ongoing AEs Per HDMTX Course
NCT01987102 (14) [back to overview]	Number of HDMTX Courses With Delayed Late MTX Elimination (Definition F).
NCT01987102 (14) [back to overview]	Number of HDMTX Courses With Delayed MTX Elimination (Definition D).
NCT01987102 (14) [back to overview]	Characterization (Number/Severity) of All Reported AEs During the ENTIRE STUDY PERIOD.
NCT01987102 (14) [back to overview]	Number of HDMTX Courses With Delayed Early MTX Elimination (Definition E).
NCT01987102 (14) [back to overview]	Number of Administered MAP Cycles Classified as Having Met the Criteria for Successful Advancement From First to Second HDMTX Course Within the Same MAP Cycle According to Definition A.
NCT01987102 (14) [back to overview]	Time to Successful MTX Elimination (Definition C)
NCT01987102 (14) [back to overview]	Number of Ongoing HDMTX Related AEs Per HDMTX Course
NCT01987102 (14) [back to overview]	Number of Administered HDMTX Courses Classified as Having Met the Criteria for Successful Advancement According to Definition A and/or Definition B
NCT01987102 (14) [back to overview]	Number of Administered MAP Cycles Classified as Having Met the Criteria for Successful Advancement to Next MAP Cycle According to Definition B.
NCT01987102 (14) [back to overview]	Number of HDMTX Courses in Which the Initial Hydration Was Increased
NCT01987102 (14) [back to overview]	Number of HDMTX Related AEs Per Severity (All Courses)
NCT02015819 (6) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)
NCT02015819 (6) [back to overview]	Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham
NCT02015819 (6) [back to overview]	Average Steady State Levels of 5-FC and 5-FU in the Brain
NCT02015819 (6) [back to overview]	Number of Participants Developing Antibodies Against NSCs
NCT02015819 (6) [back to overview]	Average Steady State Levels of 5-FC Concentrations in Plasma
NCT02015819 (6) [back to overview]	Comparison of 5-FC in the Brain to 5-FC in the Plasma
NCT02042443 (4) [back to overview]	Objective Response Rate
NCT02042443 (4) [back to overview]	Overall Survival
NCT02042443 (4) [back to overview]	Progression-free Survival
NCT02042443 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT02069704 (13) [back to overview]	Elimination Half-life (t1/2) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Objective Response Rate (ORR) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Anti-Drug Antibody (ADA) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Volume of Distribution (Vd) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Progression-free Survival (PFS) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Elimination Rate Constant (Kel) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Ctrough,ss of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Ctrough,sd of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Cmax,ss of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Cmax,sd of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Reported With BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	AUC at Steady State (AUCss) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]	Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin®
NCT02101853 (4) [back to overview]	Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients
NCT02101853 (4) [back to overview]	Overall Survival (OS) of HR and IR Relapse Patients
NCT02101853 (4) [back to overview]	Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients
NCT02101853 (4) [back to overview]	Overall Survival (OS) of LR Relapse Patients
NCT02112916 (6) [back to overview]	Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)
NCT02112916 (6) [back to overview]	EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)
NCT02112916 (6) [back to overview]	EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3
NCT02112916 (6) [back to overview]	EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond
NCT02112916 (6) [back to overview]	Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
NCT02112916 (6) [back to overview]	Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase
NCT02141295 (14) [back to overview]	Number of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab
NCT02141295 (14) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT02141295 (14) [back to overview]	Cmax Accumulation Ratio (AR) of Vanucizumab
NCT02141295 (14) [back to overview]	Plasma Clearance at Steady State (CLss) of Vanucizumab
NCT02141295 (14) [back to overview]	Duration of Objective Response, as Assessed Using RECIST v. 1.1
NCT02141295 (14) [back to overview]	Minimum Observed Plasma Concentration (Clast) of Vanucizumab
NCT02141295 (14) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Vanucizumab
NCT02141295 (14) [back to overview]	Area Under the Plasma Concentration-Time Curve (AUC) of Vanucizumab
NCT02141295 (14) [back to overview]	Percentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.1
NCT02141295 (14) [back to overview]	Volume of Distribution at Steady State (Vss) of Vanucizumab
NCT02141295 (14) [back to overview]	Progression-free Survival (PFS), Time to Event
NCT02141295 (14) [back to overview]	Overall Survival (OS)
NCT02141295 (14) [back to overview]	Plasma Terminal Half-Life (t1/2) of Vanucizumab
NCT02141295 (14) [back to overview]	Time to Reach Cmax (Tmax) of Vanucizumab
NCT02337946 (9) [back to overview]	Percentage of Participants With Grade 3 or Higher Skin Toxicity
NCT02337946 (9) [back to overview]	Percentage of Participants With Adverse Events by Severity Graded Using the Common Terminology Criteria for Adverse Events (CTCAE) Grade
NCT02337946 (9) [back to overview]	Time to Treatment Failure (TTF)
NCT02337946 (9) [back to overview]	Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization
NCT02337946 (9) [back to overview]	Overall Survival (OS)
NCT02337946 (9) [back to overview]	Percentage of Participants With Grade 2 or Higher Peripheral Neuropathy
NCT02337946 (9) [back to overview]	Progression-Free Survival (PFS)
NCT02337946 (9) [back to overview]	Percentage of Participants With Adverse Events
NCT02337946 (9) [back to overview]	Response Rate (RR)
NCT02379091 (7) [back to overview]	Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR 50) and 70% (ACR70) Response at Weeks 12 and 24
NCT02379091 (7) [back to overview]	Percentage of Participants With a Reduction of Pain as Measured Using a Visual Analog Scale (VAS) at Weeks 2, 12 and 24
NCT02379091 (7) [back to overview]	Change From Baseline in DAS28-CRP at Week 24
NCT02379091 (7) [back to overview]	ACR Numeric (N) Index (ACRn) at Week 12
NCT02379091 (7) [back to overview]	Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) at Week 12
NCT02379091 (7) [back to overview]	ACR Numeric (N) Index (ACRn) at Week 24
NCT02379091 (7) [back to overview]	Change From Baseline in DAS28-CRP at Weeks 2, 6, and 10
NCT02384850 (5) [back to overview]	Number of Patients Experiencing Adverse Events
NCT02384850 (5) [back to overview]	Number of Patients Still Alive at End of Study (Overall Survival)
NCT02384850 (5) [back to overview]	Overall Response Rate
NCT02384850 (5) [back to overview]	Progression Free Survival (PFS)
NCT02384850 (5) [back to overview]	Numbers of Patients With Dose Limiting Toxicities
NCT02394795 (7) [back to overview]	Progression-Free Survival (PFS) in Participants With Left-sided Tumors
NCT02394795 (7) [back to overview]	Overall Survival (OS) in All Participants
NCT02394795 (7) [back to overview]	Progression-Free Survival (PFS) in All Participants
NCT02394795 (7) [back to overview]	Duration of Response (DOR)
NCT02394795 (7) [back to overview]	OS in Participants With Left-sided Tumors
NCT02394795 (7) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAE)
NCT02394795 (7) [back to overview]	Number of Participants Treated With Curative Surgical Resection After Chemotherapy
NCT02508077 (1) [back to overview]	4-month Progression-free Survival (PFS) Rate
NCT02553460 (1) [back to overview]	Percentage of Treatment-related Mortality (TRM)
NCT02620865 (3) [back to overview]	Incidence of Toxicity (CTCAE Version 4.0)
NCT02620865 (3) [back to overview]	Median Overall Survival (OS)
NCT02620865 (3) [back to overview]	Progression Free Survival (PFS)
NCT02625610 (12) [back to overview]	Maintenance Phase: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
NCT02625610 (12) [back to overview]	Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score up to Safety Follow-up (Up to 152.3 Weeks)
NCT02625610 (12) [back to overview]	Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) Questionnaire Scores up to Safety Follow-up (Up to 152.3 Weeks)
NCT02625610 (12) [back to overview]	Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score up to Safety Follow-up (Up to 152.3 Weeks)
NCT02625610 (12) [back to overview]	Progression Free Survival (PFS) by Independent Review Committee (IRC)
NCT02625610 (12) [back to overview]	Overall Survival (OS)
NCT02625610 (12) [back to overview]	Objective Response Rate (ORR) by Investigator Assessment
NCT02625610 (12) [back to overview]	Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1
NCT02625610 (12) [back to overview]	Maintenance Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
NCT02625610 (12) [back to overview]	Maintenance Phase: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
NCT02625610 (12) [back to overview]	Maintenance Phase: Number of Participants With Grade Change From Baseline to Worst On-Treatment Grade 4 Hematology Values
NCT02625610 (12) [back to overview]	Change From Baseline in European Quality of Life 5-dimensions Health Outcome Questionnaire Through Visual Analogue Scale up to Safety Follow-up (Up to 152.3 Weeks)
NCT02641691 (9) [back to overview]	Complete Response Rate
NCT02641691 (9) [back to overview]	Number of Any Grade 3 or Higher Toxicities
NCT02641691 (9) [back to overview]	Number of Post Chemotherapy Grade 3 or Higher Toxicities
NCT02641691 (9) [back to overview]	Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire
NCT02641691 (9) [back to overview]	Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire
NCT02641691 (9) [back to overview]	Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire
NCT02641691 (9) [back to overview]	Quality of Anorectal Function as Measured by the FACT-C Questionnaire
NCT02641691 (9) [back to overview]	Quality of Anorectal Function as Measured by the FACT-C Questionnaire
NCT02641691 (9) [back to overview]	Quality of Anorectal Function as Measured by the FACT-C Questionnaire
NCT02730546 (1) [back to overview]	Pathological Complete Response (PathCR) Rate
NCT02828358 (5) [back to overview]	Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02890355 (6) [back to overview]	Overall Survival (OS)
NCT02890355 (6) [back to overview]	Progression Free Survival (PFS)
NCT02890355 (6) [back to overview]	Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT02890355 (6) [back to overview]	Disease Control Rate
NCT02890355 (6) [back to overview]	Overall Response Rate, ORR
NCT02890355 (6) [back to overview]	Duration of Response (DoR)
NCT02896907 (1) [back to overview]	Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	Phase 3: Number of Participants With Clinically Notable Shifts in Urinalysis Laboratory Parameters
NCT02928224 (78) [back to overview]	(Safety Lead-in) Time to Response by Investigator
NCT02928224 (78) [back to overview]	(Safety Lead-in) Time to Response by BICR
NCT02928224 (78) [back to overview]	(Safety Lead-in) Progression-Free Survival (PFS) by Investigator
NCT02928224 (78) [back to overview]	(Safety Lead-in) Progression-Free Survival (PFS) by BICR
NCT02928224 (78) [back to overview]	(Safety Lead-in) Objective Response Rate (ORR) by Investigator
NCT02928224 (78) [back to overview]	(Safety Lead-in) Objective Response Rate (ORR) by BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm
NCT02928224 (78) [back to overview]	(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm
NCT02928224 (78) [back to overview]	(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm
NCT02928224 (78) [back to overview]	(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib
NCT02928224 (78) [back to overview]	(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim Analysis
NCT02928224 (78) [back to overview]	(Safety Lead-in) Duration of Response (DOR) by BICR
NCT02928224 (78) [back to overview]	(Safety Lead-in) Duration of Response (DOR) by Investigator
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Cetuximab
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve From Zero to the Last Measurable Time Point (AUClast) for Metabolite of Binimetinib (AR00426032)
NCT02928224 (78) [back to overview]	(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim Analysis
NCT02928224 (78) [back to overview]	(Safety Lead-in) Number of Participants With Adverse Events (AEs)
NCT02928224 (78) [back to overview]	(Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Binimetinib
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)
NCT02928224 (78) [back to overview]	(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Encorafenib
NCT02928224 (78) [back to overview]	Phase 3: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters
NCT02928224 (78) [back to overview]	Phase 3: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters
NCT02928224 (78) [back to overview]	Phase 3: Number of Participants With Newly Occurring Clinically Notable Electrocardiogram (ECG) Values
NCT02928224 (78) [back to overview]	Phase 3: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities
NCT02928224 (78) [back to overview]	Phase 3: Number of Participants With Shift in Visual Acuity Logarithm of the Minimum Angle of Resolution (LogMAR) Score
NCT02928224 (78) [back to overview]	Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]	(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]	(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis
NCT03258762 (36) [back to overview]	AUC (0-inf) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]	AUC (0-24) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]	Area Under the Concentration-time Curve From Time 0 to t (AUC[0-t]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]	Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
NCT03258762 (36) [back to overview]	Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]	Area Under the Concentration-time Curve From Time 0 to 24 (AUC[0-24]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]	Apparent Volume of Distribution Following Oral Dosing (Vd/F) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]	Apparent Clearance Following Oral Dosing (CL/F) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]	Urine Potential of Hydrogen (pH) at Indicated Time Points
NCT03258762 (36) [back to overview]	Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin
NCT03258762 (36) [back to overview]	Specific Gravity at Indicated Time Points
NCT03258762 (36) [back to overview]	Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT03258762 (36) [back to overview]	Number of Participants With Abnormal Urinalysis Parameter
NCT03258762 (36) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, and QT Interval Corrected for Heart Rate by Fredericia's Formula (QTcF) Interval
NCT03258762 (36) [back to overview]	Change From Baseline of ECG Parameter: ECG Mean Heart Rate
NCT03258762 (36) [back to overview]	Change From Baseline of Clinical Chemistry Parameters: Protein
NCT03258762 (36) [back to overview]	Change From Baseline of Clinical Chemistry Parameters: Glucose, Sodium, Calcium, Potassium, and Urea.
NCT03258762 (36) [back to overview]	Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine.
NCT03258762 (36) [back to overview]	Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)
NCT03258762 (36) [back to overview]	Change From Baseline in Temperature
NCT03258762 (36) [back to overview]	Change From Baseline in Pulse Rate
NCT03258762 (36) [back to overview]	Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet and Leukocytes
NCT03258762 (36) [back to overview]	Change From Baseline in Hematology Parameter: Reticulocytes
NCT03258762 (36) [back to overview]	Change From Baseline in Hematology Parameter: Mean Corpuscular Volume
NCT03258762 (36) [back to overview]	Change From Baseline in Hematology Parameter: Hemoglobin
NCT03258762 (36) [back to overview]	Change From Baseline in Hematology Parameter: Hematocrit
NCT03258762 (36) [back to overview]	Change From Baseline in Hematology Parameter: Erythrocytes
NCT03258762 (36) [back to overview]	Vd/F of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]	Tmax of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]	Time to Maximum Observed Concentration (Tmax) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]	Terminal Half-life (t1/2) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]	T1/2 of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]	Maximum Observed Concentration (Cmax) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]	Cmax of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]	CL/F of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]	AUC (0-t) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03488225 (5) [back to overview]	Overall Survival
NCT03488225 (5) [back to overview]	Number of Participants With Minimal Residual Disease (MRD) Negativity
NCT03488225 (5) [back to overview]	Event-Free Survival
NCT03488225 (5) [back to overview]	Participants to Achieve Complete Remission (CR):
NCT03488225 (5) [back to overview]	Number of Participants With Adverse Events
NCT03504423 (3) [back to overview]	Overall Response Rate (ORR)
NCT03504423 (3) [back to overview]	Progression Free Survival (PFS)
NCT03504423 (3) [back to overview]	Overall Survival (OS)
NCT03518112 (5) [back to overview]	Overall Survival
NCT03518112 (5) [back to overview]	Participants With a Response
NCT03518112 (5) [back to overview]	Number of Participants Negative for Minimal Residual Disease (MRD)
NCT03518112 (5) [back to overview]	Event Free Survival (EFS) Where Events Defined as no Response, Loss of Response, or Death
NCT03518112 (5) [back to overview]	Duration of Response
NCT03611556 (31) [back to overview]	Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase
NCT03611556 (31) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase
NCT03611556 (31) [back to overview]	Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Number of Participants With Overall Survival Events in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Overall Survival in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase
NCT03611556 (31) [back to overview]	Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Number of Participants With Positive ADA to Durvalumab
NCT03611556 (31) [back to overview]	Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase
NCT03611556 (31) [back to overview]	Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Number of Participants With TEAEs and TESAEs in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase
NCT03611556 (31) [back to overview]	Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab
NCT03611556 (31) [back to overview]	Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase
NCT03611556 (31) [back to overview]	Serum Concentrations of Oleclumab
NCT03611556 (31) [back to overview]	Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase
NCT03611556 (31) [back to overview]	Serum Concentrations of Durvalumab
NCT03611556 (31) [back to overview]	Serum Concentrations of Durvalumab
NCT03611556 (31) [back to overview]	Plasma Concentrations of Nab-paclitaxel
NCT03611556 (31) [back to overview]	Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)
NCT03611556 (31) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase
NCT03611556 (31) [back to overview]	Serum Concentrations of Oleclumab
NCT03611556 (31) [back to overview]	Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase
NCT03771560 (5) [back to overview]	Social Responsiveness Scale (SRS) - Parent Reported Change
NCT03771560 (5) [back to overview]	Pediatric Quality of Life (PedsQL) - Parent Reported Change
NCT03771560 (5) [back to overview]	Aberrant Behavior Checklist (ABC) - Teacher Reported Change
NCT03771560 (5) [back to overview]	Aberrant Behavior Checklist (ABC) - Parent Reported Change
NCT03771560 (5) [back to overview]	Social Responsiveness Scale (SRS) - Teacher Reported Change

5-year Overall Survival Rate in Patients With Dukes' B3/C Disease

Overall survival (OS) is defined as time from randomization to death from any cause or last date known alive. Kaplan-Meier method was used to estimate 5-year OS rate (NCT00002525)
Timeframe: every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization

Intervention	proportion of participants (Number)
Perioperative 5-FU	0.666
No Perioperative 5-FU	0.612

Intervention	percentage of participants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM	96
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens	84
A2 (Disseminated, No CNS - CCG Mod BFM w/Intens	88
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy	81
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens	85
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens	85
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment	92

Intervention	percentage of patients (Number)
Patients With HLA-matched Sibling Donor	46
Patients Without HLA-matched Sibling Donors	47

Intervention	participants (Number)
	Complete Molecular Response	Major Molecular Response
Entire Cohort	9	4

Intervention	percentage of samples analyzed (Number)
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	22
Group C (Chemotherapy, Monoclonal Antibody Therapy)	70

Intervention	participants (Number)
	Toxic death	No toxic death
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	0	45
Group C (Chemotherapy, Monoclonal Antibody Therapy)	2	38

Intervention	participants (Number)
	Incidence of grade ≥ 3 stomatitis	No incidence of grade ≥ 3 stomatitis
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	4	41
Group C (Chemotherapy, Monoclonal Antibody Therapy)	6	34

Intervention	months (Median)
Phase I - Alemtuzumab and Combination Chemotherapy	58.6
Phase II - Alemtuzumab and Combination Chemotherapy	19.8

Intervention	months (Median)
Phase I - Alemtuzumab and Combination Chemotherapy	33.6
Phase II - Alemtuzumab and Combination Chemotherapy	23.1

Intervention	Participants (Count of Participants)
	Local/regional recurrence only	Distant recurrence only	Both local/regional and distant recurrence	Any recurrence	Second primary cancer	Death
Control (Arm III)	5	10	1	16	2	21
Irinocetan (Arm I)	3	15	2	20	3	19
Oxaliplatin (Arm II)	5	11	4	20	5	21

Intervention	proportion of patients (Number)
Irinocetan (Arm I)	0.814
Oxaliplatin (Arm II)	0.724
Control (Arm III)	0.655

Intervention	proportion of patients (Number)
Irinocetan (Arm I)	0.965
Oxaliplatin (Arm II)	0.843
Control (Arm III)	0.870

Intervention	proportion of patients (Number)
Irinocetan (Arm I)	0.670
Oxaliplatin (Arm II)	0.717
Control (Arm III)	0.704

Intervention	participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	26
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	12
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	43
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	14
Prednisone, Capizzi Methotrexate <10 Years	16
Prednisone, Capezzi Methotrexate >= 10 Years	95
Prednisone and High Dose Methotrexate < 10 Yrs Old	17
Prednisone and High Dose Methotrexate >=10 Years	98
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	39
Prednisone, Capezzi Methotrexate (Down's Syndrome)	3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	3
Prednisone and High Dose Methotrexate (Non Randomly Assigned)	3

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	83.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	81.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	69.1
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	91.2
Prednisone, Capizzi Methotrexate <10 Years	82.1
Prednisone, Capezzi Methotrexate >= 10 Years	73.5
Predisone and High Dose Methotrexate < 10 Yrs Old	80.8
Prenisone and High Dose Methotrexate >=10 Years	75.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	77.0
Prenisone, Capezzi Methotrexate (Down's Syndrome)	61.8
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	44.4

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	79.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	69.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	65.6
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	86.2
Prednisone, Capizzi Methotrexate <10 Years	93.8
Prednisone, Capizzi Methotrexate >= 10 Years	63.1
Predisone and High Dose Methotrexate < 10 Yrs Old	84.2
Prednisone and High Dose Methotrexate >=10 Years	73.6
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	74.6

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	66.5
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	43.3
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	35.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	80
Prednisone, Capizzi Methotrexate <10 Years	34.7
Prednisone, Capizzi Methotrexate >= 10 Years	39
Prednisone and High Dose Methotrexate < 10 Yrs Old	55
Prednisone and High Dose Methotrexate >=10 Years	47.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	49.4

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	95.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	92.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	87.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	98.1
Prednisone, Capizzi Methotrexate <10 Years	93.3
Prednisone, Capizzi Methotrexate >= 10 Years	90.2
Prednisone and High Dose Methotrexate < 10 Yrs Old	94.5
Prednisone and High Dose Methotrexate >=10 Years	90.5
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	91.6
Prednisone, Capizzi Methotrexate (Down's Syndrome)	78.3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	25.0

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	86.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	93.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	80.5
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	93.1
Prednisone, Capizzi Methotrexate <10 Years	86.5
Prednisone, Capezzi Methotrexate >= 10 Years	83.4
Prednisone and High Dose Methotrexate < 10 Yrs Old	84.2
Prednisone and High Dose Methotrexate >=10 Years	83.9
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	85.3
Prednisone, Capezzi Methotrexate (Down's Syndrome)	74.4
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	25

Intervention	Participants (Count of Participants)
	Hematologic	Non-Hematologic	Overall
Neoadjuvant Chemoradiation With Irinotecan	20	32	38
Neoadjuvant Chemoradiation With Oxaliplatin	19	29	36

Intervention	score on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan	-1.5
Neoadjuvant Chemoradiation With Oxaliplatin	3.9

levoleucovorin

Description

Cross-References

Synonyms (76)

Effects

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Pathways (4)

Research

Studies (10,278)

Study Types

Clinical Trials (705)

Trial Overview

Trial Outcomes

5-year Overall Survival Rate in Patients With Dukes' B3/C Disease

5-year Overall Survival Rate in Patients With Dukes' B2 Disease

5-year Disease-free Survival Rate in Patients With Dukes' B3/C Disease

5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease

2 Year Disease-free Survival .

Best Confirmed Response to Neoadjuvant Therapy

Grade 3 or Higher Toxicity Incidence on Step 1

Overall Survival

Progression Free Survival

Percentage of Patients With Overall Survival as Assessed by Time to Death

Event-free Survival

2 Year Event Free Survival

Complete Response Rate

2 Year Overall Survival

Disease Free Survival

Overall Survival

5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups

Number of Participants Who Achieved a BCR-ABL Response at 12 Months

5 Year Overall Survival for Autologous & Allogeneic Transplant Groups

Progression-free Survival

Response

Overall Survival

Overall Survival

Disease Free Survival

Minimal Residual Disease

Response Rate

Toxic Death

Grade ≥ 3 Stomatitis

Disease-free Survival, for Only Complete Response Patients

Number of Participants Achieving Complete Remission

Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)

Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)

Overall Survival

Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)

Failure Pattern

Proportion of Sphincter Preservation

3-year Overall Survival Rate

3-year Disease Free Survival

Correlation of Early Marrow Response Status With MRD Positive.

Correlation of Early Marrow Response Status With MRD Negative.

Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions

Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)

Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)

Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).

Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)

Disease-free Survival (Arms A and D: Wild-type KRAS Patients)

Disease-free Survival (Arms A and D: Mutant KRAS Patients)

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)

Number of Participants With Grade 3+ Treatment-related Adverse Events

Number of Participants With Grade 3+ Treatment-related Adverse Events Postoperatively

Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Completion of Post-operative Chemotherapy

Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Two Years

Change From Baseline in QLQ-C30 Global Health Status Score at Completion of Post-operative Chemotherapy

Change From Baseline in QLQ-C30 Global Health Status Score at Two Years

Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Completion of Chemoradiation

Disease-free Survival Rate at 4 Years

Distant Failure Rate at 4 Years

Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Post-operative Chemotherapy

Intervention	score on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan	0.4
Neoadjuvant Chemoradiation With Oxaliplatin	-1.6

Intervention	score on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan	-12.5
Neoadjuvant Chemoradiation With Oxaliplatin	-7.1

Intervention	score on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan	-6.8
Neoadjuvant Chemoradiation With Oxaliplatin	-1.3

Intervention	score on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan	5.9
Neoadjuvant Chemoradiation With Oxaliplatin	20.3

Intervention	score on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan	-10.3
Neoadjuvant Chemoradiation With Oxaliplatin	-12.2

Intervention	percentage of participants (Number)
Neoadjuvant Chemoradiation With Irinotecan	10.4
Neoadjuvant Chemoradiation With Oxaliplatin	20.8

Intervention	Participants (Count of Participants)
	unresectable disease	intra-abdominal metastasis	resection of the primary tumor
Treatment	4	6	9

Intervention	Participants (Count of Participants)
	Induction CT, grade 3	Induction CT, grade 4	CRT, grade 3	CRT, grade 4	Within 1 mo. post CRT, grade 3	Within 1 mo. post CRT, grade 4	2-3 mos. post CRT, grade 3	2-3 mos. post CRT, grade 4
Treatment	4	5	11	0	12	1	9	0

Intervention	percentage of participants (Number)
CNS Patients - Treatment (Combination Chemotherapy)	64.9
Testicular Relapse Patients (Combination Chemotherapy)	70

Intervention	percentage of patients (Number)
Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil	75.5
Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab	77.4